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Abstract 
Many parasites of mammals avoid elimination by varying their exposed antigens.  
African trypanosomes—deadly parasites of humans and livestock in tropical 
Africa—possess a comprehensive system of antigenic variation (AV).  
Trypanosoma brucei undergo frequent, stochastic changes to their variant 
surface glycoprotein (VSG) coats, and therefore a developing immune response 
will be only partially effective against the trypanosome population as some 
trypanosomes will have already switched to a different VSG coat.  The source of 
VSG variability is an archive of ~2000, mostly pseudogenic, silent VSG genes, of 
which only one is expressed.  VSG genes can also be segmentally recombined: 
‘mosaic’ VSGs, constructed from more than one silent VSG donor, allow both the 
reparation of pseudogenes and potentially generation of additional VSG 
variability.  The aim of this research was to investigate the patterns of 
segmental VSG gene conversion in T. brucei, and assess its contribution to AV.  
Multiple, longitudinal samples were taken from chronic infections to follow the 
course of AV, and VSG cDNA sequences were analysed, building a detailed 
portrait of VSG expression across infection.  VSG variability during an infection 
was extensive, and segmental gene conversion was found to be a frequent 
occurrence from approximately week three.  Two main patterns were found: (i) 
expressed VSGs readily acquired a 3’ end different from their silent copy, a 
pattern that probably represents the 3’ boundary of gene conversion occurring 
within the coding sequence; (ii) expressed VSGs often appeared in sets of 
related ‘mosaics’, whereby more than one donor gene had contributed to the 
putative epitope-encoding part of the VSG.  To test whether varying donor 
contributions represents an additional source of antigenic variability available to 
trypanosomes, a set of five mosaic VSGs retrieved from a single infection was 
expressed in non-switching trypanosomes and used to raise antibody responses.  
Indirect immuno-fluorescence, complement-mediated lysis, and agglutination 
assays using both polyclonal and monoclonal antibodies showed that although 
4/5 mosaics were cross-reactive, one variant was completely antigenically 
distinct.  Segmental gene conversion was therefore found to be both prominent 
in chronic African trypanosome antigenic variation, and capable of bringing 
antigenic novelty to an infection, with important consequences for the dynamics 
of AV, and the nature of selection pressure on the silent VSG archive. 
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1 Introduction 
1.1 Introduction to antigenic variation 
1.1.1 Antigenic variation is a means of coping with a changing 
immunological environment 
To a parasite, a mammal is essentially a stable, mild, nutrient-rich habitat.  An 
abundant supply of chemical energy flows through its blood vessels, dedicated 
organs degrade and excrete toxic compounds, and numerous homeostatic 
systems ensure that extremes of pH, temperature, and osmotic pressure are 
controlled.  Over the course of evolutionary history, many different kinds of 
organism have tapped these resources, benefiting from a close, exploitative 
relationship with mammals.  From miniscule viruses to giant worms, from 
bacteria to fungi and protozoa: many have succeeded.  But success is unstable: 
while mammals with adaptations allowing them to resist or eliminate parasites 
often have advantages over susceptible peers, parasites able to withstand or 
evade such adaptations are likewise selected.  This iterative process, likened to 
an arms race, has shaped the course of evolution, resulting in an extensive and 
complex mammalian immune system on one hand (Trowsdale & Parham, 2004), 
and intricate and elegant parasite strategies of outmanoeuvring it on the other 
(Finlay & McFadden, 2006) . 
 
Mammalian adaptive immune responses have staggering potential for diversity 
(for example, antibody diversity is estimated at ~1010 within a single host 
(Glanville et al., 2009)), target specific parasite antigens, and, in evolutionary 
terms, develop very rapidly.  Antigenic variation is the name given to a widely 
used parasite strategy of coping with the host’s adaptive immunity (Deitsch et 
al., 2009). Mechanisms of antigenic variation exploit the fact that an adaptive 
immune response against a particular newly encountered parasite antigen takes 
several days to reach its peak.  This lag gives time for the antigens of some of 
the parasites to change.  While the bulk of the parasite population are destroyed 
by that specific immune response, those parasites that have changed antigens 
are not.  The antigenically different parasites can proliferate to replenish the 
parasite population, and the whole process can repeat again and again as 
specific immune responses develop against successive antigens.  As a survival 
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strategy, antigenic variation relies on the expression of antigenic diversity by 
the parasite population to exceed the rate at which the host develops 
efficacious immune responses against those antigens. 
 
1.1.2 True antigenic variation is a distinct survival mechanism 
Where does antigenic variability come from?  Compared with general mutation 
of antigens caused by background cellular processes, true antigenic variation is a 
system that has evolved under pressure from adaptive immunity to present an 
ever-changing phenotype from a clonal population.  We might infer that such 
selection has occurred by witnessing rapid change to the expressed antigen, or 
by identifying distinct resources and machinery specifically associated with 
changing antigen structure (Caporale, 2003).  A clear case is the presence in the 
genome of multiple different antigen genes: an ‘archive’ of silent genes (Deitsch 
et al., 2009).  An archive is an in-built source of antigenic diversity: switching 
exclusive expression between archival copies, by transcriptional or 
recombinatorial mechanisms, changes the antigen expressed.  The potential for 
variation can be expanded further through combinatorial mechanisms: if 
segments of different archival genes are able to join in various ways to create 
antigenically distinct products, the potential antigenic diversity of a small 
archive could be greatly increased (Zhuang et al., 2007). 
 
Other mechanisms exist for specifically expressing antigenic variability.  
Accumulating point mutations in an antigen gene is a less efficient process, but 
viruses, with their smaller genomes, depend on point mutations to generate the 
variability required for persistence (Frost et al., 2005; Wolinsky et al., 1996).  In 
the case of HIV gp120, functionally-unconstrained ‘hypervariable’ loops 
sterically hinder access to invariant parts of the molecule whilst being able 
themselves to accumulate diversifying point mutations by the activity of an 
error-prone polymerase (Sodroski et al., 1998).  Variability brought about by 
differential enzyme activation—Neisseria lipooligosaccharide structures for 
example (Kahler & Stephens, 1998)—could also constitute a form of antigenic 
variation (Moxon et al., 2006; van der Woude & Bäumler, 2004).  A completely 
inclusive definition of antigenic variation might even stretch to include 
mechanisms like influenzavirus antigenic drift (Carrat & Flahault, 2007) 
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(essentially antigenic variation across a population of hosts) and the ‘controlled 
chaos’ of Schistosoma mucin polymorphisms (Roger et al., 2008). 
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Table 1.1 Mechanisms of antigenic variation.  Protozoa are coloured green, eubacteria red, 
viruses blue.  This table is intended to give an overview and is not exhaustive.  *This 
number relates to the number of antigen expression sites (see section 1.4.3).  **Unlike the 
other pathogens described here, influenza A undergoes biologically-relevant antigenic drift 
only on a population level.  ‘§’ indicates segmental combination of antigen genes occurs 
readily during infection. 
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Table 1.1 summarizes the primary mechanisms underlying antigenic variation, 
and some of the antigenically variable pathogens employing them.  Features 
common to phylogenetically diverse pathogens have convergently evolved under 
similar immunological and environmental pressures, most notably the possession 
of a silent archive and its segmental recombination to increase its total 
antigenic potential.   
 
Bearing these common strategies in mind, I shall now continue and describe the 
antigenically variable pathogen that was the primary subject of this study, the 
African trypanosome Trypanosoma brucei.   
 
1.2 African trypanosomes – historical and medical 
aspects 
1.2.1 African trypanosomes have been a focus of medical science 
for over a century 
African trypanosomes became a principal subject of medical science in the early 
1900s.  For many centuries previously, the relationship between the bite of the 
tsetse fly and a debilitating disease of humans—‘sleeping sickness’—and 
livestock—‘nagana’—had been known (Steverding, 2008).  Human African 
trypanosomiasis (HAT) manifests first as periodic fever, accompanied by 
headache, anaemia, general malaise and tell-tale swollen lymph glands.  This 
‘first stage’ of the disease can last for weeks to years, varying in severity and 
occasionally undergoing periods of asymptomatic infection, which can be 
prolonged (Jamonneau et al., 2012; Songa et al., 1991).  The ‘second stage’ of 
the disease is accompanied by central nervous system involvement, causing 
severe headache and disturbance in circadian rhythm (thus ‘sleeping sickness’) 
and culminating in irreversible coma and death (Barrett et al., 2003).  In 
animals, trypanosomiasis is often a wasting disease associated with profound 
anaemia, although different species and breeds show varying susceptibility with 
indigenous species and breeds being more resistant to the effects of the disease 
(Mulla & Rickman, 1988; Taylor, 1998). 
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Historically tolerated by socio-ecological factors such as the size and separation 
of tribes and their management of the local environment (Ford, 1969), sleeping 
sickness exploded into a transcontinental epidemic in the late 19th century 
following the huge social, ecological and economic upheavals of European 
colonial expansion1 (Lyons, 2008; Tilley, 2008).  Governments seeking to control 
the epidemic established scientific commissions into the causes and control of 
sleeping sickness (Figure 1.1).   
 
 
Figure 1.1 Photograph taken during the Third Royal Sleeping Sickness Commission, 1911 
(Uganda/East Africa).  Sir David Bruce, after whom T. brucei is named, is on the left of the 
photograph.  © Wellcome Library, London.  Permission to reproduce this image has been 
granted by the Wellcome Library. 
 
The confluence of germ theory, innovative microbiological techniques, 
precedents for insect transmission set by malaria and filariasis, and industrial 
chemistry saw, within four years (de Raadt, 2005):  
                                         
1 In his diaries written only a few decades earlier the missionary explorer David Livingstone 
reported that the bite of the tsetse in (what is now) Zambia was harmless to man (Livingstone, 
1857). 
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• the identification of the causative agent: in humans, Trypanosoma 
brucei subspecies gambiense, later, subspecies rhodesiense was also 
identified as human-infective, 
• the insect host species responsible for transmission: the tsetse fly, 
Glossina spp.),  
• a drug for its treatment, atoxyl.2 
 
A recently renewed drive towards eradicating the disease completely saw 
reported incidence of HAT drop below 10,000 cases in the year 2009 (WHO, 
2012), thanks largely to vigilant pro-active surveillance and improved diagnostic 
techniques (Cattand et al., 2001; Molyneux et al., 2010; Welburn et al., 2009) 
(Figure 1.2).  Patients diagnosed by serological tests and microscopical 
examination of blood and cerebrospinal fluid, are currently treated with the 
drugs suramin, pentamidine, melarsoprol or eflornithine, depending on whether 
parasites have penetrated the blood-brain barrier (Legros et al., 2002).  There 
have been no new drugs since the discovery that eflornithine was an effective 
trypanocide for T. b. gambiense in 1980 (Steverding, 2010).  There are currently 
no vaccines: indeed, the antigenic variability of the trypanosome’s dense surface 
coat and the immunosuppression that trypanosomes can induce make slim the 
possibility of finding an efficacious vaccine (La Greca & Magez, 2011). 
 
                                         
2 Amid a context of exoticism and imperial pride, the speed of such advances in the face of the 
epidemic's devastating effects inspired audiences in Europe and America, leading Britain's poet 
laureate to-be to write a novel on the subject (John Masefield’s ‘Multitude and Solitude’, (1909), 
in which a playwright abandons the Arts for a career as a parasitologist) and Universal Pictures 
to release a dramatic feature film (‘Nagana’, starring Melvyn Douglas (1933)). 
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Figure 1.2 Sleeping sickness surveillance by Medecins Sans Frontieres (MSF) in Central 
African Republic.  Between 2008 and 2011, prevalence in the Maitikoulou area fell from 5.9% 
to 0.5% (http://www.msf.org.uk/car.focus).  © Carmen Barra/MSF.  Permission to reproduce 
this image has been granted by MSF. 
 
 
1.2.2 African trypanosome antigenic variation is an integral part 
of their life cycle and is diagnostically relevant 
African trypanosome antigenic variation was recognized in the early 20th 
century, when, within a strain, some trypanosomes were found to survive in sera 
that lysed other trypanosomes of that strain (for example Laveran & Mesnil 
(1902), early 20th century research on trypanosome antigenic variation was 
reviewed by Soltys (1963)).  This differential response, later ascribed to the 
presence of different ‘variable antigen types’ (VATs), was eventually taken to 
explain how trypanosomes survived in a host: the sequential growth of different 
VATs was consistent with the pattern of undulating parasitaemia, cyclical fever, 
and chronicity of infection (Barry & McCulloch, 2001).  Over a hundred years 
after the initial observation of antigenic variation, it is clear that the African 
trypanosomes’ is the most comprehensive system of antigenic variation 
identified to date (Deitsch et al., 2009), an adaptation reflecting their exposed 
bloodstream habitat and precarious life cycle.  Besides revealing biological 
survival mechanisms that are fascinating and elegant in their own right, studies 
of African trypanosome antigenic variation have directly led to improved 
diagnostic tools (such as the cheap, easy to use Card Agglutination Test for 
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Trypanosomiasis (CATT) (Inojosa et al., 2006)), and have made African 
trypanosomes an excellent model for understanding this widespread parasite 
survival strategy in general. 
 
1.3 The natural history of African trypanosomes 
1.3.1 African trypanosomes probably evolved from parasites of 
arthropods  
African salivarian trypanosomes and their closest relatives form 
Trypanosomatida, a phylum of parasitic/symbiotic kinetoplastids.3  Into 
Trypanosomatida, rRNA and protein phylogenies have placed parasites of fish, 
rodents, plants, reptiles, birds, marsupials, leeches and insects alongside the 
medically important Trypanosoma cruzi, African salivarian trypanosomes, and 
Leishmania species (Simpson et al., 2006).  Trypanosomatids were most likely 
parasites of haematophagic insects before they were parasites of vertebrates 
(Hamilton et al., 2004).  During feeding, parasites that accidentally found 
themselves deposited in the blood were usually destroyed rapidly by the immune 
system.  But parasites that were able to resist immunity, multiply, and build up 
numbers in vertebrate hosts would have benefited from increased exposure and 
transmission to other feeding insects.  Opportunistic infections of 
immunosuppressed humans by monoxenous trypanosomatids (Dedet & Pratlong, 
2000) and the isolation of a Herpetomonas trypanosomatid from dogs and rats in 
Egypt found to be closely related to parasites of hemipterid bugs (Podlipaev et 
al., 2004) suggests that attempts at parasitism may occur often, although the 
development of successful long-term strategies by invaders is probably much 
rarer (Hamilton et al., 2007).   
 
1.3.2 There are seven major species of African trypanosome 
The African salivarian trypanosomes comprise seven ‘species’, described in Table 
1.2 and Figure 1.3, although it should be noted that the division between species 
and subspecies remains fluid: T. equiperdum and T. evansi could easily be 
                                         
3 Kinetoplastids themselves are a remarkable phylum of unicellular flagellate protists, exhibiting a 
number of intriguing and peculiar genetic and metabolic traits, including unprecedented 
modification of nucleotides (Borst & Sabatini, 2008) compartmentalization of glycolysis 
(Haanstra et al., 2008), and a unique mitochondrial DNA architecture (Luke! et al., 2005)–the 
kinetoplast, after which they are named. 
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considered subspecies of brucei, for example (Lai et al., 2008).  Historically, 
African trypanosomes have been confined to the range of their insect host, the 
tsetse fly,4 whose distribution extends between the Sahara and Kalahari deserts.  
Three species of animal-infective ‘African salivarian’ trypanosome (T. 
equiperdum, T. evansi, and American T. vivax) have adopted a simplified tsetse-
independent means of transmission, as described below (section 1.3.3): this 
independence has allowed them to spread beyond the range of Glossina and 
leave Africa. 
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Table 1.2 Species of African trypanosome.  Details were compiled from Gibson (2007).  Note 
the details presented here are subject to change: some species divisions indicated are weak 
(for example, those within Trypanozoon may be demoted to subspecies), whereas it is likely 
that the phylogenetic diversity seen amongst T. congolense isolates represents different 
subspecies (see Figure 1.3).  A rare case of human T. evansi infection in India reported in 
2005 (indicated by a ‘~’) was subsequently found to be associated with a deficiency in the 
patient’s trypanolytic factor (Vanhollebeke et al., 2006).  *It is likely that T. vivax are 
transmitted mechanically in regions of Africa where tsetse are sparse (Cortez et al., 2006). 
 
Of the African trypanosomes, Trypanosoma brucei has been the most intensively 
studied, being as it is the only species capable of infecting humans.  Three 
subspecies of T. brucei have been identified: the non-human infective T. b. 
brucei, the ‘chronic’ disease-causing West African T. b. gambiense, and the 
‘acute’ disease-causing East African T. b. rhodesiense.  As typing of brucei and 
                                         
4 Glossina species, of which there are about 20.  Different species have distinctly preferred 
habitats, and tsetse flies can be broadly grouped into ‘savannah’, ‘riverine’ and ‘forest’ demes 
(Krafsur, 2008). 
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rhodesiense sspp. is defined by survival in human serum, a phenotype that is 
conferred by a single gene (Xong et al., 1998), the boundary between these two 
‘subspecies’ should not be considered strict (gambiense uses different 
mechanisms for human serum resistance and thus is more distinct (Capewell et 
al., 2011)).  Two other species have also received significant attention: T. vivax, 
which causes the most virulent animal infection; and T. congolense, which is the 
most geographically widespread trypanosome in Africa. 
 
 
Figure 1.3 The evolutionary relationships of African trypanosomes.  Diagram is intended to 
show key cladistic relationships only and is not to scale.  Based on data in Gibson (2007), 
Hamilton et al. (2007) and Brun et al. (1998).  T. congolense shows considerable 
phylogenetic diversity amongst different habitats, as indicated.  *T. vivax South American 
populations are closely related to West African T. vivax (Cortez et al., 2006). 
 
1.3.3 African trypanosomes have a complex life cycle involving 
two dissimilar hosts and numerous developmental stages 
African trypanosomes are usually dixenous, alternately infecting mammal and 
insect during life-cycle progression.5 As they travel between each host 
                                         
5 The exceptions to this are T. equiperdum, T. evansi and American T. vivax.  It appears that T. 
evansi and T. equiperdum have diverged from T. brucei relatively recently (Lai et al., 2008) and 
the similarity between West African and South American T. vivax isolates indicates that the 
South American strains have African origins (Cortez et al., 2006); it can thus be assumed that 
the ancestral African trypanosome was dixenous between mammal and tsetse. 
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environment, trypanosomes undergo a number of morphological changes.  Some 
of their forms are mitotically active, specialised for colonisation and 
proliferation of a specific environment, while others are transmission-ready cell-
cycle arrested forms, pre-emptively adapted to survive as they move between 
different environments (Barry & McCulloch, 2001).   
 
For T. brucei, infection of the mammal occurs when the tsetse fly takes its blood 
meal, depositing metacyclic-stage trypanosomes subcutaneously.  The 
trypanosomes migrate to the draining lymph node and enter the vasculature, 
undergoing a morphological change to the ‘long slender’ bloodstream form.  The 
long slender form is mitotically active and undergoes repeated cycles of binary 
fission with a doubling time of about six hours (Turner et al., 1995).  Inside the 
mammal, trypanosomes generally proliferate extracellularly in the blood, lymph 
and extravascular matrix, although they are capable of invading other tissues, 
including muscle and the central nervous system (CNS).6  Besides the dynamic 
processes of immune killing and population recovery following antigenic 
variation, parasite numbers are restrained by a process of irreversible 
differentiation to a cell-cycle arrested ‘short stumpy’ form (see section 1.7.5).  
It is this short stumpy form, with a relatively short half-life of 24–72 hours (Seed 
et al., 2003) that is capable of infecting a biting tsetse fly (Robertson, 1912).  In 
the midgut of the tsetse, stumpy form trypanosomes develop into the 
proliferative procyclic form trypanosomes.  Lumenal migration from the gut to 
the salivary glands is coupled to a series of developmental changes: a procyclic 
cell differentiates into the long mesocyclic form, which undergoes asymmetric 
division to yield a small daughter cell, the progenitor for the salivary gland-
colonising proliferative epimastigote form (Vickerman, 1985).  Few 
trypanosomes survive this migration (Oberle et al., 2010).  The salivary gland 
epimastigote population grows as a dense monolayer, and is the point at which 
trypanosomes can undergo sexual genetic exchange (Gibson et al., 2008).  
Epimastigotes undergo asymmetric division to produce a trypomastigote 
daughter cell (Rotureau et al., 2012), which develops to form the mammalian-
infective metacyclic stage, and the cycle can begin again.  The lifecycle is 
shown in Figure 1.4.   
                                         
6 Tissue invasion is T. brucei specific – neither T. congolense nor T. vivax leave the blood in large 
numbers, if at all (Ssenyonga & Adam, 1974; Barry, 1986). 
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Figure 1.4 Trypanosoma brucei lifecycle.  Straight red lines indicate the development 
between different morphological forms, curved lines indicate the multiplication of the 
proliferative forms.  Transient intermediate forms that are exhibited during development 
between the key stages are not shown.  White lines indicate barriers between different 
environments (tsetse salivary gland, mammalian bloodstream, tsetse alimentary tract).  
From Barry & McCulloch (2001). 
 
Compared with T. brucei, there are some differences in the lifecycle between 
the species.  T. congolense does not colonise the salivary glands, rather, the 
epimastigote stage directly colonises the mouthparts (Peacock et al., 2012).  T. 
vivax has a simpler tsetse stage, whereby bloodstream form trypanosomes in the 
tsetse’s meal transform directly into the epimastigote form in the fly’s 
mouthpieces, without any multiplicative stage elsewhere (Aksoy et al., 2003).  
For those species and strains where tsetse infection is not advantageous—
sexually transmitted T. equiperdum, most strains of mechanically transmitted T. 
evansi and American T. vivax (Uilenberg, 1998), and indeed some laboratory T. 
brucei lines subject to long periods of rapid syringe passage or in vitro 
bloodstream form culture (Turner, 1990)—the bloodstream forms of the parasite 
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Maturation through the fly is thought to amplify the typically low parasitaemia found in the 
ma malian host, ensu ing infection of one or more hosts by a single fly, wh n compared 
with simpl  mechanical tra mission by contamination of the mouthparts wi  infect d 
blood (G bson and Bailey, 2003).  In addition, different T. brucei strains h ve the 
opportunity for sexual reproduction in t  fly (possibly at the epimastigote stage), an added 
diversification tool for the parasite (Schweiz r et al., 1988).  S me laboratory strains have 
lost the ability to be transmitted through the fly and have been t rmed monomorphic (only 
the long slend r bloodstream form is present in the vertebrate stage), whereas trypanosome 
trains that are fully competent in completing the life cycle have been termed pleomorphic 
(in the bloodstream form, the full range of forms, from long slender t  short stumpy, can 
e detected). Other differences between these two types of strain have proven to be 
imp rtant in relation to antigenic variation, as will be discuss d in section 1.4. 
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become increasingly ‘monomorphic’, with differentiation to the non-
proliferative tsetse-infective form disfavoured.7 
 
1.3.4 Antigenic variation is favoured by the African trypanosome 
life cycle and is mediated by a glycoprotein surface coat 
Transmission by haematophagic arthropod vectors provides powerful selection 
for mechanisms that prolong parasitaemia, since it is blood-borne parasites that 
are best placed to infect the vector and spread to new hosts (Barbour & 
Restrepo, 2000).  Many arthropod-transmitted pathogens persist by adopting a 
strategy of concealment and manipulation: by invading and reprogramming host 
cells they can escape the brunt of extracellular immune effectors such as 
antibodies.  This is the case for the other mammalian-infective trypanosomatids, 
T. cruzi and Leishmania spp.; the Apicomplexans Plasmodium, Babesia and 
Theileria; and eubacterial Rickettsia species, such as Anaplasma and Ehrlichia. 
 
The African salivarian trypanosomes, on the other hand, spend their mammalian 
phase extracellularly.  Immediate protection against innate immunity is achieved 
by a uniform glycoprotein ‘coat’ that densely covers the entire surface of the 
bloodstream form trypanosome, made from approximately 5.5 x 106 identical 
dimers of the African trypanosome variable antigen: variant surface glycoprotein 
(VSG) (Jackson et al., 1985). The VSG surface coat is critical for bloodstream 
survival: without it, parasites are killed by naive serum (Ferrante & Allison, 
1983; Mosser & Roberts, 1982).  VSG coats are present on both the long slender 
and the short stumpy bloodstream forms, and are also pre-emptively expressed 
by metacyclic stage trypanosomes (Vickerman, 1985).  The VSG coat is lost when 
the short stumpy form differentiates to the procyclic form in the tsetse midgut, 
to be replaced by another glycoconjugate, procyclin (Roditi et al., 1989). 
 
The VSG coat is the physical form of the trypanosome variable antigen type and 
its guise whilst in the mammal (Cross, 1975).  It is changes to the VSG coat—and 
serial adaptive immune responses against it—that are the basis of antigenic 
variation in African trypanosomes.  The VSG surface coat is shown in Figure 1.5.  
 
                                         
7 ‘Monomorphic’ trypanosomes can be contrasted with ‘pleomorphic’ trypanosomes: those that 
readily undergo differentiation to the tsetse-infective stumpy form.   
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Figure 1.5 The VSG surface coat.  (A) The VSG coat is expressed by bloodstream form 
trypanosomes.  Image shows a long slender trypanosome surrounded by red blood cells  © 
Wellcome Library, London.  Permission to reproduce this image has been granted by the 
Wellcome Library.  (B) The surface coat can be clearly seen under transmission electron 
micrography as a dense layer covering the surface of the parasite.  Image provided by L. 
Tetley, University of Glasgow.  (C) The assembled surface coat sterically hinders access of 
host immune effectors to the cell membrane or invariant surface proteins.  (D) Each VSG 
dimer is an extended structure consisting of an N-terminal domain (NTD) and a C-terminal 
domain consisting of one or two subdomains.  The N-terminal loops (indicated) represent 
the region of the glycoprotein exposed to immune effectors on an assembled surface coat.  
Images (C) and (D) were assembled using PDB structures 1vsg, 1xu6, 1rcj and 1igt, 
visualized using Pymol (Schrödinger, LLC), and were inspired by Engstler et al. (2007). 
 
The structure, production and form of the VSG coat will be described first, in 
section 1.4.  I shall then describe the diversity amongst different VSGs in the 
genome in section 1.5, and the variation in VSG expression over time will be 
covered in section 1.6.  The focus will be on the brucei clade VSGs, since they 
are best characterised. 
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1.4 The structure of the VSG surface coat 
1.4.1 Different VSGs must be antigenically distinct whilst 
performing the same function 
The function of each VSG surface coat is to provide the infecting trypanosome 
population with a defence against the host immune system (Ferrante & Allison, 
1983; Mosser & Roberts, 1982; Ziegelbauer & Overath, 1993).  The dual nature of 
mammalian immunity—non-specific immediate innate immunity, and specific 
adaptive immunity—places two opposing demands on the population of possible 
VSG molecules: 
a) Conservation of structure between VSGs.  Different VSG coats require a 
structure that is able to consistently obstruct immune effectors from 
accessing the cell membrane or invariant surface antigens. 
b) Variation of structure between VSGs.  Epitope structure must vary 
sufficiently between different VSG coats to enable antigenic variation. 
These demands have been met by a conserved tertiary structure that can be 
formed by hugely divergent amino acid sequences (Blum et al., 1993; Carrington 
et al., 1991; Marcello & Barry, 2007a).  This tertiary structure gives an extended 
form to VSG, resulting in a deep, dense coat on the parasite surface (Vickerman, 
1969). 
 
1.4.2 VSG structure is defined by long helices adorned with loops 
Each VSG unit in the closely packed surface coat is a homodimer, comprising two 
single-chain polypeptides (Auffret & Turner, 1981).  Protease digestion of T. 
brucei VSGs revealed that each VSG monomer consisted of two domains 
connected by a protease-sensitive ‘hinge’ region (Johnson & Cross, 1979): a 
larger N-terminal domain (NTD; in the region of 380 amino acids in length) 
connected to a C-terminal domain (CTD; itself composed of one or two 
subdomains each approximately 40 amino acids in length) (Carrington et al., 
1991). 
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Figure 1.6 The VSG NTD fold.  (A) The two structures of VSG N-terminal domains that have 
been solved—Lister 427-2 (left, PDB identifier 1vsg) and ILTat 1.24 (right, 2vsg)—are shown.  
For each dimer, one monomer has been coloured grey, the other according to (B).  (B) A 
representation of the mature Lister 427-2 NTD amino acid chain from amino (N) to CTD-
proximal (C) end.  Bars protruding from the top of the diagram represent conserved 
cysteine residues, connected by brackets according to the disulphide bridges they form.  
The chain is divided into three pieces (indicated by ‘residue’), and the residues 
corresponding with each piece are coloured in (A).  The predominant structures formed by 
each piece are indicated (‘structural feature’).  *ILTat 1.24 NTD is four amino acids shorter 
than Lister 427-2, and thus only residues 261-358 are coloured green for that structure. 
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The two VSG NTDs whose structure has been resolved are less than 20% identical 
at the amino acid level, yet they form a strikingly similar tertiary fold, shown in 
Figure 1.6 (Blum et al., 1993; Freymann et al., 1990).  Essentially, this fold is a 
framework of two long antiparallel alpha helices per monomer, beginning at the 
membrane-distal N-terminus and running for approximately 110 amino acids, 
standing perpendicular to the cell surface with a short loop or kink between 
them (Blum et al., 1993). The two alpha helices of each monomer interact to 
mediate VSG dimerization, forming a four-helix coiled-coil bundle on the cell 
surface (Cohen et al., 1984).  This scaffold, coloured blue in Figure 1.6, defines 
the elongated structure for VSG. Smaller elements of VSG secondary structure 
hang from this skeleton, tied together by several loops (Blum et al., 1993; 
Freymann et al., 1990): these begin at the membrane distal end of the NTD, 
wrapping around to form a ‘head’ region (coloured pink in Figure 1.6), and end 
at the bottom of the molecule, forming further short regions of secondary 
structure sometimes referred to as the ‘hips’ (J. D. Barry, pers. comm., 
coloured green in Figure 1.6).  It is these elements that decorate the framework 
alpha helices that are thought to be the primary target of antibodies: they are at 
the more exposed membrane-distal end of the molecule (Freymann et al., 1990) 
and this region shows the most variability when comparing otherwise similar 
VSGs in the field, indicating the effects of positive selection (Hutchinson et al., 
2007).  The fold is held together by disulphide bridges between conserved 
cysteine residues (Allen & Gurnett, 1983; Bussler et al., 1998), which may 
provide some structure to the potentially less ordered N-terminal loops.  
Biochemical and bioinformatic analyses of other, non-crystallized VSGs give good 
reason to believe that they too form a similar structure (Bussler et al., 1998; 
Carrington & Boothroyd, 1996; Cohen et al., 1984).  A flexible hinge region 
connects the NTD to the CTD, which is a compact structure of one or two four-
cysteine subdomains whose primary role appears to be to increase membrane-
proximal coat density and anchor the glycoprotein in the membrane 
(Chattopadhyay et al., 2005; Jones et al., 2008). 
 
All VSGs are anchored in the membrane by a glycosylphosphatidylinositol (GPI) 
group and they are also frequently N-glycosylated on at least one other site in 
the molecule (Mehlert et al., 2002).  N-glycosylation may affect the structure 
and accessibility of epitopes—either those of VSG itself (influenza 
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haemagglutinin epitopes are often altered by N-glycosylation (Caton et al., 
1982)), or those of other surface molecules by enhancing the coat’s barrier 
function (Mehlert et al., 2002).  Additionally, carbohydrate groups have been 
shown to play a structural role in maintaining VSG dimensions between variants—
the absence of a short alpha helix in the membrane proximal region of the ILTat 
1.24 NTD is compensated for by an N-linked glycosylation (Blum et al., 1993)—
which may be necessary for close packing. 
 
1.4.3 VSG is expressed from a specialised expression site 
The large surface area covered by the coat and the dense nature of its packing 
requires the production by metacyclic and bloodstream form parasites of huge 
quantities of VSG: in all, 10% of the total soluble protein content in a 
bloodstream form trypanosome lysate is VSG (Cross, 1990).  Achieving this high 
level of expression requires a large number of VSG mRNA transcripts, and this is 
perhaps one reason why VSG is transcribed from a specialised telomeric genomic 
locus: the active expression site (ES).  ESs have the unusual property of 
transcription by RNA polymerase I (Pol I), African trypanosomes representing the 
only example in Eukarya of this polymerase transcribing anything other than 
ribosomal RNA (Günzl et al., 2003).8  As ribosomal RNA represents the most 
active transcription in eukaryotic cells (Russell & Zomerdijk, 2005), it is 
plausible that Pol I transcription has been co-opted to provide the high volume 
of VSG mRNA transcripts necessary to construct and maintain the surface coat.   
 
The ESs used by bloodstream form parasites (bloodstream expression sites, BESs) 
are telomere-proximal and usually between 40 and 60 kb in size, although some 
can be shorter (Berriman et al., 2002; Hertz-Fowler et al., 2008). Figure 1.7 
shows a diagram of a BES.  Besides VSG, BESs also contain a number of 
expression-site associated genes (ESAGs) (McCulloch & Horn, 2009).  The VSG 
gene is located 5 to 10 kb from the end of the chromosome, with its 3’ end 
several hundred bp upstream of the telomere repeats (Aline & Stuart, 1989; De 
Lange & Borst, 1982).  Upstream of the VSG gene, and separating it from the 
rest of the ES, is a set of imperfect 70-bp AT-rich repeats (Campbell et al., 
1984).  Transcription of the ES is initiated at a single promoter, and mRNA for 
                                         
8 The trypanosome procyclic stage surface glycoprotein, procyclin, is also transcribed by Pol I 
(Günzl et al., 2003). 
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each of the ES’s genes is produced by trans-splicing of this polycistronic 
transcript with a 5’ ‘spliced leader’ sequence common to all trypanosome 
mRNAs (Cully et al., 1985; Parsons et al., 1984; Walder et al., 1986).  A 
trypanosome has numerous BESs, thought to number between five (E. Louis, 
University of Nottingham, pers. comm.) and 23 (Young et al., 2008b)—the total 
number is expected to vary between strains—but only one is active at a time, 
ensuring that only one VSG is expressed (see section 1.6.2).  Metacyclic form 
parasites utilise a different set of ‘metacyclic’ expression sites (MESs), which are 
much smaller than BES and contain just a VSG gene (Barry et al., 1998).  MESs 
likely evolved from BESs as ESAGs and pseudogenes are often found in the region 
upstream of their promoters (Barry et al., 1998). 
 
 
 
Figure 1.7 A bloodstream expression site (BES).  The BES is isolated from the rest of the 
subtelomere by 50-bp repeats.  Downstream of these is the ES promoter (indicated by a 
flag).  The ES contains numerous expression site-associated genes (ESAGs), the exact 
composition of which varies between ESs.  Numerous pseudogenes of ESAGs and VSGs 
can also be present (indicated by ѱ).  The VSG is separated from the rest of the ES by a 
series of 70-bp repeats.  ES shown in that of GUTat 10.1, from TREU 927 (Berriman et al., 
2002). 
 
 
The newly-translated VSG polypeptide chain contains a hydrophobic N-terminal 
signal peptide of around 30–40 amino acids (Boothroyd et al., 1981), which is 
swiftly cleaved (McConnell et al., 1981), directing the protein for secretion.  The 
maturing VSG folds and undergoes post-translational modification: the removal 
of a C-terminal GPI anchor signal peptide of 17–23 amino acids and the addition 
of a GPI anchor, and N-linked glycosylation (Ferguson et al., 1986; Mehlert et 
al., 2002).  Mature VSG reaches the surface at the ‘flagellar pocket’: an 
invagination of the plasma membrane at the base of the flagellum, where all 
endocytosis and exocytosis takes place (Overath et al., 1997). 
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1.4.4 The VSG coat is a fluid, dynamic structure 
The complete VSG coat is a bustling monolayer.  The means of their anchoring—a 
relatively small GPI anchor—means that VSGs are able to move freely across the 
surface of the parasite and also probably spin in place (Buelow et al., 1988).  
The flexibility of the linkage between the NTD and CTD suggests that they are 
also capable of bending and stretching (Chattopadhyay et al., 2005).  This fluid 
structure undergoes constant constitutive recycling at the flagellar pocket by 
endocytosis and exocytosis.  It is thought that the entire surface coat is recycled 
in 12 minutes, and at any one point approximately 9% of total VSG is internal 
(Engstler et al., 2004).  Internalized VSG passes through the endosomal system 
and is replaced on the surface (Pal et al., 2003; Seyfang et al., 1990).  VSG 
recycling also provides a complementary means of immune evasion: during 
recycling VSG-antibody complexes are separated and the antibody is 
proteolytically cleaved (O'Beirne et al., 1998).  Antibody clearance is enhanced 
by the fluidity of the coat: as the parasite swims, antibodies bound to VSGs are 
preferentially sorted by drag forces to the posterior of the parasite where they 
are more likely to enter the flagellar pocket and be cleared (Engstler et al., 
2007).  Whilst hydrodynamic flow-mediated antibody clearance to immune 
evasion is ineffective at higher antibody concentrations, it nevertheless 
potentially endows parasites with an additional means of survival in the face of 
adaptive immunity.  The non-switching short stumpy bloodstream form clears 
surface-bound antibodies more rapidly than the long slender form, perhaps 
offering them an extra level of resistance amid rising antibody levels (McLintock 
et al., 1993) and marginally increasing their chances of survival and tsetse 
uptake.  It is also possible that hydrodynamic flow-mediated antibody clearance 
from VSGs is a side effect, and that it may have a more pertinent functional role 
in clearing antibodies from partially exposed invariant antigens, or collecting 
receptor-bound transferrin (Mehlert et al., 2012; Salmon et al., 1997).   
 
1.4.5 Antigenic variation comes about by changing the VSG coat 
The above (section 1.4) describes the form and function of an existing VSG 
surface coat.  By changing the expressed VSG gene, an individual parasite 
replaces its VSG surface coat, removing the antigen against which adaptive 
immunity may be developing, and replacing it, potentially with an antigen to 
Chapter 1  39 
which the immune system is completely naïve.  The source of the variation is the 
extensive archive of silent VSG genes, the nature of which is discussed in the 
following section. 
 
1.5 VSG diversity 
1.5.1 African trypanosomes possess hundreds of silent VSGs 
The Trypanosoma brucei brucei genome is contained on 11 chromosome pairs 
(known as ‘megabase chromosomes’ between 1 and 6 Mb in size), a number of 
intermediate chromosomes (between 300 and 700 kb in size) and approximately 
100 minichromosomes (approximately 50 kb in size) (Alsford et al., 2001; 
Berriman et al., 2005; Melville, 1998).  A conspicuous feature of the genome’s 
organisation is its accommodation for VSGs.  In many eukaryotes, subtelomeres 
are loci where multigene families associated with variation can expand and 
diversify (Barry et al., 2003; Linardopoulou et al., 2005).  For T. brucei, 
disproportionally large subtelomeres—so variable between homologous 
chromosomes as to be effectively haploid—contain huge arrays of silent VSG 
genes (Berriman et al., 2005; Van der Ploeg et al., 1982).9  The basic unit of 
these subtelomeric VSG arrays are ‘VSG cassettes’ 3–4 kb long, delimited at the 
5’ end by imperfect 70-bp repeats, like those found in the ESs, and the 3’ end by 
a region spanning the 3’ end of the VSG gene, the sequence of which is often 
well conserved between otherwise divergent VSGs (Majumder et al., 1981; 
Matthyssens et al., 1981; Pays et al., 1981a; Rice-Ficht et al., 1981).  VSGs are 
also located immediately proximal to telomeres in ESs and on the ends of the 
minichromosomes, which seem to exist solely to provide an increased number of 
telomeres to store silent VSGs (Wickstead et al., 2004).  
  
In total, the number of VSGs in the T. b. brucei subtelomeric arrays is thought to 
number approximately 1800, although this probably varies slightly between 
strains.10  In the lab-adapted monomorphic parasite line (Lister 427) this number 
                                         
9 There may also exist one, unusual, chromosome internal VSG array (L. Marcello, Ph.D. thesis, 
2006, University of Glasgow).   
10 The T. b. brucei strain TREU927/4 GUTat 10.1 genome sequencing project sequenced 940 
VSGs.  The effective haploidy of the telomeres revises this number upwards to between 1500 
and 1700, and certainly no more than 2000 (Marcello & Barry, 2007).  Assuming each of the 
100 minichromosomes contains a VSG at each telomere, an approximate figure of 1800 can be 
reached. 
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is thought to be even greater due to multiple gene duplications (B. Wickstead, 
University of Nottingham, pers. comm.), suggesting that selection in the natural 
life cycle and field population of African trypanosomes may act to restrict the 
archive's total size.  T. b. gambiense appears to have a smaller archive, 
primarily due to its dearth of minichromosomes (Dero et al., 1987; Jackson et 
al., 2010).  
 
1.5.2 Archive VSGs can be grouped into different types 
VSGs are, on average, completely divergent at the amino acid level (Marcello & 
Barry, 2007a).  Despite this, silent VSGs can be identified and grouped into types 
by the spacing of codons for conserved cysteine residues11 as well as features 
relating to their processing such as their N-terminal signal peptide and GPI signal 
(Carrington et al., 1991; Marcello & Barry, 2007a).  For T. brucei, the NTD and 
CTD are typed separately (Carrington et al., 1991; Jackson et al., 2012).  
 
 
Figure 1.8 N-terminal domain types.  Example A and B type NTD-encoding regions are 
shown.  Cysteine codons are indicated by bars projecting above each image.  Brackets 
indicate those cysteines that form disulphide bridges in the mature NTD.  Details are from 
(Marcello & Barry, 2007a), (Carrington et al., 1991) and (Bussler et al., 1998). 
 
                                         
11 The main feature identified when aligning VSGs, reflecting their pivotal structural role.  Other 
variable antigens such as influenza haemagglutinin also display conserved cysteine patterns 
(Air, 1981). 
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NTDs are typed ‘A’ or ‘B’ by homology, and each has a characteristic pattern of 
conserved cysteines (Marcello & Barry, 2007a).  Examples are shown in Figure 
1.8.  Within these broad type definitions are numerous groups and subgroups, 
reflecting the diverse and divergent nature of VSGs (the previously described 
type C can be considered such a group within type A, for example) (Weirather et 
al., 2012).   
 
For the T. brucei CTDs, typing is more difficult (Weirather et al., 2012).  Their 
prevailing distinction is whether they contain one or two four-cysteine 
subdomains.  The spacing of cysteines within these subdomains, and the 
sequence of the GPI signal they possess at their C-terminus, allow CTDs to be 
typed 1–6 (Marcello & Barry, 2007a).  The relationship between the different T. 
brucei NTD and CTD types is flexible: although there is an apparent bias towards 
particular combinations, expressed and silent examples of both NTD types (A and 
B) possess related CTD types (Hutchinson et al., 2003; Marcello & Barry, 2007a).  
Domain exchange also expresses itself within the CTD: close analysis of the 
different CTD types reveals that there is promiscuous mixing between CTD types, 
which is focused towards the N-terminal end of the CTD (Marcello & Barry, 
2007a), in contrast to the apparent lack of inter-type mixing seen in the NTD.  
VSG CTD-encoding regions show greater levels of homology than VSG NTD-
encoding regions (Marcello & Barry, 2007a; Rice-Ficht et al., 1981). 
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Figure 1.9 C-terminal domain types.  The left hand side of the Figure shows example CTDs 
of each type.  Cysteine codons are indicated by bars projecting above each image, and 
brackets indicate those cysteines that form disulphide bridges in the mature CTD, where 
known.  The division between the CTD- and the GPI anchor signal-encoding regions is 
indicated by a line spanning the rectangle.  The right hand side of the Figure shows 
example GPI anchor signal sequences for the different types, with a gap indicating the 
cleavage site between the mature CTD and the signal sequence.  Data are from Marcello & 
Barry, (2007a) and Carrington et al., (Carrington et al., 1991). 
 
1.5.3 Many VSGs are in subfamilies with one or two other VSGs 
Approximately 40% of archival T. brucei VSGs exist in small subfamilies—mostly 
pairs or triplets—sharing greater than 60% amino acid identity in the NTD 
(Marcello & Barry, 2007a).  VSG subfamilies tend to be separated across 
chromosomes and across the subtelomeric arrays and are not generally located 
in contiguous loci (Beals & Boothroyd, 1992; Marcello & Barry, 2007a).  T. brucei 
VSGs thus have a low-grain level of grouping into different VSG types, and a 
high-grain level of grouping into specific subfamilies.  Between these two grades 
of differentiation there is remarkable divergence in the archive (Jackson et al., 
2012; Marcello & Barry, 2007a; Weirather et al., 2012). 
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1.5.4 The majority of T. brucei VSGs are pseudogenes 
An unexpected finding from the T. brucei genome sequencing was that only 4.5% 
of the VSGs in the subtelomeric arrays are clearly complete and functional 
(Marcello & Barry, 2007a).12  As shown in Figure 1.10, the bulk of the 
subtelomeric archive consists of VSG genes damaged by frameshifts, stop codons 
and fragmentation.  Of the pseudogenes, the majority were found to be 
dysfunctional in their CTDs.  Broadly, two explanations exist for the degree of 
pseudogenicity in the archive.  The first is that the archive is degenerate: its 
size means that the marginal fitness benefit of each individual VSG gene 
retaining its intactness is so low that most have drifted towards pseudogenicity.  
The second is that damaged VSG genes play a functional role, through acting as 
substrates for segmental gene conversion (see section 1.6.9) or by staggering 
expression (see section 1.6.12).  These two explanations need not be mutually 
exclusive. 
 
 
Figure 1.10 VSG subtelomeric array composition.  Data are from Marcello & Barry, (2007a).  
For the full-length pseudogenes, the region in which the gene is damaged is indicated: 
‘NTD’ = N-terminal domain, ‘CTD’ = C-terminal domain. 
 
                                         
12 When atypical VSGs – those with unusual GPI signals and cysteine spacing patterns that may 
compromise their expression – are included, this number is revised upwards to 14%. 
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1.5.5 VSG diversity exists across the T. brucei population 
On a broader ecological level, the antigen archives of different trypanosome 
strains interact as different competing strains are given the opportunity to 
reinfect or superinfect populations of partially immune hosts (Marcello & Barry, 
2007b).  Comparisons of field-isolated, expressed VSGs from several T. brucei 
strains with VSGs in the sequenced genomes found that the majority of VSGs 
isolated have close homologues in different species and strains (Hutchinson et 
al., 2007).  Field populations probably share a common set of VSGs that can 
diverge to become strain specific (Beals & Boothroyd, 1992) and antigenically 
distinct (Hutchinson et al., 2007).  Besides the VSG diversity present in a specific 
trypanosome’s archive, there is therefore diversity present across the population 
of trypanosomes in the field—a field ‘metagenomic’ archive of VSGs.  Mating, 
where it occurs (Macleod et al., 2001), might provide a means by which different 
strains can reassort their archives and acquire a different complement of VSGs. 
 
1.5.6 VSG diversity is ancestral amongst African trypanosomes 
Like T. brucei, T. congolense and T. vivax show a wealth of VSG diversity, and 
comparisons between the three species showed no species-specific clustering of 
VSGs, indicating that this diversity was present in their most recent common 
ancestor (Jackson et al., 2012).  Nevertheless, some differences have arisen 
between the three species as they have evolved.  Compared with the more 
recently diverged T. brucei and T. congolense, T. vivax possesses two further 
families of VSG-like genes besides type A-like and type B-like VSGs, indicating 
that T. brucei and T. congolense have both passed through bottlenecks, indeed, 
T. congolense has lost A-type VSGs altogether (Jackson et al., 2012).  The 
patterns of recombination amongst VSGs also vary: neither T. congolense nor T. 
vivax VSGs show the CTD mixing patterns of T. brucei, but instead each VSG NTD 
type is closely associated with a specific CTD type (Jackson et al., 2012).  For T. 
congolense, these CTDs can be short and proline-rich (Rausch et al., 1994; 
Strickler et al., 1987).  When comparing VSGs within a genome, another pattern 
of difference becomes clear: whilst T. brucei VSGs are highly diverse with only a 
high-grain level of grouping into small subfamilies (see section 1.5.3), T. 
congolense and T. vivax VSGs often show a gradation of differences between 
different VSGs (Jackson et al., 2012).  T. congolense and T. vivax VSG 
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repertoires are also less pseudogenic than T. brucei, with fewer than 30% of 
VSGs analysed showing pseudogenicity.  These patterns hint that the mechanisms 
that maintain and generate VSG diversity may function differently in the three 
species. 
 
1.6 Expression of the VSG archive and antigenic 
variation 
1.6.1 VSG expression is carefully controlled 
How are different VSGs from the archive expressed?  There are several broad 
patterns that will be discussed in this section:  
a) Monoallelic expression (section 1.6.2).  Of the many available antigenic 
variants, each parasite exclusively expresses a single VSG allele.  
b) VSG switching.  There are two kinds of process by which different VSG 
genes obtain the property of monoallelic expression and become 
activated: transcriptional switching (section 1.6.4) and recombinatorial 
switching (section 1.6.5). 
c) Segmental gene conversion (section 1.6.6).  Recombination can cause 
segments of different VSGs to become combined. 
d) Hierarchy (section 1.6.12).  Activation of archival VSG genes across the 
population follows a ‘semi-ordered’ progression.   
 
1.6.2 Only one VSG is expressed at a time 
Individual trypanosomes express a single VSG at a time.  This is presumably an 
advantageous strategy, as simultaneous expression of multiple VSGs would result 
in a heterogeneous coat, potentially exposing all of the expressed VSGs to the 
immune system.  If simultaneous expression were typical, parasites might 
exhaust their antigen repertoire more quickly, resulting in a shorter infection 
than had the different antigens been expressed exclusively and consecutively (in 
Giardia lamblia, interference with the mechanism of exclusive expression 
resulted in a heterogeneous VSP coat and neutralizing responses developed 
against all exposed antigens (Rivero et al., 2010)).13   
                                         
13 Dubois et al. (2005) argues counter-intuitively that trypanosomes artificially expressing surface 
coats made from two VSGs induce weaker immune responses and are resistant to immune 
killing.  As discussed in Chapter 5 (section 5.3.1.2), this finding may be an artifact of ectopic 
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The VSG that is exclusively expressed is the VSG that is present in the active ES 
(Vanhamme et al., 2000).  Monoallelic expression is therefore achieved by the 
presence of only one intact VSG in an ES, and the activation of only one ES at a 
time.  That there is only one VSG in the ES is probably a consequence of the 
mechanisms of switching rather than a strictly enforced demand, as parasites 
stably expressing multiple VSGs from the same ES at the same time can be 
artificially created (Muñoz-Jordán et al., 1996).   
 
The exclusive activation of a single ES is more strictly controlled.  Experiments 
using drug selection markers to force simultaneous activation of multiple ESs 
resulted only in unstable clones rapidly switching between two ESs (Chaves et 
al., 1999; Ulbert et al., 2002).  The rapidity with which the switching can occur, 
coupled with the lack of any detectable genetic rearrangement associated with 
the activation of an ES (see section 1.6.4), makes it likely that monoallelic 
expression is epigenetically maintained and inherited.  The most likely 
mechanism is a single multi-component complex driving transcription, which can 
contain only one ES at a time.  Immunofluorescence analyses show the 
colocalization of the active ES with a single extranucleolar pol I-containing body, 
termed the expression site body (ESB) (Navarro & Gull, 2001), whose association 
with a specific ES is stably inherited.  Identifying the causal relationship 
between the ESB and monoallelic expression remains difficult—a single ESB could 
be taken as a consequence of monoallelic expression as much as its cause (Horn 
& McCulloch, 2010)—and there are many questions about its mechanism that 
remain unanswered.  How is a single ESB maintained?  What determines its 
association with one ES and not another?  Nevertheless, the case for the 
importance of the ESB is supported by the close association between the ESB and 
the mitotic machinery, an association that is critical to the heritability of 
monoallelic expression (Landeira et al., 2009).  Comparisons of active and 
inactive ESs show that the key distinction of an active ES is not the presence of 
pol I or the initiation of transcription, but continued mRNA elongation 
(Vanhamme et al., 2000).  Low-level transcription from ‘inactive’ sites indicates 
                                                                                                                           
VSG expression.  Otherwise, it is surprising that prolonged double expression has not been 
immunologically selected, as double expressors have been identified naturally (Baltz et al., 
1986). 
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that the role of the ESB in ensuring monoallelic expression is linked more closely 
to mRNA elongation than to transcriptional initiation per se. 
 
If the ESB defines the active ES, complementary processes are at work to silence 
the inactive ones.  The main effect seems to be the telomeric position of those 
sites: artificially generated telomeres are similarly repressed, although to a 
lesser extent than inactive ESs (Glover & Horn, 2006).  A number of epigenetic 
mechanisms have been implicated in silencing (Alsford et al., 2012), including: 
• chromatin remodelling—the knockdown of various factors, including 
TbISWI (Hughes et al., 2007) and histone deacetylase DAC3 (Wang et al., 
2010) are each accompanied by a de-repression of inactive ESs at the 
promoter end; 
• nuclear location—inactive ESs are clustered at the nuclear periphery 
where their interaction with nuclear envelope proteins also contributes 
to their repression (DuBois et al., 2012); 
• the VSG sequence itself—VSG genes possess a conserved 3’ untranslated 
region (UTR), and expression of this sequence from one locus suppresses 
its transcription from other loci (S. Hutchison pers. comm., P. Batram 
pers. comm.), perhaps through competition for an mRNA stabilizing 
factor (Berberof et al., 1995).   
The number of candidate factors involved in and affected by monoallelic 
expression, alongside the intimate and essential arrangement of these systems in 
a living cell, has complicated identification of ‘the key’ causative agent.  
Indeed, it is likely that monoallelic expression and its maintenance is a 
composite and non-linear network, with many feedback loops and 
redundancies.14   
 
However monoallelic expression is ultimately achieved, it is flexible.  The 
property of exclusive expression is frequently transferred to another VSG by 
switching, and it is to this that we now turn. 
 
                                         
14 In future, mathematical modelling may be able to help assess the relative contributions of the 
various candidates in such a complex system, but such models would depend on a clear picture 
of the nature of the interactions between the various components. 
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1.6.3 Different VSGs can become exclusively expressed by 
switching 
VSG switching is the process by which the exclusively expressed VSG is changed.  
Switch rates have been estimated at 10-2–10-3 switches/cell/population (Turner & 
Barry, 1989; Turner, 1997).15  This rate was measured by assessing the number of 
parasites surviving after treatment with antiserum, and therefore is an 
aggregate measure that summarizes the effects of all productive switching 
events16 that occur readily in the early stage of infection.  A depressed rate of 
switching is one of the main distinctions of extensively syringe-passaged or 
laboratory-cultured parasites, which show rates several orders of magnitude 
lower than those of fly-transmitted pleomorphic lines (Turner, 1997); care must 
therefore be taken when extrapolating from laboratory strains to field 
populations, as the infection dynamics and relative contribution of the different 
VSG switching mechanisms may vary (Barry, 1997; Turner, 1990). 
 
There are broadly two ways in which VSG switching is achieved (Figure 1.11): 
A. Transcriptional switching does not require any genetic rearrangement.  As 
T. brucei has multiple BESs, a different VSG can be expressed by 
transferring the property of monoallelic expression from one BES to 
another (section 1.6.4).   
B. Recombinatorial switching involves the copying—or complete migration—
of a VSG into the active BES (section 1.6.5). 
C. Segmental gene conversion is a subset of recombinatorial switching, 
in which multiple silent genes contribute segments to the active VSG 
(section 1.6.6). 
 
In requiring the convergence of different factors, each of these processes has a 
different chance of successfully occurring to a given silent VSG.  The consequent 
‘activation probability’ of each silent VSG is the basis of an overall hierarchy of 
expression across infection (section 1.6.12). 
 
                                         
15 This is the figure for pleomorphic trypanosomes.  In lab-adapted monomorphic trypanosomes the 
rate is much lower, a state that can be reversed following passage through the tsetse (Turner, 
1997). 
16 Note that some switching events will be ‘non-productive’ (that is, events that do not yield a 
antigenically novel surface coat); these are discussed in section 1.6.12. 
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Figure 1.11 VSG switching.  VSG-B can be activated by: (A) Turning off VSG-A’s ES, and 
turning on an ES containing VSG-B (in situ switching).  (B) Replacing the active-ES-
occupying VSG-A with a copy of VSG-B by recombination.  Here a process of gene 
conversion is shown, leaving the silent copy of VSG-B unmodified.  (C) It is also possible 
for segments of a silent VSG (ѱVSG-C) to be copied into an ES to form a mosaic VSG (VSG-
A/C in the Figure).  This process of ‘segmental gene conversion’ can occur even when the 
silent VSG is damaged by frameshifts or stop codons (indicated by the red bar in (C)). 
 
Whilst changing the expressed VSG gene may be rapid, replacement of the 
glycoprotein coat downstream can take much longer.  VSG mRNA has a half life 
of 4.5 hours, and VSG itself has a half life of around 30 hours (Ehlers et al., 
1987; Seyfang et al., 1990).  There may be mechanisms that operate to hasten 
the replacement of a surface coat—rapid degradation of old VSG mRNA or 
increase in the rate of coat turnover following a switch, for example—but these 
have not been defined, and it may be the case that the uniformity of the VSG 
surface coat is often not absolute (Esser & Schoenbechler, 1985; Seyfang et al., 
1990). 
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1.6.4 VSGs can be activated in situ 
Switching can occur when the active ES becomes repressed and a silent ES 
becomes activated, a process that occurs without any necessary concomitant 
genetic rearrangement (Majiwa et al., 1982; Young et al., 1982; 1983).  This 
‘transcriptional switching’17 occurs rapidly in the bloodstream form (Ulbert et 
al., 2002).  An elegant model for its mechanism would be the ES body simply 
moving to a different ES (Navarro & Gull, 2001).  However, although that would 
lead to the expression of a new VSG, it appears there are other factors at work.  
The activation of a new ES and the silencing of the old one are separable 
processes—the absence of the chromatin remodelling enzyme DOT1B results in 
the residual expression of the old ES for up to two weeks after switching 
(Figueiredo et al., 2008).  The triggers prompting transcriptional switching are 
also mysterious, although the close association between the ES body and nuclear 
architecture hints that mitosis might be one occasion where the ESB-ES complex 
becomes vulnerable to disruption (Landeira et al., 2009).   
 
Transcriptional switching was found to be a major switching pathway in lab-
adapted monomorphic T. brucei lines (Liu et al., 1985) but this is may be due to 
deficiencies in aspects of their recombinatorial switching pathways: in the more 
field-relevant, rapidly-switching pleomorphic lines it appears to be a minor 
process (Robinson et al., 1999).  Transcriptional switching, by its nature, can 
only provide access to VSGs located in one of the other ESs.  What, therefore, is 
the role for transcriptional switching alongside the more flexible recombinatorial 
mechanisms?  The primary reason seems to lie not with the VSG, but with the 
expression site-associated genes (ESAGs): the different ESAG collections at 
different ESs can adapt to the peculiarities of different host species.  This might 
be the case for the transferrin receptor ESAG6/7 (Bitter et al., 1998), and 
possibly also the ESAG4 family of adenylate cyclases (Salmon et al., 2012).18  The 
presence of multiple ES may also compensate for the potentially deleterious 
recombinatorial processes occurring in the active ES (see section 1.6.10).  
 
                                         
17 Also known as in situ switching. 
18 However, inconsistent with this hypothesis is the lack of correlation between host range and 
ESAG heterogeneity (Young et al., 2008) 
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1.6.5 VSGs can be rearranged to occupy an expression site 
For most VSG genes, activation requires genetic rearrangement: the bulk of the 
archive is located in the subtelomeric arrays.  The importance of recombination 
has experimental support—a study on switching in pleomorphic lines showed 
almost all switching events in the first two relapses to be accompanied by gene 
duplication (Robinson et al., 1999) and trypanosomes lacking a key catalyst of 
recombination, RAD51, are severely deficient in switching even in a 
monomorphic trypanosome line (McCulloch & Barry, 1999).  Recombinatorial 
switching is therefore the major process in expressing trypanosome antigenic 
variability during an infection.   
 
Recombinatorial switching occurs through multiple mechanisms.  Many early 
studies found that switching was often accompanied by a duplication-
transposition of the gene that is expressed to an ES (Hoeijmakers et al., 1980; 
Pays et al., 1981b; 1983; Young et al., 1983), a process termed ‘gene 
conversion’.19  In its best-understood form, gene conversion co-opts the ancient 
DNA repair mechanism, homologous recombination (HR), to delete the existing 
ES-occupying VSG and replace it with a different VSG from elsewhere in the 
genome (Laurent et al., 1984a; Morrison et al., 2009; Pays et al., 1983).  The 
trigger is thought to be damage to the active ES, for example a double-stranded 
break in the DNA (Boothroyd et al., 2009): a likely occurrence, given the 
extremely exposed nature of the active ES’s DNA and the physical instability of 
the AT-rich 70-bp repeats just upstream (Lin et al., 2009b; Stanne & Rudenko, 
2010).20   
 
In homologous replication, following a double-stranded break, nucleases delete 
part of the sequence and expose single-stranded DNA.  RAD51 (the eukaryotic 
orthologue of eubacterial RecA), binds to the exposed strand and catalyses its 
invasion of an intact DNA duplex in a homology-dependent manner (West, 2003) 
paving the way for replication from the invading strand.  There are a number of 
                                         
19 This observation gave rise to the distinction between the ‘basic copy’ (that which is present in 
both expressor and non-expressor) and ‘expression-linked copy’ (that whose appearance 
correlated with expression, Majumder et al., 1981). 
20 The use of non-coding DNA structures to initiate recombination has also been observed in N. 
gonorrhoeae pilus antigenic variation, where a G-quadruplex structure is necessary for 
recombinatorial antigenic variation to occur (Cahoon & Seifert, 2009). 
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different ways that such replication might proceed and resolve, depending on 
the repair apparatus and location of the template (Figure 1.12).  In VSG gene 
conversion, the most likely mechanisms are strand-dependent strand annealing 
(SDSA, Figure 1.12-B) and break-induced repair (BIR, Figure 1.12-C), as double 
strand break repair (DSBR, Figure 1.12-A) can result in the crossover of flanking 
sequences and potentially lethal translocations (Morrison et al., 2009).  
Whatever the process, the result of homologous recombination is the 
replacement of the original sequence—the VSG gene and some of the flanking 
regions—with that of the template.  
 
HR is underpinned by sequence similarities between DNA sequences, as the 
invading strand needs to base pair with the template at the 5’ boundary of 
conversion, and in many cases the newly-synthesized copy of the template needs 
to bind to the sequence that is being repaired at the 3’ end.  Rates of HR in T. 
brucei are reduced as the length and degree of homology between substrate and 
template decrease (Barnes & McCulloch, 2007).  Sequence examination of ESs 
which had undergone gene conversion revealed that the 5’ boundary of 
recombination was usually located in the 70-bp repeat regions located upstream 
of the ES VSG (Liu et al., 1983), and the 3’ boundary of recombination was 
usually in the region spanning the 3’ end of the VSG (Bernards et al., 1981; Liu 
et al., 1985; Michels et al., 1983; Timmers et al., 1987).  Fittingly, these regions 
correspond with the conserved boundaries of the ‘VSG cassette’ (section 1.5.1).  
A straightforward model of recombinatorial switching therefore sees an archival 
VSG cassette replacing the telomere-proximal VSG-containing section of the ES, 
from the 70-bp repeat region to the 3’ UTR of the VSG.  Divergent sequences 
(VSG genes) are thus exchanged by a mechanism that demands high levels of 
identity between the exchanged sequences.  Alternatively, if a telomeric VSG is 
used as the template, and BIR is the process by which the template is copied, 
the 3’ boundary may not exist as replication could proceed all the way to the 
telomere end (Morrison et al., 2009).   
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Figure 1.12 Possible recombinatorial switching mechanisms.  A double stranded break in 
the 70-bp repeats is processed by various complexes to reveal single-stranded DNA ends, 
providing a substrate for a RAD51 filament to form.  RAD51 filament assembly is aided by a 
number of factors (not shown here).  RAD51 catalyses homology-dependent invasion of the 
strand into intact duplex DNA (grey lines) containing a silent VSG (green box).  Three 
pathways for the resolution of double strand breaks are known.  In each of these images, 
dashed lines indicate newly-synthesized DNA, and arrowheads indicate the direction of 
synthesis.  (A) Double strand break repair involves the synthesis of DNA from the template, 
and the strands remain base-paired.  This leads to the formation and resolution of Holliday 
junction intermediates.  Here, the reaction is shown with no cross-over of flanking 
sequences.  (B) Synthesis-dependent strand annealing (SDSA) involves the copying of the 
template sequence onto the end of the invaded strand, which can then re-anneal to the 
exposed DNA on the other side of the break.  Synthesis can then proceed from that strand, 
using the newly synthesized DNA as a template, and the reaction is resolved by ligation of 
the DNA backbone.  (C) In break-induced replication (BIR) strand invasion promotes 
formation of a replication fork with lagging and leading strands, which can potentially 
proceed all the way to the telomere end.  Image was copied and modified from (Morrison et 
al., 2009). 
 
A further pathway is the recombinatorial activation of a VSG without any 
concomitant duplication.  Here, classical recombination acts to reciprocally 
exchange chromosome ends, swapping the active ES VSG with the telomere-
proximal VSG of another chromosome (Pays et al., 1985b).  Telomere reciprocal 
exchange is prominent in monomorphic lines (Rudenko et al., 1996). 
 
RAD51-mediated homologous recombination pathways explain only part of the 
evidence.  Study of residual switch events in the absence of RAD51 revealed a 
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recombination pathway that required only very short regions of homology—as 
short as 7–13 bp—and was tolerant of mismatches (Conway et al., 2002; 
McCulloch & Barry, 1999).  Alongside stricter, classical homologous 
recombination, there are clearly more flexible mechanisms at work. 
 
1.6.6 Parts of different VSGs can be combined by segmental gene 
conversion, modifying and repairing them 
The effects of segmental gene conversion can be seen when no single genomic 
donor can be found for an expressed VSG.  Rather, two or more donors can be 
identified, each of which contributes different segments to form the expressed 
VSG.   
 
Two broad patterns of segmental gene conversion can be distinguished in VSG: 3’ 
donation (section 1.6.8) and mosaicism (section 1.6.9).  These patterns are 
linked in that they involve recombination boundaries occurring within the coding 
region, yielding an expressed VSG with more than one donor, but it is possible 
that they are the consequence of different recombinatorial mechanisms.  Table 
1.3 describes the VSGs identified to date that have apparently undergone 
segmental gene conversion. 
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Table 1.3 Previously identified segmental VSG conversion.  (i) and (ii) refer to greater and 
lesser 3’ donation events respectively, see Figure 1.13. 
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First, segmental gene conversion as a general mechanism in antigenic variation 
will be considered (section 1.6.7), before describing the patterns of segmental 
gene conversion seen amongst VSG (sections 1.6.8–1.6.10). 
 
1.6.7 Segmental gene conversion is an important process for 
many antigenically variant pathogens 
Segmental gene conversion to generate expressed variable antigens is common 
to many antigenically variable pathogens. Broadly speaking, segmental gene 
conversion occurs in two, often complementary, ways: 
(i) Variable region cassettes.  Variable antigens often possess conserved 
regions: parts of the molecule that are either functionally constrained or 
not the target of immune responses.  Rather than varying the whole 
molecule, segmental gene conversion allows just the variable regions of 
the antigen to be exchanged with archival copies.  Anaplasma marginale 
MSP2 and 3 (Barbet et al., 2000; Meeus et al., 2003), Neisseria 
gonorrhoeae pilin (Hamrick et al., 2001), Treponema pallidum TrpK 
(Centurion-Lara et al., 2004), and Mycoplasma genitalum MG192 (Iverson-
Cabral et al., 2007; Ma et al., 2007) all undergo such segmental gene 
conversions.  Using truncated, pseudogenic, variable region cassettes 
avoids the duplication of conserved regions (which could potentially suffer 
from pseudogenizing drift) and makes efficient use of a small genome (Ma 
et al., 2007). 
(ii) Recombinatorial diversity.  Successive segmental gene conversion events 
occurring within the variable region can effect antigenic variation through 
a process of progressive mosaicism during an infection.  A. marginale 
MSP2 (Futse et al., 2005) and B. burgdorferi VlsE (Coutte et al., 2009) 
both show increasingly complex segmental conversion events in their 
variable regions as infections progress, and combinatorial diversity has 
been found to mediate immune evasion (Zhuang et al., 2007) and 
superinfection (Futse et al., 2008) in Anaplasma.   
 
Amongst those pathogens that use recombination to access and express an 
archive of silent genes, segmental gene conversion could be considered typical, 
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with Borrelia hermsii the only well-defined exception to the trend (Dai et al., 
2006). 21 
 
Segmental gene conversion also shapes multi-gene families in their long-term 
evolution—evidence of its work can be seen in the antigen repertoires of 
Plasmodium falciparum (Bull et al., 2008; Rask et al., 2010) and Giardia lamblia 
(Adam et al., 2010), as well as T. brucei (Gjini et al., 2012)—although by copying 
elements between genes, segmental gene conversion can have an overall 
homogenizing effect on an archive (Nei & Rooney, 2005), particularly if segments 
are large (Martinsohn et al., 1999). 
 
1.6.8 VSG 3’ donation involves recombination events in the C-
terminal domain- and GPI anchor-encoding regions  
VSG 3’ donation has occurred when the 3’ end of the silent archival VSG is 
different from the 3’ end of its expressed form.  Examples of 3’ donation are 
shown in Figure 1.13.  Here, the term ‘3’ donation’ covers a spectrum of 
exchange, from the very 3’ most GPI anchor signal just upstream from the 3’ 
UTR that is the boundary of exchange for ‘full-length’ VSG gene conversion, 
(marked (i) on the Figure) to the entire CTD (marked (ii) on the Figure).   
 
The observed patterns of 3’ donation are usually explained by the 3’ boundary of 
the usual process of gene conversion occurring within the CTD-encoding region 
of the VSG gene (Aline et al., 1994; Michels et al., 1983; Pays et al., 1985a; 
Thon et al., 1990).  This would mean that the newly expressed VSG retains part 
of the 3’ end of the previously expressed VSG, but since this region encodes the 
buried, membrane-proximal CTD that is inaccessible to antibodies its retention 
does not compromise antigenic variation (Schwede & Carrington, 2006).  Such 
retention could, in fact, be advantageous: many silent T. brucei VSGs have 
damage to their GPI signal sequence and towards the 3’ end of their CTDs 
(Marcello & Barry, 2007a).  By repairing these genes, 3’ donation increases the 
proportion of the VSG archive available for expression.  This pattern is somewhat 
reminiscent of the ‘variable region cassette’ mechanism outlined above (section 
1.6.7).  The homology often seen between T. brucei VSG CTDs, despite complete 
                                         
21 Although segmental gene conversion has been recorded in B. hermsii, it is not a prominent 
pattern (Dai et al., 2006). 
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NTD divergence, means that the coding region could naturally act as the 3’ 
recombination endpoint instead of the 3’ UTR, particularly if just the very 3’ 
most end of the gene is retained (Liu et al., 1985; Majumder et al., 1981).  It is 
also possible that 3’ donation occurs to an existing ES VSG, as inferred by 
Marcello & Barry, (2007a). 
 
In T. congolense and T. vivax, where there are much lower levels of homology 
between VSG CTD-encoding regions, 3’ donation may occur less frequently, if at 
all (Jackson et al., 2012). 
 
 
Figure 1.13 3' donation.  When the 3’ boundary of gene conversion occurs within the open 
reading frame of the VSG, the incoming VSG retains the 3’ end of the previously resident 
VSG.  The bottom half of the image shows two possible outcomes.  Each image represents 
the nucleic acid sequence of a VSG, from 5’ to 3’, with dotted and intact lines indicating 
respectively the division between signal peptide-encoding region and NTD-encoding region, 
and NTD- and CTD-encoding regions.  A red arrowhead indicates the boundary of the 
mature CTD: the region 3’ of this encodes the GPI anchor signal sequence.  The gene 
contributing to each segment of the VSG are coloured according to the top half of the 
image.  In (i), only the GPI-anchor-encoding sequence of VSG-A is retained, whereas in (ii) 
the whole CTD-encoding region is retained. 
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1.6.9 Mosaicism generates variation across the VSG 
Mosaicism is a process of segmental gene conversion that occurs throughout the 
VSG, including in the antigenically important NTD.22  A set of mosaic VSGs 
identified by Kamper & Barbet (1992) are shown in Figure 1.14 as an example.  
Mosaic VSGs have multiple donors, each of which can contribute multiple 
segments to form an expressed VSG (in the case of WaTat 1.13, 15 segments 
have been donated by the four different donors).   
 
Compared with straightforward gene activation, mosaicism has two important 
features that could contribute to antigenic variation: 
(i) Accommodation of damaged VSG.  Like 3’ donation, mosaicism could 
access a greater portion of the silent VSG archive, allowing expression of 
otherwise inaccessible epitopes.  As infections can last years, VSG repair 
by segmental gene conversion could become the predominant means of 
expressing archive VSGs (Barbet & Kamper, 1993). 
(ii) Recombinatorial variability.  By allowing donors to combine in a multitude 
of different ways, mosaicism can increase their potential for antigenic 
novelty, increasing the number of antigenic profiles many-fold.  Such is 
the case for Anaplasma marginale and Borrelia burgdorferi (section 
1.6.7). 
 
Could segmental gene conversion amongst a limited set of donors contribute to 
antigenic variability in African trypanosomes?  Analysis of the WaTat 1.1 mosaic 
family (see Figure 1.14) with monoclonal antibodies showed that the different 
mosaics shared some epitopes but varied in others (Barbet et al., 1989).  As 
these mosaic variants—with between 0.051 and 0.105 differences/aa between 
their mature NTDs—were identified by immunological cross-reaction and isolated 
following a lengthy series of passages, it is possible that diversifying selection 
imposed by adaptive immunity over the course of an individual infection would 
favour more antigenically variant mosaics (Barbet & Kamper, 1993). 
 
                                         
22 Importantly, ‘mosaicism’ here should be distinguished from ‘double expression’—the 
simultaneous appearance of two different VSG isoforms in a surface coat—as double 
expressors are sometimes referred to ‘mosaics’ in the literature (Dubois et al., (2005), for 
example). 
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Figure 1.14 Mosaicism in the WaTat 1.1 VSG family (redrawn from Kamper & Barbet, (1992)).  
All images are to scale.  The top half of the figure shows the four putative donor sequences.  
The positions of stop codons and frameshifts, present in donors B and D, are indicated.  
The nucleic acid (NA) variability between these sequences is given in differences/nt.  The 
bottom half of the image shows four mosaic VSG sequences that were generated from these 
donors via a rabbit infection and a series of lengthy passages.  Each image represents the 
nucleic acid sequence of a VSG cDNA from 5’ to 3’, with dotted and intact lines indicating 
respectively the division between signal peptide-encoding region and NTD-encoding region, 
and NTD- and CTD-encoding regions.  Different regions of each mosaic VSG are coloured 
according to the most probable donor sequence for that region.  Segment boundaries were 
arbitrarily considered to be the midpoint of the region of identity between the two adjacent 
segments.  Sequence data were not available for the 3’ ends of the donor sequences, and 
thus the expressed mosaics are coloured white in this region.  Cysteine codons are 
represented as bars protruding from the top of the diagrams and red bars spanning the 
diagram represent positions that match none of the donors identified.  For this figure, 
GenBank sequences M83694–M83702 were used. 
 
 
1.6.10 Segmental gene conversion depends on homologies, 
and complex mosaics may be constructed by sequential 
events 
The mechanisms underlying segmental gene conversion are unclear, but 
sequence analyses suggest the process is promoted by homologies between 
donor sequences.  For mosaic VSGs, donors show sequence similarities—they are 
members of the same VSG subfamily (section 1.5.3)—but the boundaries of 
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segmental recombination lack the long regions of perfect identity that are 
associated with classical homologous recombination (Barnes & McCulloch, 2007) 
and the size of the contributed segments can also be very small (14 bp, in the 
case of WaTat 1.14 (Kamper & Barbet, 1992)).  Thus construction of mosaic VSGs 
may occur by a pathway or pathways different from that of full-length gene 
conversion: one that is held to be inefficient, due to the late appearance of 
mosaic VSGs in infection (Morrison et al., 2009), but better-able to cope with 
imperfect homologies.  The less-stringent Rad51-independent pathway is the 
most promising candidate to date (Conway et al., 2002), but direct 
experimentation has been hampered by the late appearance of mosaic VSGs in 
infection and the difficulties associated with transfecting pleomorphic 
bloodstream form trypanosomes.   
 
By examining the sequences of mosaic VSGs, the process of their construction 
can be inferred.  The best model to date holds that mosaics are ‘built up’ in an 
ES, as various donors recruited by homology contribute segments in succession to 
form a ‘string’ of mosaics (Barry et al., 2005).  Here, this model will be referred 
to as ‘progressive mosaicism’.  It draws on the work of Pays et al., (1985a), who 
observed, over a number of passages and clonings, repeated interactions with 
the same set of donor genes with an expressed copy to generate a number of 
related mosaics.  The data of Marcello & Barry, (2007a) are also consistent with 
this model, as from a single infection two mosaics with some conserved, and 
some independent, segmental conversions could be identified and from these a 
putative ‘lineage’ deduced.  This model is analogous to the patterns defined in 
A. marginale MSP2 (Futse et al., 2005) and B. burgdorferi VlsE (Coutte et al., 
2009), where donors serially contribute segments to construct increasingly 
complex antigen genes during infection. 
 
One of the appeals of progressive mosaicism is that it allows mosaics to be 
selected for function—and potentially antigenic novelty—at each step in their 
development.  The expressors of functional, antigenically distinct mosaics can go 
on to proliferate, creating a larger pool of mosaic-expressors and increasing the 
chances for further segmental gene conversion events, using the same donors, to 
occur.  Therefore, the initial event in generating a mosaic—for example 
Chapter 1  61 
repairing a pseudogenic donor—is a high barrier to entry that, once overcome, 
may pave the way for further mosaicism to occur readily. 
 
Assuming that one of the donors initiates the mosaic lineage, progressive 
mosaicism requires a dysfunctional VSG to readily occupy an ES (in the case of 
(Roth et al., 1989)).  Similarly, it is possible that segmental gene conversion 
events introduce errors (for example if they are out of frame or if they involve 
the damaged part of the donor).  How would a cell cope with a damaged VSG in 
its ES?  Studies where RNAi was used to deplete parasites of VSG mRNA induced 
global translational repression, indicating that the lack of VSG transcripts has a 
profound effect on cell biology (Smith et al., 2009).  Although this example is 
distinctly artificial, it hints at mechanisms that may feed back to the ES to 
perhaps increase recombination or trigger transcriptional switching.  The 
pathways that trypanosomes possess for sensing and degrading nonsense mRNA 
(Delhi et al., 2011) and the large number of proteins involved in facilitating VSG 
folding and quality control (Field et al., 2010) are potential candidates for the 
mechanisms by which problems with VSG production might be detected.  The 
error-prone nature of segmental gene conversion could explain the presence of 
multiple BES: providing a source for easy-to-access backup VSGs to protect 
against dangerous segmental experimentation at the active ES.  It is also 
possible that silent BES are ‘sandboxes’—loci where multiple segmental 
recombination events might occur safely without compromising transcription of 
the active VSG gene.  These silently-assembled mosaics could then be activated 
in situ (Barry & McCulloch, 2001).  Silent gene conversion (that is, not associated 
with activation) has been frequently recorded in T. brucei (Aline et al., 1989; 
Aline & Stuart, 1985; Myler et al., 1988).   
 
1.6.11 Point mutations are probably a minor source of 
antigen variability 
Could point mutation also contribute to VSG antigenic variation?  Studies have 
reported single nucleotide variation in the expressed VSG when comparing it 
with its archival copy (Lu et al., 1994; Rice-Ficht et al., 1982), and in chronic 
infection studies these mutations appear to accumulate preferentially in regions 
of the NTD that may form epitopes (Marcello & Barry, 2007a).  Point mutation 
variation is unlikely to be routinely generated by the process of gene conversion 
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itself, since there are many examples of perfect VSG copying (Graham & Barry, 
1996; Pays et al., 1985a) but the exposed chromatin structure around the active 
ES may make it particularly vulnerable (Stanne & Rudenko, 2010).  Whether such 
nucleic acid variation translates to meaningful changes in epitope structure is 
another question.  Variable monoclonal antibody binding as a consequence of 
point mutation has been reported (Baltz et al., 1991; Lu et al., 1994) but these 
variants, obtained by artificial immunological selection, may bear no 
resemblance to the consequences of immunological selection in vivo.  Whilst in 
field populations over longer time periods point mutation could be a useful way 
of generating variation (Hutchinson et al., 2007) it seems unlikely that the build 
up of point mutations in the expressed VSG occurs rapidly enough to play an 
important role during an infection (Graham & Barry, 1996).   
 
1.6.12 The appearance of different variable antigen types 
during an infection follows a hierarchy 
There is a semi-predictable ordering to the VSGs that are expressed over time in 
an infection, which can be reset when those trypanosomes are used to infect a 
naive host (Gray, 1965).  This is termed the ‘hierarchy’ of VSG expression.  The 
presence of a antigen expression hierarchy has been explained with arguments 
similar to those made for monoallelic expression: activation of archival VSG 
genes across the population must follow some order; otherwise the 
trypanosomes would rapidly expose their entire archive to the immune system 
and run out of antigens to express (Morrison et al., 2005) (this is likely the case 
for Plasmodium, which possesses a much smaller archive (Recker et al., 2011)).  
Another theory is that uncontrolled antigen variability would result in 
overwhelming parasite density and host exhaustion as the immune system is left 
unable to cope (Turner et al., 1995): extended periods of parasitaemia can exert 
a crippling energy burden on the host (Seed et al., 2003).  Neither of these 
theories is completely satisfying in light of differentiation-controlled infection 
dynamics (see section 1.7.5), as a multitude of variants could theoretically 
persist beneath the threshold of immune induction, avoiding host exhaustion by 
timely stumpy differentiation.  Perhaps expression hierarchy has been subject to 
more complex selection, involving a balance between competition amongst 
trypanosome strains and the demands for flexibility in different host types 
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(Turner, 1999) (see Chapter 6 section 6.2.4–6.2.6 for further discussion on this 
matter). 
 
A number of theories have been advanced to explain the mechanics of 
expression hierarchy (ranging from immune cross reaction to differential growth 
rates (Morrison et al., 2005)), but the best-supported and most elegant 
explanation is simple: that different VSGs have different activation probabilities.  
As the infection progresses, immune responses against the readily-expressed 
VSGs—those with high activation probability—constantly select VSGs that have 
lower activation probability (Morrison et al., 2005).  One of the consequences of 
this model is that individual VSG switches can be classified as ‘productive’ 
(activating a VSG against which antibodies have not arisen), or ‘non-productive 
(activating a VSG to which the host has developed immunity) (Turner, 1999). 
 
What is the genetic basis for a VSG’s activation probability?  As stated above 
(section 1.6.1), for a VSG to be expressed it must reside in the active ES.  
Therefore, the activation probability of a specific VSG reflects the number of 
steps required to get to that locus, and the likelihood that they will occur.  As 
the majority of VSG activation events are rooted in homology-based gene 
conversion, the homologies between the flank regions of the active ES and the 
VSG under consideration are likely to be an important determinant of activation 
probability (Morrison et al., 2005).  For those VSGs resident at telomeres, 
telomere interactions promote recombination (Barry et al., 2003) and repeats 
downstream of the VSG represent regions of 3’ homology with the active ES that 
the VSGs in the arrays do not have (Aline & Stuart, 1989).23  Accordingly, 
telomere-resident VSGs appear to be preferentially activated in the early stages 
of infection (Liu et al., 1985; Robinson et al., 1999).  Intact array VSGs rely on 
shorter, more variable homologies between their 3’ region and that of an ES VSG 
(Marcello & Barry, 2007a), but can be copied into an ES in a single step (as a 
‘cassette’).  Pseudogenic VSGs, requiring inefficient segmental conversion for 
their activation, become prominent later in infection (Pays, 1989; Roth et al., 
1989).   
 
                                         
23 In fact, as described above, if BIR is used to copy telomeric VSGs into the ES, replication could 
proceed all the way to the telomere end, making 3' homology unnecessary.  3’ homology is also 
unnecessary for reciprocal telomeric exchange. 
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An extra layer of complexity to the model comes from the fact that every 
change to the ES (for example the copying in of a new VSG cassette) can change 
the degree of homology that any archival sequence has with the ES, and thus 
their potential to interact (Pays et al., 1985a).  Although there is no evidence of 
homology-dependent switching taking place early in infection—the activation 
probability of a silent VSG seems to have little bearing on the currently-
expressed VSG (Morrison et al., 2005)—later on, during the progressive 
generation of mosaics, coding sequence homologies probably become more 
important (Thon et al., 1990).  The principle of activation-probability-driven 
hierarchy is shown in Figure 1.15.   
 
 
Figure 1.15 VSG switching hierarchy.  The intensity of shading indicates the effective 
switching rate, that is, the relative importance of each process in expressing novel VSGs.  
Transcriptional switching is likely to occur in the early stages of infection (although this has 
not been experimentally verified, and transcriptional switching may provide a supporting 
role throughout, see section 1.6.10), whereas recombinatorial switching is used throughout.  
Telomeric VSGs are activated more readily than intact genes in the subtelomeric arrays, 
which in turn are activated more readily than pseudogenes in the arrays.  In the early stages 
of infection, homologies in the flanks, such as the 70-bp repeats, mediate recombination, 
whereas as the infection progresses, segmental gene conversion requires homologies in 
the VSG coding sequence.  The scale bar at the bottom is approximate: timing likely varies 
between hosts.  Image copied and adapted from Morrison et al. (2009). 
 
Hierarchy is also flexible, with previously ‘late’ VSGs able to occupy more easily-
activated genomic locations and thus taking an earlier position in the hierarchy 
(Laurent et al., 1984b).  Such reorganisation may be important in field cases of 
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reinfection or superinfection, where hosts might already have antibodies against 
the common early-expressed VSGs.   
 
These patterns described in section 1.6 are the parasite-intrinsic processes 
behind antigenic variation.  The raison d’etre of antigenic variation is its 
interaction with the host.  It is to this extrinsic process that we now turn.   
 
1.7 Host-parasite interactions in African trypanosome 
infections 
1.7.1 The VSG surface coat is the point of contact between 
parasite and host 
To the immune system, a living bloodstream form trypanosome is essentially 
invisible but for its surface coat, a fluid, repetitive array of identical VSG 
subunits.  How does the immune system ‘see’ VSG, and respond to it?  The 
structure and orientation of VSG on the surface and its close packing makes the 
N-terminal loops of the glycoprotein the most likely interface with the immune 
system (Mehlert et al., 2002).  It is likely that the epitopes they form are 
conformational, complicating efforts to identify them by mutagenesis or tryptic 
digestion (Pinder et al., 1987).  Studies using monoclonal antibody competition 
to map the number and structure of the epitopes on an intact surface coat 
estimated that each VSG has between one and four distinct epitopes (Clarke et 
al., 1987; Hall & Esser, 1984; Masterson et al., 1988; Miller et al., 1984a, b; 
Pinder et al., 1987; Theodos et al., 1990) and analyses using mosaic VSGs 
identified an epitope corresponding with a loop on the side of the VSG (Hsia et 
al., 1996). 
 
Besides the form of VSG on a live parasite, VSG can be released from the 
parasite surface (Black et al., 1982; Seyfang et al., 1990), and damaged or dying 
parasites are also likely to be present during an infection.  The role that these 
forms of VSG play in infection outcome are unclear: soluble VSG appears not to 
bind anti-trypanosome antibodies strongly (Black et al., 1982), but the 
activation of B-cells may be assisted by damaged trypanosomes, perhaps 
because the parasite’s motility is compromised (Black et al., 2010; Sendashonga 
& Black, 1982). 
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1.7.2 Antibodies against VSG drive the host response 
Antibodies against VSG clearly play the central role in the host adaptive 
response to trypanosome infection (Campbell & Phillips, 1976; Guirnalda et al., 
2007; Magez et al., 2008; Morrison et al., 1982).  The huge range of antibodies 
available to the mammalian immune system is thanks to a mechanism of 
recombination and mutagenesis across the developing B-cell population, 
selecting for immense variation within structural constraints (Tonegawa, 1983).  
Generation of antibody diversity is thus mirrored by the mechanisms that 
antigenically variable pathogens have evolved to evade it. 
 
Antibody levels rise rapidly, related to parasite burden, and remain high over 
the course of infection (Barry & McCulloch, 2001).  Decavalent IgM isotype 
antibodies are thought to be the initial response to a VSG, although bivalent IgG 
is also seen (Radwanska et al., 2000; Taylor, 1998). Whilst the kinetics of the 
response against a specific VSG are probably variant-independent, there exists a 
lower bound of sensitivity, whereby low levels of a specific antigen are not able 
to trigger a corresponding antibody response (Morrison et al., 1982): a 
phenomenon that may have consequences for the antigenic variation as minor 
variants may be able to persist undetected.  
 
VSG-bound antibodies kill parasites by activating complement, which can either 
lyse parasites directly (Van Meirvenne et al., 1995) or activate parasite-killing 
macrophages (Guirnalda et al., 2007; Holmes et al., 1979; Pan et al., 2006).  
Antibody responses have been associated with spontaneous self-cure in livestock 
infections (Nantulya et al., 1984; 1986; Penchenier et al., 2005).  Variant-
independent responses, mediated by trypanotoxic cytokines (Magez et al., 1999) 
and nitric oxide (Vincendeau et al., 1992), have also been proposed; however, 
their in vivo effects are unclear and their overall contribution to the dynamics of 
infection is probably minor (Hertz & Mansfield, 1999). 
 
1.7.3 Host factors influence infection outcome 
Host-intrinsic factors have a powerful impact on the outcome of infection. 
Different species and breeds of animal host are differently affected by infection.  
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Some hosts are completely refractory, baboons, for example (Wheeler, 2010), 
whilst amongst others there is a broad spectrum of outcomes, ranging from 
exceptional susceptibility (horses and European cattle breeds, for example) to 
varying degrees of ‘trypanotolerance’, where symptoms are mild and the 
parasite population is maintained at very low, often undetectable numbers 
(Guirnalda et al., 2007; Mulla & Rickman, 1988; Taylor, 1998) 
 
Innate immunity clearly plays the pivotal role in refractory hosts, with a 
trypanolytic serum factor implicated (apolipoprotein L-1 (Vanhamme et al., 
2003)).24  The spectrum of susceptibility and tolerance is harder to dissect, but 
using different species, breeds and genetic knockouts some broad patterns have 
been identified.  Control of pathogenesis (where parasitaemia can be sustained 
with few ill effects) and control of parasites (where the parasite load is 
repressed) are likely linked through the inflammatory cytokines TNF-! and IFN-" 
(Magez & Caljon, 2011).  Higher levels of IFN-" and TNF-! stimulate immunity 
and are required for controlling the initial parasite load (Hertz et al., 1998; 
Magez et al., 1999) but as the infection progresses the suppression of their 
activity through IL-10 is important to minimise immunopathogenesis (Guilliams 
et al., 2007).  Indeed, IL-10-negative mice are exceedingly susceptible to 
trypanosomiasis, probably due to immunopathogenic responses (Baetselier et 
al., 2001; Namangala et al., 2001).  Although much of our knowledge of the 
immunology of trypanosomiasis comes from model systems, particularly mice, 
there are indications that these findings do have veterinary and medical 
relevance (Kennedy, 2007; Magez & Caljon, 2011).   
 
1.7.4 African trypanosomes can induce immunosuppression in 
their hosts 
Trypanosome infections are known to induce immunosuppression in their hosts, 
linked to the activity of suppressor macrophages whose release of 
immunomodulatory cytokines may skew the immune response away from 
productive antibody responses and towards immunopathogenesis (Askonas et al., 
                                         
24 It is interesting to note that the resistance of T. b. rhodesisense to human trypanolytic factor is 
mediated by a VSG-like protein, encoded by the ‘serum resistance associated’ (SRA) gene 
located in the ES (DeGreef & Hamers, 1994; Campillo & Carrington, 2003; Xong et al., 1998).  
The ES may therefore act as a general contingency locus (Pays et al., 2001) and the structure 
of the VSG fold itself may be one that is easily co-opted to perform other roles (Carrington & 
Boothroyd, 1996). 
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1979; Mansfield & Paulnock, 2005).  In T. brucei infections of mice, considerable 
B-cell dysfunction causes serious disruption to antibody responses.  As infections 
progress, trypanosomes induce apoptosis in marginal zone B-cells, rendering 
hosts susceptible to re-challenge with previously encountered antigens, including 
VSG coats (Radwanska et al., 2008).  It is likely that this phenomenon is 
unusually exaggerated in hosts that sustain an exceptionally high parasitaemia 
for their body mass, such as mice (La Greca & Magez, 2011): in other hosts B-cell 
dysfunction and its effects may be less extreme.25 
 
1.7.5 Density-dependent differentiation controls parasite numbers 
and provides transmission-ready parasites 
Alongside the extrinsic force of the immune system, trypanosomes have an 
intrinsic mechanism of population control.  In contrast to monomorphic 
trypanosomes, pleomorphic trypanosome infections of immunocompromised 
animals do not rapidly overwhelm or kill their host (Magez et al., 2008; Seed & 
Sechelski, 1988).  Instead, parasitaemia is maintained at constant, high levels 
for many weeks, thanks to the irreversible differentiation to non-proliferative 
tsetse-infective ‘short stumpy’ form.  Stumpy differentiation is critical for tsetse 
transmission—and hence trypanosome persistence in its natural habitat—
therefore mechanisms that maximise and prolong the presence of stumpy forms 
are probably subject to strong selection.  Infections routinely show an 
abundance of short stumpy trypanosomes (MacGregor et al., 2011; Robertson, 
1912).  The soluble, parasite-produced signal for differentiation, ‘stumpy 
induction factor’ (SIF) is unknown, but it has a density-dependent effect on the 
parasite population (Reuner et al., 1997).  Short stumpy differentiation is 
therefore a negative feedback loop, which stabilises total parasitaemia, 
preventing early death of the host (Seed et al., 2003) and providing an plentiful 
source of short stumpy form cells to maximise tsetse-infectivity.   
 
Stumpy differentiation has important consequences for antigenic variation.  
Because they cannot proliferate, stumpy form trypanosomes do not change their 
VSG coat, indeed, VSG transcription is repressed within the limit of detectability 
                                         
25 If, on the other hand, absolute B-cell dysregulation is more widespread amongst hosts, the 
selection pressures favouring the evolution of the elaborate system of trypanosome antigenic 
variation would be mysterious, since parasites would only need to possess a handful of distinct 
antigens if they were able to abrogate immunological memory altogether. 
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(Amiguet-Vercher et al., 2004).  The total population of parasites undergoing 
VSG switching is therefore reduced to a smaller set of ‘stem cell’-like 
proliferative slender form cells, potentially restricting antigenic diversity across 
the trypanosome population (MacGregor et al., 2011).  In addition, if the effects 
of SIF are variant-independent, stumpy differentiation could affect rarer VSG 
expressors as well as the predominant VSG.  This non-specificity might repress 
the emergence of some variable antigen types, possibly allowing their 
persistence ‘below the radar’ of immune sensitivity (Gjini et al., 2010).26  The 
dynamics of differentiation are host-dependent, with the parasite population 
stabilising at different levels in different hosts (Seed & Sechelski, 1988): host 
processes may influence parasitaemia indirectly, perhaps by producing, 
sequestering, or removing SIF (or SIF analogues). 
 
1.8 The dynamics of antigenic variation 
1.8.1 Mathematical models help to describe relationships 
between processes in antigenic variation 
A recent mathematical model by Gjini et al. (2010) has expanded on previous 
modelling attempts (Frank, 1999; Lythgoe et al., 2007) to shed some light on the 
relationships between antigenic variation, VSG switching hierarchies, and 
(variant-independent) population control through density-dependent 
differentiation.  Briefly, the model showed that as the number of easily-
activated variants increases (relative to the sensitivity of the immune response) 
the greater the role of differentiation in controlling parasitaemia, since the 
number of different variants at low concentration cannot all induce sufficiently 
powerful specific immune responses for their rapid elimination.  Similarly, the 
larger the size of the trypanosome population, the greater the likelihood that 
harder-to-activate variants will appear in an infection, since switching is 
parasite-intrinsic.  As the balance of infection tilts towards differentiation-based 
control, opportunities for tsetse transmission increase, but so does the risk of 
premature host death as a consequence of persistent high parasitaemia (Seed et 
al., 2003).  These key interactions are summarized in Figure 1.16.  By 
partitioning the archive into ‘blocks’ of distinct activation probabilities—an 
                                         
26 Similar effects might also result from variant-independent host immune responses, although 
without concomitant production of the tsetse-infective form.   
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expression hierarchy—a hybrid strategy is adopted: peaks of parasitaemia 
dominated by differentiation, punctuated by periods of remission. This model is 
able to broadly recreate experimentally observed patterns of infection (Barry, 
1986; Morrison et al., 2005).   
 
Another interesting prediction of the model is that partial cross-reaction 
between variants can actually increase the period that the later variant is 
present by preventing those parasites from reaching the numbers required to 
trigger a late-variant-specific immune response.  This could have special 
relevance in progressive mosaicism, where antibodies raised against an early 
variant may be inefficient at (but still capable of) killing a later, related mosaic 
(Kamper & Barbet, 1992).   
 
 
Figure 1.16 Dynamics of antigenic variation.  As described in the text, the activation of many 
variants means that the dynamics of a trypanosome population are controlled primarily by 
differentiation.  Processes that favour and disfavour trypanosome persistence in an 
ecosystem are indicated by green and red bars respectively.  The opportunities for 
transmission, and probabilities of host exhaustion or self-cure, are indicated by the 
intensity of shading.   
 
1.8.2 Antigenic variation exists in a complex ecosystem 
From a parasite point of view, host responses, and host effects on 
differentiation, are unknown quantities that can vary considerably between 
hosts. These forces set the boundaries within which antigenic variation and 
differentiation interact (Barry, 1986).  A broad ecological picture of African 
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trypanosomes reveals an environment where competing parasite strains straddle 
geographically discontinuous populations of mammals and tsetse flies (Krafsur, 
2008; Munang'andu et al., 2012).  Trypanosomes’ obligatory parasitism demands 
flexibility in their survival strategies.  Their system of antigenic variation has 
evolved to reflect these demands, and should be considered in this context 
(Marcello & Barry, 2007b). 
 
1.9 Outstanding questions and aims of the project 
1.9.1 Research question 
Segmental gene conversion remains a somewhat elusive process in African 
trypanosomes.  It is known to occur later in infection, but only a few mosaic, 
expressed VSGs have been identified, often following immunological selection, 
and almost all of these from separate infections.  The facts that pseudogenicity 
dominates the VSG archive (Marcello & Barry, 2007a), and that segmental gene 
conversion is capable of generating sufficient antigenic novelty to sustain 
chronic infections of A. marginale and B. burgdorferi (Coutte et al., 2009; 
Zhuang et al., 2007) indicates that segmental gene conversion may play a 
prominent role during African trypanosome infections, particularly when the 
host has mounted responses to easily-activated VSGs. 
 
The question at the centre of this project is: what is the contribution of 
segmental gene conversion to T. brucei antigenic variation?  Does segmental 
gene conversion readily access damaged archival VSGs and introduce antigenic 
variability into expressed VSGs?  Answering these questions requires a broad 
knowledge of the VSGs expressed during infection, and how they relate to the 
silent archive.  To investigate whether segmental gene conversion contributes 
directly to antigenic variability during an infection, the changes in epitope 
structure caused by segmental gene conversion also need to be understood.   
 
1.9.2 Experimental approach 
To do this, I monitored VSG expression in individual infections over time.  
Longitudinal samples of trypanosomes were taken from several mouse infections, 
and the sequences of VSGs they were expressing were retrieved.  These samples 
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focused on the later stages of infection, where segmental gene conversion was 
previously identified as a prominent process in antigenic variation (Marcello & 
Barry, 2007a).  Expressed sequence data were compared with the genome 
sequence and with one another to get a general understanding of VSG variability 
during an infection and how it changes over time (Chapter 3).  Closer analyses of 
the VSGs sequenced allowed inference of segmental gene conversion events and 
possibly the identification of progressive mosaicism occurring within an infection 
(Chapter 4).  Different-but-related mosaics retrieved from a chronic infection 
were subjected to serological analysis to investigate whether mosaicism could 
contribute directly to antigenic variation (Chapter 5).  The results will be 
discussed in the context of other host and parasite processes, as well as the 
broader evolution of antigenic variation, in Chapter 6.
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2 Materials and Methods 
2.1 Procedures related to running chronic mouse 
infections and growing trypanosomes in vivo 
2.1.1 Trypanosome strains used 
Two different parasite strains were handled: bloodstream form TREU 927/4 
GUTat 10.1 (Turner et al., 1990) in vivo, and bloodstream form Lister 427 13-90 
(Wirtz et al., 1999) in vitro and in vivo.  The strains were kindly given by L. 
Marcello and C. Harkins respectively. 
 
2.1.2 Host immunosuppression 
Immunosuppression of Balb/c or ICR mice to assist trypanosome growth (when 
initiating infections from blood straw stabilate, for example) was performed by 
intraperitoneal administration of cyclophosphamide (250 mg.kg-1 body weight) 1–
24 h prior to trypanosome injection.  Cyclophosphamide solution was made 
(Sigma-Aldrich, Gillingham, UK, cat. no. C7397-1G) in phosphate buffered saline 
(PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4·2H2O, 1.76 mM KH2PO4, pH 7.2) 
and passed through a 0.2 #m pore size syringe filter.  Single-use ampoules were 
prepared and stored at -20ºC for up to three months. 
 
2.1.3 Trypanosome growth and collection 
All infections were initiated by intraperitoneal injection of parasites in a volume 
no greater than 0.5 ml.  Parasites in blood straw stabilates were first thawed in 
approximately 100 #l incomplete HMI-9 medium (see section 2.3.1) before 
injection.  Parasites from cell culture were collected by centrifugation at 320 g 
for 10 mins and resuspended in 150 #l complete or incomplete HMI-9 for 
injection.  Where necessary, parasites from blood were diluted using incomplete 
HMI-9. 
 
To prepare parasites for clonal infections, trypanosomes were optically cloned.  
All materials and samples were pre-cooled to 4ºC to prevent evaporation, and 
the cloning procedure was carried out in a 4ºC cold room.  Blood containing 
trypanosomes was diluted iteratively with trypanosome dilution buffer (TDB; 5 
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mM KCl, 80 mM NaCl, 1mM MgSO4, 20mM Na2HPO4, 2mM NaH2PO4, 10 mM 
glucose, pH 7.4 (Cross, 1975)) to achieve a working concentration.  A Terasaki 
plate (Greiner, Stonehouse, UK) was prepared by lining its edges with tissue wet 
with deionised H2O, and a paperclip end was used to place one small drop of the 
trypanosome suspension into each well.  The drops were examined by phase-
contrast microscopy at 400x magnification.  Those wells containing drops holding 
single trypanosome were verified by a second party, flooded with 10 #l complete 
HMI-9, and the contents transferred to a microfuge tube containing 150 #l 
complete HMI-9 for immediate injection.   
 
2.1.4 Collection of blood samples from infections 
To monitor parasitaemia, small (~1 #l) blood samples were collected by tail 
venepuncture and a thin film prepared by mounting the sample on a slide 
beneath a glass coverslip.  By observation at 400 x magnification, parasitaemia 
could be estimated according to the ‘rapid matching’ method of Herbert & 
Lumsden (1976).  Where more accurate counts were required (for example when 
initiating infections) blood was diluted 1:20 with 0.85% w/v ammonium chloride 
and incubated at room temperature for 10 mins to lyse erythrocytes.  The 
number of parasites in the sample could then be counted using an Improved 
Neubauer Haemocytometer (Hawksley, Lancing, UK).   
 
For larger samples (for extraction of mRNA, gDNA or plasma), blood was 
collected from ongoing infections by tail venesection, or from terminal 
infections by exsanguination by cardiac puncture under terminal anaesthesia.  
Blood was collected in Carter’s Balanced Salt Solution (CBSS; 25 mM HEPES, 120 
mM NaCl, 5.4 mM KCl, 0.55 mM CaCl2, 0.4 mM MgSO4, 5.6 mM Na2HPO4, 11.1 mM 
D-glucose, pH 7.4) supplemented with 5% w/v tri-sodium citrate as an 
anticoagulant.  For on-going infections, no more than 10% of blood volume was 
collected at any one time, and no more than 15% of blood volume was collected 
over a 28 day period.  Blood volume was calculated as ~5.5 ml per 100 g of body 
weight (Eppig et al., 2012). 
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2.1.5 Immunization of animals for the purpose of raising 
antibodies 
The standard procedure for infection to raise antibodies was as follows: 1 x 106 
cells were injected intraperitoneally into a Balb/c mouse.  When the 
parasitaemia exceeded antilog 7.2 ml-1 blood (scored by rapid matching), mice 
were cured by a dose of 20 mg.kg-1 cymelarsen.  Cymelarsen solution was 
prepared prior to injection by dissolving the powdered drug (Rhône Mérieux, now 
Merial, Duluth GA, U.S.A.) in PBS and passing through a 0.2 #m pore size syringe 
filter.  Plasma and splenocytes were retrieved and processed 5–7 days after drug 
cure.   
 
2.1.6 Stabilates from blood samples 
Stabilates were prepared by mixing blood 2:1 with 22.5% v/v dimethyl 
sulphoxide (DMSO) in CBSS as a cryopreservant.  In seven cases, triladyl (Minitüb, 
Tiefenbach, Germany, cat. no. 13500/0250) was used as a cryopreservant, by 
mixing blood 1:1 with 25% v/v triladyl in CBSS.  In either case, the blood-
cryopreservant mixture was injected into fine-bore polyethylene tubing, cut to 
size to form ‘straws’, and placed into a cryotube (Alpha Labs, Eastleigh, UK, cat. 
no. LW3532) perforated to allow contact between the liquid nitrogen and the 
straws.  Stabilate tubes were insulated by wrapping in cotton wool and 
transferred to a -80ºC freezer overnight.  Frozen stabilates were then 
transferred to a liquid nitrogen tank for long-term storage. 
 
2.2 Preparation of blood samples 
2.2.1 Preparing plasma from blood samples 
To purify plasma from total blood, blood samples were centrifuged at 14,000 g 
for 10 mins.  The supernatant was transferred into a clean microfuge tube and 
again centrifuged at 14,000 g for 10 mins.  The supernatant was transferred into 
a further clean microfuge tube and sodium azide was added as a preservative, to 
a final concentration of 0.05% w/v.   
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2.2.2 Erythrocyte lysis 
For the extraction of gDNA or RNA from blood-borne parasites, the erythrocytes 
present in the blood sample were first osmotically lysed.  Five volumes of 
Erythrocyte Lysis Buffer (ELB; Qiagen, Crawley, UK, cat. no. 79217) were added 
to one volume of blood, and the sample incubated on ice for 15 mins.  Every five 
mins the sample was mechanically agitated by inversion.  The sample was 
centrifuged at 320 g for 10 mins and the supernatant discarded.  The pellet was 
resuspended in 400 #l ELB and collected by centrifugation again at 320 g for 10 
mins.  The supernatant was again discarded, at which point the pellet was ready 
for gDNA or RNA extraction.   
 
Retrieving both parasites and plasma from the same blood sample was possible 
through an initial centrifugation at 320 g for 10 mins.  The supernatant fraction, 
containing the plasma, could be purified according to section 2.2.1 above; the 
pellet could be resuspended in five volumes of the original blood sample volume 
of ELB and processed according to the protocol in the previous paragraph. 
 
Parasites prepared in this manner were subjected to nucleic acid extraction as 
described in sections 2.4.1 and 2.4.11 below. 
 
2.3 In vitro culture and manipulation of trypanosomes 
2.3.1 Culturing trypanosomes 
In vitro culture of bloodstream form Lister 427 13-90 trypanosomes was achieved 
by using ‘complete’ HMI-9 medium (Hirumi & Hirumi, 1989).  Pre-formulated 
HMI-9 powder was provided by Gibco (Paisley, UK, cat. no. 074-90915N) and 
supplemented with 3% w/v NaHCO3 and 200 #M beta-mercaptoethanol to 
produce ‘incomplete’ HMI-9; medium could be completed by the replacement of 
20% v/v with foetal bovine serum (FBS; Invitrogen, Paisley, UK, cat. no. 10108-
157).  Medium was sterilised by filtration through a 0.2 #m bottle-top filter and 
incomplete medium was stored at 4ºC for up to six months; complete medium 
for no longer than a week.  When working with parasites collected from in vivo 
experiments, medium was supplemented with penicillin-streptomycin (Sigma-
Aldrich, Gillingham, UK, cat. no. P4333) at a 1:1000 dilution.  Where 
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appropriate, the growth medium was supplemented with drugs for selection: 
hygromycin (Source Bioscience, Nottingham, UK, cat. no. ant-hg-1) at 5 #g.ml-1, 
neomycin (Sigma, Gillingham, UK, cat. no. G8168) at 2.5 #g.ml-1, puromycin 
(Merck, Darmstadt, Germany, cat. no. 540222-100MG) at 1 #g.ml-1, blasticidin 
(Merck, cat. no. 203351-10ML) at 5 #g.ml-1.  Cultures were kept at 37ºC in a 
humidified 5% CO2 incubator, and subcultured regularly to avoid over-growth 
(the cell density was not permitted to exceed 2.5 x 106 ml-1). 
 
2.3.2 Transfecting trypanosomes 
Transfections were carried out using the AMAXA Nucleofactor apparatus (Lonza, 
Basel, Switzerland), following a protocol provided online by G. Cross 
(http://tryps.rockefeller.edu/Protocols/transfection_amaxa.pdf).  90 ml of 
complete HMI-9 was supplemented with the drugs appropriate for parental cell 
growth and divided amongst three tubes, so that the first tube (A) contained 30 
ml of medium and the two other tubes (B & C) contained 27 ml of medium.  The 
medium in the tubes was prewarmed to 37ºC.  Approximately 30 x 106 cells were 
harvested by centrifugation at 320 g for 10 mins at room temperature, and 
resuspended in 100 #l Amaxa Human T-cell Nucleofactor solution (Lonza, cat. 
no. VPA-1002) at 4ºC.  The cells were added to a cuvette alongside 10 #l of 
linearized plasmid DNA in distilled water (0.5–1 #g.#l-1 concentration) and 
transfected according to Program X-001.  The contents of the cuvette were 
transferred to tube A of prewarmed medium and mixed well.  From tube A, 3 ml 
of the cell suspension were transferred to tube B and mixed well (giving a 1:10 
dilution).  From tube B, 3 ml of the cell suspension were transferred to tube C 
and mixed well (giving a 1:100 dilution).  The contents of each tube were spread 
across the wells of a 24 well tissue culture plate, giving three 24 well plates with 
1 ml per well.  Between six and 18 h later, 75 ml complete HMI-9 was 
supplemented with the drugs appropriate for parental cell growth, and the 
selective drug at double the normal concentration, and pre-warmed to 37ºC.  1 
ml of the selective medium was added to each well of the three plates.  The 
wells were inspected for growth six days after transfection, and the clonality of 
the transfectants could be estimated by counting the number of positive wells 
per plate with reference to the Poisson distribution (fewer than 30% of wells 
showing growth indicates that >80% of the positive wells were seeded with only 
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one drug-resistant transfectant).  Where necessary parasites could be recloned 
as described below. 
 
2.3.3 Cloning trypanosomes 
Trypanosomes were cloned by diluting parasites to ~0.5 ml-1 in fresh complete 
HMI-9 supplemented with the appropriate drugs, and spreading across the wells 
of a 96 well plate, 200 #l per well.  Wells were inspected for growth 6 days after 
cloning, and the clonality of lines could be estimated as described in section 
2.3.2 above.   
 
2.3.4 Preparation of cultured trypanosomes for molecular biology 
procedures 
Parasites were collected from a culture in log phase growth and pelleted at 320 
g for 10 mins.  The supernatant was discarded and the pellet was washed in 1 ml 
PBS or TDB, and pelleted again at 320 g for 10 mins.  On discarding the 
supernatant, the pellet was ready for use.   
 
2.3.5 Stabilates of in vitro cultures 
In vitro stabilates were prepared from cultures in the log phase of growth, with 
a density between 1–2 x 106 parasites ml-1.  Glycerol, previously sterilized by 
autoclaving, was added as a cryopreservant to a final concentration of 10% v/v 
and the suspension was transferred to a cryotube (Alpha Labs, Eastleigh, UK, 
cat. no. LW3532) and frozen as described in section 2.1.6. 
 
2.4 Basic laboratory procedures 
2.4.1 RNA isolation 
The cell pellets obtained as described above (sections 2.2.2 and 2.3.4) were 
resuspended in 350 #l Buffer RLT (provided with the kit) supplemented with 1% 
v/v beta-mercaptoethanol and processed using the RNeasy kit (Qiagen, Crawley, 
UK, cat. no. 74104) according to the manufacturer's instructions.  Approximately 
0.5–1 x 107 cultured parasites were used for RNA extraction.  DNA digestion was 
carried out using the on-column DNase kit (Qiagen, cat. no. 79254).  RNA yield 
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and quality were assessed photospectometrically using a Nanodrop 1000 (Thermo 
Scientific). 
 
2.4.2 cDNA synthesis 
RNA (maximum 1 #g) was used as the template for cDNA synthesis.  cDNA 
synthesis was carried out using the SuperScript III First Strand Synthesis System 
kit (Invitrogen, Paisley, UK, cat. no. 18080-051) according to the manufacturer's 
instructions.  For each sample, a negative control to which no reverse 
transcriptase was added was also performed: this would exclude the possibility 
that downstream PCR products were amplified from residual contaminating 
genomic DNA.  For all cDNA synthesis reactions the primer used was oligo[dT]20.   
 
Those cDNA samples from which full-length VSG sequences would be amplified 
(as described in 2.4.3 below) were purified using a column purification kit (PCR 
Purification Kit, Qiagen, Crawley, UK, cat. no. 28104). 
 
2.4.3 Polymerase Chain Reaction (PCR) 
To amplify full-length VSG sequences for cloning and sequencing, the 
proofreading polymerase Herculase II Fusion (Agilent, Wokingham, UK, cat. no. 
600675) was used to maximise sequence accuracy.  For this reaction, primers 
corresponding to the spliced leader and the conserved 3’ 16-mer were used 
(Appendix 7.1).  Reactions comprising of 2–4 #l of cDNA, 2 #l of each primer at a 
working concentration of 10 #M, 1 #l of a dNTP mix (each dNTP at 10 mM), 10 #l 
5x Herculase Reaction Buffer (provided with enzyme kit), 5 #l MasterAmp 10x 
PCR Enhancer (from Cambio, Cambridge, UK, cat. no. ME81201), 1 #l Herculase II 
Fusion enzyme, and made up to 50 #l with deionized H2O.  Deionized H2O (dH2O) 
was provided by a MilliQ purification machine (Millipore, Billerica MA, USA).  
Reactions were cycled using a Robocycler PCR machine (Stratagene); reaction 
conditions were 5 mins at 95ºC, followed by 30 cycles of 1 min at 95ºC, 2 mins at 
40ºC and 2 mins at 68ºC, and a 5 min final extension at 68ºC.  Products were 
analysed by agarose gel electrophoresis and purified by gel extraction. 
 
For other PCR reactions, Taq polymerase provided by New England Biolabs was 
used (NEB, Hitchin, UK).  Each 25 #l reaction contained template, 1 #l of each 
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primer from a working concentration of 10 mM, 0.5 #l of a dNTP mix (each of 
dATP, dCTP, dGTP and dTTP at 10 mM), 2.5 #l of 10x Thermopol reaction buffer, 
0.25 #l Taq enzyme at 5 U.#l-1 and made up to 25 #l with dH2O.  Reaction 
conditions were generally as follows: 5 mins at 95ºC, followed by 30 cycles of 50 
seconds at 95ºC, 50 seconds at an annealing temperature between 50 and 63ºC, 
1 min at 68ºC, and a 5 min final extension at 68ºC.  The annealing temperature 
used would vary according to each primer pair; for most reactions it was 50ºC.  
 
All primers for PCR were provided by Eurofins MWG Operon (Ebersburg, 
Germany) and their sequences can be found in Appendix 7.1. 
 
2.4.4 Restriction digestion  
Restriction digestions were performed using enzymes supplied by New England 
Biolabs (Hitchin, UK) in the recommended buffers provided.  Usually, 10 units of 
enzyme were added per #g of DNA, and reactions were incubated at 37ºC for 1–2 
h.  Where necessary, restriction digests were purified by gel extraction, column 
purification, or phenol-chloroform extraction.   
 
2.4.5 Annealing primers 
To generate the SbfI sites required in the pVSG plasmid (Chapter 5), 
complementary oligonucleotides containing the SbfI site flanked by HindIII and 
EcoRI sites were ordered from Eurofins MWG Operon (see Appendix 7.1 for 
details).  4 #l of each oligonucleotide (100 #M concentration) were added to 
58.67 #l dH2O and 133.33 #l 1.5x annealing buffer (100 mM Tris HCl pH 7.5, 1 M 
NaCl, 10 mM EDTA pH 8.0).  The reaction was incubated as follows: 85ºC for 2 
mins, 65ºC for 15 mins, 37ºC for 15 mins, 4ºC for 15 mins.  The products were 
electrophoretically separated on a 4% agarose gel (Lonza, Basel, Switzerland, 
cat. no. BMA 50101), and purified by gel extraction.   
 
2.4.6 Agarose gel electrophoresis and gel extraction 
Separation of DNA by electrophoresis was achieved by loading on 1% agarose gels 
(Invitrogen, Paisley, UK, cat. no. 15510-027) run at 30–120 V in 1 x TAE buffer 
(40 mM Tris, 19 mM acetic acid, 1mM EDTA).  For routine analysis of DNA, 1% 
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w/v agarose in 1 x TAE buffer gels were used.  SYBR-Safe DNA stain (Invitrogen, 
cat. no. S33102) was used at 1:10,000 dilution to allow visualization of DNA 
under ultraviolet light.  Gels were visualised using a Bio-Rad GelDoc (Bio-Rad).  
Images were collected using Quantity One (Bio-Rad) contrast adjusted using the 
GNU Image Manipulation Program (GIMP Development Team, gimp.org). 
 
Where separated DNA was to be extracted from the gel, a sterile scalpel blade 
was used to carefully excise the desired band and place it into a sterile 
microfuge tube.  It was processed using the Qiagen Gel Extraction Kit (Qiagen, 
Crawley, UK, cat. no. 28706) according to the manufacturer's instructions. 
 
2.4.7 Southern blotting 
To blot DNA from an agarose gel, the gel was prepared by incubating in 125 mM 
HCl for 10–15 mins, rinsing in dH2O, and soaking in denaturing solution (0.5 M 
NaOH, 1.5 M NaCl) for 30 mins.  The gel was then transferred to neutralising 
solution (1 M Tris base, 1.5 M NaCl, 186 mM HCl) and incubated for 30 mins.  The 
gel was then soaked in 20x SSC solution (3 M NaCl + 0.3 M sodium citrate).  All 
incubations were carried out at room temperature.  DNA was blotted from an 
agarose gel onto a nylon membrane (Hybond-XL, GE Healthcare, Chalfont St 
Giles, UK, cat. no. RPN303S) by capillary action overnight.  DNA was crosslinked 
to the membrane by ultraviolet radiation (UV Stratalinker 2400, Stratagene, two 
rounds of the ‘auto-crosslink’ program).   
 
For the preliminary dot blots, the membrane was prepared by soaking in 6x SSC 
solution (diluted 20x SSC in dH2O) for 10 mins.  Each plasmid sample was 
adjusted to give a final concentration of 6x SSC, 0.4 M NaOH, 10 mM EDTA, 
boiled at 100ºC for 10 mins and placed on ice.  Each sample was spotted onto 
the wetted membrane, 2 #l at a time.  The membrane was dried, rinsed briefly 
in 2x SSC, and air dried before crosslinking as with gel blots. 
 
Non-radioactive probes were made from PCR amplified DNA using the Amersham 
CDP-Star kit (GE Healthcare, cat. no. RPN3680), following the manufacturer's 
instructions.  This kit utilises the activity of a probe-bound thermostable alkaline 
phosphatase which catalyses the breakdown of a dioxetane substrate, releasing 
light which is captured on an X-ray film.  The kit instructions were followed for 
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hybridization of the probes to the blots, washing the blot, and application of the 
detection reagent.  Blots were wrapped in Saran wrap (Saran, Racine WI, U.S.A.) 
and exposed to X-ray film (Kodak, Geneva, Switzerland, cat. no. 8143059) in 
light-sealed cassettes.  Films were developed using a Konica SRX101A auto-
developer machine. 
 
2.4.8 DNA plasmid cloning 
The full-length VSG sequences were cloned using a TOPO TA cloning kit 
(Invitrogen, Paisley, UK, cat. no. K4500-01).  Because Herculase II Fusion has 
proofreading capability, their products required overhanging deoxyadenosine (A) 
residues to be added by treatment with Taq polymerase before cloning.  8.7 #l 
of gel extracted PCR product was added to 1 #l 10x Thermopol buffer, 0.2 #l 
dNTP mix and 0.1 #l Taq polymerase (reagents as used for PCR, section 2.4.3).  
The reaction was incubated at 70ºC for 15 mins.  These products were TOPO 
cloned without any additional purification step.  TOPO TA cloning was carried 
out according to the manufacturer's instructions, with a 15 min room 
temperature ligation reaction for maximal diversity of cloned PCR products.  
These ligation reactions were used to transform chemically competent TOP10 
Escherichia coli cells (provided with the kit) as described in section 2.4.9. 
 
For the ligation reactions carried out in the generation of the pVSG plasmids, 
plasmid backbones were first treated with calf intestinal phosphatase (CIP, 
acquired from New England Biolabs, Hitchin, UK, cat. no. M0290S) to remove 
reactive phosphate groups that could contribute to plasmid recircularization.  
0.5 units of CIP were added to each #g of DNA in 1x NEBuffer 3 (supplied with 
the enzyme) and the reaction was incubated at 37ºC for 1 hour.  For ligation, 
purified digested DNA of both insert and vector were combined at a molar ratio 
of 3:1 insert:vector in 8 #l dH2O.  10 x ligase buffer (provided with the enzyme) 
and 1 #l 400 U.#l-1 T4 DNA ligase (New England Biolabs, cat. no. M0202S) were 
added to the reaction.  Ligation reactions were usually incubated for one hour at 
room temperature before being used to transform chemically competent E. coli 
cells as described in section 2.4.9.   
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2.4.9 Escherichia coli transformation 
For the products of TOPO cloning reactions, TOP10 Escherichia coli cells were 
used (provided with the cloning kit).  For general transformations, either DH5-α 
or EL-2925 Dam- E. coli cells were used.  For both cell types the transformation 
reaction was the same.  2–5 #l of ligation reaction, or ~25 pg of purified plasmid 
was added to a vial containing approximately 150 #l competent cells and 
incubated on ice for 25 mins.  The vial was then heat shocked at 42ºC for 40 
seconds.  The cells were left to recover on ice for approximately five mins, 
before 250 #l SOC recovery medium (5 g yeast extract, 20 g tryptone, 0.5 g NaCl, 
10 ml 1M MgCl2, 10 ml 2M glucose, 10 ml 1M MgSO4 in 1 L), was added and the 
cells incubated at 37ºC in a shaking incubator for one hour to allow antibiotic 
resistance gene expression.  Transformed cells were spread on LB agar plates 
containing 100 #g.ml-1 ampicillin (Sigma, Gillingham, UK, cat. no. A9518).  LB 
agar was made using L-Broth (see section 2.4.10) to which 20 g.L-1 agar had been 
added.  The volume of transformed cells spread was adjusted to ensure 
convenient spacing of colonies.  Where blue-white screening was required (to 
test for insertion in the TOPO clones, for example), the plates were prepared 
beforehand by spreading 40 #l of a 40 mg.ml-1 X-gal (Melford, Ipswich, UK, cat. 
no. 7240-90-6) in dimethylformaldehyde (DMF) solution and incubating at 37ºC 
for one hour.  Plates spread with transformants were incubated at 37ºC 
overnight and stored inverted at 4ºC.   
 
2.4.10 Plasmid isolation 
Colonies containing the desired plasmid were used to inoculate 6 ml overnight 
cultures of lysogeny broth (L-Broth: 5 g yeast extract, 10 g tryptone, 10 g NaCl in 
1 L H2O, autoclaved) supplemented with 100 #g.ml-1 ampicillin.  Transformants 
containing desired plasmids were generally identified by colony PCR.  A number 
of colonies could be picked, and each resuspended in 30 #l dH2O.  10 #l of this 
resuspension was used as a template for PCR using appropriate primers, the 
remainder, if the PCR gave a positive result, was used to inoculate a 6 ml 
overnight culture.  Where larger plasmid yields were required, multiple 6 ml 
overnight cultures inoculated with the same colony were set up.  Approximately 
18 h later, the cells in the overnight culture were collected by centrifugation at 
2000 g for 10 mins and processed using a small-scale plasmid purification kit 
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(Miniprep kit, Qiagen, Crawley, UK, cat. no. 27106, carried out according to the 
manufacturer's instructions).  Plasmid yield and quality was routinely assessed 
photospectrometrically using a Nanodrop 1000 (Thermo Scientific). 
 
2.4.11 Genomic DNA extraction 
Cell pellets obtained as described above (section 2.1.3) were resuspended in 500 
#l trypanosome lysis buffer (50 mM Tris pH 8, 1 mM EDTA, 100 mM NaCl, 1% SDS) 
containing 100 #g.ml-1 proteinase K (Invitrogen, Paisley, UK, cat. no. 25530015)  
The reaction was incubated at 37ºC for 24–48 h, before proceeding with phenol-
chloroform extraction and ethanol precipitation.  Genomic DNA (gDNA) yield and 
quality was assessed photospectrometrically using a Nanodrop 1000 (Thermo 
Scientific). gDNA was stored in Tris-EDTA buffer (TE Buffer: 10 mM Tris HCl, 1 
mM EDTA, pH 8.0) at 4ºC or -20ºC. 
 
2.4.12 DNA purification by phenol-chloroform extraction and 
ethanol precipitation 
To purify genomic DNA or digested plasmid DNA for transfection, phenol-
chloroform extraction was carried out.  One volume of 
phenol:chloroform:isoamyl alcohol 25:24:1 (Sigma-Aldrich, Gillingham, UK, cat. 
no. P3803) was added to each volume of DNA and mixed well by vortexing.  The 
mixture was centrifuged at 14,000 g in a benchtop centrifuge for 10 mins and 
the aqueous phase carefully retrieved by Gilson pipette and transferred into a 
clean sterile microfuge tube.  One volume of phenol:chloroform:isoamyl alcohol 
was added to the retrieved aqueous layer, the mixture vortexed and again 
centrifuged at 14,000 g in a bench- top centrifuge for 10 mins, and the aqueous 
(top) phase again taken into a fresh microfuge tube.  Phenol-chloroform 
extraction was followed by ethanol precipitation. 
 
Ethanol precipitation was used to purify DNA from salt and solvent 
contaminants, and to concentrate DNA (for transfection, for example).  Two 
volumes of ethanol precipitation mix (made from 40 ml 100% ethanol and 2 ml 3 
M sodium acetate and supplemented with 20 #l 20 mg.ml-1 glycogen (Fermentas, 
St. Leon-Rot, Germany, cat. no. R0561)) was added to the sample and the 
mixture incubated at -80ºC for at least one hour, promoting precipitation of the 
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DNA.  The precipitated DNA was pelleted by centrifugation at 14,000 g for 30 
mins in a 4ºC chilled centrifuge, and the supernatant discarded.  The DNA was 
washed in ice-cold 70% ethanol in deionized H2O and again pelleted by 
centrifugation.  The supernatant was removed completely and the pellet left to 
dry at room temperature.  It was then dissolved in either dH2O or TE buffer. 
 
2.4.13 SDS-PAGE 
For the analysis of crude cell lysates in Chapter 5, SDS-PAGE was used to 
separate the proteins and determine the relative molecular weight of the 
variant band.  SDS-PAGE was carried out using precast NuPage 10% Bis-Tris 
acrylamide gels in 1x MOPS SDS running buffer (Invitrogen, Paisley, UK, cat. nos. 
NP0301BOX and NP0001 respectively).  Crude cell lysates were made by washing 
a cell pellet twice in TDB, and resuspending it in protein loading buffer (PLB, 2% 
SDS w/v, 0.05M Tris, 10% glycerol v/v, 0.1% bromophenol blue w/v for 1x), to a 
final concentration of 1x, mixing well, and boiling at 100ºC for 10 mins.  
Aggregates in the samples were collected by centrifugation at 14,000 g 
immediately before loading the samples to prevent the bands from running 
unevenly.  Approximately 5 x 106 cell-equivalents were loaded in each lane.  
Gels were photographed as described in section 2.4.6 above. 
 
For those bands subjected to tryptic digest mass spectrometry analysis, the 
indicated bands were excised from the gel using a clean, sterile scalpel and 
placed in a sterile microfuge tube.  Mass spectrometry was carried out by 
Richard Burchmore at the University of Glasgow facility, and peptide masses 
were used as queries in the MASCOT database (www.matrixscience.com). 
 
2.4.14 Sequencing 
All sequencing was performed by the Sequencing Service at the University of 
Dundee (Dundee, UK) and Eurofins MWG Operon (Ebersburg, Germany). 
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2.5 Generation of hybridoma lines for the production of 
monoclonal antibodies 
2.5.1 Media for the generation and maintenance of hybridomas 
RPMI (Roswell Park Memorial Institute) incomplete medium was used to wash 
cells and as the basis of cell culture medium.  Incomplete RPMI consisted of RPMI 
1640 (Gibco, Paisley, UK, cat. no. 31870-025) supplemented with 25 mM HEPES 
at a pH of 7.2.  Batches of this medium were prepared and filter sterilised, and 
maintained at 4ºC for up to six months. 
 
RPMI complete medium was used as the growth medium for myeloma and 
hybridoma cells.  To produce 500 ml of this medium, 445 ml of incomplete RPMI 
were supplemented with 250 #l 0.1 M beta-mercaptoethanol, 5 ml 200 mM L-
glutamine (Sigma-Aldrich, Gillingham, UK, cat. no. G7513-100ML) and 50 ml fetal 
bovine serum (Sigma-Aldrich, cat. no. F9665).  Complete medium was stored at 
4ºC for no more than 7 days. 
 
RPMI-HFCS complete medium was used to promote the growth of hybridoma cells 
at low concentration (for example after fusion or cloning).  To produce 100 ml of 
this medium, 2 ml hybridoma fusion and cloning supplement (HFCS, Roche, 
Mannheim, Germany, cat. no. 11 363 735 001) were added to 97 ml incomplete 
RPMI supplemented with 1 ml 200 mM L-glutamine and 50 #l 0.1 M beta-
mercaptoethanol.  Where required, antibiotics (0.2 ml 10 mg.ml-1 gentamycin 
sulphate in dH2O (Sigma-Aldrich, cat. no. G1264-250MG)) and antifungals (0.8 ml 
250 #g.ml-1 amphotericin B (Sigma-Aldrich, cat. no. A2942-100ML)) could replace 
an equivalent volume of incomplete RPMI.   
 
HAT (hypoxanthine-aminopterin-thymidine) medium was used as the selection 
medium for hybridoma cells.  Samples of HAT 50x concentrate (MP Bio, Illkirch, 
France, cat. no. 091680849) were stored at -20ºC.  To produce 1x HAT, 2 ml of 
50x concentrate were added to 98 ml RPMI-HFCS complete medium.   
 
Polyethylene glycol (PEG) solutions were used to induce cell fusion.  PEG of 
molecular weight 1500 was obtained from MP Bio (cat. no. 151915).  Two 
solutions, A and B were made up as follows.  Solution A, 50 grams of PEG 1500 
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were dissolved in 55 ml RPMI incomplete medium.  15 ml dimethyl sulphoxide 
(DMSO) was added, and the solution sterilised by passing through a 0.2 #m pore 
size syringe filter.  This gave 41.6% PEG/15% DMSO.  Solution B, 50 grams of PEG 
1500 were dissolved in 150 ml RPMI incomplete medium and the solution 
sterilised as with solution A.  This gave 25% PEG.  PEG solutions were stored at 
4ºC for no more than three months. 
 
2.5.2 Myeloma cell lines 
All hybridoma lines generated were produced using the p3-x63-ag8 clone 653 
myeloma cell line (source stabilate prepared by S. Terry, University of Glasgow).  
Stabilates of this cell line were kept frozen in liquid nitrogen at a concentration 
of 3 x 106 ml-1 in 90% fetal bovine serum/10% DMSO until ready for use.  One 
week before fusion, an ampoule of cells was removed from liquid nitrogen and 
heated to 37ºC.  The contents were added to 8 ml RPMI incomplete medium and 
centrifuged at 200 g for 7 mins.  The cell pellet was resuspended in 5 ml RPMI 
complete medium, transferred to a tissue culture flask and incubated at 37ºC, 
5% CO2 in a humidified atmosphere.  Cells were examined daily and regularly 
subcultured to keep them in log phase growth at approximately 1–5 x 105 
cells.ml-1.  Viable cell counts were performed by trypan blue exclusion (1:1 cell 
suspension:trypan blue; trypan blue acquired from Fluka, Gillingham, UK, cat. 
no. 93595-50ML).  For fusion, 107 myeloma cells were required, which were 
obtained from up to 100 ml of cells in log phase growth.   
 
2.5.3 Fusion of splenocytes and myeloma cells 
The spleens of mice immunized as described above (section 2.1.5) were 
collected under sterile conditions into 5 ml incomplete RPMI.  The spleen was 
placed in a petri dish containing 5 ml incomplete RPMI at room temperature and 
placed between two sterile pieces of nitex gauze (a kind gift from C. Hansell, 
University of Glasgow).  Using the plunger of a syringe, the spleen was gently 
strained through the gauze, and the gauze was removed along with any 
remaining clumps of fat and connective tissue.  The cell suspension remaining in 
the petri dish was transferred to 50 ml of RPMI incomplete medium and pelleted 
at 200 g for 7 mins at room temperature.  The supernatant was discarded and 
the pellet washed again in 50 ml RPMI incomplete medium.  The cell pellet was 
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resuspended in 10 ml RPMI incomplete medium and viable cells counted by 
trypan blue exclusion as described above; viability was always greater than 90%.  
For fusion, all solutions were pre-warmed to 37ºC.  108 spleen cells and 107 
myeloma cells were mixed in 50 ml of RPMI incomplete medium and pelleted by 
centrifugation at 200 g for 7 mins.  The supernatant was removed completely.  
To the pellet, 0.5 ml PEG solution A was added dropwise over a 30 second 
period.  During this process, the tip of the pipette was used to disrupt the 
pellet.  The tube was gently rocked for another 30 seconds.  0.5 ml PEG solution 
B was then added, and the pellet mechanically agitated using the tip of the 
pipette for 2–3 mins.  40 ml HAT selection medium supplemented with 
gentamycin and amphotericin B was added drop-wise over a 10 min period with 
constant rocking of the tube, after which time 60 ml HAT selection medium 
supplemented with gentamycin and amphotericin B was added.  The cell 
suspension was added to the wells of five flat-bottomed 96 well microtitre 
plates, 200 #l per well, and incubated at 37ºC in 5% CO2 in a humid atmosphere 
for 10 days without feeding. 
 
On day 10, the plates were observed macroscopically from below.  Colonies of 
hybridoma cells were visible in approximately 40–60% of the wells, and wells 
showing growth were recorded.  15 #l of supernatant from the wells showing 
growth were removed for antibody screening.  Cells in wells secreting desired 
mAbs (as determined by indirect immunofluorescence described in section 2.6.2 
below) were removed by gently tritiating the well and transferring the resulting 
cell suspension into 1 ml of prewarmed RPMI-HFCS complete medium. 
 
2.5.4 Hybridoma cloning 
Hybridoma lines were cloned by limiting dilution as soon as possible after fusion.  
Viable cell counts were carried out by trypan blue exclusion.  Cells were diluted 
with RPMI-HFCS and placed in a 96 well plate so that 16 wells received 
approximately 1 hybridoma cell each, eight wells received approximately 0.1 
hybridoma cell each and eight wells received approximately 0.01 hybridoma cell 
each.  Wells showing growth at the greatest dilution were selected for 
screening, carried out as described in 2.6.2.  The clonality of the wells could be 
estimated by reference to the Poisson distribution as described in section 2.3.2.  
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Hybridoma lines secreting the desired mAbs were cloned twice to ensure 
clonality.   
 
2.5.5 Maintenance of hybridoma cell lines and production of 
mAbs 
Cultures of hybridoma cells were examined daily and regularly subcultured to 
keep them in log phase growth at approximately 1–5 x 105 cells.ml-1.  Viable cell 
counts were performed by trypan blue exclusion.  To produce a stock of desired 
mAbs, 50 ml cultures of hybridoma cells were set up, and allowed to overgrow.  
Cell death could be estimated by microscopic examination of the cultures: when 
cells began to detach from the bottom of the plate (after approximately 1 week) 
the supernatant was collected by centrifugation at 3200 g for 10 mins to remove 
cells and debris.  Sodium azide was added to the supernatants as a preservative 
at a final concentration of 0.05%. 
 
2.5.6 Cryopreservation of myeloma and hybridoma cells 
To prepare cells for cryopreservation, 3 x 106 cells per stabilate were collected 
by centrifugation and resuspended in 1 ml of 90% fetal bovine serum/10% DMSO.  
The cell suspension was transferred to a cryotube and frozen as described in 
section 2.1.6.  Removal of hybridoma cells from stabilate was performed as 
described for myeloma cells, above. 
 
2.6 Analysis of antibody responses 
2.6.1 Preparation of acetone-fixed slides 
Acetone-fixed slides of in vitro parasite cultures were prepared by resuspending 
cultured parasites in complete HMI-9 at a concentration of 2 x 107 parasites.ml-1.  
Thin films of this suspension were spotted on the surface of a clean glass slide 
using a Gilson pipette.  The thinness of the film was critical to ensure rapid 
drying of the slide.  As many as 12 spots could fit on a slide.  When the slide had 
dried, it was submerged in a Coplin jar containing acetone at room temperature 
for 10 mins.  The slide was then air dried.  For longer-term storage, fixed slides 
could be wrapped in tissue and placed in a sealed plastic bag with silica gel (4–7 
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mesh, Fisher Scientific, Loughborough, UK, cat. no. S/0760/53) as a desiccant, 
and frozen at -20ºC. 
 
2.6.2 Immunofluorescence assay on acetone-fixed slides 
Immunofluorescence screening using acetone-fixed trypanosomes was the assay 
used to screen hybridoma lines.  Undiluted supernatant from hybridoma cultures 
was used as the primary antibody in this assay.  A paint pen (‘Mark-Tex’, Menke, 
Santa Fe CA, U.S.A.) was used to draw hydrophobic circles around the spots on 
the slide, forming wells to use as reference and preventing cross-contamination 
of antibodies during the preparation of the slide.  Undiluted hybridoma culture 
supernatant was added to the slide, and the slide incubated in a humid chamber 
for 30 mins at room temperature.  The slide was washed twice with PBS.  
Secondary antibodies, at a 1:2000 dilution in PBS supplemented with 1% BSA 
(Sigma-Aldrich, Gillingham, UK, cat. no. A4503) were applied to the slide.  The 
secondary antibodies used in all cases were Alexa 488-conjugated goat anti-
mouse IgG H+L (Invitrogen, Paisley, UK, cat. no. A-11001) which reacts against 
IgG heavy chains and both classes of immunoglobulin light chain from mouse, 
and, where isotype differentiation was required, Alexa 594-conjugated goat 
anti-mouse IgM (# chain) (Invitrogen, cat. no. A-21044) which is specific for the 
IgM isotype.  The slide was again incubated in a humid chamber for 30 mins at 
room temperature, before being washed twice with PBS and mounted using 
Vectashield + DAPI (Vector Laboratories, Peterborough, UK, cat. no. H-1200).  
Slides were examined using a Zeiss Axioscop 2 mot + microscope at 1000x 
magnification.  Each slide would routinely include parasites expected not to 
react, as a negative control for non-specific antibody binding.  Images were 
collected using Openlab 5.0 software (Improvision, Waltham MA, U.S.A.) and 
contrast adjusted using GNU Image Manipulation Program (GIMP Development 
Team, gimp.org). 
 
2.6.3 Live cell immunofluorescence 
To test whether antibodies are able to recognize the intact VSG surface coat, 
the primary antibody was applied to live cells and fixed using formaldehyde.   
For this assay, 1 x 106 cells were required per reaction.  All centrifugation steps 
were carried out at 1200 g for 7 mins at 4ºC.  Preparations of TDB or PBS 
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supplemented with 1% BSA (Sigma-Aldrich, Gillingham, UK, cat. no. A4503) were 
filter sterilised using a 0.2 #m pore size syringe filter before use.  8% 
formaldehyde solution was prepared in a fume hood in advance.  16 g 
paraformaldehyde powder (Honeywell Riedel de Haën, Seelze, Germany, cat. 
no. 16005) was dissolved in 50 ml water at 60ºC (using 10 #l 10M NaOH to aid 
solubility), 10 ml 10x PBS was added and the volume made up to 100 ml.  The pH 
of the solution was measured using pH paper and dilute HCl added to reach a 
final pH of 7.2.  The prepared formaldehyde solution was distributed into single-
use tubes and frozen at -20ºC and used within 6 months. 
 
Cells from culture were resuspended in TDB and collected by centrifugation.  
Cells were resuspended in 100 #l primary antibody solution.  For polyclonal 
antibodies from plasma, this solution was 1:25 dilution in TDB + 1% BSA, and for 
monoclonal antibodies the primary antibody solution was undiluted supernatant.  
Cells were incubated on ice for 10 mins.  100 #l 8% formaldehyde solution was 
added and mixed well, and the reaction incubated on ice for 10 mins.  The cells 
were collected by centrifugation and washed twice with 200 #l PBS.  The cells 
were then resuspended in 100 #l secondary antibody solution.  For this assay, 
secondary antibodies (as described above) were at 1:500 dilution in PBS + 1% 
BSA.  The cells were incubated on ice for 15 mins, washed twice in PBS, 
mounted on a glass slide and examined as described above.  This method is a 
modified version of that kindly provided by M. Engstler (Universität Würzburg, 
pers. comm.). 
 
2.6.4 Complement-mediated lysis and agglutination assay 
To test whether antibodies had functional activity, complement-mediated lysis 
was carried out.  Complement-competent plasma was prepared from freshly 
collected guinea pig blood by centrifugation at 14,000 g for 10 mins, retrieving 
the supernatant into a fresh tube, removing any remaining blood cells by an 
additional 10 min 14,000 g centrifugation, and again retrieving the supernatant 
into a fresh tube.  This purified plasma (guinea pig plasma, GPP) was divided 
into small samples, frozen, and stored at -80ºC until ready for use.  On the day 
of the experiment, GPP was thawed and centrifuged at 14,000 g for 10 mins to 
separate any aggregates that may have formed.  Representative polyclonal 
antibodies directed against the various antigens under consideration were 
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serially diluted in the guinea pig plasma, and spread across the wells of a 
Terasaki plate (Greiner, Stonehouse, UK), 5 #l per well.  5 #l of trypanosomes 
resuspended in GPP were added to each antibody dilution.  For this assay, 
50,000 cells were required per well (that is, 1 x 107 parasites.ml-1).  The 
reaction was incubated at room temperature for one hour before observation 
under phase contrast microscopy at 400x magnification and scoring the wells for 
cell death.  For each parasite line, cells were incubated at the same 
concentration in guinea pig plasma to control for non-specific killing. 
 
To test whether antibodies were able to agglutinate parasites, agglutination 
assays were set up.  These were broadly similar to the complement-mediated 
lysis assay, above, except that antibodies were diluted, and parasites were 
resuspended, in TDB.  For this assay, 100,000 cells were required per well (that 
is, 2 x 107 parasites.ml-1).  The reaction was incubated at room temperature for 
30 mins before observation under phase contrast microscopy and scoring the 
wells for agglutination.  For each parasite line, cells were incubated at the same 
concentration in TDB to control for non-specific aggregation. 
 
2.7 Bioinformatics and in silico sequence manipulation 
2.7.1 Manual sequence manipulation 
Sequences were assembled, visualised, compared and analysed using CLC 
Genomics Workbench (CLC Bio, Aarhus, Denmark), eBioX (developed by Erik 
Lagercrantz, available at www.ebioinformatics.org/ebiox), custom Ruby and 
BioRuby scripts I wrote (Goto et al., 2010) and Aquamacs (developed by David 
Reitter, available at aquamacs.org).   
 
For the VSG clone sequences, details of manual sequence manipulations were 
recorded in an Excel spreadsheet (Appendix 7.2.3).  Full-length assembled 
sequences were saved as FASTA files corresponding with their unique clone name 
(XX-YYcZZ, where XX was the infection number, YY the day of collection and ZZ 
a numeric identifier) and placed together in a directory. 
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2.7.2 Analysis of sequences 
2.7.2.1 Grouping of sequences into ‘sets’ 
VSG clone sequences were placed into ‘sets’ according to their BLAST matches 
to a database of genomic VSG sequences (Altschul et al., 1990) and their 
alignments with one another.  The genomic VSG database is described in 
Appendix 7.2.4.  Clone sequences were aligned automatically using Clustal W 
(Larkin et al., 2007).  Details of each set—its constituent clones and best-
matching genomic copies, alongside notes and other comments—were recorded 
in separate flat text files.  The format of these text files was standardized so 
they could be parsed easily by Ruby script.  For each set, alignments of the full-
length nucleic acid sequences, and mature N-terminal domain (identified as 
described in section 2.7.2.2) amino acid sequences, were stored in separate 
directories.  In some cases, alignments were altered by hand to improve 
matching to putative donors.   
 
2.7.2.2 Identifying features of VSG sequences 
For each VSG, there were considered to be 50 amino acids in the C-terminal 
domain before the first conserved cysteine (Marcello & Barry, 2007a).  This 
assumption was used to assign the junction between N- and C-terminal domains 
(the first position of the first codon encoding the C-terminal domain) for each 
clone; this datum was recorded for each clone in a script-parsable text file.  The 
SignalP 4.0 server (Petersen et al., 2011) was used to predict the length of the 
N-terminal signal peptide for each clone, this datum (the third position of the 
last codon of the signal peptide) was stored alongside the information on domain 
junctions.  The position of the N- and C-terminal domain junction, and the 
position of the N-terminal signal peptide cleavage, were usually the same for all 
clones of a set.  Where they were not, the positions were standardized for each 
set (according to the mode), to simplify the analyses.  Where the position of GPI 
anchor signal cleavage was required, the length of the GPI anchor was 
determined by reference to known VSG GPI anchor signal sequences (Marcello et 
al., 2007), or using the big-PI (Eisenhaber et al., 1999) or Fraganchor (Poisson et 
al., 2007) servers. 
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2.7.2.3 Identification of ‘read’ donors 
Where one or more VSG clones had no match in the genomic VSG database for 
part or all of their sequence, putative ‘read’ and ‘mc’ donors could be identified 
and assembled as follows.  The part(s) of the clone for which no donor could be 
found were used as queries in BLAST searches of several ‘reads’ databases 
(described in Appendix 7.2.5).  Matching reads were retrieved from these 
databases, and compared with the clone sequence using CLC Genomics 
Workbench.  Reads that were similar to the clone and different from all 
identified genomic copies were assembled to form a contig.  Occasional 
mismatches between the reads were treated as follows.  If the mismatch 
occurred towards the ends of a read, it was considered to be the result of poor 
quality sequencing, and was corrected in favour of the other read(s).  If the 
mismatch occurred in the middle of the read, but more than one other read did 
not contain the mismatch, it was corrected in favour of the other reads.  If the 
mismatch occurred in the middle of the read, and there was only one other read 
with which to compare it, the mismatch was corrected in favour of the 
corresponding clone sequence.  Putative read assemblies were saved as FASTA 
files and were placed in a separate directory.  They are described in Appendix 
7.2.6. 
 
2.7.2.4 The semi-automated analysis of sequences using scripts 
With the text files describing each set’s constituent clones and their putative 
donor sequence(s), the multiple sequence alignment for that set, and the 
position of the N-terminal signal sequence and N- and C-terminal domain 
boundary for each clone of that set in place, an automated BioRuby script was 
written to describe the features of each clone and its relationship with the 
donor(s).  This script is ‘vsg_analysis_from_aln.rb’ and is freely available on 
request.  Essentially, the script took an alignment in FASTA format and 
identified clone sequences and donor sequences according to their names.  Each 
clone sequence was considered in turn.  The clone sequence was examined, and 
each position was compared with each donor sequence at that position.  For 
each position, a ‘piece’ object was created, which contained a list of the 
matching donors at that position.  These ‘pieces’ were accumulated to form 
‘blocks’.  The list of blocks simply starts as the list of pieces, but it is 
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progressively condensed in an iterative process: if adjacent pieces match the 
same donor(s), those pieces are accumulated in a block, corresponding with 
their shared donor.  Blocks expand to accumulate all possible pieces.  This 
process continues across the sequence, until blocks can accumulate no more 
pieces.  At the end of the process, ambiguous blocks (blocks that still match 
more than one donor) are weighted towards the overall best-matching donor for 
that clone.  Following the process of accumulation, blocks are corrected to give 
the junctions.  Pieces at the edges of the blocks that are ambiguous between 
that block’s donor and the donor of an adjacent block constitute the junction.  
These pieces are equally distributed between the two contesting blocks.  The 
script also removes gaps from the alignment, records the position of cysteine 
codons and positions where the clone sequence matches none of the putative 
donors (and the non-synonymity of that mismatch), calculates the best matching 
donor, and extracts the data on the N- and C-terminal domain boundary and N-
terminal signal peptide from the data file.  All this information is transcribed 
into a script-parsable text file, which was placed in a different directory.  
Variations on ‘vsg_analysis_from_aln.rb’ were used to ‘strip out’ data of interest 
for various bioinformatic studies.  Semi-automated analyses were complemented 
by at least one manual analysis to control for bugs in the scripts. 
 
2.7.2.5 Graphical representation 
The script-parsable data files produced in section 2.7.2.4 were described 
graphically using the Ruby script ‘vsg_diagram.rb’ (freely available on request).  
This program simply read in the information in one or more of the script-
parsable data files and transcribed this information as a Scalable Vector 
Graphics (.svg) file that could be visualised using many internet browsers and 
image manipulation programs.  These diagrams were used as tools to indicate 
what sequence alignments should be investigated manually for segmental gene 
conversion.  Variations on ‘vsg_diagram.rb’ were also used to represent other 
data where required.  The analysis of sequences was an iterative process: the 
graphical representation of the data indicating where reanalysis was required.  
These graphical representations formed the basis for the VSG diagrams provided 
in this document; where necessary they were manipulated further using the GNU 
Image Manipulation Program (GIMP Development Team, gimp.org). 
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3 VSG expression in chronic mouse infections 
3.1 Introduction 
3.1.1 What VSGs are expressed during infection? 
Previous findings have hinted at the importance of segmental gene conversion in 
generating expressed VSGs as Trypanosoma brucei infections progress (Barbet & 
Kamper, 1993; Marcello & Barry, 2007a).  Segmental gene conversion could offer 
several key benefits to the trypanosome population.  Firstly, it allows expression 
of VSGs damaged by pseudogenicity, which comprise the bulk of the archive 
(Marcello & Barry, 2007a).  Damaged VSG activation could become important as 
responses accumulate against easier-to-activate undamaged VSGs.  Secondly, it 
introduces variability in expressed variants, which could contribute directly to 
antigenic variation.  Other antigenically variant pathogens use the combinatorial 
power of segmental gene conversion to generate huge antigenic diversity 
(Brayton et al., 2001; Coutte et al., 2009; Palmer et al., 2009).  Segmental gene 
conversion could also affect the rate at which silent VSGs are activated, helping 
to bring about a hierarchy of expression (Pays, 1989).27 
 
To understand the role of segmental gene conversion in Trypanosoma brucei 
antigenic variation, a detailed picture of the VSGs expressed over the course of 
infection was required.  A pilot study investigating infections at a single 
timepoint suggested a prominent role for mosaic VSGs in late stage infection 
(Marcello & Barry, 2007a).  The approach of Marcello & Barry (2007) was 
expanded, with longitudinal sampling allowing individual infections to be 
followed over time, enabling changes in the antigenic profiles of the resident 
trypanosome population to be identified.  By comparing expressed VSGs with one 
another and with those present in the genome, the extent of segmental gene 
conversion—in particular expressed mosaic VSG formation—could be estimated.  
These data also provided material for further analyses in subsequent chapters. 
 
                                         
27 These possibilities are discussed further in Chapter 6 (section 6.4), in light of the results 
presented here. 
Chapter 3  99 
3.1.2 Key hypotheses to be tested 
To investigate the distinctive features of VSG expression during infection, 
repeated samples were taken longitudinally from a number of infections to 
address the following hypotheses: 
(i) Early appearance of intact VSGs.  Each infection is hypothesised to 
display unique characteristics, but at earlier timepoints and in numerous 
infections, a subset of frequently-activated VSGs will be detected.  
Intact, full-length, and telomere proximal genes have a greater 
activation probability as they require fewer genetic rearrangements to 
become a functional, active-expression-site-occupying VSG and hence 
are more likely to be expressed earlier on in numerous infections (Aline 
et al., 1985; Laurent et al., 1984a; Morrison et al., 2005).  Telomere-
proximal VSGs are also more likely to physically interact with the 
telomere-proximal BES (Barry et al., 2003). 
(ii) Late appearance of damaged VSGs, through segmental gene conversion.  
As an infection progresses the host develops responses to the subset of 
easily accessible genomic copies.  Antibodies might select for rarer 
genetic rearrangements—segmental gene conversions that have repaired 
damaged silent VSGs—leading to an increased detection of mosaic VSGs 
at later timepoints (Marcello & Barry, 2007a; Pays, 1989; Roth et al., 
1989). 
(iii) Progressive mosaicism.  As infections continue through the late stage, 
repeated incidences of segmental gene conversion will ultimately result 
in the expression of increasingly complex mosaic antigens (as seen in 
Anaplasma marginale by Palmer et al., 2007).  When such segmental 
conversions change the epitope structure of the expressed VSG, a series 
of related yet antigenically distinct mosaic VSGs may persist over time in 
an infection: a ‘string’ of mosaics (Barry et al., 2005). 
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3.2 Experimental approach 
3.2.1 VSG sequences were amplified, cloned and sequenced from 
longitudinal samples 
To address these questions, individual infections of mice were sampled at 
different points in time, and the expressed VSG sequences were retrieved.  Mice 
provide an accessible model of mammalian infection: they reliably maintain a 
high parasitaemia with Trypanosoma brucei (depending on strain), they seldom 
self-cure, and they are easy to work with and maintain.  In addition, the range 
of immunological knockouts available means that further studies could easily 
investigate the impact of different aspects of the host immune system on any 
phenomena identified here. 
 
The rapidity with which parasites switch antigen expression (estimated to be as 
high as 0.01 per cell per division (Turner & Barry, 1989; Turner, 1997)) precludes 
the isolation of different antigens by cell cloning, as cloned parasites would 
likely switch before they reach required numbers.  Therefore, antigen mRNA 
sequences were isolated and amplified for sequencing.  Currently, the short read 
length approach employed by ‘next-generation’ Illumina sequencing would make 
assembly of mosaic VSGs not unambiguous, so VSG sequences selectively 
amplified from reverse-transcribed RNA were cloned using a commercial PCR 
subcloning kit and sequenced by the Sanger chain-termination method as 
described in Chapter 2 (section 2.4.14).  Sequences could then be analysed 
bioinformatically to reveal patterns of VSG expression across infection.28 
 
3.2.2 Assumptions of experimental approach 
As a way of investigating the antigenic profile of the parasite population, this 
mRNA cloning and sequencing approach makes several assumptions about VSG 
expression and trypanosome population structure, which although justified 
should be made explicit. 
 
                                         
28 The small blood samples necessitated by ethical and legal considerations meant that only mRNA 
could be reliably retrieved from longitudinal samples (although see Chapter 2 section 2.2). 
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3.2.2.1 VSG mRNA is a valid proxy for the VSG surface coat.   
Despite strong evidence that all detectable full-length VSG mRNA is produced 
from the active ES (reviewed in Chapter 1, section 1.6.2) it is possible that 
mRNA can be transcribed but not culminate in being expressed as a surface coat.  
A plausible example would be a cell in which a VSG gene with a premature stop 
codon or frameshift has entered the active expression site: transiently, these 
cells would transcribe a VSG that cannot be translated to protein.  This state will 
be resolved either by the cell switching expression from the damaged gene to an 
intact one, by the cell’s inability to produce a complete surface coat (resulting 
in elimination by the innate immune system (Ferrante & Allison, 1983)), or 
possible cell death through global translational repression (Smith et al., 2009).  
Due to the preferential degradation of nonsense mRNA transcripts (Delhi et al., 
2011) and the need for the cell to replace the constantly turning-over coat 
(Seyfang et al., 1990) it was assumed that the effects of mistranscription would 
be minor.  Stumpy form trypanosomes downregulate transcription from their BES 
(Amiguet-Vercher et al., 2004) and so it is possible that their surface coats will 
be underrepresented in the mRNA if their population is not representative of the 
proliferative VSG-transcribing long slender forms. 
 
3.2.2.2 All VSG mRNA contains primer binding sites for the VSG amplifying 
primers.   
The forward primer binds to the spliced leader sequence trans-spliced onto the 
5’ end of all trypanosome mRNAs (Parsons et al., 1984; Walder et al., 1986).  
The reverse primer binds to a conserved 16-mer found in the 3’ untranslated 
region of all VSG mRNAs (Matthyssens et al., 1981; Merritt et al., 1983; Michels 
et al., 1983).  There is also experimental evidence that this 16-mer has a pivotal 
role in silencing non-active VSGs (see Chapter 1 section 1.6.2), further 
supporting the assumption that the primers are sufficient and exclusive for the 
expressed VSG (S. Hutchison pers. comm., P. Batram pers. comm. Berberof et 
al., 1995).  Prior to these experiments being carried out (March 2009), the exact 
16-mer was identified in all but two of the sufficiently long VSG mRNA sequences 
retrieved from the NCBI nucleotide database (www.ncbi.nlm.nih.gov, those that 
differed, differed by only a single nucleotide). 
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3.2.2.3 Blood sampled by tail venesection is representative of the whole 
infection.   
Bottlenecks restricting the movement of either parasites or immune effectors 
between tissues would likely result in the course of antigenic variation to run 
semi-independently either side of the bottleneck.  The most pertinent example 
of this would be the immunoprivileged central nervous system (Jennings et al., 
1979).  However, experiments addressing this question have found similar 
patterns of VATs occurring in different tissues, indicating that the potential 
effects of differential tissue location would probably be small (Turner et al., 
1986).  As peripheral blood29 is the easiest and most humane tissue to collect 
regularly, it forms the most immediately accessible experimental model.  
 
3.2.2.4 Amplification and cloning of VSG sequences is not grossly biased or 
mutagenic.   
There is abundant evidence suggesting that the amplification of certain 
sequences proceeds more quickly or effectively than others (Arezi et al., 2003).  
It is therefore possible that amplification and cloning inherently favours certain 
VSGs over others.  To minimise this possibility, an enzyme with proven efficacy 
at amplifying diverse sequences, Herculase II Fusion polymerase, was used for 
amplification for cloning (Agilent, Wokingham, UK).  In addition, further PCR 
reactions were carried out on cDNA to examine the potential for cloning and 
sequencing bias (section 3.5.2).  It is also possible that the process of 
amplification and cloning introduces mutations, discussed in more detail in 
Chapter 4 (section 4.2). 
 
3.3 Retrieval of VSG sequences 
3.3.1 Samples were taken to focus on the later stage of infection 
To follow changes in VSG expression over time, multiple samples from individual 
infections were required.  Humane restrictions on the total volume of blood 
sampled over the course of infection (maximum 15% of total blood volume over a 
28 day period) and a desire to strike a balance between breadth and depth of 
                                         
29 The terminal samples in all cases were collected by exsanguination by cardiac puncture under 
terminal anaesthesia, to maximise the size of the sample. 
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sampling meant that each mouse could be sampled only a limited number of 
times.  The later, chronic stage of infection was of particular interest, as natural 
infections of mammals often proceed for many months before resolution 
(Guirnalda et al., 2007; Nantulya et al., 1984; Penchenier et al., 2005; Songa et 
al., 1991).  Previous studies have broadly described the patterns of the first 
relapse peak of infection (occurring around day 10–14 (Miller & Turner, 1981; 
Myler et al., 1988; Robinson et al., 1999)).  Furthermore, a previous pilot study 
on which the present analyses have been based has indicated the predominance 
of less-well-characterised mosaic VSGs from approximately day 21 onwards 
(Marcello & Barry, 2007a).  Therefore, samples were collected from eight mice 
to focus on this later stage of infection, between days 20 and 34.  Three further 
infections also cover earlier timepoints.  Details of the infections are shown in 
Table 3.1.   
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Table 3.1 Chronic mouse infections.  The relationship between the inocula is shown in 
Appendix 7.2.1.  Inoculum size was measured by haemocytometer for all cases except for 
mouse 08 and mouse 09 where the inoculum was optically cloned.  10,000–40,000 parasites 
was considered sufficient to reliably establish infection by intraperitoneal inoculation.  
LM_XX refers to 11 infections analysed previously by Marcello & Barry (2007a). 
 
Some of these infections were carried out to address specific experimental 
questions (for example the primary clonal infections in mice 08 and 09) but were 
subsequently used as a source of material for the VSG expression analysis 
described here; in these cases the sequences retrieved will be discussed both in 
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the context of the other infections, and separately in the context of the specific 
experimental questions being addressed.  As 37 VSG sequences described in 
previous work (Marcello & Barry, 2007a) will be frequently referred to in this and 
the following chapter, the infections from which they were obtained are also 
described in the Table.  All chronic mouse infections were carried out using the 
‘genome strain’ of T. brucei—specifically a recently recloned TREU 927/4 GUTat 
10.1 stabilate kindly provided by L. Marcello.  The pedigree of the parasites used 
in these infections is shown in Appendix 7.2.1. 
3.3.2 Parasitaemias followed a broadly similar pattern in different 
infection 
The parasitaemias of the 11 infections were monitored by rapid matching 
(Herbert & Lumsden, 1976).  Graphs of parasitaemia over time are shown in 
Figure 3.1, and for clarity the exemplary parasitaemia of mouse 05 is shown 
separately in Figure 3.2 (the individual parasitaemias for the other mice are 
shown in Appendix 7.2.2).   
 
The parasitaemias followed a broadly similar pattern.  In all infections except 
one of the clonal infections (mouse 08), a ‘first peak’ of parasitaemia was seen 
between days four and six, marked A in Figure 3.2, reaching as high as antilog 
8.1 parasites.ml-1.  The parasitaemia then fell and remained reasonably stable 
between antilog 7.2 parasites.ml-1 and antilog 7.8 parasites.ml-1 for the next 15 
to 20 days of infection (marked B on Figure 3.2).  Interestingly, all but two of 
the infections studied showed a dramatic (ten-fold) drop in parasitaemia 
approximately 3 weeks into the infection (occurring approximately between days 
21 and 26, marked C on Figure 3.2).30  This state lasted for one or two days, 
after which the parasitaemia recovered.  A similar transient drop in parasite 
numbers at approximately week 3 of infection was also observed in the 
infections carried out by (2007a).  Possible explanations for this phenomenon are 
discussed below, in sections 3.5.4 and 3.5.5. 
 
                                         
30 The exceptions are mouse 02, which sees a dip in parasitaemia later (day 29), and mouse 10, 
which sees a dip in parasitaemia earlier (around day 16). 
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Figure 3.1 Parasitaemias.  Mice were examined daily from day 4 of infection onwards and 
parasitaemia estimated by rapid matching (Herbert & Lumsden, 1976). 
 
 
 
Figure 3.2 Mouse 05 parasitaemia.  Points A, B and C are discussed in the text.  
 
  
!"#$
!"!$
%"#$
%"!$
&"#$
&"!$
'"#$
'"!$
("#$
#$ )$ *$ +$ ,$ !$ %$ &$ '$ ($ )#$ ))$ )*$ )+$ ),$ )!$ )%$ )&$ )'$ )($ *#$ *)$ **$ *+$ *,$ *!$ *%$ *&$ *'$ *($ +#$ +)$ +*$ ++$ +,$
!"
#$
%&
'(
!)
!*
+,-
*'.
'/
$'0
$%
%1
'
1!2'%3'+"3-4#%"'
#)$
#*$
#+$
#,$
#!$
#%$
#'$
#($
)#$
))$
)*$
!"#$
!"!$
%"#$
%"!$
&"#$
&"!$
'"#$
'"!$
#$ ($ )$ *$ +$ !$ %$ &$ '$ ,$ (#$ (($ ()$ (*$ (+$ (!$ (%$ (&$ ('$ (,$ )#$ )($ ))$ )*$ )+$ )!$ )%$ )&$ )'$ ),$ *#$ *($ *)$ **$ *+$
!"
#$
%&
'(
!)
!*
+,-
*'.
'/
$'0
$%
%1
'
1!2'%3'+"3-4#%"'
!" #"$"
%&'()"*+",-.-(/0-)1/-"
Chapter 3  106 
Between days 29 and 34 parasitaemia could reach very high levels.  In one case, 
observed ill effects led to the euthanasia of the animal at day 29 (mouse 06).  
The median life expectancy for a Balb/c mouse infected with a pleomorphic 
trypanosome line31 is 35 days (Magez et al., 2008), and all experiments were 
terminated before then (the median length of infection was 31 days). 
 
The lack of distinct peaks and generally high parasitaemia indicates that density-
dependent differentiation is likely to be the dominant factor controlling the 
parasite population in these infections (Gjini et al., 2010; MacGregor et al., 
2011).  Short stumpy form trypanosomes were often observed when assessing 
parasitaemia microscopically, although their abundance was not formally 
measured. 
 
3.3.3 VSG sequences were readily amplified from trypanosome 
mRNA 
From individual infections, blood samples were taken by repeated tail 
venesection32 into CBSS buffer containing 5% w/v sodium citrate anticoagulant.  
Erythrocytes were osmotically lysed, total RNA was extracted and reverse 
transcribed using an oligo[dT] template, and the synthesized cDNA was column 
purified.  Details of the protocol are in Chapter 2 (sections 2.2 and 2.4).   
 
cDNA corresponding to full-length VSG mRNA was selectively amplified by PCR.  
To control for the possibility of genomic DNA (gDNA) contamination, each 
reaction was also carried out on the products of a ‘cDNA synthesis’ reaction to 
which no reverse transcriptase had been added.  No products could be seen in 
any VSG PCR gDNA control.  Indeed, because the primers used target the trans-
spliced leader sequence, no products of the correct size are seen even if the PCR 
is carried out on purified gDNA (data not shown).  A portion of each PCR reaction 
was separated on a 1% agarose gel, shown for mouse 01–06 and FF in Figure 3.3.  
The remainder of each reaction, run on a separate gel, was purified by gel 
                                         
31 In the case of Magez et al. (2008) the trypanosome line in question was AnTat 1.1E, but a similar 
trajectory is seen in infections with TREU 927/4 (C. M. R. Turner, pers. comm.) 
32 The exception was the terminal sample, which (as described above) was collected by 
exsanguination by cardiac puncture) 
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extraction, ensuring that all of the gel corresponding to the 1300–1700 bp size 
markers was collected.  Samples from mice 10–12 were prepared by H. Wang. 
 
 
Figure 3.3 Amplification of VSG cDNA.  The products of VSG amplification reactions from 
cDNA and controls for gDNA contamination.  FF is the inoculum source (day 2 of infection).  
The smaller band seen in each case is likely due to the 16-mer primer binding to an 
alternative, unknown template, as the primer is short and reaction annealing temperature is 
low (40ºC), smaller products were previously seen in similar reactions by Merritt et al., 
(1983). 
 
To compare the sizes of the VSG amplicons over the course an infection, a 
sample of gel-purified PCR product from each timepoint of mouse 01–06 was run 
in adjacent lanes on a 1% agarose gel.  The result is shown in Figure 3.4.  The 
band can clearly be seen to change apparent size as each infection progresses, 
and at some timepoints numerous bands, or a tight smear, can be seen.  This 
indicates the presence of different-sized amplicons at different timepoints, or 
within a timepoint, as would be expected from a product that is known to vary 
considerably during infection. 
FF 
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Figure 3.4 VSG amplicon sizes change over course of infection.  Purified products from the 
VSG amplification reactions were analysed for each infection (01–06) by separating in 
adjacent lanes of a 1% agarose gel.  The associated parasitaemias for each infection are 
shown.  Dotted lines represent sampling times.  A dagger above the parasitaemia indicates 
the point where the parasitaemia undergoes a transient dip (point ‘C’ in Figure 3.2), which 
varies slightly in time and extent between infections. 
Chapter 3  109 
 
Figure 3.4 (continued) 
 
Chapter 3  110 
3.3.4 664 full-length VSG clones were sequenced 
To retrieve the nucleic acid sequences of the VSGs expressed during infection, 
the PCR products were subcloned, screened and sequenced as described in 
Chapter 2 (sections 2.4.8, 2.4.9 and 2.4.14).  Briefly, the products were A-tailed 
and ligated into the vector, and used to transform competent E. coli cells.  
White colonies were screened for insert-containing plasmids by PCR using M13 
forward and M13 reverse primers.  Plasmids from those colonies yielding a 
product of estimated size 1200–1700 bp were purified using a small-scale plasmid 
DNA purification ‘miniprep’ kit (Qiagen, Crawley, UK) and was tested by EcoRI 
digest.  Samples of each isolated plasmid had their insert sequenced by Eurofins 
MWG Operon (Ebersberg, Germany) using the M13 forward and M13 reverse 
primers that bind on either side of the multiple cloning site.  Clones from mice 
10–12 were prepared by H. Wang. 
 
Cloning efficiency varied between attempts but was generally good.  For 
example, in the initial round of cloning, of the 372 colonies screened, 312 were 
found to contain an insert (an average of 10 positive per 12 colonies tested).  
This is an improvement on that recorded previously (approximately one positive 
in 10 colonies tested, L. Marcello, Ph.D. thesis, 2006, University of Glasgow), 
likely due to the additional cDNA purification step here improving PCR efficacy. 
 
Table 3.2 shows the total numbers of VSG plasmid clones prepared and 
sequenced for each mouse-timepoint.  Eleven plasmid clones were prepared 
from mouse FF, the mouse used to amplify parasites to initiate infections in 
mice 01–06.  In an attempt to capture the total antigenic variability present, a 
greater number of clones were sequenced from two infections (mice 04 and 05). 
For most clones, one forward and one reverse read gave a sufficiently long (~200 
bp) region of exact overlap allowing their sequences to be confidently assembled 
to give the sequence of the full-length clone.  In 56 cases, internal sequencing 
reactions were performed to confirm the correct sequence of the assembly.  
Ambiguities, when present, were always corrected in favour of minimising the 
number of differences between similar clones and between the clone and its 
putative genomic copy (see section 3.4.2).  For 19 clones, a failure in one of the 
sequencing reactions resulted in a partial sequence.  These partial sequences 
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could nevertheless be identified by reference to other complete clones retrieved 
from that timepoint or infection.   
 
 
Table 3.2 Sequenced clones retrieved from various timepoints of chronic mouse infections. 
19 of these are incompletely assembled.  *Includes 37 data from Marcello & Barry (2007a) 
(LM_01–11).   
 
Each assembled sequence was verified as being that of a VSG by BLAST identity 
to a VSG present in the ‘genomic VSG database’ (see section 3.4.2 and Appendix 
7.2.4 for details) or by comparison of the spacing of conserved cysteine residue 
codons with that of known VSGs (Carrington & Boothroyd, 1996; Marcello & 
Barry, 2007a).  Of the 684 clones analysed, just one was not identifiably a VSG 
and so was excluded from further analysis.  Primers mismatching early in the 
PCR reaction may have produced this non-VSG amplicon.33  
 
                                         
33 Preliminary studies carried out without the cDNA purification step showed a much greater 
number of non-VSG sequences being cloned (data not shown).  Non-specific amplification was 
likely due to residual oligo[dT] from first-strand synthesis acting as an alternative primer to the 
16-mer, allowing amplification of all cDNAs. 
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For each of the 47 mouse-timepoints, between four and 35 VSG clones were 
identified, and in total, 664 full-length sequences were retrieved.34  The median 
number of clones retrieved per infection was 45.5, and the median number of 
clones retrieved per timepoint was 11.  Each clone was given a three-part name: 
XX-YYcZZ, where XX is the mouse number, YY is the day of infection from which 
that clone was amplified, and ZZ is a numerical identifier. 
 
The clone sequences were manually manipulated prior to further analysis.  The 
sequences were cropped to the putative open reading frame (ORF), assumed to 
begin with the first ATG codon 3’ of the spliced leader at the 5’ end of the 
sequence, proceed with no in-frame stop codons, and end with an in-frame stop 
codon, usually TAA, approximately 1500 bases downstream.  Occasionally the 
ORF could not be found.  In 43 cases failure to identify the ORF was due to an 
insertion or deletion mutation that disrupts the frame of the gene.  Such ‘errors’ 
were recorded and corrected with reference to other, undamaged sequences 
from a similar timepoint or infection.  In 12 other cases failure to identify the 
ORF was due to a substitution mutation creating a stop codon in the middle of 
the gene, which was usually left uncorrected since it seldom disrupted 
downstream analyses.  All manual edits to clone sequences are described in 
Appendix 7.2.3, and the names of the clones themselves suffixed with ‘-add’, ‘-
del’ or ‘-edit’ according to their modification.  The sources of the errors are 
described and discussed in more detail in Chapter 4 (section 4.2.3).  In one case 
an assembly of the clone could not be completed, and the draft assembly 
sequence is suffixed ‘-draft’.  The 19 clones for which full-length sequences 
were not determined could be partially analysed, and these clone sequences 
were suffixed ‘_x’.  The open reading frames of the cloned VSGs ranged in 
length between 1300 and 1710 bp, with most being between 1460 and 1600 bp 
long.   
 
The regions of each VSG clone encoding the N- and C-terminal domains was 
predicted by reference to similar annotated genomic copies in VSGdb (Marcello 
et al., 2007).  For those clones with no clear matches in VSGdb, the region 
encoding the C-terminal domain was defined using the positions of conserved 
                                         
34 684 clones analysed, minus the one that was not a VSG, minus the 19 for which only one 
sequencing reaction was achieved. 
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cysteine residues as described in Chapter 2 (section 2.7.2.2).  The length of the 
N-terminal signal peptide, which is cleaved from the mature VSG, was predicted 
using the SignalP 4.0 algorithm (Petersen et al., 2011).35  Both the FragAnchor 
algorithm (Poisson et al., 2007) and the big-PI predictor (Eisenhaber et al., 
1999) were used to predict the functionality of GPI anchor signal sequences 
when required. 
 
3.4 Identification and classification of expressed VSGs 
3.4.1 Expressed VSGs can be grouped into sets 
At a given point in time during an infection, we might expect to find many 
related parasites expressing identical or closely related VSGs, having descended 
from an ancestor that switched to express this VSG, evaded the immune 
response and proliferated.  We might also expect to find similar VSGs expressed 
in different infections, representing different populations activating the same 
silent VSG. To examine the relationships between the sequenced expressed 
VSGs, the clones were first compared with one another.  These comparisons 
revealed two broad patterns of variation between the clones.  Clones group in 
‘sets’: members of one set of clones are much more similar to one another than 
they are to any member of another set.  To illustrate this grouping, Figure 3.5 
shows a midpoint-rooted tree drawn from a Clustal alignment of the 137 
different VSG clones retrieved between days 20 and 32 from mouse 05, which 
constitute 30 sets.  The variation between clones of one set and clones of 
another is referred to as ‘between-set’ variation.  The other pattern of variation 
can be seen when comparing different clones within a set—in the Figure, Set_14 
shows the most widespread ‘within-set’ variation, whereas Set_21 shows little 
within-set variation.   
                                         
35 In the rare cases where they did not exactly coincide, the N-terminal signal peptide cleavage site 
and the boundary between N-and CTDs was standardized for similar VSGs (that is, VSGs of the 
same set) to simplify analyses. 
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Figure 3.5 Relation between 137 VSG sequences retrieved from mouse 05.  Nucleic acid 
sequences were aligned using Clustal and the corresponding phylogenetic tree visualised 
with FigTree (A. Rambaut, University of Edinburgh).  Set_14 and Set_21, showing greater 
and lesser degrees of within-set variation respectively, are highlighted.  
 
To analyse these complementary kinds of variation, all 683 expressed VSG 
sequences from the 11 experimental infections were grouped into sets based on 
sequence similarity.  The maximum amount of variation seen when comparing 
the full-length nucleic acid sequences of two set members (maximum within-set 
variation) was 0.25 differences/nt, whereas the minimum amount of variation 
seen when comparing two sequences of different sets (minimum between-set 
variation) was 0.41 differences/nt.36  Assigning sequences to sets was therefore 
unambiguous.  In total, the 683 expressed VSG sequences formed 81 distinct 
sets.  Some sets were very highly represented amongst the clones, whereas 
others had just one clone; the number of clones comprising each set varies 
between one (42 sets had just one member) and 123 (Set_08).   
 
The 37 sequences retrieved by Marcello & Barry (2007a) from 11 experimental 
infections were reanalysed in a similar way.  These formed 20 sets,37 18 of which 
                                         
36 The mean between-set variation was 0.59 differences/nt, not substantially less than what is seen 
comparing randomized sequences (~0.75 differences/nt). 
37 Marcello & Barry (2007) used the term ‘VSG’ to group the expressed VSG sequences for 
analysis.  This was disfavoured here, to emphasise that (i) for many sets there is not 
necessarily a one-to-one relationship with a single genomic copy, and that (ii) there can be 
biologically-relevant variation amongst members of the set (Chapter 4).   
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overlapped with the 81 sets described above.  The two sets that did not overlap 
comprised VSGs detected at timepoints underrepresented in the data presented 
here (day 9 of infection).  Bringing together all the expressed VSG sequence data 
collected from TREU 927/4 GUTat 10.1 infections to date, 83 different sets have 
therefore been identified.  Each set was given an arbitrary number (Set_01–
Set_84).38  All the expressed VSG clones isolated here and those described by 
Marcello & Barry (2007a), and the sets they form, are described in Appendix 
7.2.3. 
 
First, the patterns of, and processes contributing to, between-set variation will 
be considered.  Between-set variation constitutes the most dramatic variation 
between VSG sequences, and therefore presumably contributes most to 
expressed antigen diversity over the course of an infection.  Then, in Chapter 4, 
the patterns and processes of within-set variation will be investigated. 
 
3.4.2 Sets correspond with genomic copies of VSGs 
In its simplest form, we might consider different members of a particular set as 
being the expressed forms of one or more specific silent archival VSG genes (the 
‘donors’), copied into a BES and then being activated.  VSG sequences belonging 
to the same set were identified in separate infections, consistent with the 
hypothesis that these expressed sequences represent independent activation of 
the same silent VSG.  Between-set variation thus represents the activation of 
different silent VSGs.   
 
To investigate the relationship between expressed VSG sequences and sequenced 
genomic VSGs, each expressed VSG clone was compared to the ‘genomic VSG 
database’ (the source of which is described in Appendix 7.2.4) using BLAST 
(1990).  All genomic VSGs that gave a BLAST E-value of less than 1e-100 were 
investigated.  Particular focus was put on similarities in the putative NTD-
encoding part of the gene, due to greater homologies between CTDs (Rice-Ficht 
et al., 1981), the occurrence of 3’ donation (covered in Chapter 4, section 4.4), 
and the fact that the CTD is not exposed to the immune system (Schwede et al., 
                                         
38 To be consistent with the previous study, sets 01—21 were given numbers corresponding to the 
‘VSG’ nomenclature of Marcello & Barry (2007a).  As VSG 14 and VSG 15 of that study qualify 
as being members of the same set, they were subsumed into Set_14, so there is no ‘Set_15’. 
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2011).  In addition to the genomic VSG database, a database of unassembled 
reads was consulted (the ‘reads database’, described in Chapter 2 section 
2.7.2.3), representing minichromosomal sequencing, intermediate chromosome 
sequencing, and unassembled reads from the megabase chromosome sequencing 
project).  Candidate contiguous reads found in this way were assembled to form 
putative set-matching donors; those reads contributing to each assembly are 
shown in Appendix 7.2.6.   
 
As expected, all clones within a set identified the same genomic VSGs.  For some 
sets, a number of potential donors were found.  In some cases these represent 
families of related genomic VSGs, whereby a sequence with identity to one 
member of the family will likely have similarly high levels of identity to other 
family members (40% of VSGs are in such subfamilies (Marcello & Barry, 2007a)).  
In other cases, it may be that more than one donor genomic VSG is contributing 
to the expressed VSG to form a mosaic VSG.  All matching potential genomic 
copies were recorded for closer analysis. 
 
There remained eight sets for which no matching genomic sequence could be 
found at all.  These sets probably match genomic VSGs which are not present in 
any publicly-available sequencing attempt to date, and are most likely from 
minichromosomal telomeric loci which are currently under-represented in 
genome sequence data. 
 
3.4.3 Expressed VSGs correspond imprecisely with their 
associated genomic copies 
To examine in more detail the relationships between the expressed forms of the 
VSG gene and their putative silent genomic form(s), multiple sequence 
alignments of each retrieved clone sequence and all its putative donors were 
carried out.  For each position in the alignment, identities between the clone 
and each genomic copy were recorded.  The results were plotted 
diagrammatically for each clone, and diagrams and alignments studied by eye.  
When comparing each clone sequence with its matching genomic copies, four 
different kinds of variation were seen.  Examples of each are shown in Figure 
3.6: 
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(i) Single base mismatches.  Single base mismatches were seen both when 
comparing an expressed VSG sequence with the genome, and when 
comparing expressed VSG sequences within the same set.  It may be that 
single base mismatches are artefacts generated by the process of 
amplification and cloning; this possibility is considered in depth in 
Chapter 4 (section 4.2). 
(ii) 3’ donation.  In many cases, an expressed gene matched its putative 
genomic copy very well in the region encoding the N-terminal domain, 
but very poorly towards the 3’ of the gene, in the region encoding the C-
terminal domain.  This pattern could also be seen when comparing 
similar expressed clones within a set: they are identical in the ~1000 bp 
at the 5’ end of the gene, but show high levels of variation towards their 
3’ end.  This kind of variation is likely to come about by 3’ donation, a 
process of segmental gene conversion in which the N-terminal-domain-
encoding region of one VSG is joined to a different C-terminal-domain-
encoding region (see section 1.6.8). 
(iii) Mosaicism.  Often, a gene would show high levels of identity with a 
putative genomic copy in parts of its sequence, but match that copy 
poorly in other parts.  These areas of mismatch were often 
complemented by one or more different genomic copies.  One 
explanation for these complementary patterns of matching and 
mismatching is that segments of one gene are replacing segments of the 
other to generate the expressed VSG, as described previously (see 
section 1.6.9).  This process of segmental gene conversion forms a 
‘mosaic’ VSG, with multiple contributing donors.  
(iv) Missing donor sequence.  Some genes showed one or more promising 
genomic copies following BLAST analysis, but alignments showed 
considerable variation between the expressed VSG and all putative 
genomic copies.  Comparing members of this set found in different 
infections or at different timepoints often revealed identical patterns of 
mismatch to the putative genomic copies.  The most likely explanation 
for this was that the true genomic copy contributing to this set has not 
been found; instead the BLAST search identified a related member of the 
VSG family, against which the comparisons were done. 
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In many cases, combinations of these different types of variation were seen, for 
example a clone having undergone 3’ donation and possessing single base 
mismatches in the 5’ NTD-encoding region, or a clone having apparently been 
constructed by segmental gene conversion, but the database missing one of the 
donor sequences.  Because of the possibility that patterns of variation between 
an expressed VSG set and its genomic copies could be more parsimoniously 
explained by the presence of an as-yet-unknown additional silent VSG, within-set 
variation between expressed clones from different infections was examined; this 
approach was the favoured means of identifying patterns of within-set 
variation.39  Identical patterns of apparent ‘point mutation’, ‘3’ donation’ or ‘N-
terminal mosaicism’ in these clones would hint at such an unidentified donor.  
Detailed analysis of all of these patterns is covered in Chapter 4.   
 
Variation between the expressed VSG and its best-matching putative genomic 
copy was prevalent and often considerable.  Indeed, only 5 of the 664 clone 
sequences matched a genomic copy perfectly.   
 
                                         
39 Southern blot hybridizations would be the most rigorous method of establishing the number of 
related silent copies in the genome.  This was carried out for one set (section 4.5.9). 
  
 
 
Figure 3.6 Examples of different patterns of divergence from putative genomic copies.  Each diagram shows a different cDNA clone, with predicted signal 
peptide and N- and C-terminal domain encoding regions marked.  Cysteine codons are shown as bars projecting above the diagram.  Each clone was 
aligned with putative genomic copies (described under the clone name) and mismatches recorded.  Mismatches are shown as red bars spanning the 
diagram.  For the N-terminal mosaic more than one donor is shown.  Mismatches with each donor were recorded (lower image) and segments matching 
each donor are coloured by donor in the upper image.  Junctions between segments are drawn at the midpoint of the region of identity between donors.  
For more detail see Chapter 4 section 4.5.1. 
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Figure 3.7 The expression of genomic VSGs during infection.  The upper diagram shows, for each of the 83 sets detected across all 22 infections, the 
properties of the putative genomic copies.  Based on the number and properties of the associated genomic copies, the expressed VSG sets could be 
classified, as shown in the bar chart underneath.  The fraction of sets classified in each way is overlayed on the bar chart.  There was one set for which 
patterns of mosaicism could be inferred but no associated genomic copy could be found (see Chapter 4 section 4.5.1).  The ‘X’ indicates Set_01, which 
corresponds with Tb10.v4.0001, also known as GUTat 10.1, BES-occupying at the beginning of infection and also possessing a silent telomeric copy (J. D. 
Barry, pers. comm.) 
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Together, these results allowed the likely genomic copies for each set to be 
assigned, and their properties to be investigated.  Genomic copies were 
classified as ‘full-length intact’, ‘atypical’, or ‘pseudogene’, using the 
annotations present in VSGdb.  Where the donor had been assembled using reads 
from the ‘reads database’, the donor was classified ‘read’, unless the read was 
annotated as minichromosomal, in which case the donor was classified 
‘minichromosomal’.  Where a donor could not be found it was classified 
‘unknown’.  
 
Each set of expressed VSGs was itself classified based on the classification and 
number of contributing donors.  Those sets whose members often show patterns 
of mosaicism were classified as ‘N-terminal mosaic’.  Those sets showing the 
contribution of only one VSG to the N-terminal domain, and a putative genomic 
copy of that donor could be found in the subtelomeric arrays, were classified as 
‘non-mosaic array donor’.40  Those sets showing the contribution of only 
minichromosomal reads to the N-terminal domain were classified as 
‘minichromosomal’.  Those sets for which only a (non-minichromosomal) read or 
set of reads could be identified were classified ‘read’, and those sets for which 
no satisfactory donor(s) could be found were classified ‘unknown’.41  The 
involvement of 3’ donation was detected to varying degrees over all set classes, 
including those classified ‘non-mosaic array donor’.  Figure 3.7 shows the 
classification of the genomic copies contributing to each expressed VSG set, and 
the set’s classification. 
 
3.4.4 Activation of damaged VSGs is not disfavoured 
Eleven out of 83 of the total sets detected (~13.5%) represent the non-mosaic42 
activation of an intact or atypical VSG from the VSG arrays.  Considering the fact 
that other array VSGs must undergo varying degrees of repair for their 
expression, this is comparable with the proportion of full-length, intact/atypical 
silent VSGs in the archival arrays (14%, (Marcello & Barry, 2007a)).  On the other 
                                         
40 It is possible that there are additional, possibly telomeric, copies of the ‘non-mosaic array’ 
donors. 
41 Partial donors could be found for some ‘unknown’ sets, but they were not sufficient for the set to 
be reclassified. 
42 However, some of these show 3’ donation that may have come about by mosaic-like events 
accumulating in their 3’ ends (discussed further in Chapter 4). 
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hand, those full-length, intact VSGs whose expression is reported here are just a 
fraction of the total full-length, intact silent VSGs in the arrays (known to 
number at least 43, (Marcello & Barry, 2007a)), many of which were not assigned 
to any expressed sets at all.   
 
There are certainly other full-length, intact genomic copies, currently 
unassembled, that directly correspond to some of the other sets.  For example, 
those minichromosomal, read and unknown sets detected early on in infection 
probably correspond with intact telomere-proximal VSGs (as described in section 
3.5.5).  It is also possible that other full-length, intact silent VSGs were 
expressed during the infections but were not detected—perhaps the time of their 
appearance was underrepresented in the sampling timepoints.  Here, times of 
sampling focussed on the later stage of infection, with the majority of clones 
(629/720) coming from days 20–34 when mosaic VSGs were known to 
predominate (Marcello & Barry, 2007a).  However, considering the 4–5 week 
infections as a whole, full-length, intact genomic copies do not appear to be 
‘exhausted’ before the expression of damaged VSGs becomes prevalent, counter 
to the hypothesis that antibodies raised during infection are required to select 
for ‘rare’ segmental gene conversions.   
 
Seven sets detected in these infections directly correspond with specific 
damaged43 genomic copies (pseudogenic towards their CTD-encoding region), and 
the involvement of up to 43 damaged genomic copies could be detected.44  
Damaged by frameshifts, stop codons and fragmentation, these genes cannot be 
straightforwardly expressed.  Examining these sets in closer detail, it is apparent 
that processes of mosaicism and 3’ donation have enabled (partial) expression of 
these silent VSGs.  Twenty-eight out of the 83 sets show patterns of N-terminal 
domain mosaicism, and 3’ donation is detectable in 47 of the sets.  The integrity 
of the silent VSG is apparently not the main determinant of its expression 
probability. 
 
                                         
43 That is, non-mosaic array donors annotated ‘pseudogene’. 
44 This figure includes 31 array pseudogenes, three minichromosomal read assemblies and nine 
other read assemblies.  For more details see Appendix 7.2.9. 
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Besides enabling expression, the processes of mosaicism and 3’ hybridism have 
generated variation in the expressed clones.  This variation is clear not only 
when comparing the expressed clone with its assigned donors, but also when 
comparing similar expressed clones with one another (within-set variation), 
suggesting that activation of some genomic copies goes hand-in-hand with the 
generation of diversity in the expressed antigen population.  Could this diversity 
also contribute directly to antigenic variation by generating novel epitopes?  This 
question will be considered in detail in Chapters 4 and 5.   
 
Given the extreme variation between expressed VSG clones from different sets 
at the amino acid level, it is reasonable to believe that different sets are 
antigenically distinct from one another.  Compared with within-set variation, 
variation between clones of different sets is consistently greater.  The activation 
of different sets by the parasite population—by any means—is therefore the most 
obvious source of antigenic variability over the 4–5 week infections presented 
here.  It is the patterns of appearance and disappearance of distinct sets, 
corresponding with the activation of completely different silent VSGs, that 
represent the classical process of African trypanosome antigenic variation, and it 
is to these patterns that I now turn. 
 
3.5 Patterns of antigenic variation 
3.5.1 Different VSGs were detected at different times 
The classical model of African trypanosome antigenic variation predicts that, as 
an infection progresses, the successive immune responses mounted by the host 
against parasite surface coats constantly select those parasites which have 
switched to express an ‘unused’ VSG.  Within an infection, we might therefore 
expect to find different sets being expressed at different timepoints, as the host 
eliminates those parasites that have not switched.   
 
To investigate the patterns of between-set antigenic variation over the course of 
infection, bubble charts were drawn for each infection and are shown in Figure 
3.8.  Each chart shows time on the x-axis and the different expressed VSG sets 
on the y-axis.  For each timepoint, a circle indicates the presence of an 
expressed VSG clone from that set.  The area of the circle is proportional to the 
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fractional abundance of clones from that timepoint belonging to that particular 
set.  The figures inside the bubbles indicate the total number of clones 
belonging to that set at that timepoint.45  These charts show three broad 
patterns in set expression: 
(i) Variation in the different sets detected over time within an infection.  
For example, in mouse 05, clones belonging to Set_08 were found at day 
20, but were not seen in any subsequent timepoints, whereas clones 
belonging to Set_21 were not found at the earlier timepoints, and were 
seen only from day 27 onwards.  These patterns might be expected, as 
antibodies clear earlier variant sets and later variant sets expand to fill 
their place. 
(ii) Persistence of specific VSG sets over time within an infection.  For 
example Set_14 in mouse 04 and mouse 05 is found in all samples 
between days 21 and 31 (mouse 04), and 23 and 31 (mouse 05).  The 
processes leading to apparent persistence are considered in the broader 
context of antigenic variation in section 3.6.3. 
(iii) Occasional reappearance of a VSG set in an infection.  For example, 
Set_08 is present at days 20, 23 and 32 in mouse 01, but is not detected 
at the intermediate timepoints.  Reappearance of a VSG set in the later 
stages of infection may be due to that variant’s high activation 
probability: in periods of high parasitaemia, many parasites will undergo 
futile switching to an easily-activated VSG and will be rapidly killed by 
the previously-developed immune response (Turner, 1999).  Other 
processes that may contribute to reappearance are similar to those of 
persistence, and are discussed in section 3.6.3. 
  
                                         
45 Note that the relationship between the number of clones of a particular set retrieved at a 
timepoint and the abundance of that particular set in the original mRNA is not known: increased 
numbers of clones of a particular set may simply represent sequences that are preferentially 
amplified and/or cloned.  However, no difference was found in the GC content (a factor 
commonly contributing to inefficient PCR) between sets for which 10 or more clones were 
retrieved and those for which only one clone was retrieved (data not shown). 
Chapter 3  125 
 
 
Figure 3.8 Bubble charts of VSG sequence detection.  Different charts have been drawn for 
each infection.  VSG sets and their classification are on the y-axis, and the time of sampling 
is on the x-axis.  The area of each bubble is proportional to the fractional abundance of 
clones of that set at that timepoint.  The actual number of clones is overlaid on the bubble.  
The dagger indicates the transient dip in parasitaemia marked ‘C’ on Figure 3.2 (see 
Appendix 7.2.2 for parasitaemias).  Set_08 and Set_22 are indicated by ‘ ’ and Set_14 is 
indicated by ‘–‘.  
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3.5.2 PCR analysis was consistent with clone sequencing 
Although the detection of a member of a specific set at a timepoint confirms its 
presence, its non-detection does not necessarily indicate its absence.  As clones 
were selected for screening arbitrarily, it may have simply been the case that at 
those timepoints where the set was not detected, the set was present but clones 
were not selected.  This was a particular concern for those timepoints where 
relatively few clones were sequenced. 
 
To control for this possibility, PCRs were carried out directly on the cDNA 
product using primer pairs specific for different VSG sets.  Primers were 
designed using all available sequence information, taking into account known 
within-set variation to allow annealing to any member of the set.  Each primer 
pair amplified a region of the gene ~500–1000 bp long.  Primer pairs were 
designed for six representative sets, as shown in Table 3.3, and tested for 
specificity on genomic DNA and plasmid clone DNA (data not shown).  PCRs were 
performed on cDNA and plasmid DNA controls from the five timepoints of three 
separate infections (mouse 01, 04 and 05), as well as from the infecting 
population (feeder mouse FF).  The reaction products were run on a 1% agarose 
gel.  For each timepoint, primers directed against tubulin were used to control 
for equal sample loading.  For these experiments Taq polymerase was used.  The 
results of the PCRs are shown alongside the corresponding bubble charts to allow 
easy comparison are shown in Figure 3.9. 
 
The PCRs broadly corresponded with the cloning shown in the bubble charts, 
confirming the process of between-set variation over the course of infections.  
For example, the sets detected by cloning and sequencing only at day 21 in 
mouse 04 and mouse 05 (Set_22 and Set_08) did not give a strong PCR product at 
any other timepoint in either of those infections.  Similarly, Set_21, which was 
identified in the sequences only at the later timepoints, was only amplified from 
the later cDNA samples. 
 
Chapter 3  132 
 
 
Figure 3.9 Antigenic variation PCRs.  Seven primer pairs were used to test expression of six 
antigen sets and tubulin (to control for equal template loading).  Samples from four 
infections were tested: mouse 01 (A), mouse 04 (B), mouse 05 (C) and mouse FF (D).  
Reactions were carried out on total cDNA, as well as the product of a reaction from which 
reverse transcriptase was absent, as a control for gDNA contamination.  For each reaction, 
the corresponding line from the bubble chart (Figure 3.8) is shown, so the results can be 
easily compared. 
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Figure 3.9 (continued) 
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Figure 3.9 (continued) 
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Table 3.3 VSG sets tested by PCR.  *Set_08 may have an additional, non-array copy at the 
beginning of infection (see Chapter 4 section 4.4.3). 
 
In some cases, there was a discrepancy between the PCR analysis and the 
cloning.  PCR analysis revealed the presence of VSG sets not detected by cloning 
(for example, Set_21 was not detected by cloning in mouse 01).  This was most 
Figure 3.9 (continued) 
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frequently seen towards the later timepoints.  PCR analysis also identified the 
reactivation of VSG sets not detectable at intermediate timepoints, the most 
striking of which is Set_01, the only set identifiably expressed by the parasites 
used to initiate the infections46 (material collected from the feeder mouse FF).  
The processes leading to reactivation of early VSGs are discussed in section 
3.6.3.  On the other hand, some sets represented by many clones were 
identified only very weakly by PCR if at all, for example Set_12 in mouse 05.  
Poor amplification might have been due to differences in primer binding or the 
relative processivity of the different polymerases used for the PCR reactions 
(Arezi et al., 2003). 
 
3.5.3 Infections showed unique patterns of VSG expression 
The VSG sets detected varied uniquely between each infection.  Figure 3.10 
shows these patterns as a network, in which a connection between nodes 
represents detection of different VSG sets within an infection.  Some sets were 
uniquely connected to infections, whereas others were shared amongst 
infections.  This result is consistent with the hypothesis that VSG expression is 
‘semi’-ordered, rather than strictly orchestrated, perhaps providing flexibility in 
a partially-immune host.   
   
It might be the case that deeper sampling and sequencing would reveal further 
VSG sets that are shared between infections, but are being kept below the level 
of detection here by short-stumpy differentiation.  Mouse 04 and 05, from which 
more clones were retrieved than the other infections, showed a greater number 
of uniquely-detected sets. 
                                         
46 Also known as GUTat 10.1, and Tb10.v4.0001. 
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Figure 3.10 Expression of VSG sets in different infections.  The larger, yellow nodes 
represent the different infections.  Smaller nodes represent VSG sets.  Edges indicate that 
the set was detected in that infection by sequencing, with dotted and intact lines 
representing identification before and after day 20 respectively.  Infection nodes have been 
grouped according to their time of sampling, as earlier timepoints have not been sampled in 
so great a depth.  Sets detected in more than one infection are shown inside the ring of 
infection nodes, whereas sets unique to an infection are outside.  
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3.5.4 Infections showed great expressed VSG diversity 
The bubble charts presented in section 3.5 show that a wide range of different 
VSG sets could be detected in a small blood sample collected at a single point of 
the infection.  The number of different variable antigen types present in an 
infection is referred to as the ‘variant richness’ of the population.  Variant 
richness can be considered alongside ‘variant evenness’—the relative abundance 
of different variable antigen types—as measures of expressed antigen diversity 
(Hill, 1973). 
 
A crude estimation of variant richness could be achieved by counting the number 
of sets present at different timepoints.  Considering richness or unevenness as 
concerned simply with the number and relative abundance of different sets 
ignores the presence of extensive within-set variation that also contributes to 
diversity (discussed more fully in Chapter 4).  However, this simplification lends 
confidence to the assertion that the estimated variant diversity is functional in 
antigenic variation, as many cases of within-set variation (in particular, point 
mutations and 3’ donation) will probably not affect the epitope structure of the 
antigen.   
 
To compensate for a lack of saturation in sequencing—at most timepoints, many 
sets were represented by just one clone, leaving it likely that further sequencing 
would identify additional sets at that timepoint—the Chao 1 richness estimator 
(Chao, 1987) was calculated using the statistical package EstimateS (R. Colwell, 
http://purl.oclc.org/estimates).  This approach estimates total variant richness 
using the number of ‘singletons’ and ‘doubletons’ in the population (the sets 
represented by one or two members respectively) as a way of gauging the 
likelihood of identifying additional sets with further sequencing.  For this 
analysis, the diversity of each sample of mouse 04 and mouse 05 was estimated, 
as similar numbers of clones were obtained from each sample (between 20 and 
30) and the increased number of clones sequenced from each sample gave a 
better idea of total richness (diversity estimates depend greatly on the size of a 
sample (Hill, 1973)).  
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Table 3.4 EstimateS calculations.  The richness estimate was Chao 1, calculated using 
correction for bias, and relates to total predicted antigen richness (number of variants 
present).  The large margin of error (particularly amongst mouse 05 timepoints) is reflective 
of the proportion of singleton and doubleton sets. 
 
Evidently, the antigen profile of the parasite population at a single point in an 
infection can be remarkably heterogeneous.  Some samples showed little variant 
richness, particularly those taken at day 20/21.  At these timepoints, samples 
were dominated by one of two sets: Set_22 in mice 02 and 04, and Set_08 in 
mice 01, 03, 05, 06, 08 and 09 (this can be seen in Figure 3.8, where Set_08 and 
Set_22 are indicated by a ‘’).  It is possible in these cases that unevenness in 
the population is crowding out minor variants that are nonetheless present: 
deeper sequencing of the sample taken at day 21 of mice 04 and 05 showed 
smaller variant subpopulations existing alongside a dominant set.  Crowding out 
might be expected in cases where differentiation is the predominant factor 
controlling infection dynamics—minor variants are suppressed below the level 
required for immune stimulation by stumpy induction factor released by the 
dominant variant (Gjini et al., 2010). 
 
Following day 20/21, many infections showed an apparent increase in diversity.  
This is seen most clearly in mice 01, 02, 03, 05 and 06, which show Set_08 or 
Set_22 sets at day 20/21, and their absence at day 23 or day 27 with a number 
of other sets becoming detectable in their place (witness the large number of 
sets becoming detectable at day 27 in the bubble charts, and in Figure 3.11).  
For many infections, this change in expressed diversity corresponded with the 
transient but substantial dip in parasitaemia.  Perhaps the crash in parasite 
numbers was due to the bulk of the parasite population—expressing either 
Set_08 or Set_22 VSG surface coats—being eliminated by an immune response, 
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exposing minor variant subpopulations that were detected as they expanded 
over the subsequent days.   
 
3.5.5 VSG expression followed a hierarchy loosely based on 
genomic locus 
The classical model of African trypanosome antigenic variation predicts that 
different genomic VSGs have different activation probabilities, which are 
believed to be a consequence of their genomic location (VSGs located on 
telomeres are activated more readily), their identity to existing expression-
linked copies (greater homology increases chance of activation) and their 
functionality (damaged VSGs are harder to activate) (see Chapter 1 section 
1.6.12).  Previous studies have demonstrated a ‘hierarchy’ in VSG expression, 
whereby some VSGs were detected earlier in infection than others, linked to 
their genomic locus (Morrison et al., 2005). 
 
To investigate the expression hierarchy of the VSG sets expressed by this T. 
brucei line, the times at which each of the 83 sets were detected were plotted.  
The results are shown in Figure 3.11. 
 
First, the ‘early’ timepoints, before day 20, will be considered.  These data 
came from fewer infections and thus represent a smaller set of samples (just 91 
clones) than the later timepoints.  Nevertheless, these infections were broadly 
consistent with one another, with many of the sets detected in more than one 
infection (see Figure 3.10).  Eighteen sets were identified prior to day 20.  The 
majority (11/18) were classified as minichromosomal, or unknown.  It is likely 
that these correspond to telomeric donors, as minichromosomal VSGs are 
telomere-proximal and the telomeres of all chromosomes are underrepresented 
in the sequencing data.  Three early-appearing sets matched VSGs present in the 
subtelomeric arrays.  Set_01 corresponds with Tb10.v4.0001/GUTat 10.1, the 
dominant VAT of the parasites initiating the infection, a VSG that is present in 
the active ES of those parasites but also has a copy in the subtelomeric VSG 
array of chromosome 10 (Tb10.v4.0001).47  It is possible that Tb09.v4.0077 and 
Tb927.5.5080, which correspond with Set_08 and Set_19 respectively, also had 
                                         
47 There is also a silent telomere-proximal copy of Tb10.v4.0001 (J. D. Barry, pers. comm.) 
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extra telomere-proximal copies present at the start of infection, facilitating 
their early activation.48  Two sets classified as ‘mosaic’ appear before day 20: 
Set_04 and Set_22.  Not all donors for Set_04 have been identified, and the 
Set_04 clone appearing before day 20 (identified by Marcello & Barry, (2007a) at 
day 9) is potentially a mosaic predecessor rather than the product of segmental 
gene conversions itself (this is investigated further in Chapter 4 section 4.5.8).  
Set_22 was not detected until day 17, and then only in one infection (mouse 11), 
although its predominance in mice 02 and 04 at their earliest-sampled point 
(days 20 and 21 respectively) suggests that this is a mosaic set that has a 
tendency to appear earlier than other mosaics (and indeed many array genes).  
Bearing these exceptions in mind, the early stage of infection was associated 
primarily with the expression of VSGs whose genomic locus is either unknown or 
telomere-proximal (minichromosomal). 
 
The later stages of infection were sampled in much greater depth (days 20–34, 
629 clones).  Longitudinal samples from the three infections for which early-
stage data was available (mice 10, 11 and 12) showed that the sets present in 
the later stages of those infections are broadly similar to the sets detected in 
infections for which only later-stage data was available (see Figure 3.10) 
consistent with the premise that all infections are following similar patterns.  
Despite the greater number of sequences retrieved from each timepoint of these 
infections, samples taken on days 20/21 and 23 remained dominated by sets 
which were detected earlier in other infections.  Set_08 was detected in mouse 
11 and 12, and several infections by Marcello & Barry (2007a), with its earliest 
appearance at day 7 (mouse 11).  Set_22 was detected in mouse 11 at day 17.  It 
therefore appears to be the case that at this point in time, around day 20, the 
trypanosome population of each infection was predominantly expressing an 
early-type VSG set.   
 
                                         
48 Patterns of within-set variation for Set_08 suggest this may be is the case, see Chapter 4 section 
4.4.3. 
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Figure 3.11 Different sets appear at different points in infection.  The 83 sets detected 
across 22 chronic mouse infections are on the y-axis (ordered by time of appearance), and 
time is on the x-axis.  Sets are coloured by their classification.  A square indicates detection 
of that set at that timepoint in one or more infections.  The range of detection of a set is 
highlighted in a lighter shade.  This figure also includes the 37 sequence data from the 11 
infections carried out by (Marcello & Barry, 2007a), which contribute 19 unique data points.  
‘X’ indicates Set_01, which is known to be telomere-proximal, and ‘ ’ indicates Set_08 
(blue) and Set_22 (red). 
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As discussed in sections 3.3.2 and 3.5.4, the parasite population often drops at 
around day 23, which coincides with the detection of a number of VSG sets, the 
majority of which are not identified at any earlier timepoints.  Accurate 
identification of activation hierarchy is made difficult here as the detection of a 
set corresponds with its expansion in the population rather than directly to its 
activation.  Where the dynamics of infection are dominated by differentiation, 
the activation of a set may not immediately be followed by its expansion, as 
variants expressing an antigenically novel VSG can still be suppressed by 
differentiation.  Nevertheless, variant sets corresponding with VSGs that are 
easier to activate are best placed to replace a dominant variant when it is 
cleared by immunity.  Polyclonal activation of easier-to-activate variants (Lee & 
Van der Ploeg, 1987; Timmers et al., 1987) would make theirs a larger 
subpopulation, better able to outcompete other variants, provided they have not 
yet induced a specific immune response themselves (see Chapter 6 section 6.2.3 
for further discussion). 
 
Sixty-five variant sets first appear after the early stage of infection (that is, on 
or after day 20 in any infection).  Of these, 26 sets showed patterns of N-
terminal mosaicism.49  Of the 39 that did not show N-terminal mosaicism in any 
instance, 16 matched VSGs present in the subtelomeric arrays, seven matched 
read assemblies, and for 16 sets no convincing genomic copy could be found.  In 
the data here, there was no obvious difference in time of appearance between 
mosaic VSGs and the non-mosaic activation of array donors, hinting that mosaic 
VSGs—many of which are formed from pseudogenic donors—are no more difficult 
to generate than straightforward expression-linked copies of many subtelomeric 
VSGs.  The dominance of mosaics is consistent with the findings of section 3.4.4 
that, in the later stage of infection, damage to genomic VSGs is not an 
exceptional impediment to their expression. 
 
                                         
49 The 28 sets described in Chapter 4 section 4.5.4, minus Set_04 and Set_22.  As discussed in 
Chapter 4 (section 4.5.8) there was no clear pattern of progression for many mosaic sets—
apparent mosaic predecessors arising from single donors were identified rarely (Set_04 being 
an exception, above)—so the appearance of a ‘mosaic’ set was generally coincident with the 
appearance of its mosaicism. 
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3.6 Discussion 
3.6.1 Antigen expression can be followed in vivo 
The results presented in this chapter show that retrieving samples longitudinally 
from chronic infections is a valid method of analysing the patterns of antigen 
expression in Trypanosoma brucei infections.  In this section, the main 
conclusions will be summarized and discussed in relation to the dynamics of T. 
brucei antigenic variation. 
 
Two approaches were used to identify VSG expression in infections: cloning and 
sequencing of expressed VSGs, and PCR on total cDNA using variant-specific 
primers.  Using these approaches, changes in the expression patterns of 
different VSG sets were identified.  These patterns were consistent with the 
premise that over the course of T. brucei infection, the trypanosome population 
undergoes antigenic variation: different silent VSGs were activated and 
antibodies were raised against them.  There was also evidence to suggest that 
differentiation plays an important role in the dynamics of antigenic variation in 
infections with this combination of trypanosome strain and host species.  
 
3.6.2 Key findings of this chapter 
3.6.2.1 Segmental gene conversion is involved in expression of many VSGs 
Most expressed VSGs did not match genomic copies exactly, a discrepancy arising 
in many cases from apparent segmental gene conversion: mosaicism and 3’ 
donation.  Amongst all the VSG sets detected over 4–5 weeks of infection, one 
third showed patterns of mosaicism in the N-terminal domain.  Many more sets 
showed clones that had undergone some 3’ donation in their expression.  
Divergence from the genomic copies was often necessary for expression, as most 
of the genomic VSGs associated with expression were damaged.  If these 
genomic copies were indeed the donors that became expressed (for reasons of 
time, direct association by Southern blotting, cloning and sequencing was not 
tested) it appears that damaged VSGs were readily expressed during infection, 
thanks to segmental gene conversion, and were not clearly disfavoured when 
compared with intact array VSGs.   
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If silent VSG expression is frequently accompanied by the generation of 
diversity, not all expressed antigenic variability need be genomically encoded at 
the start of infection.  Mosaic VSG formation could introduce antigenic 
variability through recombination of a small set of donors. 
 
3.6.2.2 There is considerable diversity in the variant antigen population 
during infection 
In a single infection, mouse 04, the trypanosome population showed a total of 31 
different sets, many of which showed substantial variation amongst their 
members.  Therefore, despite the isolation of 153 VSG clones, it is highly 
unlikely that the full antigenic diversity of this infection has been captured.  
Similar patterns were seen in all infections studied, indicating that T. brucei 
populations can show exceptional antigenic variability over the course of 
infection.  MacGregor et al. (2011) predicted that the low frequency of 
proliferative slender form trypanosomes present in a differentiation-controlled 
infection would result in a low rate of productive antigenic variation, 
inconsistent with the data presented here.  The most likely reason for their 
underestimation of antigenic variability is that the linear, sequential switching 
pattern employed by their model precludes the presence of minor variant 
subpopulations in an infection (MacGregor et al., 2011).  In fact, the dominance 
of differentiation-based control may enhance the antigenic diversity present in 
an infection by suppressing minor variant subpopulations below the threshold for 
antibody induction (Gjini et al., 2010).  Formal comparison with an experimental 
model where immunity-based control is dominant is now required to test this 
hypothesis.  
 
3.6.2.3 The later stage of infection shows expression of subtelomeric array 
VSGs and frequent segmental gene conversion 
It was only in the later stages of infection, after approximately day 20, that the 
sets that appeared were clearly linked with VSGs from the subtelomeric arrays, 
and that patterns of mosaicism became frequent.  Before this point, the early 
stages of infection were associated with VSGs that likely correspond with 
telomere-resident donors, which are known to be activated more readily 
(Morrison et al., 2005).  The transition between these two stages, around day 
23, often coincided with a transient dip in parasitaemia, which could represent 
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the clearance of parasites expressing the most easily activated ‘early’ variants, 
allowing ‘late’ variants to expand in the following days. 
 
3.6.3 Why do some VSG sets persist over time? 
When stimulated under ideal conditions, anti-VSG antibodies develop rapidly, 
reaching a peak approximately six days post-stimulation (Reinitz & Mansfield, 
1988).  In this study, some variant sets were found to persist in the population 
for longer periods.  How might this persistence have come about? 
(i) Insufficient numbers to stimulate immune response.  The dominance of 
differentiation-based control could have worked to suppress the 
expansion of a variant subpopulation, keeping it below the threshold 
required to induce an antibody response (Morrison et al., 1982) and 
allowing it to persist in the population without being cleared.   
(ii) The set was easily activated.  VSGs with a high activation probability 
that appear early in infection will induce a specific antibody response 
that makes subsequent activation of that VSG futile.  However, when 
sampling enough parasites there will be a transient window in time when 
mRNA for the VSG is present but there is not yet enough mature VSG in 
the surface coat for the parasite to be killed.  If the parasitaemia is 
particularly high (as it was towards the end of infection, section 3.3.2), 
the total number of individual trypanosomes futilely activating an easily-
activated VSG would be proportionally high, which could explain the 
continued presence of VSG sets, and would also explain the (occasionally 
observed) reappearance of VSG sets.  These patterns were predicted by 
the model of Lythgoe et al. (2007) (J. D. Barry, Pers. Comm.). 
(iii) Immunosuppression.  As African trypanosome infections progress, mice 
increasingly suffer from immunosuppression that could relieve the 
extrinsic selection force of the immune system.  A weak, absent or 
ineffective immune response could have allowed variant expressors to 
persist without clearance.  The apparent clearance of variants suggests 
that, in general, immunosuppression is probably not absolute.  Immunity 
may, however, become less sensitive or slower to respond as infections 
go on. Lymphadenopathy and splenomegaly, which may disrupt the 
efficient development of an immune response, were observed during 
these infections (data not shown).  Immune responses against the 
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numerous different variants present must also compete for resources.  In 
conjunction with differentiation-based control or easy variant activation, 
partial immunosuppression could help explain the patterns of 
persistence.   
(iv) Within-set variation was providing sufficient variation in the antigenic 
profile of the VSG set to enable immune evasion.  The NTD amino acid 
sequences of two VSGs within a set can vary by as much as 0.219 
differences per amino acid.  This variability may, in some cases, result in 
changes to the epitope structure of the antigen, enabling evasion of 
adaptive immune effectors through progressive mosaicism.  Persistence 
through progressive mosaicism may be enhanced if an ineffective 
immune response raised against an earlier mosaic variant can inhibit the 
development of an effective immune response against its successors 
(Gjini et al., 2010).  However, many of the sets persisting here did not 
show exceptional within-set variation in the NTD.  The ability of within-
set variation to contribute to antigenic variation is considered further in 
Chapters 4 and 5. 
 
These possibilities are not mutually exclusive: it is possible that all four can help 
to explain the patterns of persistence of a set.  Further experiments are 
required to assess their relative contributions to infection dynamics in this host. 
 
3.6.4 How might these findings have differed in other 
experimental models? 
African trypanosome antigenic variation is a strategy that has evolved flexibility 
to adapt to different hosts.  The number of different processes, host and 
parasite, that interact to produce the dynamics of antigenic variation can 
produce a phenotype that can vary considerably between different models of 
infection.  How might the key findings summarized in section 3.6.2 have varied 
under different conditions? 
 
The expression of VSG is a parasite-intrinsic process: expression of different 
variants occurs in culture (Doyle et al., 1980).  The appearance of a variant in an 
infection depends on the host insofar as different hosts can harbour different-
sized parasite populations (carrying capacity), and their immune systems 
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respond to those populations at different rates (Gjini et al., 2010).  Hosts with a 
smaller carrying capacity (rabbits, for example) and a more responsive immune 
system might be expected to show less variant diversity during an infection and 
a clearer pattern of parasitaemic peaks than the experimental mice here (Barry, 
1986).  Patterns of activation hierarchy might be easier to distinguish, as 
immunity-based control becomes predominant. 
 
The relationship between expressed VSGs and the archive is almost certainly 
host-independent, and thus patterns of within-set variation would likely appear 
in other experimental models (Barbet et al. (1989), Thon et al. (1989) and Roth 
et al. (1989) all identified mosaicism amongst trypanosomes retrieved from 
infections of rabbits).  Segmental gene conversion is frequent in the later stage 
of infection as array VSGs become expressed.  Not only does segmental gene 
conversion allow expression of damaged array VSGs, but it also introduces 
another layer of diversity in the expressed VSG population. 
 
3.6.5 Further experiments 
Now that the key VSG sets expressed during TREU 927/4 GUTat 10.1 infection 
have been identified, further experiments could accurately quantify the 
proportion of parasites expressing different VSGs over the course of infection, 
for example using quantitative RT-PCR.  To assay the host responses, protein 
microarrays could be employed: preliminary collaborations with the Felgner Lab 
at the University of California, Irvine to produce a protein microarray of key T. 
brucei antigens is underway.  If the dynamics of density-dependent 
differentiation were monitored alongside (MacGregor et al., 2011), the 
predicted interactions between differentiation, immunity and antigenic variation 
(Gjini et al., 2010) could be tested directly. 
 
Much of the inference of the status and location of genomic copies is based on 
an incompletely sequenced genome, missing some of the VSG arrays of 
homologous chromosomes and VSGs present on the mini- and intermediate 
chromosomes (Berriman et al., 2005).  A more comprehensively sequenced 
genome, and in-depth analyses of genomic DNA by Southern blotting and cloning 
would clarify the number, location and identity of different associated genomic 
copies, and confirm the relationship between the expressed VSGs and their 
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genomic copies.  It is also possible (but unlikely, see Chapter 4) that a more 
comprehensive database may reveal further, as-yet-unknown full-length intact 
genomic copies corresponding to the mosaic sets.  Deeper and more frequent 
sampling could help build up a more comprehensive picture of VSG expression, 
particularly at points where VSG expression shows extensive richness and 
evenness.  Although this study favoured cloning individual VSG sequences to get 
unambiguous high-resolution information about individual sequences and to 
simplify assembly (particularly of mosaic VSG clones), it is possible that a high-
throughput next-generation RNA sequencing approach could be developed to 
capture the full picture of antigenic diversity within a sample.   
 
3.6.6 Concluding remarks 
Considering just between-set antigenic variation, it seems clear that these 
infections are far from exhausting their intact VSG repertoire—35 intact, full 
length genomic copies were not identified by sequencing from any of the 
infections analysed.  There were also some 81 atypical VSGs, whose unusual GPI 
anchor signal sequences could be easily overcome by a short 3’ donation, that 
were also not identified.50  Yet these infections the expression of many silent 
VSGs was apparently accompanied by the introduction of variation consistent 
with mosaicism. 
 
Why might a parasite population with an apparently strong hand start playing an 
increasingly risky game, combining and recombining its antigen genes?  The 
primary explanation, that segmental gene conversion is an occasional event that 
occurs solely to allow expression of damaged VSGs, and hence is selected as the 
host develops antibodies against the products of intact VSGs, is not supported by 
either of two independent lines of evidence.  Firstly, across all infections 
analysed to date, it does not appear that all, or even most, of the most-
accessible VSGs are expressed (and therefore neutralised) before segmentally-
converted VSGs appear.  Secondly, within-set variation is frequently seen within 
a timepoint.  Were it the case that segmental gene conversion was a very 
unusual event endowing its bearer access to a valuable antigen, we would 
                                         
50 Both of these figures were obtained by collecting the names of all ‘functional’ or ‘atypical’ VSGs 
from VSGdb, and subtracting from the list those VSGs whose expression was detected (in any 
form) in the infections presented here. 
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expect all segmentally-converted VSGs within a timepoint to be identical: clones 
descended from the single parasite which had made the daring switch.  But this 
is not the case.  These patterns of within-set variation are considered in the 
following chapter. 
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Chapter 4 
Variation amongst expressed VSGs
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4 Variation amongst expressed VSGs 
4.1 Introduction 
4.1.1 Variation is present between similar expressed VSGs 
As described in Chapter 3, the VSGs expressed in the experimental infections 
could be grouped into ‘sets’.  The members of each set were more similar to one 
another than to any members of any other set, and each set is thought to 
represent the expression of one or more specific genomic VSGs.  Variation 
between sets—switching expression between discrete genomic VSGs—corresponds 
with the classical process of African trypanosome antigenic variation.  However, 
it was also found that, alongside ‘between-set’ variation, expressed VSGs 
belonging to a set frequently varied from their putative genomic copy and from 
one another.  Broadly, three patterns of ‘within-set’ variation could be observed 
in the sequence data: point mutation, 3’ donation, and mosaicism.  Each of 
these patterns has been identified in expressed VSGs by previous studies (see 
Chapter 1 sections 1.6.6–1.6.11 for a detailed discussion).  The latter two 
represent processes of segmental gene conversion, as they are gene conversion 
events where the boundaries of recombination occur within the VSG coding 
region to produce a composite VSG.   
 
What is the role of within-set variation in trypanosome antigenic variation?  As 
described in the previous chapter, differences between expressed VSGs and their 
related genomic copies produced by segmental gene conversion allows the 
expression of pseudogenic genomic VSGs.  Yet variation amongst related VSGs 
can also be identified within an infection.  By introducing a further layer of 
variability amongst expressed VSG, within-set variation could potentially play a 
role in immune evasion, by producing antigenically distinct but sequence-related 
variants. 
 
4.1.2 Key hypotheses to be tested 
To assess the contributions of mosaicism, 3’ donation and point mutation to VSG 
expression and antigenic variation, the patterns of within-set variation in the 
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720 VSG sequences described in Chapter 3 were analysed bioinformatically and 
experimentally with regards to the following hypotheses: 
(i) Within-set variation between expressed VSGs—and between an expressed 
VSG and its putative genomic donor(s)—is routinely generated over the 
course of infection.  That is, within-set variation does not simply 
represent the straightforward activation of related VSGs already present 
in the genome of the inoculum, or experimental artefact. 
(ii) Variation between the expressed VSG and its putative genomic copy 
allows the expression of damaged silent VSGs.   
(iii) Patterns of within-set variation are consistent with a role in changing 
epitope structure.  By modifying the exposed NTD sufficiently, within-set 
variation could directly contribute to immune evasion. 
(iv) Within-set variation accumulates over the course of infection.  If within-
set variation is playing a role in antigenic variation in the infections 
here, trypanosomes that have accumulated events in their expressed 
VSG by segmental gene conversion and/or point mutation are more likely 
to survive and become detected at later timepoints. 
 
4.1.3 Investigating within-set variation 
To investigate within-set variation, sequence-related expressed VSGs were 
aligned with one another and with their putative donors, and the alignments 
were studied both by eye and automatically using custom BioRuby scripts 
(Chapter 2, section 2.7.2.4).  As described in Chapter 3 (section 3.4.3), patterns 
of within-set variation were identified in two complementary ways.  First, by 
comparing expressed VSG clones with their putative donor(s), regions where the 
expressed sequence did not match the donor sequence were identified (variation 
‘from donor’).  Second, expressed VSG clones of a set were compared with one 
another.  Regions where the expressed clones varied from one another could be 
identified (variation ‘amongst clones’).  Variation amongst clones reveals 
changes to the expressed form of VSG, and comparing variation amongst clones 
retrieved from a single infection indicates the possible contribution of such 
variation to antigenic variation.  In addition, variation amongst clones was useful 
for inferring the involvement of unannotated genomic copies, as identical 
patterns appearing in different infections indicates the involvement of an 
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unidentified template and/or divergence between the clone used for genome 
sequencing and the clone used for these infections.   
 
The different patterns of variation—point mutation, 3’ donation and mosaicism—
were identified as follows: 
(i) Where mismatches (either from the donor or amongst clones) were 
isolated, and no alternative template containing a region with these 
differences could be found, they were investigated as point mutations.   
(ii) Where mismatches were clustered towards the 3’ end of the gene, they 
were investigated as cases of 3’ donation.  In some cases, donors for the 
3’ end could be found.   
(iii) Where clusters of mismatch appeared within the gene they were 
investigated further as potential mosaics.  Additional donors containing 
regions corresponding exactly with the cluster of mismatching bases 
could often be found.  Occasionally, additional donors corresponding 
with the cluster of mismatching bases could not be found.  In this case, 
the set was not classified as a mosaic (instead it was classified as 
‘unknown’ and was not investigated further), except where mosaicism 
could be inferred by comparison amongst clones (described in section 
4.5.1). 
 
4.1.4 Each pattern of within-set variation will be considered in 
turn 
This chapter will consider each of the different patterns of within-set variation 
in turn, ending each section with a short summary.  First, patterns of point 
mutation will be described: whether they are generated over the course of 
infection, and what their contribution to antigenic variation might be (section 
4.2).  Then, segmental gene conversion will be considered.  The question of 
whether the observed patterns of segmental gene conversion are likely to be 
genuine will be considered separately (section 4.3) before moving on to discuss 
3’ donation (section 4.4) and mosaicism (section 4.5).  Finally (section 4.6), the 
results of the previous sections will be brought together to address the key 
question of this chapter: whether and how within-set variation might contribute 
to antigenic variation. 
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4.2  Point mutations 
4.2.1 Point mutations were present in VSG sequences 
Many viruses depend on the accumulation of point mutations in their antigens for 
immune evasion within a host, or across host populations (Boni, 2008; Sodroski 
et al., 1998).  Under selective pressure, variation can arise in an individual base 
that changes VSG epitope structure sufficiently to allow escape from a 
monoclonal antibody (Baltz et al., 1991).  Were this process rapid and extensive 
enough, evasion of a polyclonal antibody response might be possible.  Is there 
any evidence in the collected sequence data that immune evasion by the 
accumulation of point mutations occurs over the course of the trypanosome 
infections? 
 
Many expressed sets showed the presence of ‘point mutations’51: isolated single 
differences found both amongst expressed clone sequences, and between an 
expressed clone sequence and its putative genomic copy.  Point mutations were 
the only source of within-set variation identifiable in the VSG N-terminal domain 
(NTD)-encoding region for 30 of the 83 sets. 
 
4.2.2 Some point mutations were probably generated over the 
course of infection 
To investigate whether observed point mutations are experimental artefacts, the 
estimated rate at which single-base mismatches might be artefactually 
introduced by amplification and cloning was calculated.  Published fidelity 
measurements for the two polymerases employed in sequence amplification 
(SuperScript III (Invitrogen, Paisley, UK); Herculase II Fusion, (Agilent, Stockport, 
UK)) were combined to calculate a predicted error rate per sequence. 
 ! !""#" ! !!!! !" ! !!!!!!!!! 
 
                                         
51‘Point mutation’ is generally taken to mean variation at a specific position introduced by an 
enzyme as it copies a template strand.  However, the possibility that the apparent point 
mutations observed here are in fact introduced by short gene conversion events with 
unidentified non-homologous donors cannot be ruled out. 
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where !!!"! is the error rate of SuperScript III per base (1 / 37037), ! !  is the 
error rate of Herculase II per base (1 / 770000), ! is the average length of a VSG 
nucleic acid sequence (1500 bp) and ! is the average number of times a 
sequence has been copied in an ideal, 30 cycle PCR reaction (29). 
 
To predict the proportion of sequences containing one or more mismatches, the 
Poisson distribution was used.   
 ! ! ! !!! !!!!!  
 
where ! is probability of event (!!!""#"!) and ! is number of events (!, that is, 
sequences with no errors).  The probability of one or more errors was 
calculated: 
 !!! !! ! !! !!!! !!!!!!!!!!!!!!! !! !!! !!!!!!!!!!!!!!! !!!"#$%!
   
or, 9.2% of sequences would be predicted to have one or more errors, were 
these two polymerases the only source of variation.   
 
Assuming that the published fidelity rates for these two polymerases are 
dependent on numerous, unaccounted for reaction variables (such as salt 
concentration, template composition, and so on), the same calculation was 
carried out using error rates ten times greater than published.  Under these 
conditions, 62.1% of sequences would be predicted to have one or more 
artefactual errors and 1.1% of sequences two or more artefactual errors.  This 
value is still markedly less than the observed frequency of point mutations (see 
section 4.2.4) suggesting that experimental artefact alone cannot account for 
the variation observed. 
 
Another line of evidence that point mutations genuinely existed in expressed 
VSGs came from the identification of the same point mutations in independent 
amplification reactions made from samples taken from the same infection.  
Examples can be found in mouse 05 Set_13 and Set_21, shown in Appendix 7.3.1.  
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The different patterns of point mutations seen in samples taken from different 
infections (including the primary clonal infections) hints that point mutation 
variation was generated independently in different infections. 
 
Together, these analyses suggest that point mutations did occur over the course 
of infection, although further experiments are required to formally verify their 
appearance, such as cloning from genomic DNA at the beginning and end of 
infection. 
 
4.2.3 Some point mutations resulted in non-functional VSG 
sequences 
It was noted during assembly of the VSG sequences that 61 expressed VSG clones 
contained apparent mutations that would prevent their functional translation or 
vary the structure of the GPI anchor signal sequence: insertions and deletions 
causing frameshifts, and substitutions generating internal stop codons.  Most of 
these errors were corrected during sequence assembly by reference to similar, 
undamaged clones from the same sample, as described in Appendix 7.2.3.52  
Close examination of these sequences show that in 35 cases these errors have 
been introduced by the expansion or contraction of a poly-A/T tract: regions 
that are particularly prone to artefactual damage during amplification as the 
polymerase can ‘slip’ as it passes through them.  The CTD-encoding portion of 
many of the VSGs under consideration here contain poly-A/T tracts.  Previously, 
Rice-Ficht et al. (1982) found the artefactual contraction of a poly-A tract in one 
of their sequencing reactions from genomic DNA.  That none of the non-
functional VSG sequences was found in independent transcription-amplification 
reactions is consistent with the occurrence of some artefactual point mutations 
in the sequence data.  It is therefore likely that there are both genuine and 
artefactual point mutations in the sequence data.  As a consequence the 
patterns of point mutation should be interpreted with caution. 
 
                                         
52 In addition, three clones showed the loss of a fragment of their sequence, a phenomenon that 
could be ascribed to residual recombination occurring in the E. coli cells used to amplify the 
sequence-containing plasmid. 
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4.2.4 Does point mutation contribute to antigenic variation? 
The variation introduced into the expressed NTD by point mutation is shown in 
Table 4.1.  The maximum amino acid distance between related mature NTDs was 
calculated for all sets where a clear genomic copy could be identified and point 
mutation was the only pattern of NTD variability.  Point mutation introduced 
variability amongst related VSG NTDs of up to 0.057 differences/aa.  Within an 
infection, variability was lower, with most sets showing fewer than 0.010 
differences/aa.   
 
Is there any evidence that point mutation contributes to antigenic variation?  
Nine sets were chosen for closer analysis.  These sets were chosen as they 
matched their putative genomic copy well in the NTD-encoding region (there 
was no evidence of identical patterns of mutation in different infections, and no 
evidence of N-terminal mosaicism), they had multiple clones which could be 
compared with one another, and they were representative of the totality of sets 
in that some appeared early, some late, and some across infection.  The chosen 
sets also showed generally higher levels of variation than other sets so were 
considered a strong test of the null hypothesis that patterns of point mutation 
do not contribute substantially to antigenic variability.  For these analyses, just 
the NTD-encoding region was considered, to isolate point mutation variation 
from variation caused by 3’ donation (which was frequently observed, section 
4.4).  First, the distribution of point mutations appearing independently in 
different infections was tested, to see whether point mutations generally cluster 
in particular regions of the NTD.  For each set, the position of all differences 
amongst expressed VSG sequences was recorded.  The maximum number of 
differences occurring within a region of defined size (‘the sliding window’) was 
counted, and their position was recorded.  This is the observed maximum.  To 
assess whether these differences were non-randomly distributed, 10,000 random 
distributions of the same number of differences were created for each set, and 
the maximum number of differences occurring within the sliding window was 
counted for each of these.  The rank of the observed maximum amongst the 
simulated maxima corresponds with a p-value.  The results of these analyses are 
shown in Table 4.2.   
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Table 4.1 Expressed N-terminal domain variability introduced by point mutation.  Mature 
NTD amino acid sequences from sets where point mutation was the only identifiable source 
of NTD variability were compared.  ‘# of infxn’ = number of infections in which that set was 
detected; ‘# of clones’ = total number of clones obtained.  The maximum difference between 
related sequences (‘Max set’), related sequences expressed within an infection (‘Max 
infection’), and sequences and their putative donor (‘Max from don’) were calculated using 
ClustalW.  The measure of the differences is differences/aa in the mature NTD.  The top ten 
sets are highlighted in red.  Sets referred to in Table 4.2 are indicated by a ‘＊ ’. 
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Table 4.2 Distribution of N-terminal domain point mutations.  The positions of non-
synonymous point mutations were analysed by a sliding window of indicated size.  The 
region where most point mutations were located was recorded (‘Max’ = the number of 
mutations in this region, ‘Position’ = the position in the nucleic acid alignment).  ‘Max’ was 
compared with the maximums obtained from 10,000 simulations in which point mutations 
were randomly distributed, and ‘Rank’ describes its rank amongst these simulations.  
Significance at the 0.05 level is indicated in bold.  Similar results were obtained when 
considering total point mutations, except in those sets indicated by a ‘＊ ’ (p-values were not 
improved), and/or by increasing window size to 100.   
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Table 4.3 (Non-)synonymity of N-terminal domain point mutations.  For each set under 
consideration, the proportion of non-synonymous sites in its corresponding donor’s NTD-
encoding region was calculated (‘Prop. donor sites ns’).  Each clone of that set was 
considered in turn, and the number of synonymous and non-synonymous point mutations 
in the NTD-encoding region recorded.  For each set, the maximum number of total point 
mutations seen in a clone, and the number of these that were non-synonymous in brackets, 
is given in the column ‘Max (ns)’.  The proportion of non-synonymous point mutations 
(Prop. ns) was calculated for each set by taking all the point mutations seen in that set 
together, and dividing the number of non-synonymous point mutations by the total.  This 
value was divided by the proportion of non-synonymous donor sites to give a total dn/ds 
ratio.  dn/ds ratios > 1 are shown in bold. 
 
Non-random distribution of point mutation variation amongst clones was found, 
but was set-specific.  There was no region of the domain in which point 
mutations uniformly accumulated, either when considering all domain types 
together, or separating into A and B NTD types. 
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If point mutations causing a change in VSG epitope structure were favoured, the 
dn/ds ratio (the ratio of non-synonymous mutations per non-synonymous site to 
synonymous mutations per synonymous site) amongst members of a set might be 
expected to be significantly greater than 1: point mutations that change protein 
structure being more successful, and hence more frequently detected, than 
those which have no effect.  The number of non-synonymous and synonymous 
sites for each set’s putative donor was counted and compared with the total 
number of non-synonymous and synonymous mutations observed for each clone 
of that set, and the dn/ds ratio calculated.  The results are shown in Table 4.3.  
As can be seen, there is not a general trend towards non-synonymous over 
synonymous mutations.  It is possible that by considering the entire sequence of 
the NTD-encoding region as a whole, the selection for non-synonymous 
mutations specific codons is being masked by no, or negative selection, at other 
codons.  To test this, a fixed effects likelihood model (Kosakovsky Pond & Frost, 
2005) was used, which tests for the presence of positive or negative selection at 
each individual codon.  In none of the sets examined53 was there significant 
positive selection detectable at any codons (data not shown).   
 
Together, there is no evidence that point mutations played an important role in 
varying the antigenic profile of the parasite population during these infections.  
Their possible contribution to the biology of African trypanosome antigenic 
variation is discussed in more detail in Chapter 6 (section 6.3.2). 
  
                                         
53 There were insufficient unique sequences to analyse Set_82. 
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4.3 Segmental gene conversion 
4.3.1 Segmental gene conversion probably occurred during 
infection 
Before discussing the patterns of segmental gene conversion observed here, the 
question of whether they are generated over the course of infection must be 
addressed.  Both mosaicism and 3’ donation have been analysed in depth by 
PCR, Southern blotting and genomic cloning numerous times (see Chapter 1 for a 
review) demonstrating that these segmental gene conversion events readily 
occur during VSG expression.  For reasons of time, similar analyses could not be 
performed on any but a few of the sequences reported here.  Nevertheless, 
bioinformatic analyses of the data could go some way to addressing the question 
of whether the segmental gene conversion variation observed generally occurs 
during infection. 
 
First, the possibility that apparent segmental gene conversions are an 
experimental artefact will be considered.  Second, the possibility that apparent 
segmental gene conversions represent variation pre-existing in the genome of 
the inoculum will be considered. 
 
4.3.1.1 Was segmental gene conversion an experimental artefact? 
Studies on reverse transcriptase and thermostable DNA polymerases have shown 
that ‘copy choice’ can cause recombination between sequences during 
polymerisation, as the DNA polymerase switches between templates (Odelberg 
et al., 1995; Zaphiropoulos, 2002).  Template switching as the main cause of 
apparent segmental gene conversion was considered, but discounted here for 
three reasons.   
(i) The Herculase II Fusion polymerase used for PCR amplification is based 
on Pfu DNA polymerase, which does not show any evidence of template 
switching (Shafikhani, 2002). 
(ii) Were template switching the main cause of apparent segmental gene 
conversion, it would be unusual to find identical patterns of segmental 
gene conversion from different transcription-amplification reactions.  
Here, VSGs having undergone 3’ donation or mosaicism could often be 
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found from independent transcription-amplification reactions.  Examples 
can be found in Appendix 7.3.4.  
(iii) Were it the case that template switching was occurring at an 
appreciable level, we would expect to see, from the same reverse 
transcription-amplification reaction, identical regions in clones from 
different sets, representing the templates between which the 
polymerase had switched.  The observed patterns of segmental gene 
conversion were inconsistent with this model.54  
 
These observations make template switching an unconvincing explanation for the 
patterns and prevalence of segmental gene conversion observed here, however, 
further experiments would be necessary for each sequence to rule out template 
switching as a contributing factor altogether. 
 
4.3.1.2 Were identified mosaic and 3’ donation VSGs already present in the 
inoculum genome? 
The parasites used to initiate the infections came from the same clone used for 
the genome sequencing (Berriman et al., 2005).  Nevertheless, it is likely that 
there were further unsequenced or unannotated VSG genes in the inoculum that 
were not present in the genomic VSG database (Marcello & Barry, 2007a).  The 
patterns of segmental gene conversion were studied to assess whether the 
apparent segmental gene conversion events observed here represented the 
straightforward expression of as-yet-unknown full-length VSGs present in the 
genome of the inoculum.  Identical patterns of segmental gene conversion in 
different infections indicate either that identical gene conversion events 
occurred independently in different populations, or, more likely, that these 
variants were present in the genome of the parasites used to initiate the 
infections.  Close analysis of sequences showed some identical patterns of 
segmental gene conversion occurring in different infections, hinting at the 
contribution of unannotated genomic variation.  However, the number of VSGs 
apparently formed by segmental gene conversion made unannotated genomic 
variation an implausible explanation for most of the segmental gene conversion 
                                         
54 In some cases (see section 4.4.4), clones from different sets had similar 3’ regions, but in almost 
all cases the similar 3’ region-bearing VSGs of different sets were retrieved from different 
reverse transcription-amplification reactions. 
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events described here, as it would require the parasites to possess huge families 
of closely related VSGs, and often activate them all at a similar time.  Genome 
analyses of VSG subfamilies suggests that this is not the case (rather, 40% of 
VSGs are in small subfamilies, most of which contain two members (Marcello & 
Barry, 2007a)). 
 
The parasites used for most of the infections had a common source, cloned six 
passages previously (~72 generations, assuming a doubling time of six hours and 
approximating time in each mouse at three days, see Appendix 7.2.1).  It is 
possible that over this period the population became heterogeneous, with some 
individual parasites undergoing segmental gene conversion events (possibly in a 
silent locus) that become expressed in the experimental infections.  In this case, 
although the observed variation might have arisen rapidly from an individual 
parasite, technically it would not have developed over the course of the specific 
experimental infection under consideration.  To assess whether a potentially 
polyclonal inoculum population could have influenced the patterns of segmental 
gene conversion observed, primary clonal experimental infections (initiated by a 
single parasite) were analysed.  The variety of different mosaic VSGs derived 
from a single infecting parasite (described in section 4.5.3) suggests that 
segmental gene conversion occurs readily over the course of a 4–5 week 
infection, lending support to the premise that the segmental gene conversion 
events observed here generally occurred over the course of an infection.  
 
4.3.2 Segmental gene conversion was analysed as 3’ donation 
and mosaicism 
Patterns of presumed segmental gene conversion were separated here into 3’ 
donation and mosaicism.  Broadly, 3’ donation introduces specific variation in 
the CTD-encoding region of the expressed VSG, whereas mosaicism introduces 
variation within the NTD-encoding part of the gene.  These patterns of variation 
are likely a consequence of homologies between donor sequences.  The donors 
combining in 3’ donation (where they have been found) shared little overall 
nucleotide identity (with short regions of homology located in the CTD-encoding 
region, or the region encoding the hinge between N- and CTDs), whereas donors 
combining to produce mosaics showed homology across their entire length.  Roth 
et al. (1986) made the distinction between ‘hybrid’ VSGs, constructed from VSG 
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genes that do not have extensive sequence homology, and ‘mosaic’ VSGs 
produced from members of a highly related gene family.  A distinction based 
solely on donor homologies was not possible here, due to the difficulty in 
identifying full-length donors for many 3’ donations (see section 4.4.4).  
Therefore, ‘3’ donation’ was made a more inclusive term than ‘hybridism’, 
covering all putative recombination events that modify the 3’ end of the 
expressed VSG.  Where identified, specific 3’ donors indeed had little homology 
with the N-terminal donor of the expressed VSG.  On the other hand, 
‘mosaicism’ included all putative segmental conversion events occurring in the 
NTD-encoding region, which incidentally always involved related donors (section 
4.5.5).  The involvement of mosaic donors in the CTD-encoding region of a VSG 
was also considered mosaicism. 
 
Mosaicism and 3’ donation may be united in a common homology-driven 
recombination mechanism but their distinction was found to be a useful way of 
categorizing the patterns of within-set variation observed here, allowing 
variation that affects the epitope-containing NTD to be considered separately 
from that affecting just the buried CTD.  
 
4.4 3’ donation 
4.4.1 3’ donation was frequently observed 
3’ (CTD) donation in VSGs comes about when the region of the VSG gene 
encoding the membrane-distal NTD of the protein is joined to a different 
sequence in the CTD-encoding region (see Chapter 1 section 1.6.8).  3’ donation 
was identified by comparing expressed clones with their putative genomic copy 
donors and finding abundant mismatches towards the 3’ end of the gene, and by 
comparing the members of a set with one another and finding expressed VSG 
clones with high levels of identity in their NTD-encoding region with numerous 
differences from one another in their CTD-encoding region.   
 
The most likely means by which a VSG comes to acquire a different 3’ end is 
during the formation of its expression-linked copy, when the 3’ boundary of 
recombination occurs within the coding region of an expression-site-occupying 
VSG.  The 3’ end of the previous VSG is therefore retained and joined to the 
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NTD-encoding region of the incoming VSG.  However, it is also likely that events 
can accumulate in the CTD-encoding region of a VSG in situ (Marcello & Barry, 
2007a). 
 
Inclusive criteria for 3’ donation (specific variation from a donor or variation 
amongst clones) found 3’ donation occurring in 47/83 sets.  A more conservative 
definition (specific variation from a donor and variation amongst clones) found 
3’ donation in 23/83 sets (see Appendix 7.3.2 for details).  Thus the expressed 
form of a VSG often acquired a 3’ end that was different from its silent form. 
 
4.4.2 3’ donation allowed the expression of damaged VSGs 
In replacing the 3’ end of a silent VSG, 3’ donation can repair damage to that 
VSG’s CTD or GPI anchor signal sequence.  Of the silent VSGs corresponding with 
the 47 sets for which 3’ donation was observed, 16 relied on 3’ donation to 
repair pseudogenic CTD-encoding regions,55 and 10 silent VSGs whose CTD 
function was uncertain (‘atypical’ VSGs) underwent 3’ donation.   Several of 
these pseudogenic or atypical VSGs were the primary contributing donors to 
mosaic sets.  By undergoing 3’ donation, these mosaic donors acquired 3’ ends 
that had little or no overall homology with any of the other mosaic donors.  The 
different degrees of 3’ donation, and the nature of the silent copies undergoing 
3’ donation, are summarized in Figure 4.1. 
 
In one case an expressed VSG (04-21c25, the sole member of Set_58) acquired an 
apparently dysfunctional 3’ end, lacking a GPI anchor signal sequence due to a 
premature in-frame stop codon.  This clone may represent the stochasticity of 
segmental gene conversion and VSG activation—occasionally damaged VSGs may 
occupy active expression sites, although (presumably) only transiently (see 
Chapter 3 section 3.2.2.1).
                                         
55 Four of these were read assemblies, two of which were a minichromosomal read assemblies. 
  
 
Figure 4.1 Summary of 3’ donation events.  The diagram shows, for the 83 sets detected across all infections, the properties of the primary genomic copy.  
Compared with the diagram in Chapter 3 (Figure 3.7), donor genes that apparently contributed only to the NTD-encoding regions of mosaic sets are not 
shown, and this diagram has been reordered according to presence of 3’ donation (‘± 3’ donation’ indicates 3’ donation identified in some clones).  The 
pseudogenicity of each of the donors is indicated by a diagonal line across the gene marker.  A small black square for read assemblies indicates that this 
assembly didn’t cover the whole expressed VSG, and therefore it is possible that it is damaged further.  Note that one set shows a damaged donor CTD but 
no 3’ donation; in this case damage towards the 5’ end of the CTD had been repaired by mosaicism and thus was not counted.  This diagram was drawn 
using the more inclusive definition of 3’ donation (variation from donor or variation amongst clones).
file:///Users/jpjh/Dropbox/WORK/pieces/analysis/set_donor_properties/F_cons.svg
1 of 1 16/07/2012 09:55
!"#$"%&'()&'!#$"%&'()&'"*'"(++",+&'-.! /&"-0*%-',-"&1"#$"%&'()&'!
2',+3.*0-"%-4'*)&'"&1"#$"%&'()&'"5-*67-8"18&9"%&'&8:"&8"(9&';.6",+&'-.<"
13++"+-';67:"*'6(,6"
(6=>*,(+"
>.-3%&;-'-"
8-(%."?"9*'*,78&9&.&9(+"
8-(%."
3'@'&A'"
>.-3%&?/BC"
>.-3%&?DBC"
*',&9>+-6-".-E3-',-"
F"&1".-6.".7&A*';"%*G-8-'6">(H-8'."&1"#$"%&'()&'"
C&'&8";-'-5.<"
.3IJ-,6"6&"#$"
%&'()&'""
K-6LMN"59*'*,78&9&.&9(+"DBC?>.-3%&"('%"DBC?>.-3%&<"A(.">.-3%&"&'+="*'"67-"9&.6"O$"-'%"
&1"67-"DBC:"('%"A(."8->(*8-%"I="9&.(*,*.9P""K-6LOQ"5',>"('%"&8<"%*%'$6"7(0-"-'&3;7"8-(%"6&"
,&0-8"67-"#$"-'%:"I36"67-",+&'-."A-8-"(++"*%-'),(+"(6"67*.">&*'6P""R&8"67&.-".-6."*%-')4-%"&'+="
I="A*67*'?.-6"0(8*()&':"*6"A(."(..39-%"67(6"&'-".-6"&1"0(8*('6."7(%"'&"#$"%&'()&'"5673."67-"
3'@'&A'."*'"!"#$"%&'()&'P"
"
"
#S"QT"#U"
Chapter 4  168 
 
 
4.4.3 The extent of 3’ donation varied 
The extent of 3’ donation varied.  Some expressed VSGs showed substantial 
donation, in which their whole CTD-encoding region was replaced; others 
showed variation solely towards the 3’ end of the CTD-encoding region, and 
others had changes to just their most 3’ end, in the GPI anchor-encoding region.  
Examples of different degrees of 3’ donation are shown in Figure 4.2. 
 
 
 
Figure 4.2 Degrees of 3’ donation.  Diagrams showing the CTD-encoding regions of four 
expressed VSG clones demonstrate different degrees of 3’ donation events.  Each diagram 
shows a summary of the alignment (5’–3’) between the CTD-encoding regions of an 
expressed VSG clone and its primary donor.  Cysteine residues are shown as bars 
extending above the diagram, and a red arrowhead indicates the beginning of the cleaved 
GPI anchor signal sequence.  Mismatches between the clone and the donor are shown as 
red bands extending across the diagram.  The CTD-encoding nucleic acid variability 
(differences/nt between expressed VSG and primary donor) is given for each example.  For 
minor donation events, a portion of the translated alignment is shown. 
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Although the period before day 20 is covered by fewer data (91 clones, 
compared with 629 clones on and after day 20) making direct comparison with 
the later period qualified,56 it is interesting to note that only 3/18 sets from this 
period of infection, Set_08, Set_74 and Set_22, showed patterns of 3’ donation.  
Of these, Set_08 showed identical patterns of variation in all eleven infections in 
which it was detected, including both of the clonal infections, hinting that this 
particular 3’ variant was pre-existing in the inoculum.57  The later stage of 
infection showed 3’ donation in 46/75 sets.  This observation is consistent with a 
model in which 3’ donation becomes more prominent in the activation and 
expression of VSGs as an infection progresses.58 
 
4.4.4 The donors of 3’ ends often corresponded with likely 
telomere-proximal VSGs 
Preliminary attempts to identify the 3’ donor were only successful in cases 
where a substantial part of the CTD-encoding region had been replaced, as VSGs 
show generally high levels of homology towards their most 3’ end, particularly in 
the GPI anchor-encoding region (Majumder et al., 1981; Matthyssens et al., 
1981; Pays et al., 1981a; Rice-Ficht et al., 1981).  Donors were therefore only 
investigated for cases where there was at least 75 bp of 3’ donation.  The 
involvement of a mosaic VSG’s donors in the CTD-encoding region (C-terminal 
mosaicism) of that VSG was also excluded from this analysis, as this pattern is 
considered alongside N-terminal mosaicism in section 4.5.59  BLAST searches of 
the genomic databases enabled identification of putative 3’ donor sequences for 
13 of the different 3’ donation variants.  Matches in the 3’ region were also 
found by comparing VSGs from different sets, allowing the identification of a 
further six 3’ variants.  Identified 3’ variants are shown in Table 4.4.  As is clear 
                                         
56 As 3’ donation was identified in part by variation between clones, the greater the number of 
sequences retrieved, the greater the probability of identifying 3’ donation, thus this analysis is 
somewhat biased against finding 3’ donation in the earlier timepoints. 
57 Note added in proof: a Southern hybridization carried out following submission of this thesis gave 
results inconsistent with this hypothesis (data not shown). 
58 For this analysis one pre-day 20 set, Set_04, was discounted from the pre-day 20 count as 3’ 
variation in this set was detected only at day 27.  3’ donation in sets that had appeared pre-day 
20 were counted again if they showed 3’ donation on or after day 20 (that is, Set_08 and 
Set_22).  
59 However, instances where mosaic VSGs have acquired 3’ donors in a similar manner to non-
mosaic VSGs, (that is, involving donor sequences that have overall low homology with the 
primary donor), were investigated. 
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in the table, the same 3’ end could be a donor in a number of different sets, as 
also shown in Figure 4.3. 
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Table 4.4 Identified 3’ variants.  Each identified 3’ donation variant is given an identifier (a–s, 
first column).  3’ ends matching VSGs from another set are indicated under ‘Source set’.  
The time of first detection of that set is indicated under 'Notes', as are those reads found in 
the minichromosomal read database.  For Set_23, only one clone was found, and no donor 
could be found for it, but it matched Set_64 in the 3’ end.  In the case of variant d, matches 
were not for the entire 3’ donation.  Those reads showing ‘TTAGGG’-like sequence 3’ of the 
VSG are indicated with a ‘＊ ’.  Example patterns of 3’ donation variants used in figures 
elsewhere in this thesis are provided as a reference. 
 
The majority of identifiable 3’ donors correspondeded with minichromosomal 
reads and VSG sets expressed early on in infection, both of which are likely to 
represent telomere-proximal VSGs.  Indeed, TTAGGG-like repeats were 
identified downstream of the coding region in many of the reads shown in Table 
4.4: these may represent the telomere repeats themselves, or more likely a 
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region of homology often found upstream (Aline & Stuart, 1989).  This finding is 
consistent with a model in which the 3’ donation was acquired during the VSG’s 
duplication into a telomere-proximal locus (Michels et al., 1983; Pays et al., 
1985a) although it is also possible that sequence exchange could have occurred 
by telomere interaction following gene conversion. 
 
The failure to identify 3’ donors for all sequences was probably due to the fact 
that telomere-proximal VSGs are underrepresented in the genome sequence 
data.  Furthermore, efforts to identify donors may have been complicated by 
successive 3’ donation events at a telomere each leaving small portions of 
residual sequence, producing a composite 3’ end of the expressed VSG whose 
complex construction could not be dissected. 
 
 
Figure 4.3 Many sets, same 3’ end.  Three diagrams representing cDNA clones belonging to 
three different sets (Set_22, Set_56 and Set_31) are shown.  The division between N- and 
CTD-encoding regions is indicated by a black bar.  A thick dotted line indicates the division 
between the N-terminal signal peptide-encoding region and the mature NTD-encoding 
region.  Cysteine codons are represented by a bar projecting above the diagram.  For the 
mosaic VSGs from Set_22 and Set_31 segments matching different donors are shown in 
different colours.  Mismatches with all donors are shown as red bars spanning each 
diagram (see Figure 4.8 for details on how diagrams of mosaics were drawn). The primary 
donors of Set_22 and Set_55 are pseudogenic in the CTD: the location in the alignment 
where degeneration begins is indicated by a red cross.  3’ variant b (see Table 4.4) 
contributed the 3’ end for each of these VSGs: the boxed region (233 nt) contains only two 
nt differences between the three sequences (<0.01 differences/nt), whereas the unboxed 
region has variability between 0.492 and 0.539 differences/nt.  Each of these sequences was 
identified in independent reverse transcription-amplification reactions from that infection.  A 
Set_22 3' donation event identical to 02-20c06 was also identified in mouse 04, indicating 
that this particular 3’ variant may have been present in the genome of the inoculum (see 
Figure 4.13). 
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4.4.5 The same VSG could acquire many different 3’ ends 
While the previous section (4.4.4) showed that that different silent VSGs could 
be activated in similar ways, it was also observed that the same silent VSG could 
be activated in different ways.  Different 3’ donations to produce different 
members of Set_27 are shown in Figure 4.4.  In some cases, the acquisition of 
different 3’ ends could be identified within an infection.  The most likely 
explanation for this pattern is that the same VSG became polyclonally activated, 
acquiring a different 3’ end each time it was copied into an expression site 
(Michels et al., 1983; Timmers et al., 1987). 
 
 
Figure 4.4 Same set, many 3’ ends.  Three diagrams representing cDNA clones belonging to 
the same set, Set_27, are shown.  The diagrams are annotated as in Figure 4.3.  
Tb09.142.0470, the donor of Set_27, is pseudogenic in the CTD, and a red cross indicates 
the position in the alignment where the degeneration begins.  For each clone, the damaged 
donor has been repaired with a different 3’ donor variant.  The identifier of the 3’ variant 
type contributing to each clone is shown to the right of each sequence.  In the boxed region, 
the clones show variability between 0.008 and 0.011 differences/nt, whereas they show 
0.357 to 0.458 differences/nt in the 3’ end.  In the case of the day 27 clone from mouse 04, a 
black bar under the sequence indicates a region of low identity with the Set_27 donor and 
the 3' donor sequence, with may correspond with a residual sequence from multiple 3' 
donation events at this site.  A Set_27 3' donation event identical to day 23 mouse 04 variant 
was also identified in mouse 05, indicating that this particular 3’ donation variant may have 
been present in the inoculum genome. 
 
 
Set_12 VSGs from mouse 04 showed great variety in their CTD-encoding regions 
(more than six distinct variants).  Some examples are shown in Figure 4.5.  Due 
to the lack of saturation in the sequencing, it is likely that even the observed 
degree of variation was an underestimation of the total population diversity in 
this set.  Donors could not be found for the extreme 3’ end, but Tb11.v4.0021 
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(12-B) contributed segments to the 3’ part of the gene (see also footnote 66).  It 
is possible that a lineage within the mouse 04 infection silently acquired a 
telomere-proximal copy of the Set_12 donor (Tb11.30.0005, 12-A), which was 
easily and frequently activated in a polyclonal manner to produce the variety of 
3’ donation events observed.  The identification of Set_12 at many timepoints in 
this infection (Set_12 was detected in all mouse 04 samples between days 21 and 
31) is consistent with this theory, as the mRNA of an easily activated VSG may 
continue to be detectable even in the presence of antibodies.  However, it is 
also possible that variation accumulated in the 3’ end of an expression-linked 
Set_12 VSG, perhaps through mosaic-like processes: 12-B and 12-A show greater 
identity in their 3’ ends than they do throughout the rest of the sequence (see 
footnote 66).  For other sets, the number of different variants seen within an 
infection was usually three or fewer. 
 
4.4.6 3’ donation can change the C-terminal domain type of a VSG 
When comparing expressed VSG clones with their putative genomic donors, 3’ 
donation was apparently able to exchange different CTD types.  CTDs were 
typed by eye, using Carrington et al. (1991) and Marcello & Barry (2007a) as 
guides (see Chapter 1, section 1.5.2), as current alignment-based approaches 
have been unable to reliably classify the different domain types (Weirather et 
al., 2012).   
 
This process of CTD exchange is consistent with the well-mixed nature of the 
archive: although there is some bias in the archive between N- and CTD type 
combinations, all combinations of different N- and CTD types are present 
(Marcello & Barry, 2007a).  The different domain type combinations seen in the 
relatively short periods presented here allows us to speculate that the 
expression site is a locus where mixing of domains can take place, although it is 
currently unclear how recombined expression-linked VSGs become archival 
copies (see Chapter 6 section 6.4.7).  There is no functional difference ascribed 
to different CTD types, but it is possible that combining different N- and CTDs 
has a role in determining activation probabilities of expressed VSGs (since 
homology in the CTD-encoding region can act as a substrate for recombination), 
or in the generation and evolution of diversity in the VSG archive.  
  
 
Figure 4.5 Variety amongst Set_12 C-terminal domains.  Amino acid sequences of the CTDs of representative Set_12 variants from mouse 04 are shown.  
Cysteine residues are highlighted in yellow, and the predicted GPI anchor signal sequences are coloured in dark grey.  Amongst these clones, there are 
two broad patterns: a type 5 CTD (indicated in dark purple) and a type 4 CTD.  Sequences were aligned and arbitrarily coloured light purple, red, blue or 
black to emphasise differences amongst expressed sequences.  Stars under the alignment indicate identity amongst all expressed sequences.  The 
variability amongst these clones was calculated for the NTD and the N-terminal end of the CTD, and for the C-terminal end of the CTD and are given above 
the clone sequences (measured in amino acid differences/position).  Below the clone sequences, sequences of the main donor (12-A; Tb11.30.0005) and a 
C-terminal donor that contributes to many variants (12-B; Tb11.v4.0021 contributes most substantially to the day 29 variant here) are given.  Stars under 
the donor sequences indicate identity between the donors.  12-A has a frameshift towards its most 3’ end, which was corrected to give the sequence here; 
the position of the frameshift is indicated by a double-strikethrough.
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Figure 4.6 C-terminal domain exchange.  Diagrams representing cDNA clones are annotated 
as in Figure 4.3.  The position in the alignment where the Set_56 donor becomes degenerate 
is indicated by a red cross.  ‘unk’ = unknown 3’ donor. 
 
 
4.4.7 Boundaries of recombination 
The boundaries of 3’ donation were not evenly distributed throughout the CTD-
encoding region.  For each set, the locations of 3’ donation boundaries were 
recorded.  The 3’ donation boundary was considered to be the region where an 
expressed VSG sequence begins to diverge from the primary donor.  Boundaries 
were grouped into regions according to structural features of the CTD in which 
they occurred.  The different regions were: 5’ of the tetra-cysteine subdomains, 
amongst the cysteine codons of the first subdomain, between subdomains, 
amongst the cysteine codons of the second subdomain, between the subdomain 
and the GPI signal-encoding region, within the GPI signal-encoding region.  The 
locations of the 3’ donation boundaries are shown in Figure 4.7. 
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Figure 4.7 Location of 3' donation boundaries.  For each set, the location of 3’ donation 
boundaries was recorded.  This diagram shows the number of sets with one or more clones 
possessing 3’ donation boundaries in the region of the CTD identified.  Some sets showed 
differing degrees of 3’ donation, thus the figures do not total 47.  Conserved cysteine 
residues are shown as bars projecting above the diagrams, and the putative GPI signal-
encoding region is shown in orange.  Type 2 CTDs possess a longer region between the last 
cysteine and the GPI signal sequence, so they were considered separately from types 4 and 
5a.  
 
Chi-squared tests indicated that it is unlikely that 3’ donation boundaries were 
randomly distributed across the CTD-encoding region.60  For the two subdomain 
CTDs, 3’ donation boundaries primarily occurred in the first subdomain and in 
the region between the subdomains, whereas for type 2, boundaries occurred 
most frequently in the region between the subdomain and the GPI anchor.  
These patterns probably reflect archive homologies: previous studies of archive 
VSGs show considerable mixing between the first subdomain of types 1, 3 and 6 
(L. Marcello, Ph.D. thesis, 2006, University of Glasgow) 
 
The features of the boundary of 3’ donation were examined in 16 cases.  These 
cases were chosen as both the primary and the 3’ donor could be identified, and 
                                         
60 For this test, types 1, 3, 5b and 6 were considered together, to give sufficient data.  There was 
insufficient data to test types 4 and 5a.  ‘Expected’ values were obtained by calculating the 
proportions of the CTD occupied by the different regions.  For this, the CTDs of ILTat 1.24 (for 
types 1, 3, 5b and 6) and MITat 1.2 (for type 2) were used as approximate standards.  For type 
1, 3, 5b and 6, p < 0.05; for type 2, p < 0.001. 
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they belonged to several different sets.  In each case, the boundary of 3’ 
donation occurred in a region of identity 7–27 bp long (median = 12) amidst a 
region of <0.1 differences per nt of 9–107 bp long (median = 35.5).  The donors 
had 0.307–0.487 differences per nt across their entire lengths (median = 0.444).  
Details are in Appendix 7.3.3. 
 
4.4.8 How could 3’ donation contribute to antigenic variation? 
For most sets, 3’ donation was the greatest source of within-set variation.  
Considering that variation in the CTD cannot directly contribute to antigenic 
variation, this finding initially seems counterintuitive.  However, the substantial 
variation between sequence-related, expressed VSGs towards their 3’ ends likely 
corresponds with the different VSGs that they displaced as their telomere-
proximal copies were formed.  Variation in expressed VSGs at their 3’ ends is 
therefore consistent with a model of VSG activation in which the 3’ boundary of 
gene conversion is often within the coding sequence.  The role for 3’ donation in 
antigenic variation is therefore as a route for the expression of different silent 
VSG NTDs—including those with dysfunctional CTDs—rather than itself being a 
means of generating antigenic novelty.  This is analogous to the use of 
hypervariable cassette regions by other antigenically variant pathogens (see 
section 1.6.7).  
 
4.5 Mosaicism 
4.5.1 Mosaics were constructed from multiple donor sequences 
Mosaicism in expressed VSGs is the result of recombination events—segmental 
gene conversions—with boundaries occurring throughout the VSG gene, including 
the NTD-encoding region.  Mosaic VSGs identified to date involve two or more 
related VSG donors (Roth et al., 1986).  Here, for brevity and familiarity, each 
donor of a mosaic set was named XX-Y, where XX is the number of the set to 
which the donors contribute and Y is a unique capital letter identifier (A–D).  A 
key is provided in Table 4.5. 
 
Putative mosaics identified as described in section 4.1.3 were investigated in 
depth by multiple sequence alignment.  The sequences of putative mosaics and 
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their donors were aligned, and for each position in the alignment, identity 
between a clone and each donor was recorded.  These patterns of matching and 
mismatching were examined.  In many cases, blocks of matching and 
mismatching with the donors could be seen: in some parts of the sequence, 
donor A might match the clone identically and donor B match the clone poorly, 
in other parts donor B might match much better than donor A, as shown in 
Figure 4.8 (A).  The diagrams were simplified further, by describing the mosaic 
as being composed of the blocks from each donor.  In these diagrams, the 
boundary between the blocks is arbitrarily located at the midpoint of the region 
of identity between the expressed clone and the two combining donors (the 
‘mosaic junction’).  Blocks that were required because of a single base 
difference between a clone sequence and the donor sequence contributing the 
surrounding blocks were generally not included.   
 
 
Figure 4.8 Identifying mosaicism.  (A) A multiple sequence alignment with Tb11.09.0005, 
Tb11.13.0003 and tryp_XI-1034g11 showed blocks of matching and mismatching.  By 
assembling these blocks, a diagram of the full length sequence can be drawn, where 
different colours represent the contributing blocks.  (B) Comparison of two clones from 
Set_69 shows variation similar in pattern and greater in extent to that seen when comparing 
two clones belonging to a verified mosaic set, although no donors could be found for 
Set_69. 
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Comparing putative mosaic sequences with one another aided identification of 
mosaics by indicating the involvement of unknown genomic copies.  For 
example, it remains possible that putative mosaics are, in fact, the 
straightforward expression of an unknown genomic VSG.  Were many identical 
apparent ‘mosaic’ VSGs identified in different infections, we might doubt that 
these clones were indeed true mosaics.  In more complicated cases, comparing 
clones with one another revealed possible further unidentified donors.  For 
example, if expressed putative mosaic clones (particularly from different 
infections) had a region of high identity with one another that had low identity 
to all of the known donors, a further donor may have contributed to the mosaic 
at this position.  Second, comparing clones with one another revealed mosaicism 
in sets for which only one—or even no—genomic copy could be found.  For 
example, Set_69 clones showed patterns of identity and mismatch with one 
another reminiscent of mosaic sets, even though none of their associated 
genomic copies could be found.  This example is shown in Figure 4.8 (B).  
Mosaicism could therefore be defined conservatively, considering only those sets 
for which donors could be found and variation amongst clones was observed, or 
more inclusively, extending the definition to those sets showing variation 
consistent with mosaicism but lacking identification of all donors, and those sets 
for which comparison with putative donors but no comparison amongst clones 
could be performed.  For the most part, the more inclusive definition of 
mosaicism has been used in this thesis.  The means by which each mosaic set 
was identified is included in Table 4.5. 
 
4.5.2 Mosaics were verified by PCR 
To test directly whether mosaic VSGs are indeed formed de novo during an 
infection and are not a product of in vitro template switching, PCR analyses 
were carried out on Set_14.61  Primers were designed to bind to both putative 
donors either side of a junction observed in expressed clones, as shown in Figure 
4.9.  PCR was carried out on genomic DNA from pre-infection parasites and on 
genomic DNA from parasites collected at the end of the infection62 (days 29–32) 
                                         
61 Further investigations into segmental gene conversions were carried out following submission of 
this thesis.  See ‘Note Added in Proof’, Appendix 7.4.2 for further details. 
62 Mosaics possessing the Set_14 junction were observed in the cDNA made from terminal 
samples of infections of mouse 01, 03, 04, 05 and 06.    
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using different combinations of the four primers, and the products were 
separated by agarose gel electrophoresis.  The results are shown in Figure 4.10.  
The reaction designed to detect the mosaic junction was able to amplify a 
product only from post-infection gDNA, and even then, only from infections 
where that mosaic had been identified by cloning and sequencing.  The mosaic 
junction was not detectable in pre-infection gDNA. 
 
 
Figure 4.9 Design of PCR.  Primers designed to bind to specific donors corresponding to 
Set_14 (A) and Set_10 (B) were used to investigate mosaicism.  For each primer set, the two 
donors and a mosaic VSG sequence are shown.  Arrows indicate the primer binding sites 
on each sequence. 
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Figure 4.10 Results of PCR (1).  PCR was carried out on ~30 ng gDNA template using 
different combinations of the primers shown in Figure 4.9 (A).  In addition, primers directed 
against RNA polymerase I were used as a control for reaction input.  Plasmids containing 
related mosaic VSGs that either did (+), or did not (-), contain that particular junction were 
used as controls.  Non-specific primer binding due to high identity between primer and 
template sequence and high concentration of template means that a small amount of 
product can be seen in the negative controls.  ‘FF’ indicates gDNA made from the source of 
the inoculum (see Appendix 7.2.1 for the pedigree).  The terminal gDNA samples from 
infections 01–06 were retrieved between days 29 and 32. 
 
Similar experiments were designed for a Set_10 mosaic junction, and preliminary 
results from an experiment performed by H. Wang show that this mosaic 
junction was also not detectable in the pre-infection genomic DNA (Figure 4.11). 
 
!!"#
!$!#
%&'#
$"$#
((# "&# "'# "!# ")# "$# "*# +# ,#
-./0123#456785.0#9:;<#=851#26=>4?56#
<=,@8#
<=,<8#
@=,@8#
A5.#B#
C>/4?56#
D&),E#
>F->47>3#02G>#DH-E#
/63#-502?56#5=#
/1-.2456#
8>0I.70#>F->47>3#
=851#4.56269#/63#
0>JI>64269#
,# +# ,# +# +# +# +#
Chapter 4  182 
 
 
Figure 4.11 Results of PCR (2).  PCR was carried out on ~30 ng gDNA template using 
different combinations of the primers shown in Figure 4.9 (B), and using primers directed 
against RNA polymerase I as a control for equal loading.  A smaller non-specific product 
can be seen in the reactions, probably a consequence of primer dimerization.  For reasons 
of time the reaction was performed only on two samples, and controls were not available for 
all reactions.  ‘F3’ indicates gDNA made from the source of the inoculum (see Appendix 
7.2.1 for the pedigree).  This experiment was performed by H. Wang.  See also Figure 7.36 
(Appendix 7.4.2). 
 
 
4.5.3 Related mosaics appear in primary clonal infections 
Although the parasites used to initiate all infections had recently been cloned, it 
is possible that the line had become heterogeneous since cloning, potentially 
accumulating numerous silent segmental gene conversions amongst its members.  
To investigate the ability of T. brucei to produce mosaic diversity during an 
infection, primary clonal infections (initiated by a single parasite) of mouse 08 
and 09 were set up.   
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Figure 4.12 Mosaics in clonal infections.  Diagrams of the NTDs of mosaic VSGs retrieved 
from clonal infections 08 and 09 are shown.  Diagrams of each mosaic were drawn 
according to Figure 4.8 (A).  Only a portion of the mosaic is shown, as the full sequence for 
17-A was not available.  The maximum variability amongst mature NTDs within each 
infection, measured in differences/aa, is shown (‘mature NTD AA variability’), to give an idea 
of the antigenic variability introduced by mosaicism.  Below the mosaic diagrams is a 
diagram showing the locations of nucleic acid differences between the two putative donors, 
and the number of differences/nt (‘NA variability between donors’) to give an idea of the 
sequence identity between donors.  All the diagrams are aligned, allowing the amount of 
variation introduced by each segmental conversion to be assessed.  Both of the donors are 
pseudogenic: the type of damage and its location in the alignment is shown in between the 
mosaics and donors diagrams. 17-A is tryp_XI-1058d01_assembly, 17-B is Tb11.57.0032. 
 
 
Set_17 mosaic VSGs were identified at day 34 in both primary clonal infections.  
Each clonal infection showed the presence of more than one distinct mosaic 
variant, and each variant was unique to the infection in which it was detected.  
Different Set_17 VSGs were also detected in mouse 03, mouse 10 and mouse 12, 
and in the pilot study (Marcello & Barry, 2007a); these showed patterns different 
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from those seen in the clonal infections.  The genomic copy corresponding to the 
tryp_XI-1058d1 read assembly (17-A) appeared to be the primary donor of the 
mosaic set, with Tb11.57.0032 (17-B) contributing smaller segments and 
Tb09.244.0090 (17-C) contributing less frequently.  Unfortunately, the read 
assembly was only 881 bp long, so only a part of the NTD could be analysed with 
reference to the genome.  Figure 4.12 shows diagrams showing patterns of NTD 
mosaicism for example mosaics from this set.  For the most part, each infection 
showed a different pattern of mosaicism despite using the same donors, 
consistent with the hypothesis that mosaic sets progress independently in each 
infection. 
 
The fact that mosaic junctions could not be detected in pre-infection gDNA 
(section 4.5.2) together with the variety of related mosaics that could be 
identified from primary clonal infections lends support to the hypothesis that 
mosaicism is readily generated over the course of infection, and confidence to 
the apparent mosaic sequences retrieved.  With this in mind, the patterns of 
mosaicism can now be considered. 
 
4.5.4 Mosaicism was frequently observed, and various mosaic 
sets were identified 
Mosaicism could be identified in 28/83 sets, with 16 of these fulfilling the more 
conservative definition of mosaicism (variation from putative donor sequences 
and variation amongst clones63).  First, selected mosaic sets will be described.  
Then, the general patterns of mosaic VSGs will be summarized. 
 
The following subsections will explore selected mosaic sets.  These sets were 
selected as a number of clones for each set were available and donors could be 
identified.  Full diagrams for all mosaic variants can be found in Appendix 7.3.4.  
Diagrams of mosaics were coloured arbitrarily, although an effort was made to 
maximise contrast.  Mosaic sets previously identified (Marcello & Barry, 2007a) 
were coloured consistently with that work.   
 
                                         
63 Of these, four sets had donors for which a full-length sequence was unavailable, thus under an 
even stricter definition of mosaicism (full-length donor sequences identified) the count is revised 
downwards to 12. 
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Figure 4.13 Set_22 mosaics.  Diagrams of each mosaic were arranged and annotated 
similarly to Figure 4.12.  The corresponding 3' donation variants are indicated to the right of 
each mosaic diagram.  For this set, three donors were implicated so each diagrams showing 
the locations of nucleic acid differences between each pair of donors are given.  22-A is 
Tb05.5K5.330, 22-B is Tb11.21.0004 and 22-C is Tb927.5.4840. 
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Figure 4.14 Set_10 mosaics.  Diagram is arranged and annotated similarly to Figure 4.13.  
10-A is Tb11.31.0001, 10-B is Tb10.v4.0161 and 10-C is Tb11.14.0001. 
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4.5.4.1 Mosaic Set_22 
Set_22 (Figure 4.13) showed the earliest-appearing mosaicism,64 identified 
between days 17 and 23 in three infections.  The patterns of segmental 
conversion in Set_22 can best be described as the activation of the C-terminally 
pseudogenic 22-A thanks to 3’ donation, followed by varying patterns of 
segmental involvement of 22-B and 22-C towards the 5’ end of the gene.  There 
was some consistency in the 3’ donation events between mosaics appearing in 
different infections, hinting that a copy of the donor may have acquired a 
functional 3’ end before the infections began and may help to explain this 
mosaic set’s relatively early appearance (see section 3.5.5).  The patterns of 
variation in the NTD-encoding region were distinct to infections. 
4.5.4.2 Mosaic Set_10 
Set_10 (Figure 4.14) is a large mosaic set, showing diverse variants both within 
an infection and across different infections.  Its main donor65, 10-A, was an 
intact VSG, which appeared to have acquired segments of the NTD-pseudogenic 
10-B and 10-C in its NTD over the course of infection.  10-B appeared 
particularly prone to contributing a segment around the second cysteine of the 
mature NTD.  In some cases, 10-C also contributed segments to the CTD-
encoding region, producing examples of C-terminal mosaicism.  
 
4.5.4.3 Mosaic Set_64 and Set_32 
Set_64 (Figure 4.15) came about by 64-A undergoing reparation of its 
pseudogenic CTD through interaction with one of a number of different 3’ ends, 
and the N- and C-terminal pseudogene 64-B contributing various segments to the 
NTD.  Set_32 (Figure 4.16) is representative of many of the mosaic sets 
identified, in that it was formed by a full-length VSG and a read sequence.  The 
two clones were identified in the same infection and appear to have been 
formed by the activation of C-terminal pseudogene 32-A by 3’ donation, 
followed by segmental conversion with 32-B in the NTD. 
                                         
64 The earlier appearance of Set_04 probably did not involve segmental gene conversion, as 
discussed in section 4.5.8. 
65 Marcello & Barry (2007) identified Tb11.v4.0074 as the main donor of their Set_10 mosaic VSG-
22-07-02.  However, it was found that the introduction of 10-A (Tb11.31.0001) as a putative 
donor made Tb11.v4.0074 redundant, as all set members could be explained without it.  
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Figure 4.15 Set_64 mosaics.  Diagram is arranged and annotated similarly to Figure 4.13.  
Both donors show degeneration towards their 3’ end, the position in the alignment where 
degeneration begins is indicated by a red cross.  64-A is Tb927.8.420 and 64-B is 
Tb09.244.0360. 
 
 
 
Figure 4.16 Set_32 mosaics.  Diagram is arranged and annotated similarly to Figure 4.13.  
32-A is Tb09.v2.0090 and 32-B is tryp_IXa-10f02_assembly.  As donor B was incomplete, 
donor nucleotide comparisons could only be carried out for a portion of the sequence. 
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4.5.4.4 Mosaics summary 
Table 4.5 shows details of all sets displaying apparent NTD mosaicism.  Those 
sets discussed in the text and other diagrams are indicated by distinctive 
colours.  The following sections describe some of the general patterns observed 
in mosaic VSGs.  
 
4.5.5 Mosaic VSGs were formed from similar donors 
All the mosaics detected in these infections shared high levels of identity with 
one another and with their donors, particularly in the NTD-encoding region.  
Each mosaic’s donors were therefore members of the same VSG subfamily.  
Furthermore, the same few donors apparently contributed to form all of the set's 
expressed mosaic VSGs.  As a consequence, all the mosaics of a set had the same 
NTD type as one another, and all were more similar to one another than they 
were to any VSG of another set.  Mosaic VSG formation, therefore, did not 
appear to be a ‘free-for-all’—in these comparatively short 4–5 week infections, 
there were apparently restrictions on the involvement of more variant donors in 
the NTD.  This is in contrast with 3’ donation, which seemed to be more 
promiscuous.66 
                                         
66 The exception to this is Set_12, which Marcello & Barry (2007a) showed involved the more 
variant donors 12-A (Tb11.30.0005) and 12-B (Tb11.v4.0021).  However, the involvement of the 
additional donor was only in the very 3’ most end of the NTD-encoding region (after position 
980).  As a consequence, this set was not considered here to be an example of mosaicism 
(instead an example of 3’ donation).  Although the two donors had 0.360 differences/nt when 
their sequence is considered as a whole, variability was concentrated in the more 5’ end of the 
NTD encoding region where they did not segmentally combine (0.449 differences/nt before 
position 980; 0.203 differences/nt after position 980).   
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Table 4.5 Summary of mosaicism.  For each set the means of identification (comparison with donors and/or comparison amongst clones) is indicated in the 
corresponding column by a ‘＊ ’.  The maximum variability amongst clones of each set, clones of that set within an infection is given, as well as the 
pairwise variability between donors.  Variability in this table is given as the number of differences between mature NTDs per amino acid: damaged donors 
were corrected conservatively to allow translation.  Samples of the colours used to identify donors that feature in other Figures in this chapter are given 
alongside the donor name.  Donor names in bold indicate the primary donor of a set, where one could be identified.  Where donor names are italicized, 
these donors do not explain all the N-terminal variability of that set (the donor sequences were incomplete and/or there was the contribution of further 
unidentified donors).  'Donor properties' represents data from VSGdb supplemented by additional analyses; brackets indicate a partial read sequence that 
does not cover an entire VSG gene. Where the comparison is bracketed, it was carried out using one or more incomplete sequences.  Table continues on 
following pages.  
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Table 4.5 (continued) See Appendix Figure 7.13 for details on Set_20.
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The greatest degree of variation between donors was seen between 
Tb11.13.0003 (14-B) and the tryp_XI-1034g11 read assembly (14-C), which 
contribute to Set_14 mosaic VSGs; these two donors had 0.269 differences/nt 
across their entire length.  The most similar donors, Tb09.354.0060 (31-A) and 
Tb927.6.5370 (31-B) had 0.059 differences/nt.  In general, mosaic donors had 
between 0.1 and 0.2 differences/nt across their full-lengths, and between 0.1 
and 0.35 differences/aa in their mature NTD.67 
 
The apparent demand for identity between donors suggests that increasing 
divergence between donors inhibits their ability to interact and form functional 
mosaics.  It might therefore be expected that mosaics with more similar donors 
would tend to appear earlier in an infection.  However, a preliminary 
investigation into this relationship saw no obvious correlation between time of 
first appearance and identity between donors for the mosaics identified here 
(data not shown).  It is possible that the differentiation-based control likely 
dominating in these infections complicated this analysis, as the expansion (and 
hence detection) of a particular mosaic lineage became separated in time from 
its construction, due to suppression of that subpopulation by differentiation. 
 
 
Figure 4.17 Mosaicism repairs pseudogenes.  For the 28 sets undergoing mosaicism, each 
putative donor is indicated by a coloured square.  The properties of the donors are 
indicated, according to the key.  This figure is a cropped version Figure 3.7, with additional 
details on the pseudogenicity of the donors. 
                                         
67 Frameshifts in the NTD-encoding region of mosaic donors were corrected for this analysis by the 
addition or deletion of bases.  In no cases did such modifications increase variation between 
donors. 
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As detailed in Figure 4.17, mosaicism allowed the partial expression of damaged 
silent VSGs.  Of the 28 sets, 16 showed the repair of a pseudogenic donor by 
mosaicism.68 
 
4.5.6  Segmental gene conversion did not demand perfect identity 
The homology between donors apparently required for mosaic construction 
indicates that this process of segmental gene conversion was probably catalysed 
by a type of homologous recombination, whereby identities between donor 
sequences were required to guide introduction of the converted segment.  To 
investigate the sequence requirements for segmental gene conversion, 435 
boundaries of segmental gene conversion from Set_04, Set_10, Set_14, Set_22, 
Set_31, Set_32 and Set_40 were studied.  Three properties associated with 
recombination—low GC-content, length of perfect identity between donors, and 
the presence in the donors of palindromic sequences—were investigated.  
 
Beyond the general homology seen between mosaic donors, there were no 
outstanding features common to all the boundaries of segmental gene 
conversion.  In some cases, a region of perfect identity between donors at the 
boundaries was not present, suggesting that perfect identity between donors is 
not required at the boundary of segmental gene conversion.  It is possible that 
identity with the donors was ablated by the subsequent occurrence of point 
mutations at that position.  However, the identification of little (less than 3 bp) 
or no identity at the boundaries of 33 apparent segmental gene conversion 
events, from five out of seven sets investigated, makes this explanation 
unconvincing. 
 
4.5.7 Similar mosaic junctions were identified in different 
infections 
In some cases, mosaic donors appeared to interact at the same position forming 
a ‘conserved’ mosaic junction.  Conserved junctions were seen most strikingly 
with Set_14 mosaics, shown in Figure 4.18.  Other examples were found in 
Set_04 and Set_17.  In each of these cases, the boundary of recombination 
occurred in a region of complete identity between the donors 5–10 bp long.   
                                         
68 This figure does not include those sets involving the repair of CTD pseudogenes by 3’ donation. 
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Figure 4.18 Conserved mosaic junction.  At the top, diagrams representing expressed VSGs 
from five infections are shown.  The conserved mosaic junction is indicated by a dotted line.  
At the bottom, a multiple sequence alignment of the region covering the junction is 
provided: the sequences, in order from top to bottom, are a cDNA clone sequence, donor 
14-A, donor 14-B.  The cDNA clone sequence matches all the clones at the top, except that 
from mouse 05 (two point mutations) and from LM_10 (another segmental involvement of 
14-B to the 5’ end).  The underlined regions of 14-A and 14-B match the cDNA clone 
sequence exactly.  Asterisks below the alignment indicate positions where both donors 
match.  14-B possesses an in-frame ‘TAG’ stop codon, coloured red.  14-A is Tb11.09.0005 
and 14-B is Tb11.13.0003.  Between the cDNA diagrams and the sequence alignment, a 
diagram representing the locations of nucleic acid differences between 14-A and 14-B is 
provided.  Other diagrams of Set_14 mosaics are shown in section 4.5.10. 
 
The most straightforward explanation for this finding is that there were silent 
genes containing these specific junctions present in the genome at the beginning 
of infection.  However, the PCR analysis on the Set_14 junction in section 4.5.2 
!"#$%&'()*&+, -"#$%&'()*&+,
.*+&/0,
1%12)%,
!"# $"#
%&'()*+&#
,-./# ,-.0#
1#
2,#
34&)*+&#
2$#
2-#
2!#
25#
…CTGCATCGACGGCCAAACCGGGATGAAA AACTGCGC AACAGCTGCCCACGGAACAACGACAAAC…	
…CTGCATCGACGGCCAAACCGGGATGAAA AACTGCGC GGCAACACCACACGGCGTAACCACAGCA…	
…TTGTGTCGACGGACAAACGGGAATGTAG AACTGCGC AACAGCTGCCCACGGAACAACGACAAAC…	
  **  ******* ***** ** *** *  ********   ** *  * *****   *** ***    	
678,2#
2# ,92#29:# 29-# 295# 29;#<)=>(#?=@#AB?C#
Chapter 4  196 
 
suggests that if this particular junction was present in the inoculum, it was 
present in just a small number of the infecting parasites, below detection 
levels.69  Further experiments are required to resolve this question.  It is 
interesting to note that Kamper & Barbet (1992) identified a 24 bp mosaic 
junction that was the same in three independently isolated mosaics (Watat 1.12, 
1.13 and 1.14, see Chapter 1 section 1.6.9), although it is possible that this 
particular junction of theirs could be traced back to an initial rabbit infection.  
Were conserved mosaic junctions genuine, it would suggest that certain 
segmental conversion events are favoured over others, hinting at the 
mechanisms underlying mosaic VSG formation.   
 
4.5.8 There was only limited evidence for progressive mosaicism 
Mosaics are hypothesised to ‘build up’, in either an active or silent ES (Barry et 
al., 2005).  In this model, one donor is first copied into the ES.  Other donors 
then interact with the first donor, sequentially contributing segments to build an 
increasingly complex string of mosaic VSGs over time.  
 
The data presented in Figure 4.19 show some evidence for this process 
occurring.  For example, Set_40 had two donors, 40-A (Tb11.1480, a VSG with an 
atypical GPI anchor sequence) and 40-B (Tb10.v4.0063, an N-terminal 
pseudogene).  Barring a few point mutations and a short 3’ donation correcting 
the GPI anchor sequence, a clone detected at day 27 in mouse 02 (02-27c01, 
indicated by a star in Figure 4.19) showed identity with 40-A across its whole 
length.  Yet at the same timepoint in this infection, three other related variants 
were found, each of which had blocks that mismatch with 40-A and show greater 
identity at these positions with the N-terminally pseudogenic 40-B.  These other 
                                         
69 An approximate calculation, where the mass of DNA present in a single parasite genome is 26 
Mbp x 2.5 (to account for the fact that the genome project sequenced only haploid megabase 
chromosomes) x 610 = ~40 x 109 Da, finds that approximately 15,000 copies of a single-copy 
gene are present per nanogram of pure trypanosome gDNA.  For the PCR reactions in section 
4.5.2, 30 ng gDNA was used.  A PCR titration experiment using limiting dilutions of isolated 
plasmid template found that the PCR reaction performed to detect the junction was sensitive 
enough to detect the mosaic junction when the template was present in as few as 1000 copies 
(data not shown), although it is likely that reactions using gDNA templates are in general less 
sensitive than using plasmid templates due to impurities in the preparation and non-specific 
interactions between template DNA and primers. 
Chapter 4  197 
 
variants could have been formed by 40-B contributing segments to an 
expression-linked copy of 40-A (represented by the starred clone).   
 
 
Figure 4.19 Set_40 progressive mosaicism.  Diagram is arranged and annotated similarly to 
Figure 4.13.  Mouse 04 variants were more variant from one another than they were from 
their putative predecessor (the 'early' mouse 02 variant).  40-A is Tb11.1480 and 40-B is 
Tb10.v4.0063.  The black bar under the donor comparison indicates a region of sequence 
missing in 40-B. 
 
Similarly with Set_04 (Figure 4.20): a clone retrieved from day 32 of mouse 01, 
and a clone identified by (Marcello & Barry, 2007a) (from infection LM_03), are 
almost identical (a diagram representing these clones, 01-32c11 and VSG-09-03-
04, is indicated by a star in Figure 4.20).  Unfortunately, no genomic copy donor 
could be found to match these sequences for the full length, however, both of 
these sequences match the 851 bp long tryp_X-54b12.q1c-rev read assembly (04-
A) very well for its entire length.  Across its length, 04-A contains no stop codons 
or frameshifts.  The other clones of this set show the involvement of 
Tb10.v4.0061 (04-B), an N- and C-terminal VSG pseudogene that has apparently 
contributed one large segment in the case of the mouse 05 variant, and has 
undergone more complex segmental conversion events in the case of the mouse 
06 variant, and the other variant from mouse 01.   
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In neither of these cases do we see increasing involvement of the additional 
donor in an infection over time: for Set_40 the clones from mouse 02 showing 
progressive mosaicism were all retrieved from the same point, and for Set_04 
the more complex clone from mouse 01 was retrieved from the earlier 
timepoint.  In other cases, patterns of progressive mosaicism were even more 
elusive.  Many sets, for example Set_10, show similar or identical mosaics at 
sequential timepoints, as can be seen in Figure 4.14.  Other sets show 
apparently more complex mosaics at earlier timepoints, for example Set_04 in 
mouse 01, Set_14 in mouse 05 or Set_10 in mouse 04 (Figure 4.20, Figure 4.23 
and Figure 4.14 respectively).  When considering all mosaics together there was 
not a clear general progression from simple to more complex mosaics across an 
infection as it progresses. 
 
 
Figure 4.20 Set_04 progressive mosaicism.  Diagram is arranged and annotated similarly to 
Figure 4.12 however maximum variability for each expressed sequence was calculated by 
comparison with the putative predecessor (the day 09 / day 32 variant present in LM_03 and 
mouse 01 and indicated by a star).  04-A is tryp_X-54b12.q1c-rev_assembly and 04-B is 
Tb10.v4.0061. 
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4.5.9 Diverse mosaics were constructed from the same donors 
Mosaic donors combine in diverse ways to yield considerable expressed NTD 
variation amongst members of the set (see section 4.5.10).  Within an infection, 
the mosaic sets have between 0.024 and 0.219 differences/aa across the 
expressed NTDs of their least related members.   
 
Are the expressed mosaics of a mosaic set more diverse than the silent donors 
that create them?  To investigate this question, the ‘expressed’ (that is, 
excluding the sequence encoding the signal peptide) NTD aa variability between 
mosaic donors70 were compared with the expressed NTD aa variability between 
the most divergent mosaics that they form.  The data is included in Table 4.5 
above.  For all sets, mosaic donors were themselves more divergent than the 
expressed mosaics they generate.  This is perhaps not surprising, considering 
that more variant, degenerate parts of donors may be the regions preventing 
their full-length expression.  The implications of this finding are discussed in 
Chapter 6 (section 6.4.5). 
 
4.5.10 Diverse mosaics appeared within an infection 
To examine more closely the mosaics present in an infection, Set_14 mosaics 
were studied in greater detail.  This set was selected for in-depth analysis as it 
was detected in many infections (five here, plus one in the pilot study), and in 
three of these infections it was detected at many timepoints.  It is therefore a 
regular participant in TREU 927/4 infections.  Some of its clones were verified 
experimentally by PCR.  Finally, Set_14 mosaics had the highest levels of within-
set variation, and are thus an interesting example of the degree of variation that 
can be generated by segmental gene conversion. 
 
Set_14 mosaics were apparently constructed from four different donors: 
Tb11.09.0005 (14-A), Tb11.13.0003 (14-B), a read assembly constructed from 
tryp_IXa-24h09.q1c-rev, tryp_XI-1034g11.p1k and tryp_XI-1034g11.q1k-rev 
(tryp_XI-1034g11_assembly, 14-C), and Tb10.v4.0009 (14-D).  These donors have 
at most 0.269 differences/nt across their whole length.  To investigate whether 
                                         
70 Donor damage was corrected for this analysis, see footnote 67. 
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there were further unknown genomic copies that might have contributed to the 
mosaic set, a probe made from the 14-A NTD-encoding region was hybridized to 
a dot blot of Set_14 mosaics and a Southern blot of ten samples of pre-infection 
TREU 927/4 genomic DNA digested with one of ten different restriction enzymes. 
The results of these hybridizations are shown in Figure 4.21 and Figure 4.22.  
The dot blot shows that the probe was able to bind to all of the Set_14 mosaics, 
making it likely that it would identify all related donors in the gDNA.  On the 
Southern blot, bands corresponding to 14-A, 14-B and 14-D could be identified by 
reference to the location of restriction enzyme sites in the published genome 
sequence.  There were two further bands identified in many of the reactions, 
one of which hybridized more strongly to the probe than the other.  Given the 
results of the dot blot, the weaker-hybridizing band (indicated by a ball-and-
stick) likely corresponds with the silent copy matching the read assembly, 14-C.  
This indicates that there was probably a further related genomic VSG that has 
not yet been sequenced.  The involvement of a potential further donor in the 
construction of mosaics is unclear, however, since in general there are few 
regions of identical variation in different infections (with the exception of that 
referred to and experimentally tested in section 4.5.2 above), and even 14-D did 
not appear to contribute significantly to the mosaic set.71 
 
Within an infection, these donors joined in varied ways to generate a wide 
variety of different mosaics.  This was seen most extensively in the two 
infections studied in greater depth, mouse 04 and mouse 05.  Set_14 variability 
is shown in Figure 4.23.   
 
                                         
71 Further Southern hybridizations were performed following submission of this thesis.  These 
experiments resolved the question of the additional bands in Figure 4.22.  See Figure 7.38 
(Appendix 7.4.3) for further details. 
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Figure 4.21 Dot blot of related mosaic DNA.  The blot was prepared using isolated plasmid 
as described in Chapter 2, hybridized with a probe complementary to 14-A, and washed to 
high stringency (70ºC, buffer prepared according to kit instructions).  For each sequence, 
the number of nucleic acid differences between the probe sequence and the sequences of 
the blotted DNA per base is indicated.  Data are also included for donors 14-C and 14-D, but 
as these sequences were not cloned into a plasmid they could not be included on the blot. 
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Figure 4.22 Southern blot of gDNA. The blot was prepared using pre-infection 927 genomic 
DNA digested with one of ten restriction enzymes as described in Chapter 2, hybridized with 
a probe complementary to 14-A and washed to high stringency (70ºC, buffer prepared 
according to kit instructions).  Bands corresponding with the predicted sizes of each of the 
donors identified in the genome (14-A, 14-B and 14-D) are indicated.  Two additional bands 
could be identified in many lanes, one binding the probe more strongly than the other 
(indicated by an arrowhead and a ball-and-stick respectively).  Set_14 mosaics were not 
detected in pre-infection cDNA.  Additional bands seen in the samples digested with KpnI 
and SpeI could be due to star activity as the reaction was not carried out with high-fidelity 
versions of the enzyme.  Note that this figure has been superseded by a technically superior 
one: Figure 7.38 (Appendix 7.4.3). 
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Figure 4.23 Set_14 mosaics.  Diagram is arranged and annotated similar to Figure 4.13.  
Variation in the length of the CTD-encoding region means that this part of the diagram is not 
necessarily aligned with the donor comparisons.  14-B had no junctions with 14-D, so this 
comparison has not been included.  14-A is Tb11.09.0005, 14-B is Tb11.13.0003, 14-C is 
tryp_XI-1034g11_assembly and 14-D is Tb10.v4.0009. 
!"#$%&'()*&+, -"#$%&'()*&+,
.*+&/0,
1%12)%,
!"#
$%&#'(#
)*(+,-'*#)*(+,-'*#
."#
/.#
/0#
/1#
.2#
3#
/2#45#
46/21#
/0#
7#
7#
7#
/.#
.2#
/1#
4!#
46212#
./#4.#
8+9:25#
46/.4#
46/52#
46/;1#
25<=# 25<># 25<?# 25<@#
46//0##
462.;##
7#
7#
4# 264#46/# 465# 46;# 46A#8,%B+#C%D#EFCG#
34,)(&(5,
H#
H#
I#
Chapter 4  204 
 
 
 
Figure 4.23 (continued).  14-D comparisons are not shown, as 14-D does not contribute to 
the NTD-encoding regions in these mosaic variants.   
 
4.5.10.1 The development of Set_14 mosaics: later stages 
First, consider the later-stage mosaics of this family: those identified from day 
27 in six infections.  These are the mosaics possessing the conserved mosaic 
junction identified in section 4.5.7.  Marcello & Barry (2007a) speculated that 
the Set_14 mosaic lineage identified in that pilot study began as a full-length 
copy of 14-A, which acquired a segment from 14-B to form an intermediate 
mosaic.  Such a ‘mosaic intermediate’ was found in two clones in mouse 04, 
indicated by ‘†’ in Figure 4.23.  As with the mosaics identified in the pilot study, 
further involvement by 14-B appears to develop this lineage further in mouse 04 
to give those variants that are present at days 29 and 31.  Similar mosaic 
intermediates may have occurred undetected in mouse 01, mouse 03, mouse 05 
and mouse 06, and led to the Set_14 mosaics in those populations, although the 
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Set_14 mosaic identified in mouse 06 hints at a different route whereby the 3’ 
boundary of conversion of the inserted 14-B segment is 3’ of the coding 
sequence.  The expression of full-length 14-A was not detected; indeed, it is 
possible that the atypical nature of its GPI anchor signal sequence precludes its 
full length expression (the 3’ end of 14-A was not seen in any Set_14 VSG 
clones). 
 
4.5.10.2 The development of Set_14 mosaics: early stages 
In mouse 04 and mouse 05, an earlier stage in the development of Set_14 
mosaics was found, examples of which can be seen at days 21 and 23.  This stage 
probably began with an expressed gene similar to 14-C, such as that indicated by 
‘‡’ in Figure 4.23, which overcame its pseudogenicity by mosaicism in its CTD 
with 14-D and either 14-B (mouse 04) or 14-A (mouse 05).  The expressed VSG 
probably underwent various gene conversions with all three of the other donors 
to yield the apparently more complex early Set_14 mosaic VSGs.  It is not known 
whether early-stage Set_14 mosaics were present in the other Set_14-expressing 
infections, or whether early-stage Set_14 mosaic expression necessarily 
preceded the later form.  
 
One explanation for the apparently more complex Set_14 mosaics occurring 
earlier in infection than the apparently more simple Set_14 mosaics is that the 
interactions between donors required to generate the later-appearing mosaics 
may occur at a region where the donors do not so readily recombine.  As 
described in section 4.5.7 the mosaic junction leading to the later-stage Set_14 
mosaics is strictly conserved between infections, suggesting that there may be 
restrictions on the ability of these two donors to directly interact.  Therefore, 
whilst superficially appearing simpler, the likelihood of the ‘intermediate 
mosaic’ forming may be lower than the apparently more ‘complex’ mosaic 
interactions that give the earlier-stage Set_14 mosaics. 
 
4.5.10.3 The development of Set_14 mosaics: summary 
Bringing this all together, a more complex hypothesis for how Set_14 mosaics 
have been constructed is described in Figure 4.24 and Figure 4.25 for mouse 04 
and mouse 05 respectively. 
  
 
Figure 4.24 Development of Set_14 mosaics in mouse 04.  Day of expression of selected variants is included on the left hand side of the variant.  (A) The 
early stages were probably initiated by a copy of 14-C undergoing segmental conversion in its 3' end to overcome C-terminal pseudogenicity.  This variant 
was not detected in any samples, but the common 14-C/14-D CTD was seen in many clones at day 23.  (B) The inferred progenitor accumulated segments 
of 14-A and 14-B.  The detection of the more complex variant at day 21 (before the others) indicates that this progression probably occurred rapidly in a 
subpopulation.  The earlier variant was still detectable at day 27.  (C) The inferred progenitor also acquired multiple segments from 14-A in a process that 
was probably independent from (B).  (D) The later stage of the mosaic development was probably initiated by a full-length copy of 14-A, which acquired a 
segment from 14-B to produce the conserved mosaic junction (blue vertical arrowhead) and the variants present at day 27 (E).  (F) Meanwhile, other 
interactions between 14-A, 14-C and a 3' donor produced another variant at day 27.  This variant could have been produced either from development of the 
14-D-like progenitor, the 14-A like progenitor, or possibly interactions between the two.  (G) The 14-A/B variants at (E) undergo further interactions with 14-
A and 14-B to produce the later-stage variant, which was the only form detected at days 29 and 31 of infection. 
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Figure 4.25 Development of Set_14 mosaics in mouse 05.  Mouse 05 saw a smaller group of variants than mouse 04, but their progression can fit a similar 
pattern.  (A) Again, the accumulation of many segments by a repaired 14-C could explain the mosaic variant (B) that persists between days 23 and 29 in this 
infection.  (C) A repaired 14-A could have led to the two variants detected at day 27, each of which (D, E) could have each developed by the independent 
contribution of 14-C segments to the NTD of 14-A (and, to a lesser extent, contribution of 14-B segments).  The repaired 14-A could have produced a mouse 
04-like 'mosaic intermediate' undetected in this infection (F), which accumulated further segments from 14-B to become the later variant seen at day 31 (G). 
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4.5.11 Could mosaicism contribute to antigenic variation? 
Mosaicism introduced considerable variation into the NTD of VSGs during an 
infection, by enabling partial expression of damaged VSGs and by combining 
donor sequences in different ways.  Abundant variants produced from the same 
set of donors were identified over the course of infection.  Could mosaic 
variation be sufficient to change epitope structure and therefore contribute to 
immune evasion directly?  Addressing this question bioinformatically is 
complicated by the fact that approaches to assess positive selection are 
sensitive to the presence of recombination (Kosakovsky Pond et al., 2006).  The 
fact that the donors of identified mosaics shared substantial identity with one 
another could potentially limit the degree of antigenic variability they could 
introduce.  Nevertheless, for some sets, the variation introduced rapidly into the 
NTD by mosaicism approaches levels associated with antigenic distinctiveness 
(Barbet et al., 1989; Pays et al., 1985a).  Therefore, as described in the 
following chapter, the ability of segmental gene conversion to change VSG 
epitope structure was addressed experimentally. 
 
4.6 Discussion 
4.6.1 VSGs have multiple levels of variation in an infection 
Chapter 3 revealed that, within an infection, a range of different antigen sets 
could be detected over time, representing the switching between different 
genomic VSGs typical of T. brucei antigenic variation.  Looking at those sets of 
antigens in more detail, we uncover a further level of diversity amongst 
expressed VSGs.  Related expressed VSGs often vary from one another, and from 
their best-matching genomic copy.  This diversity takes the form of point 
mutation, 3’ donation, and mosaicism.  The bioinformatic and experimental 
analyses of the different patterns of diversity presented in this chapter allow us 
to draw a number of conclusions about the extent of these different processes, 
and their potential roles in infection.  
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4.6.2 Key findings of this chapter 
4.6.2.1 Diversity amongst expressed VSGs is generated rapidly 
T. brucei does not possess huge families of closely related VSG genes (Marcello & 
Barry, 2007a), so most of the variability amongst sequence-related, expressed 
VSGs appearing in each infection must have been produced in the period since 
the parasites were last cloned.  For most of the infections, this period was ~72 
generations.  The extensive variability seen amongst mosaics in the clonal 
infections is consistent with a model whereby diverse related mosaics and 3’ 
donation events routinely occur over the course of a 4–5 week infection. 
 
4.6.2.2 The contribution of point mutations to antigenic variability within an 
infection is probably minor 
Point mutations were detected in expressed VSG at a rate greater than that 
expected from experimental artefact.  However, they did not vary expressed 
VSGs extensively, and their effects—changing single amino acids at a time—were 
minor when compared with other patterns of variation occurring alongside them 
in the parasite population (such as between-set variation covered in Chapter 3, 
and segmental gene conversion considered in sections 4.4 and 4.5).  Therefore, 
in the context of a single infection, the selective advantages bestowed by point 
mutation are likely to be negligible.  Their potential role in the biology of 
African trypanosome antigenic variation is likely to be longer-term. 
 
4.6.2.3 The 3’ end of an expressed VSG is often acquired from a different 
donor 
Most sets showed some evidence of variation amongst their members at their 3’ 
ends, which in many cases was considerable.  Where they were identified, most 
of the 3’ ends that were provided by a different donor came from likely 
telomere-proximal VSGs, indicating that the expressed VSG probably acquired its 
3’ end as it was copied into a telomere-proximal locus.  3’ donation allowed the 
expression of damaged VSGs and could also recombine different types of CTD.  
The variation amongst sequence-related, expressed VSG in their 3’ ends 
observed during an infection is consistent with the polyclonal activation of VSGs, 
in which each event generates a distinct expressed copy (Michels et al., 1983; 
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Timmers et al., 1987), although the possibility that variation accumulated in the 
3’ end of the expressed VSGs cannot be ruled out. 
 
4.6.2.4 A diverse range of mosaic VSGs is frequently observed within an 
infection 
Mosaicism was prevalent, particularly at later timepoints.  Short of switching 
VSG NTDs completely, mosaicism was the most powerful means of introducing 
variation into the exposed part of the antigen.  Complex mosaics developed 
rapidly, during an infection.  A restricted palette of genomic VSGs could 
generate considerable diversity amongst expressed VSGs: from four silent donors 
eight distinct NTD variants were witnessed within an infection.  Mosaicism 
allowed the contribution of damaged VSGs, but the variability amongst mosaics 
identified within an infection—even within a sample from that infection—hints at 
another possible role for mosaicism.  
 
4.6.3 How might these findings have differed in other 
experimental models? 
The mechanisms generating within-set variation are almost certainly parasite-
intrinsic, so the patterns of variation observed during these infections are not 
limited to this experimental model per se.  However, the strength of selection 
by the immune system and the total parasite population size could affect the 
degree of variation that is observed amongst expressed VSGs.  Considering the 
results of Chapter 3 and previous studies (MacGregor et al., 2011) differentiation 
was probably the dominant factor in these infections.  Where the dynamics of 
infection are controlled primarily by the immune system, variation that does not 
change epitope structure will be disfavoured.  As a consequence, variation 
produced by differences in 3’ donation, as well as many point mutations and 
instances of mild mosaicism, may become harder to detect, while the greater 
selective advantage of more dramatic segmental gene conversion events in the 
NTD-encoding region might make such mosaics more pronounced. 
 
Longer infections where there is greater selection for antigenic novelty and a 
larger parasite population may facilitate the development of more complex 
antigenically distinct mosaic VSGs.  Such circumstances may also break down the 
apparent requirement for homologous mosaic donors, revealing rare variants 
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that have undergone non-homologous segmental gene conversion events in their 
NTD.  
 
4.6.4 Concluding remarks 
In many cases, the expression of VSGs appears to go hand-in-hand with the 
generation of diversity, as VSGs acquire point mutations, different 3’ ends or 
segments from related genes.  Can such variation vary epitope structure?  Point 
mutations are unlikely to vary VSGs rapidly enough to enable immune evasion.  
3’ donation accesses genomically-encoded NTD variability, greatly increasing the 
antigenic variability available to the trypanosome, but does not itself vary the 
epitope-bearing NTD.  Could mosaicism in the NTD introduce antigenic novelty, 
given that related mosaics utilize the same group of sequence-related VSG 
donors?  To answer this question, the ability of mosaicism to change VSG epitope 
structure was addressed experimentally.  The results are described in the 
following chapter. 
212 
 
Chapter 5 
The epitope structure and antigenic 
function of mosaic VSGs
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5 The epitope structure and antigenic function of 
mosaic VSGs 
5.1 Introduction 
5.1.1 Can the products of mosaic VSGs contribute to antigenic 
variation during an infection? 
As seen in the previous chapter, a variety of related mosaic VSGs could be 
detected within a single infection.  Were it the case that mosaic construction 
was a one-off event, occurring at low frequency and simply providing occasional 
access to damaged silent VSGs, we would not expect to see many manifestations 
of that repaired gene.  The diversity and abundance of related mosaics existing 
in an infection suggest instead that segmental gene conversion leading to mosaic 
VSG expression is a dynamic, on-going process.  However, it may simply be the 
case that once an expression-linked copy of a VSG is created it is especially 
vulnerable to recombination with other, highly related VSGs, resulting in little or 
no impact on its antigenic profile.  Mosaic VSG donors have high levels of 
sequence identity with one another, suggesting that a restricted set of donor 
genes is favoured in the creation of mosaics.  This narrow palette may not be 
sufficient to generate antigenic novelty in the VSG coat within the course of a 4–
5 week infection.    
 
Is mosaic VSG construction capable of generating new epitopes, or introducing 
new epitopes from pseudogenic donors, over the course of an infection?  That is, 
does mosaic VSG construction play a direct role in antigenic variation during an 
infection?   
 
5.1.2 Key hypothesis to be tested 
The aim of this chapter was to examine the antigenic profiles of related mosaic 
VSGs occurring within a single infection.  The (null) hypothesis to be tested was 
that an antibody response raised against a surface coat made from the product 
of any member of a mosaic VSG set found within an infection is able to recognize 
surface coats made from products of any other member of that mosaic VSG set 
found within that infection.  That is, within an infection, the products of related 
mosaic VSGs are antigenically cross-reactive. 
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To test this hypothesis, a representative mosaic VSG set from one infection was 
selected and studied in depth.  Of all the mosaic VSGs observed in chronic 
mouse infections to date, Set_14 mosaics are the best characterized, both 
experimentally and bioinformatically.  Set_14 mosaic cDNA clones were 
retrieved from six out of 15 chronic mouse infections analysed72 (see Chapters 3 
and 4 for further details).  From a single infection (mouse 04), eight distinct 
Set_14 mosaic cDNA clones were retrieved, representing a diverse range of 
related mosaics.  The presence of these mosaics spanned ten days in this 
infection, which normally would exceed the time for specific antibodies to arise.  
The diverse and prevalent Set_14 mosaic set, summarized in Figure 5.1 and 
Table 5.1, was therefore deemed to be the best available to test the null 
hypothesis outlined above. 
 
Of the Set_14 mosaic VSGs found in mouse 04, six were selected for testing: 04-
21c04, 04-23c07, 04-23c40, 04-23c48, 04-27c44 and 04-29c06.  For brevity and 
clarity, these clones are referred to as variants ‘21’, ‘23a’, ‘23b’, ‘23c’, ‘27’ 
and ‘29’ respectively. In addition, to investigate the epitope structures of Set_14 
mosaics further, a related mosaic from mouse 05, was studied: 05-27c09, 
referred to as variant ‘05-27’.  Diagrams representing each of these mosaics are 
indicated in Figure 5.1 by a ‘＊’.  All seven of these VSGs have been formed by 
the segmental combination of four putative donors.  The mature NTD amino acid 
variability, and the full-length nucleic acid variability, between the different 
mosaics are indicated in Table 5.1. 
 
Note added in proof: experiments conducted following submission of this thesis 
revise some of the results and analyses presented in this chapter.  The text here 
has been left uncorrected.  Although the overall conclusions of this chapter 
remain the same, the reader is urged to consult Appendix 7.4.4 for further 
details. 
                                         
72 Five of the 11 infections presented here, plus one out of four infections to progress into the 
chronic stage previously reported by Marcello & Barry (2007). 
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Figure 5.1 Twelve diverse Set_14 mosaic VSGs identified in mouse 04 and mouse 05.  In 
diagrams representing cDNA sequences, a black bar indicates the boundary between N- and 
CTD-encoding regions.  A dotted line indicates the division between the N-terminal signal 
peptide-encoding and mature NTD-encoding regions.  Cysteine codons are represented by a 
bar projecting above the diagram.  Segments donated by the putative donors 14-A, 14-B, 14-
C and 14-D are coloured in different shades of green, according to the key at the bottom of 
the image.  The mouse and day of infection where each of these mosaic variants was 
identified is shown on the left hand side of the Figure.  ‘＊ ’ indicates those mosaics 
investigated in this chapter.  The names referring to each of these mosaics are referred to 
are given on the right hand side, next to each cDNA diagram.   
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Table 5.1 The Set_14 mosaic VSGs under investigation were compared with one another and with their putative donors.  For each comparison, the mature 
NTD amino acid variability (top right half of the matrix) and full-length nucleic acid variability (bottom left half of the matrix) are given in differences/aa and 
differences/nt respectively.  For the expressed mosaics, variabilities of less than 0.1 are highlighted in red.  The best matching donor (that is, the lowest 
variability between an expressed mosaic and a donor) is indicated, for each mosaic, in bold.   
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5.2 Experimental approach 
5.2.1 Overview of experimental design 
VSGs possess a characteristic tertiary structure thought to be critical to their 
function (Blum et al., 1993), are post-translationally modified by N-glycosylation 
(Mehlert et al., 2002), and their close packing in the complete surface coat 
shields their membrane-proximal end from access by antibodies and other 
immune effectors (Schwede et al., 2011).  The intact surface coat may also 
induce different qualities of immune response compared with inoculation with 
purified protein coupled with adjuvant (Clarke et al., 1987; Miller et al., 1984b; 
Theodos et al., 1990).  Therefore, rather than exogenously expressing tagged 
versions of the products of mosaic VSGs in an established bacterial protein 
expression system, each of the VSGs under investigation was expressed as an 
intact surface coat by a laboratory-adapted strain of Trypanosoma brucei. 
 
Transgenic trypanosomes expressing different Set_14 VSG coats were used to 
initiate infections of mice, which were cured by chemotherapy at the first 
parasitaemic peak.  This elicited an antibody response against that specific 
mosaic variant.  Antibody-containing plasma was harvested, adding to a panel of 
polyclonal antibody responses directed against each variant.  The ability of each 
antibody response to bind and neutralize different Set_14 VSG surface coats was 
assayed on live trypanosomes by immunofluorescence, complement mediated 
lysis, and agglutination.  In addition, several monoclonal antibody (mAb)-
producing hybridoma lines were cloned, to further dissect the immune response, 
and specifically identify epitopes shared amongst related mosaics. 
 
5.2.2 Mosaics were expressed using a two-plasmid system 
To generate a trypanosome line stably expressing a mosaic VSG as its surface 
coat, a two-plasmid system was used.  Previously, Smith et al. (2009) used 
plasmid p221_PUR117VSG_UTR to target VSG 427-4 (VSG117, see footnote7373) to 
                                         
73 Throughout this Chapter, the Lister 427 VSGs are referred to by their ‘preferred name’ (as 
documented by ‘Lister 427 VSG Summary’, G. Cross, pers. comm.), with the word ‘Lister’ 
omitted for brevity.  Their ‘local name’ is also provided where they are introduced.  For 
reference, the four Lister 427 VSGs referred to in this Chapter are Lister 427-2 (VSG221), Lister 
427-4 (VSG117), Lister 427-6 (VSG121) and Lister 427-9 (VSGVO2 or 17.23). 
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the promoter-proximal end of bloodstream expression site (BES) 1 of the Lister 
427 strain of T. brucei, yielding clones expressing two VSGs from the same 
expression site.  A further round of transfection with plasmid pBS_VSG221KO 
replaced the endogenous telomere-proximal VSG at that expression site, VSG 
427-2 (VSG221), with a selectable marker (G. Rudenko, Imperial College London, 
pers. comm.), resulting in clones expressing just the exogenous, promoter-
proximal VSG under double drug selection.   
 
Plasmid p221_PUR117VSG_UTR, kindly gifted by G. Rudenko, was modified to 
allow expression of the Set_14 mosaic VSGs.  First, the VSG 427-4 gene was 
replaced with a multiple cloning site containing recognition sites for the 
restriction endonuclease SbfI as described in Chapter 2 (section 2.4.5).  This 
modified p221_PUR117VSG_UTR was relabelled ‘pVSG’ for brevity.  Each of the 
Set_14 mosaic VSGs to be investigated was amplified from its respective cloning 
plasmid using primers that added SbfI sites to the amplicon74, was purified on a 
1% agarose gel, and was cloned into the SbfI site of pVSG.  Clones were 
sequenced using primers pVSG_insert_F and pVSG_insert_R (see Appendix 7.1) to 
ensure correct orientation and that no errors had been introduced.  Figure 5.2 
shows a diagram of the modified plasmids and the transfection strategy.  
Plasmids were linearized using NotI and XhoI for transfection. 
 
Lister 427, a laboratory-adapted trypanosome line, was used as the background 
for these experiments.  Not only is it easily cultured and genetically modified, 
but it also has a repressed rate of VSG switching compared with more animal-
adapted strains: measured to be as low as 10-7 per cell per generation 
(McCulloch et al., 1997).  In addition, the dual plasmid system outlined above 
had already been used successfully with this line (Smith et al., 2009).  
Specifically, an RNAi-capable line (13-90) was used (Wirtz et al., 1999), in case 
future experiments were to investigate the relationship between surface coats 
constructed from mosaic VSGs and other cellular processes.   
                                         
74 The entire VSG insert was amplified from the cloning plasmid and cloned into pVSG.  Each 
cloned sequence therefore included 17 bp of the spliced leader sequence at its 5’ end, and a 
portion of the 3’ UTR (up to and including the 16-mer) at its 3’ end (these portions were not 
present in the VSG 427-4 in the unmodified p221_PUR117VSG_UTR plasmid).  The additional 
sequence at the 5’ end of the VSG did not introduce any open reading frames.  The Set_14 
mosaic from day 27 (04-27c44) possessed an atypical GPI anchor signal sequence—possibly 
due to a frameshift at its extreme 3’ end—that was not corrected here.  The results described in 
the rest of this Chapter indicate that this atypical GPI anchor signal sequence was processed as 
normal. 
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Figure 5.2 Plasmids and transfection strategy.  Bloodstream expression site 1 (BES1) is 
shown.  (A) First, transfection with pVSG linearized by NotI and XhoI causes integration of 
the exogenous VSG at the promoter proximal end of BES1.  Crosses indicate the region in 
which homologous recombination occurs.  Selection of clones is achieved with puromycin.  
(B) A second round of transfection with pBS_VSG221KO linearized by NotI and XhoI 
replaces the endogenous VSG 427-2 with a resistance marker, and selection of clones is 
achieved with blasticidin.  Double resistant clones have therefore integrated the exogenous 
VSG, and lost the endogenous VSG, in BES1.  The acceptor sites for the trans-spliced 
leader sequence are indicated by black circles, and copies of the 16-mer sequence are 
indicated by vertical arrowheads. 
 
5.2.3 RT-PCR showed expression of the mosaic VSGs in Lister 
427 
The two-plasmid system was employed to generate trypanosomes expressing just 
the Set_14 mosaic VSGs under investigation.  In addition, trypanosomes 
expressing just VSG 427-4 were generated by the same process (using the 
unmodified VSG 427-4-containing plasmid p221_PUR117VSG_UTR).  The VSG 427-
4-expressing trypanosomes were used as a control to assess whether any of the 
effects observed were due to the artificial nature of the expression system, 
rather than the expression of a mosaic VSG.   
 
After the first round of transfection, the VSG expression of clones growing on the 
appropriate drugs was tested by PCR on cDNA (RT-PCR).  All clones showed dual 
expression of the exogenous VSG and the endogenous VSG 427-2 (data not 
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shown).  After both rounds of transfection, stabilates of the clones were 
prepared and VSG expression was again tested by RT-PCR.  RT-PCR was carried 
out using primers directed against VSG 427-2, Set_14 mosaic VSGs, VSG 427-4, 
and two further VSGs commonly expressed by Lister 427, VSG 427-6 (VSG121) 
and VSG 427-9 (VSGVO2).  The results are shown in Figure 5.3.  As can be seen, 
trypanosomes subjected to transfection with both plasmids were expressing the 
exogenous VSG, and were no longer expressing VSG 427-2.  In most cases, no 
expression of either VSG 427-6 or VSG 427-9 could be detected.75 
 
5.2.3.1 Digestion of amplification products showed no other VSG transcripts 
To exclude the possibility that VSGs other than the exogenous, promoter 
proximal VSG were being expressed, all sequences possessing the VSG-specific 
16-mer in their 3’ UTR were amplified from cDNA using VSG-specific primers (as 
in Chapter 3 section 3.3.3).  The products were gel-purified, digested with 
EcoRV ‘high fidelity’ (HF) restriction endonuclease and separated on an agarose 
gel (Figure 5.4).  All the Set_14 mosaic VSGs under investigation have an EcoRV 
recognition site at approximately 400 bp.  Cut and uncut PCR product was run on 
a gel.  In the cut lane, bands with an approximate size of 1000 bp and 400 bp 
can be seen.  No residual uncut product is seen in the lanes containing product 
treated with the enzyme.  This result indicates that all detectable products 
possess the EcoRV site predicted of the Set_14 mosaics.  Three representative 
mosaic-expressing lines were tested by amplification-digestion: 21, 23a and 29. 
 
                                         
75 The exception to this is the 05-27-expressing trypanosomes, which show product from both the 
VSG 427-6 and VSG 427-9 reactions.  The most likely explanation for this pattern is that theirs 
has become a meroclonal population: possibly trypanosomes in their population switched as the 
clone expanded.  As the 05-27 clones were obtained only towards the end of the project it was 
not possible to re-clone them.  The fact that the 05-27 trypanosome population may be 
expressing other VSGs alongside the Set_14 mosaic demands that the results obtained with 
this line must be interpreted carefully. 
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Figure 5.3 Post-cloning RT-PCR.  Six primer pairs were used to test expression of different 
VSGs and tubulin (to control for equal template loading).  cDNA from nine lines was tested.  
Reactions were carried out on total cDNA, as well as the product of a reaction from which 
reverse transcriptase was absent, as a control for gDNA contamination.  The Set_14 mosaic 
expressors are indicated by a bar above the lane labels.  Dotted lines have been placed over 
the image to aid identification of the cDNA template used for each reaction.  
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Figure 5.4 Amplification-EcoRV restriction digest.  cDNA from unmodified trypanosomes, as 
well as those from lines expressing Set_14 variants 21, 23a and 29, was amplified using 
primers directed against the spliced leader and the VSG-specific 16-mer.  The product was 
gel purified.  100 ng of the purified product was digested with EcoRV-HF for 10 hours and 
separated on a 1% agarose gel alongside 100 ng of undigested product. 
 
5.2.4 SDS-PAGE showed a variant band that was verified by mass 
spectometry 
To ensure that transcripts detected by RT-PCR were being translated into a 
protein coat, crude cell lysate was run on SDS-PAGE (Figure 5.5).  As can be 
seen, the thick Coomassie-blue-stained band corresponding to VSG 427-2 seen in 
the untransfected cells was lost in all the modified lines, and replaced with a 
different-sized band.  The distance that each of these variant bands had 
migrated broadly corresponds with the relative predicted molecular weights of 
the different VSGs under investigation (Table 5.2), in that 21, 23a, 23b and 23c 
are all expected to have similar molecular weights to that of each other, 
whereas 27 and 29 are expected to be ~5 kDa larger.  Discrepancies between the 
predicted molecular weight and the distance that they have migrated, 
particularly when comparing the Set_14 VSGs with the VSG 427-2 and VSG 427-4 
controls, could be due to the extent of glycosylation in these different VSGs: as 
shown in Table 5.2, the Set_14 VSGs under consideration all have more Asn-Xaa-
Ser/Thr potential glycosylation sites than VSGs 427-2 or 427-4. 
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Figure 5.5 SDS-PAGE.  Crude cell lysate from 5 x 106 cultured cells was separated on a 10% 
Bis-Tris acrylamide gel.  Lysates from the Set_14 mosaic expressors are indicated by a 
bracket above the lane labels, ‘unmod’ indicates the unmodified 427-2-expressing line.  The 
variant band lies between the weight markers corresponding with 48 and 66 kDa.  
Arrowheads mark those lanes for which the variant band was excised and examined by 
mass spectrometry. 
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Table 5.2 Expected mass of VSGs.  The predicted molecular weights of the different mature 
VSGs were calculated by cropping the predicted N-terminal and GPI anchor signal 
sequences from the amino acid sequences, and calculating the molecular weight of the 
remaining sequence using CLC Genomics Workbench.  The number of putative 
glycosylation sites was found by searching the sequence for asparagines followed by any 
amino acid, followed by either serine or threonine.  
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For three of the Set_14 mosaic expressors, 21, 23b and 29, this band was excised 
from the SDS-PAGE gel and analysed by tryptic digest mass spectrometry (R. 
Burchmore, University of Glasgow) to test whether they corresponded with the 
anticipated VSG.  In all three cases, both of the Set_14 donors present in the 
standard MASCOT database, 14-A (Tb11.09.0005) and 14-B (Tb11.13.0003; for 
this study a custom database containing the complete mosaic sequences was not 
used) were represented, they were each identified by at least one significant 
peptide match, and they were the only VSGs identified. 
 
5.2.5 Transgenic trypanosomes were expressing the mosaic VSG 
In summary, analyses of both RNA and protein of the doubly-transfected Lister 
427 lines indicate that the trypanosomes were expressing the exogenous, 
promoter-proximal VSG, and that this VSG mRNA was being translated to 
protein.  With the exception of 05-27, there was no evidence that any other VSG 
was being expressed. 
 
5.2.6 Transgenic trypanosomes showed abnormal growth in 
culture 
Compared with wild-type Lister 427 cells, the doubly-transfected transgenic VSG 
expressors showed some differences in growth under standard in vitro culture 
conditions.  The following qualitative observations were made casually as cells 
were being prepared for experiments.  Compared with wild-type cells, the 
transgenic cell lines appeared to yield a greater frequency of ‘monster’ cells, 
with a swollen cytoplasm, multiple flagella, and occasionally detached flagella.  
They appeared to be more sensitive to high cell density (>2 x 106 ml-1) than the 
unmodified cells, with recovery from a period of overgrowth often impossible.  
In addition, transgenic cell lines would occasionally form clumps of cells, even at 
relatively low cell density (~1 x 105 ml-1), a phenomenon usually seen only in 
overgrown wild-type cell cultures.  Finally, on occasion, the resistance of the 
transgenic cell lines to the two drugs used for selection was lost, with the cells 
showing greatly reduced motility and death.  Loss of drug resistance could occur 
despite continued exogenous VSG expression (detected by RT-PCR, data not 
shown).   
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One possible mechanism accounting for poor growth and drug sensitivity in these 
lines is the architecture of the modified expression site.  As seen in Figure 5.2, 
the exogenous VSG and drug selection markers introduced to the expression site 
contain additional untranslated regions.  There is some recent evidence that the 
conserved 16-mer present in the VSG 3’ untranslated region is involved in 
silencing of inactive VSG genes (S. Hutchison & D. Horn, pers. comm.; P. Batram, 
pers. comm.).  The exact mechanism is unknown, although it may be through 
competition for an RNA binding protein.  The modified expression site contains 
16-mers linked both to the expressed VSG and to the blasticidin resistance 
gene.76  Interference between these sequences could plausibly account for some 
of the behaviour of these lines. 
 
Notwithstanding these differences from wild-type cell growth, the transgenic 
cell lines generally grew well in culture, and could be maintained for many 
weeks with continued transgenic VSG expression (confirmed by RT-PCR, data not 
shown). 
 
5.2.7 Transgenic trypanosomes showed abnormal growth in vivo 
To raise antibodies against the various surface coats under investigation, both 
untransfected and transgenic trypanosomes were used to infect mice.  Mice 
rapidly mount an antibody response against the highly immunogenic VSG surface 
coat of African trypanosomes.  Once mice have been exposed to a particular 
surface coat, the trypanosomes can be cleared by treatment with cymelarsen 
(20 mg.kg-1).  This is necessary as the Lister 427 line used as the background 
strain for the transgenic VSG expressors is monomorphic and hence highly 
virulent: without treatment the mice rapidly succumb to the infection.  Post-
treatment, the immune response against VSG continues to develop, and 
antibodies at high titre can be retrieved with the blood 7–12 days after infection 
(although they appear sooner, J. D. Barry, pers. comm.).  
 
Preliminary infections of mice demonstrated that a substantially greater 
intraperitoneal inoculum of transgenic trypanosomes was required to establish 
                                         
76 In the case of the Set_14 mosaic-expressing trypanosomes, the promoter-proximal (exogenous) 
VSG possesses two 16-mers and the blasticidin resistance gene possesses one.  In the case of 
the VSG 427-4-expressing trypanosomes, there is just one additional 16-mer, associated with 
the blasticidin resistance gene.  This discrepancy was due to the means by which the Set_14 
mosaics were cloned from their subcloning plasmids into pVSG (see footnote 74). 
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infection compared with untransfected cells.  It was found that an 
intraperitoneal inoculum of 1 x 106 trypanosomes was required to reliably 
establish an infection (compared with 5000 or fewer unmodified Lister 427, G. 
Cross pers. comm.).  With inoculum sizes of 5000 or 50,000, the trypanosomes 
could not always establish an infection; this was found to be true even in mice 
immunosuppressed with cyclophosphamide (data not shown).  In addition, mice 
could, on occasion, control the infection, leading to decrease in parasitaemia 
(data not shown).  Poor in vivo growth has previously been observed with similar 
VSG transgenic trypanosomes lines (G. Rudenko, pers. comm.), and was found to 
be the case both for Set_14 mosaic expressors, and the control VSG 427-4 
expressor, which is known not to inhibit growth when expressed endogenously. 
 
To test whether poor in vivo growth was due to a problem with the expression of 
the exogenous VSG or the loss of the telomere-proximal VSG 427-2, double 
expressors (which had undergone only one round of transfection to insert a 
promoter-proximal exogenous VSG, leaving the telomere-proximal VSG 427-2 
intact) were also used to infect animals.  Unlike the single expressors, the 
double expressors could initiate infections with a smaller inoculum size of 5000, 
in the three instances attempted (data not shown),77 suggesting that it is the 
replacement of the telomere-proximal VSG 427-2 gene with a drug resistance 
gene that is largely responsible for poor in vivo growth. 
 
Because growth in culture places selective pressures on trypanosomes that might 
be suboptimal for growth in vivo, attempts were made to increase the virulence 
of transgenic trypanosome lines by rapidly passaging through mice every 1-3 
days.  Such attempts were made with three trypanosome lines (expressing 
Set_14 variants 21, 23a and 29), before recloning and testing by RT-PCR to 
ensure continued exogenous VSG expression.  However, no substantial increase 
in infectivity was observed (data not shown).   
 
Despite the poor in vivo growth and survival compared with wild-type cells, the 
transgenic lines could still be used to raise antibodies, as an immune response 
develops even following inoculation with osmotically lysed trypanosome ghosts 
(Hsia et al., 1996).   
                                         
77 In vivo growth of double-expressors was tested only for Set_14 mosaics 21, 23a and 29. 
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5.2.8 Recently cloned cells were used for experiments and 
expression was verified by RT-PCR 
Considering the unpredictable growth in culture (see section 5.2.6), care was 
taken to ensure that those trypanosomes used to initiate infections and run 
experiments were indeed expressing the transgenic VSGs under investigation by 
using cells that had very recently been cloned under drug selection and tested 
by RT-PCR.78  For the immunofluorescence experiments, trypanosomes were 
grown from RT-PCR-tested stabilates (see section 5.2.3) in the absence of drug 
selection for no longer than one week, to ensure healthy cells.  During this time 
all immunofluorescence experiments were conducted (sections 5.3.1 and 5.3.5).  
A similar approach was used for the complement-mediated lysis and 
agglutination experiments (sections 5.3.2, 5.3.3 and 5.3.6).  RT-PCR was carried 
out on the cultures after the experiments.  The results of the RT-PCR following 
the complement-mediated lysis and agglutination experiments are shown in 
Figure 5.6; similar results were obtained following the immunofluorescence 
experiments (data not shown). 
 
As can be seen, the cultures used for the experiments were still expressing the 
transgenic VSGs under investigation.  Expression of other Lister 427 VSGs (VSG 
427-6 and VSG 427-9) could also be detected, at varying levels in different 
cultures, suggesting that, in the absence of drug selection, there are present 
within the cultures trypanosomes that have come to express different VSGs 
(either through in situ switching to another expression site, or through 
duplication into BES 1).  However, the abundance of the product amplified using 
transgenic VSG-specific primers suggests that there remained many 
trypanosomes in the culture that continued to express the exogenous VSG, 
lending support to the premise that the experiments were indeed conducted on 
the VSG surface coats under investigation. 
 
                                         
78 The results of this RT-PCR were the ones shown to illustrate transgenic VSG expression in 
Figure 5.3. 
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Figure 5.6 Post-complement-mediated lysis RT-PCR.  An experiment identical to that 
described in Figure 5.3 was carried out using the same cultures as used for the 
complement-mediated lysis and agglutination assays.  The Figure is annotated as Figure 
5.3.  Note that compared with Figure 5.3, VSG 427-4 and 05-27 expressor reactions were 
loaded into different lanes. 
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5.2.9 Antibodies against the mosaic coats were raised by 
infection and cure 
The standard procedure for infection to raise antibodies was as follows: 1 x 106 
trypanosomes were injected intraperitoneally into a Balb/c mouse.  When the 
parasitaemia exceeded antilog 7.2 parasites.ml-1 (as scored by the method of 
Herbert & Lumsden, 1976) mice were cured by a dose of cymelarsen.  Five to 
eight days after cure, blood was collected by cardiac puncture under terminal 
anaesthesia into CBSS containing 5% w/v sodium citrate.  Plasma was retrieved 
by centrifuging the sample at 14,000 g for 10 minutes, removing the supernatant 
into a clean microfuge tube, centrifuging the supernatant again for 10 minutes, 
again removing the supernatant into a clean microfuge tube, and adding, as a 
preservative, sodium azide to a final concentration of 0.05%.  At least two anti-
plasma were raised against each trypanosome line under consideration.  Anti-
plasma were named ‘anti-XX (Y)’ where XX is the variant against which they 
were raised, and Y is a capital letter from A–D to distinguish the different replica 
anti-plasma.  From four infections, splenocytes were also retrieved for the 
purposes of generating hybridoma lines (see section 5.3.4). 
 
The question of whether those trypanosomes present in the infection were 
indeed continuing to express the exogenous VSG was tested for three of the 
Set_14 mosaic expressors (21, 23a and 29).  Samples of blood taken by 
venesection at the peak of parasitaemia were tested for exogenous VSG 
expression by RT-PCR.  An abundant product was seen when using the Set_14 
mosaic VSG-specific primers, with weak or no product from primers directed 
towards the other Lister 427 VSGs (data not shown), lending support to the 
premise that the trypanosomes present at the time of cure were indeed 
expressing the exogenous VSG under investigation.79 
 
With mosaic VSG-expressing trypanosomes and antibodies against them in hand, 
experiments could be carried out to assess their serological relationships. 
                                         
79 In addition, samples of blood taken from infections with three Set_14 mosaic expressors (21. 23a 
and 29) were tested by indirect immunofluorescence with the monoclonal antibodies mAb-21A 
and mAb-29B (see section 5.3.5).  The overwhelming majority of trypanosomes (>99% of >300 
observed) present in the 21 and 23a infections reacted with mAb-21A, and the overwhelming 
majority of trypanosomes present in the 29 infections reacted with mAb-29B (data not shown), 
again in support of the premise that the mosaic VSGs were being expressed by the infecting 
trypanosomes. 
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5.3 Serological analysis of mosaic VSGs 
5.3.1 Indirect immunofluorescence showed mosaic expressors 
were antigenically distinct 
5.3.1.1 Indirect immunofluorescence was performed on formaldehyde-fixed 
cells 
To test whether polyclonal antibodies raised against one variant could bind to 
that and another variant surface coat, indirect immunofluorescence 
(immunofluorescence assay, IFA) was carried out on live cells.  For these 
experiments, the polyclonal antibodies present in the harvested plasma were 
used as the primary antibody, and fluorescently labelled goat anti-mouse Ig 
antibodies were used as the secondary antibody.  Preliminary studies (and 
previous work (J. D. Barry, pers. comm.)) indicated that, were live cells to be 
used, these experiments would need to be carried out and scored rapidly as 
surface bound antibodies are rapidly sorted to the posterior of the trypanosome, 
internalized, and degraded (Engstler et al., 2007; O'Beirne et al., 1998; Pal et 
al., 2003).  The number of antibody-antigen combinations to be examined was 
too many for such an approach to be feasible, therefore formaldehyde fixation 
was investigated.  Formaldehyde kills and preserves cells and tissues by 
crosslinking exposed proteins (Fox et al., 1985).  Because formaldehyde fixation 
can result in the addition of antigen-masking groups to exposed proteins, it 
could change the structure of exposed epitopes.80  The potential for antigen 
masking could have complicated interpretation of the immunofluorescence data, 
so the effects of fixation in the presence of primary antibody were investigated.  
Preliminary experiments identified no non-specific fixation of primary antibody 
if formaldehyde fixative was briefly applied in its presence, and substantial 
posterior accumulation of antibody was seen if a wash step was included 
between treatment with primary antibody and formaldehyde fixation.  For the 
purposes of identifying exposed epitopes by immunofluorescence, it was 
therefore decided that cells would be briefly fixed in the presence of the 
primary antibody, ten minutes after addition.   
 
                                         
80 From the technical advice sheet: ‘Fixation and Permeabilization for IHC and ICC’, Abcam, 
Cambridge, UK. 
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All procedures were carried out at 4ºC, or on ice.  Briefly, cultured cells were 
washed in trypanosome dilution buffer (TDB, (Cross, 1975)) + 1% w/v bovine 
serum albumin (BSA), and resuspended in anti-plasma at a 1:25 dilution in TDB + 
1% w/v BSA.  The suspensions were incubated for 10 minutes, after which 
formaldehyde in PBS was added to a final concentration of 4% w/v.  Fixation was 
carried out for 5 minutes.  Cells were washed twice with phosphate-buffered 
saline (PBS) and resuspended in secondary antibody81 at a 1:500 dilution in PBS + 
1% w/v BSA.  After incubation for 15 minutes, the cells were washed twice again 
in PBS, mounted and visualized.  This method is a modified version of that kindly 
provided by M. Engstler (pers. comm.). 
 
5.3.1.2 Some mosaic VSGs cross-reacted, others were antigenically distinct 
Indirect immunofluorescence was carried out as described above for nine 
different trypanosome lines and 22 different anti-plasma.82 Figure 5.7 shows 
three representative cells from each antigen-antibody combination.  This figure 
is summarized in Table 5.3.   
 
Figure 5.7 ! Indirect immunofluorescence with polyclonal antibodies.  Indirect 
immunofluorescence was carried out on live cells using different antiplasma as described in 
the text.  Samples of stained cells were mounted on glass slides and observed at 1000x 
magnification in the DIC, FITC and PE channels.  The different antiplasma used are 
indicated at the top.  For each antiplasma-VSG combination minimally 200 trypanosomes 
were observed microscopically in all channels.  Images of three representative 
trypanosomes (i–iii) in the DIC and FITC channels are provided for each antibody-antigen 
combination.  ‘Unmod’ refers to the 427-2-expressing unmodified 13-90 trypanosomes.  
Additional images are provided for the anti-427-4-427-4 combination.  Note: following 
submission of the thesis, additional experiments were performed that revise some of the 
results presented in this figure.  Please see Appendix 7.4.4 and 7.4.5 for details. 
 
 
 
                                         
81 The secondary antibodies used in all cases were Alexa 488-conjugated goat anti-mouse IgG 
H+L (Invitrogen, Paisley, UK) which reacts against IgG heavy chains and all classes of 
immunoglobulin light chains from mouse, and, where isotype differentiation was required, Alexa 
594-conjugated goat anti-mouse IgM (! chain) (Invitrogen, Paisley, UK) which is specific for the 
IgM isotype. 
82 For reasons of time, some of the replica anti-plasma could not be tested on all trypanosome lines 
(most notably VSG 427-4 expressors).  
  
 
Figure 5.7 IFA with polyclonal antibodies.  See previous page for details. 
  
 
Figure 5.7 (continued) 
 
  
 
Figure 5.7 (continued) 
 
  
 
Figure 5.7 (continued) 
 
  
 
Figure 5.7 (continued) 
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Figure 5.7 (continued) 
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Table 5.3 Indirect immunofluorescence with polyclonal antibodies.  A summary of the 
results shown in Figure 5.7.  ‘+++’ indicates strong, eggshell-like fluorescence.  ‘++’ 
indicates strong fluorescence, but perhaps with a speckled appearance or posterior 
accumulation.  ‘+’ indicates patchy or weak fluorescence.  ‘~’ indicates very weak 
fluorescence that was seen on only a few trypanosomes.  ‘-‘ indicates no signal.  Cells are 
coloured in intensity according to the strength of their signal.  Where two different scores 
are given, separated by a ‘/’, the results varied within a sample, or between replica 
antiplasma.  Note: following submission of the thesis, additional experiments were 
performed that revise some of the results presented in this table.  Please see Appendix 7.4.4 
and 7.4.5 for details. 
 
First, the patterns of cross-reaction between antibodies and antigens will be 
considered.  As expected, antibodies raised against unmodified, VSG 427-2-
expressing trypanosomes did not crossreact with any of the transgenic cell lines.  
In a reciprocal manner, antibodies raised against the transgenic cell lines did not 
bind to unmodified VSG 427-2-expressing trypanosomes.  Similarly, (albeit with 
one exception, discussed below), antibodies raised against transgenic VSG 427-4-
expressing trypanosomes did not bind to the Set_14 mosaic-expressing 
trypanosomes, and neither did antibodies raised against any of the Set_14 
mosaic-expressing trypanosomes bind to the VSG 427-4-expressing controls. 
 
On the other hand, antibodies raised against several of the Set_14 variants were 
able to bind to other Set_14 VSG coats.  This cross-reaction was exactly 
reciprocal.  Specifically, polyclonal antibodies raised against any of Set_14 
variants 21, 23a, 23c or 27 were able to bind to all four of these antigens.  These 
antigens also cross-reacted reciprocally with a Set_14 variant identified in 
another infection, 05-27.  Serological cross-reaction was not seen with the 
Set_14 variant retrieved from the later timepoint of the same infection (day 29), 
and neither did antibodies raised against variant 29 bind to any of the other 
Set_14 variants. 
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Taken together, these results suggest that of the Set_14 variants identified in a 
single infection, 21, 23a, 23c and 27 shared at least one epitope that was 
exposed on the surface of the live trypanosome, and none of these putative 
epitopes was possessed by 29. 
 
The pattern of cross-reaction shown by the Set_14 variant 23b is harder to 
interpret.  Antibodies raised against trypanosomes expressing this mosaic did not 
crossreact with any of the other antigens under consideration, including those 
formed from related Set_14 mosaic VSGs.  This seems to suggest that this 
surface coat was also antigenically distinct from those of the other Set_14 
variants.  However, this lack of cross-reaction was not exactly reciprocal: in 
some cases, antibodies raised against other Set_14 mosaic expressors were able 
to bind to 23b-expressing trypanosomes (anti-23c (B) and anti-27 (A)).  In one 
case a mouse exposed to VSG 427-4-expressing trypanosomes produced 
antibodies that could bind to 23b-expressing trypanosomes.  This unexpected 
observation indicates that the results of experiments on the 23b-expressing line 
should be interpreted carefully, and is discussed in detail in light of other results 
(section 5.3.7). 
 
Next, the qualitative staining patterns will be considered.  As shown in Figure 
5.7, in both cases unmodified VSG 427-2-expressing trypanosomes treated with 
homologous primary antibodies displayed a uniform, ‘eggshell’-like pattern of 
fluorescence across their entire surface.  This eggshell staining was occasionally 
seen in the case of the transgenic trypanosomes (for an example, see 05-27).  
However, a qualitatively different staining pattern was also observed, with a 
distinctly punctate, ‘speckled’ effect, and extensive accumulation of stain 
around the posterior and flagellar pocket of the trypanosome (for an example, 
see 05-27).  Both eggshell and speckled trypanosomes were identified in the 
same preparation (the case of VSG 427-4-expressing trypanosomes treated with 
anti-427-4 (B)).   
 
Initially it was considered that the speckled staining pattern was due to aberrant 
artefactual structure of the transgenic VSG surface coat, but this hypothesis is 
not consistent with the results of the mAb analysis described in section 5.3.5.  
More likely the poor growth of transgenic trypanosomes in vivo led to those mice 
having less exposure to those antigens than mice infected with unmodified VSG 
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427-2-expressing trypanosomes, resulting in a weaker immune response and 
lower plasma antibody titres.  To test whether low antibody concentration could 
cause the speckled staining pattern in unmodified 427-2-expressing 
trypanosomes, immunofluorescence using limiting dilutions of primary antibody 
was carried out.  Although a weaker signal was seen as the primary antibody was 
diluted, the characteristic punctate speckledness was not seen, suggesting that 
it was not simply antibody concentration that contributed to speckledness (data 
not shown).  An attempt was made to boost the antibody titres by allowing the 
infections to progress further.  This met with some success: anti-29 (D) shows a 
stronger, less specked staining pattern than the other anti-29 antibodies, which 
were produced from animals cured earlier in infection (data not shown).83   
 
The accumulation of stain around the flagellar pocket was most likely due to the 
concentration of antibodies in this location by hydrodynamic drag, which, 
although reduced at lower incubation temperature, is not ablated (Engstler et 
al., 2007).  Preliminary studies in which a wash step was included between 
treatment with primary antibody and fixation exaggerated this accumulation 
further, as trypanosomes had more time to sort bound antibodies to this location 
(data not shown).  As can be seen in Figure 5.7, there is a difference in degree 
in posterior antibody accumulation between different antigen-antibody 
combinations.  This could be caused by variation in both titre and isotype 
composition of the different polyclonal antibody preparation, as antibody 
concentration and isotype both affect the rate and extent to which the 
antibodies are sorted on the trypanosome's surface (Engstler et al., 2007). 
 
5.3.2 Antigenic distinctness protected the later mosaic from 
complement mediated lysis 
To test whether the apparent antigenic distinctness of some Set_14 variants had 
functional significance, allowing bound antibodies to activate complement and 
kill the trypanosomes, live cells were exposed to varying concentrations of the 
antibody in the presence of complement-competent plasma (the complement-
mediated lysis, CML, assay).  Briefly, complement-competent plasma was 
                                         
83 In this context it is interesting to note the results of Dubois et al. (2005) who reported reduced 
antibody responses against transgenic double-VSG expressing trypanosomes.  It may be that 
impaired antibody responses are a general feature of trypanosomes manipulated to express 
transgenic VSGs rather than a phenomenon particular to double-VSG expression. 
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prepared from freshly collected guinea pig blood by centrifugation at 14,000 g 
for 10 minutes, retrieval of the supernatant into a fresh tube, removal of any 
remaining blood cells by an additional 10 minute 14,000 g centrifugation, and 
again retrival of the supernatant into a fresh tube.  This purified guinea pig 
plasma (GPP) was divided into small volumes (1–2 ml), frozen, and stored at -
80ºC.  On the day of the experiment, GPP was thawed and centrifuged at 14,000 
g for 10 minutes to separate any aggregates that may have formed.  
Representative polyclonal antibodies84 directed against the variants under 
consideration were serially threefold diluted in the GPP, and 5 !l drops were 
distributed into the wells of a Terasaki plate.  5 !l of 1 x 107 ml-1 trypanosomes, 
prepared in advance by resuspending cultured cells in the correct volume of 
guinea pig plasma, were added to the antibody dilutions.  The plate was covered 
and the reaction was incubated at room temperature for one hour before 
observation under phase contrast microscopy and scoring each well for dead 
cells.  The maximum dilution of antiplasma that could still cause substantial cell 
death (>95%) was recorded.  For each trypanosome line, cells were incubated at 
the same concentration in GPP to control for non-specific killing. 
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Table 5.4 Complement-mediated lysis with polyclonal antibodies.  Representative 
antiplasma (anti-427-2 (B), anti-21 (B), anti-23a (A), anti-23b (A), anti-23c (A), anti-27 (A), anti-
29 (D) and anti-427-4 (A)) were serially diluted threefold with guinea pig plasma and 50,000 
trypanosomes in an equal volume of guinea pig plasma (GPP) were added.  The reaction 
was incubated in a humid Terasaki plate for one hour at room temperature, and the 
maximum dilution of antiplasma causing >95% cell death was recorded for each antiplasma-
VSG combination.  ‘-‘ indicates no cell death up to 1/6 dilution.  ‘X’ indicates experiment was 
not performed.  As a negative control, cells were incubated in GPP without antiplasma.  
Note: following submission of the thesis, additional experiments were performed that revise 
some of the results presented in this table.  Please see Appendix 7.4.4 and 7.4.5 for details.  
                                         
84 Representative anti-plasma were used for the CML and the agglutination assays, as there was 
insufficient time to perform the assay with all available antiplasma.  For these experiments, anti-
unmodified (B), anti-21 (B), anti-23a (A), anti-23b (A), anti-23c (A), anti-27 (A), anti-29 (D) and 
anti-427-4 (A) were used.  Only homologous polyclonal antibody CML and agglutination assays 
were performed with 05-27. 
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The results of this experiment are shown in Table 5.4. Important to note is that 
the survival of the trypanosomes in GPP indicates their possession of an intact 
surface coat (Ferrante & Allison, 1983).  Consistent with the 
immunofluorescence, the four cross-reacting Set_14 variants showed reciprocal 
complement-mediated lysis, whereas VSG 427-2-expressing trypanosomes and 
mosaic variant 29-expressing trypanosomes appeared to be antigenically 
distinct, both from the cross-reacting Set_14 variants and one another (time 
restrictions prevented this assay from being applied to 05-27-expressing 
trypanosomes).   
 
Similar to the results of the immunofluorescence, the 23b-expressing cells 
showed cross-reaction with anti-VSG 427-4, as well as with some of the 
antibodies raised against other Set_14 variants.  The non-reciprocal cross-
reaction of 23b, and susceptibility of 23b to anti-427-4, may represent general 
fragility of the cultured cells in suboptimal conditions (GPP).  It may also 
represent genuine cross-reaction, and will be discussed in section 5.3.7.  
 
In general, the transgenic trypanosomes required higher concentrations of anti-
plasma to cause lysis when compared with the anti-plasma raised against VSG 
427-2.  The reduced potency of the anti-plasma could be a manifestation of the 
speckled staining pattern seen in immunofluorescence, corresponding with a 
reduction in the total number of antibodies binding. 
 
5.3.3 Agglutination assays are consistent with complement-
mediated lysis and immunofluorescence 
A third approach to investigating the antigenic relatedness of the Set_14 variants 
was the agglutination assay.  Within a certain stoichiometric range, VSG-binding 
antibodies are able to characteristically agglutinate trypanosomes.  
Agglutination happens rapidly, and can be easily observed under phase contrast 
or bright field microscopy.  Briefly, trypanosomes and antibodies were prepared 
as for the complement-mediated lysis assay, except trypanosome dilution buffer 
(TDB) was used as the diluent and the medium for trypanosome resuspension 
(rather than GPP).  For this assay, trypanosomes were at a concentration of 2 x 
107 parasites.ml-1.  Plates were incubated at room temperature for 30 minutes 
before the wells were examined and scored using phase contrast microscopy at 
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400x magnification.  The maximum dilution of antiplasma able to agglutinate 
trypanosomes was recorded. 
 
The results of the agglutination assays are shown in Table 5.5.  These results are 
broadly consistent both with the immunofluorescence and with the complement-
mediated lysis experiments.  Some non-reciprocated reaction was seen at higher 
concentrations of the anti-29 antibodies.  The reasons for this are unclear, but it 
may be that the transgenic cells were particularly prone to agglutination: 
witness the difference in titres seen between the CML and agglutination assays 
with antiplasma raised against variant 27, for example.   
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Table 5.5 Agglutination with polyclonal antibodies.  Representative antiplasma (the same as 
Table 5.4) were serially diluted threefold with TDB and 100,000 trypanosomes in an equal 
volume of TDB were added.  The reaction was incubated in a humid Terasaki plate for one 
hour at room temperature, and the maximum dilution of antiplasma causing agglutination 
was recorded for each antiplasma-VSG combination.  ‘-‘ indicates no agglutination up to 1/6 
dilution.  As a negative control, cells were incubated in TDB without antiplasma.  ‘X’ = 
experiment not performed.  Note: following submission of the thesis, additional experiments 
were performed that negate some of the results presented in this table.  Please see 
Appendix 7.4.4 and 7.4.5 for details. 
 
 
5.3.4 Monoclonal antibodies were generated to investigate 
specific epitopes 
To dissect the epitope structure of related mosaic VSGs, splenocytes from 
infected mice were fused to form immortal, antibody-producing hybridomas.  
These were cloned, providing a pure source of monoclonal antibody (mAb). 
 
Briefly, spleens were aseptically harvested from mice killed by exsanguination 
under terminal anaesthesia.  These were the same mice from which polyclonal 
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antibodies were obtained.85  Splenocytes were fused to cultured P3-X63-Ag8-653 
myeloma cells using concentrated PEG solutions (as described in Chapter 2, 
section 2.5.3) distributed across the wells of five 96-well cloning plates, and 
incubated at 37ºC in 5% CO2 in air.  Twenty-four hours after fusion, cells were 
put under selection by adding HAT selection medium to each well of the plate to 
a final concentration of 1x.  Cells were screened by indirect 
immunofluorescence for mAb production 10–12 days after cloning.  Wells 
containing hybridoma producing antibodies of interest were recloned by limiting 
dilution two further times to ensure pure populations of hybridoma. 
 
Supernatants from wells showing hybridoma growth were screened at each 
cloning step by differential indirect immunofluorescence.  Undiluted 
supernatants were applied to slides containing acetone-fixed trypanosomes 
expressing the surface coat under investigation or unmodified trypanosomes 
expressing VSG 427-2 as a negative control.  Slides were incubated in a humid 
chamber for 30 minutes at room temperature.  They were then washed twice in 
PBS, before the secondary antibodies (see footnote 81) were applied at a 1:2000 
dilution in PBS with 1% BSA.  Slides were again incubated in a humid chamber for 
30 minutes at room temperature, washed twice again, and mounted in 
Vectashield DAPI mounting reagent (Vector Laboratories, Peterborough, UK).  
Slides were examined using a ‘Zeiss Axioscop 2 mot +’ microscope at 1000x 
magnification.  Comparison of fluorescence at 488 nm and 594 nm (‘FITC’ and 
‘PE’ channels) allowed isotyping of the antibodies present, as IgM isotype 
antibodies binding the Alexa-594 labelled secondary antibodies would give a 
strong signal at 594 nm.  Antibodies giving no signal at 594 nm were assumed to 
be IgG, although it is impossible to be sure as the secondary antibody used can 
also bind to other isotype light chains.  Double-cloned cell lines were grown in 
100 ml complete RPMI for approximately one week until the cells began to die, 
and the supernatant was harvested by pelleting the cells at 14,000 g for ten 
minutes.  Sodium azide was added to a final concentration of 0.05% as a 
preservative.  These stocks of culture supernatant were used as the source of 
mAbs for the experiments described in the next section.  
 
                                         
85 Ultimately monoclonal antibodies were obtained from animals that provided anti-21 (A) (‘04-
21c04-1.1H5a’, named mAb-21B for brevity), anti-21 (C) (‘04-21c04-2G1a3’, named mAb-21A 
for brevity), anti-29 (A) (‘04-29c06-1F10a’, named mAb-29B for brevity) and anti-29 (C) (‘04-
29c06-3D8c’, named mAb-29A for brevity). 
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The production of hybridomas producing mAb of interest was attempted for 
three different Set_14 mosaic variants, 21, 23a and 29.  However, cloned, 
reactive mAb were obtained for only two of these variants, 21 and 29.  
Compared with previous work (J. S. Crowe, Ph.D. thesis, 1983, University of 
Glasgow), this is a relatively low number of mAbs.  As shown in Figure 5.7 above, 
polyclonal responses against transgenic VSG-expressing trypanosomes often gave 
a weaker signal than those responses against unmodified VSG 427-2-expressing 
trypanosomes.  A weaker signal may be due to lower concentration of these 
antibodies in the plasma, which in turn may be due to lower numbers of anti-
VSG antibody-producing B-cells in the spleen, which could also account for the 
decreased number of hybridoma clones retrieved. 
 
5.3.5 Monoclonal antibody cross-reaction broadly corresponded 
with that of the polyclonal antibodies 
The four mAbs produced were tested on acetone-fixed trypanosomes, in the 
same manner as supernatant screening (briefly described in section 5.3.4 
above), and the results are shown in Figure 5.8 and in Table 5.6.  The results 
broadly corresponded with the results of the polyclonal antibodies.  The two 
mAbs raised against Set_14 variant 29 detected just this mosaic variant, and did 
not bind to any of the other antigens tested.  This demonstrated that 29 had at 
least one epitope, possibly two, which were not present on any of the other 
Set_14 mosaics.  The two mAbs directed against variant 21 had different 
patterns of cross-reaction.  The IgM isotype mAb (mAb-21B) bound to variant 23a 
as well as 21.  The IgG isotype (mAb-21A) was more promiscuous, reacting with 
variants 23a, 23c, 27 and 05-27 as well as 21. This pattern of cross-reaction 
indicated that there was at least one epitope shared amongst all five of these 
Set_14 variants, and another epitope possessed by just two of them, (21 and 
23a).  None of the mAbs produced recognized 23b. 86 
 
The process of acetone fixation permeabilizes the trypanosome as it disrupts the 
surface membrane, also causing the disruption of the VSG surface coat, exposing 
epitopes that would otherwise be buried on a living trypanosome.  To test 
whether any of the mAbs produced recognized epitopes exposed on a live 
                                         
86 Note: experiments performed following submission of this thesis revise some of the statements in 
this paragraph.  Please see Appendix 7.4.4 and 7.4.5 for further details. 
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trypanosome’s surface coat, indirect immunofluorescence was carried out on 
live cells using mAbs.  The method was the same as that used for polyclonal 
antibodies, described in 5.3.1.2, except instead of a 1:25 dilution of mouse anti-
plasma, undiluted hybridoma culture supernatant was used as the primary 
antibody. 
 
The results for mAb-21A and mAb-29B are shown in Figure 5.9, and are 
summarized in Table 5.6.  No fluorescence was seen from mAb-21B or mAb-29A 
(data not shown), indicating either that the epitopes recognized by these 
antibodies were buried in an intact surface coat, or that the antibodies were at 
such low concentration in the supernatant that they were unable to cause a 
reaction in live cell immunofluorescence.  Given the clear staining seen using 
acetone-fixed cells, the first possibility—that they target buried epitopes—is the 
more likely one.     
 
The epitope recognized by mAb-21A, on the other hand, was evidently exposed 
on live trypanosomes.  The patterns of cross-reaction corresponded exactly with 
the immunofluorescence carried out on acetone-fixed trypanosomes, and with 
the immunofluorescence seen for the polyclonal antibodies raised against this 
VSG (section 5.3.1.2).  However, unlike the polyclonal antibodies the staining 
pattern seen with this mAb is the classical eggshell-like staining, suggesting that 
the speckled pattern seen with the polyclonal antibody immunofluorescence was 
due to the quality and/or concentration of the antibody present, rather than the 
structure of the surface coat. 
 
The mAb mAb-29B is harder to interpret.  Although it definitely recognized an 
exposed epitope on live 29-expressing cells (compare with the result of mAb-
29A), the staining pattern was quite different, showing very weak, speckled 
staining.  This staining pattern was somewhat reminiscent of the polyclonal 
antibody staining pattern.  Such a staining pattern could have been produced if 
the antibody was at low concentration in the supernatant (although the clear 
binding to acetone-fixed cells suggests that this was not the case).  A more likely 
explanation is that the epitope targeted by this particular mAb was only partially 
exposed on the surface.  Steric hindrance prevented many of these antibodies 
binding on a live surface coat, but once the cells were disrupted by acetone 
Chapter 5  251 
 
fixation, the antibody was able to bind more easily, giving the more uniform 
staining pattern seen in Figure 5.8. 
 
Figure 5.8 ! Indirect immunofluorescence with monoclonal antibodies on fixed 
trypanosomes.  Indirect immunofluorescence was carried out on acetone-fixed cells using 
different hybridoma supernatants as described in the text.  Samples were observed at 1000x 
magnification in the DAPI, FITC (able to detect Alexa 488) and PE (able to detect Alexa 594) 
channels.  The different source supernatants are indicated at the top.  For each supernatant-
VSG combination over 200 trypanosomes were observed microscopically in all channels.  
Images of three representative trypanosomes (i–iii) in the DAPI and FITC channels are 
provided for each antibody-antigen combination for mAb-21A, mAb-29A and mAb-29B; for 
mAb-21B images are provided in the DAPI and PE channels (as this mAb was able to bind to 
the Alexa 594-conjugated anti-mouse ! chain secondary antibody).  Note: following 
submission of the thesis, additional experiments were performed that revise some of the 
results presented in this figure.  Please see Appendix 7.4.4 and 7.4.5 for details. 
 
  
 
Figure 5.8 Indirect immunofluorescence with monoclonal antibodies on fixed parasites.  See previous page for details. 
  
 
Figure 5.8 (continued) 
  
Figure 5.9 Indirect immunofluorescence with monoclonal antibodies on live parasites.  See following page for details. 
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Figure 5.9 ! Indirect immunofluorescence with monoclonal antibodies on live 
trypanosomes.  Indirect immunofluorescence was carried out on live cells using different 
hybridoma supernatants as described in the text.  This image was prepared and is 
annotated as in Figure 5.7.  Note: following submission of the thesis, additional experiments 
were performed that revise some of the results presented in this figure.  Please see 
Appendix 7.4.4 and 7.4.5 for details. 
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Table 5.6 Indirect immunofluorescence with monoclonal antibodies.  A summary of the 
results shown in Figure 5.8 and Figure 5.9.  ‘+++’ indicates strong fluorescence, ‘+’ indicates 
a weak or patchy fluorescence, ‘-‘ indicates no signal.  ‘X’ indicates no data for that 
antibody-VSG combination.  Note: following submission of the thesis, additional 
experiments were performed that revise some of the results presented in this figure.  Please 
see Appendix 7.4.4 and 7.4.5 for details. 
 
 
5.3.6 Monoclonal antibodies gave a consistent result with 
complement lysis and agglutination assays 
To test whether the live-cell binding by mAb-21A and mAb-29B seen using 
immunofluorescence corresponded with functional activity, CML assays were set 
up.  Broadly, the method was identical to that described in section 5.3.2 and 
5.3.3.  In this case, however, undiluted supernatant was used as the source of 
the primary antibody.   
 
The results are shown in Table 5.7 and closely match the results of the 
immunofluorescence.  Corresponding with its weak immunofluorescence staining 
pattern, mAb-29B showed no reaction on variant 29, and so was not tested on all 
antigens.  Compared with the polyclonal antibodies, mAb-21A was able to 
activate complement and lyse the cells at a higher dilution. Agglutination assays 
were set up using mAb-21A, the results of which are shown alongside the CML 
results in Table 5.7.   
  
Chapter 5  256 
 
!"#$
%&'(%))%*$
+,-./0,$ +,-./12$
,3345$ 678$ 678$
$$ 9/:./$ !" !" !"
7
;)
<=
>$
%&
'(
%)
);
()
$ /0$ """#$#%&" """#$#%&" !"
/?<$ """#$#%&" """#$#%&" !"
/?-$ !" !" '"
/?>$ """#$#%&" """#$#%&" !"
/:$ """#$#%&" """#$#%&" !"
/1$ !" !" !"
@A./:$ """#$()"" """#$#%&" '"
"" 9/:.9$ !" !" '"
Table 5.7 Complement-mediated lysis and agglutination assays with monoclonal antibodies.  
‘Aggln’ = agglutination assay.  Reactions were performed and scored as with polyclonal 
antibodies (Table 5.4 and Table 5.5).  ‘X’ indicates no data for that antibody-VSG 
combination.  Note: following submission of the thesis, additional experiments were 
performed that revise some of the results presented in this figure.  Please see Appendix 
7.4.4 and 7.4.5 for details. 
 
In general, the mAbs gave a much more unambiguous result than the polyclonal 
antibodies, consistent with their specificity for a single epitope that is either 
present or absent. 
 
5.3.7 Behaviour of 23b-expressing trypanosomes was consistent 
with double expression 
The results of the 23b-expressing cell line superficially indicated that this VSG 
encoded a product antigenically distinct from those of the other Set_14 mosaic 
VSGs under investigation: antibodies raised against trypanosomes expressing this 
VSG showed no cross-reaction with any of the other cell lines by either 
immunofluorescence, complement-mediated lysis, or agglutination.  None of the 
mAbs that reacted with the other variants recognized 23b in 
immunofluorescence assays.  However, these patterns were not completely 
reciprocal: trypanosomes expressing 23b reacted to antibodies raised against 
other Set_14 VSGs, and, unexpectedly, to antibodies raised against VSG 427-4-
expressing trypanosomes. 
 
The fact that the antibodies raised against 23b were specific for 23b suggests 
this discrepancy was primarily due to the cells themselves, rather than a genuine 
example of VSG cross-reaction.  To test whether the cells were expressing any 
other VSGs besides the Set_14 mosaic under consideration, PCR was attempted 
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on cDNA produced from cloned cells87 using VSG-specific primers (as in section 
5.2.3.1).  As can be seen in Figure 5.10, the 23b-expressing cells clearly showed 
two distinct bands of between 1500 and 1700 bp.  One interpretation of this 
observation is that individual 23b-expressing cells were simultaneously 
expressing two different VSGs.  Besides increasing the number of epitopes 
exposed on the trypanosome surface, this may have made this trypanosome line 
especially fragile. 
 
 
Figure 5.10 Variant 23b-expressing clones were probably expressing an additional VSG.  
cDNA from lines expressing Set_14 variants 21, 23b and 29 was amplified using primers 
directed against the spliced leader and the VSG-specific 16-mer and the products separated 
on a 1% agarose gel.  The source of the template is shown at the top of each lane.  Template 
cDNA made from cells immediately after cloning (‘post-cloning’) and from cells after the 
complement-mediated lysis (‘post-CML’) and agglutination assays was used.  Arrowheads 
indicate the additional, unexpected bands in the 23b lanes. 
  
 
One model for the unexpected behaviour of 23b-expressing cells, drawing 
together all available evidence, is that the plasmids did not both correctly 
integrate in this line, leaving doubly-transfected cells expressing both 23b and 
an unknown endogenous Lister 427 VSG, ‘VSG X’.  The SDS-PAGE result and mass 
spectrometry suggested that if two VSGs were present, 23b was probably at least 
equally represented.  However, VSG X would still have been expressed on the 
trypanosome surface.  During the course of the antibody-production infections, 
trypanosomes multiplying rapidly without on-going drug selection may have 
switched to express a different VSG.  In one of the VSG 427-4-expressor 
infections, a trypanosome early on switched expression to VSG X, causing a 
                                         
87 The cDNA template was the same as that for the PCR analyses presented in Figure 5.3.  There 
was not sufficient time to reclone these cells, as the original clones were only obtained towards 
the end of the project. 
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strong antibody response to be raised against both VSG 427-4 and VSG X, 
producing the patterns of cross-reaction seen in the previous sections.  One way 
of testing this hypothesis would be to test all of the antibodies raised against a 
panel of endogenous Lister 427 VSGs.  Observing some occasional cross-reaction 
would be consistent with this model.  A complementary approach would be to 
show that antibodies verified to be specific to VSG 427-4 (perhaps mAbs) show 
no cross-reaction whatsoever with 23b. 
 
However, without further evidence either way, it is not possible to say whether 
23b is indeed antigenically distinct from the other Set_14 mosaics, as its lack of 
reaction may have been due to its co-expression alongside another VSG. 
 
As described in section 5.2.3, variant 05-27 also showed expression of non-
Set_14 mosaic VSGs.  The positive reaction of 05-27 with mAb-21A (raised 
against the verified variant 21 expressors) indicates that 05-27 is being 
expressed by most of these trypanosomes, and is cross-reactive with other 
Set_14 mosaics. 
 
5.3.8 Summary of experimental results: related mosaics can be 
antigenically distinct 
Table 5.8 shows a summary of all the experimental results presented in this 
chapter.  Figure 5.11 shows the Set_14 mosaics investigated in this chapter, 
arranged according to their antigenic relatedness.  Polyclonal 
immunofluorescence, complement-mediated lysis, and agglutination assays 
showed that the Set_14 mosaic variant expressed on day 29 of the infection of 
mouse 04 shared none of its epitopes with earlier-expressed variants 21, 23a, 
23c and 27.  These earlier variants share at least one epitope that was exposed 
on the intact surface coat, an epitope that was also present on a related mosaic 
from a different infection (05-27).   
 
From the same set of donors, mosaicism generated an antigenically novel variant 
(29) that did not cross-react serologically with those variants expressed earlier in 
the infection. 
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Table 5.8 Summary of serological analyses of Set_14 mosaic VSGs.  A summary of the results shown in Table 5.3, Table 5.4, Table 5.5, Table 5.6 and Table 5.7. 
‘I’ indicates the results of IFA on live cells, ‘C’ indicates the results of CML, ‘A’ indicates the results of agglutination, ‘I(f)’ indicates the results of IFA on 
acetone fixed cells.  For the immunofluorescence assays, ‘3’ indicates strong, eggshell-like fluorescence.  ‘2’ indicates strong fluorescence, but perhaps with 
a speckled appearance or posterior accumulation.  ‘1’ indicates patchy or weak fluorescence.  ‘-‘ indicates no signal.  For CML and agglutination assays, the 
score is given as the number of threefold dilutions still able to give a signal (that is, 1 = 1/6, 2 = 1/18, 3 = 1/54 and so on).  ‘X’ indicates that that particular test 
was not carried out with that antibody-VSG combination.  23b was omitted due to inconsistencies in VSG expression (section 5.3.7). The non-reciprocal cross-
reaction seen in the agglutination test with variant 29 is discussed in section 5.3.3.  Note: following submission of the thesis, additional experiments were 
performed that revise some of the results presented in this figure.  Please see Table 7.10 for an updated version, and Appendix 7.4.4 and 7.4.5 for details. 
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Figure 5.11 Variant 29 was antigenically distinct.  The diagrams of the different mosaic 
VSGs examined in this chapter (shown in Figure 5.1) have been rearranged according to 
antigenic cross-reaction.  The maximum variability amongst mature NTDs of the cross-
reacting group was 0.150 differences/aa (23a and 27), whereas the minimum variability 
between variant 29’s mature NTD and that of any member of the cross-reacting group was 
0.125 differences/aa (29 and 21). 
 
 
5.4 Structural analysis of distinct mosaics 
5.4.1 What amino acid differences were required for antigenic 
novelty? 
To study the relationship between amino acid sequence and antibody binding, 
the amino acid sequences of the mosaic VSGs were analysed in depth with 
reference to the experimental results, to ask the question: ‘what changes at the 
amino acid level abrogate specific antibody binding?’.   
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Working from the premise that the amino acid chains probably fold in a similar 
manner for all of the related Set_14 VSGs under investigation, the aligned amino 
acid sequences of the different variants were compared.  The alignment did not 
include any gaps.  Differences in amino acid residues between the VSGs were 
considered for each position in the alignment.  If a VSG that did not bind a 
particular antibody had a different amino acid from all of the antibody-binding 
VSGs at a given point in the alignment, the change could have contributed to the 
antibody’s inability to bind. 
 
The polyclonal antibodies showed reciprocal cross-reaction between variants 21, 
23a, 23c, 27 and 05-27.  Variant 29, which appeared in the same infection as 
variants 21, 23a, 23c and 27, did not bind antibodies raised against those 
variants; neither did those variants bind antibodies raised against variant 29.  
The differences contributing to variant 29’s complete antigenic distinctness 
were investigated by recording those positions in the alignment where variant 29 
was different from all of the cross-reacting VSGs.  Twenty-six such differences 
were found.  The positions of these differences in the amino acid sequence of 
the NTD are shown in Figure 5.12.  Variation associated with the abrogation of 
antibody binding was present in the more C-terminal two-thirds of the NTD.  The 
structural features of this region are considered further in section 5.4.2 below, 
and in Table 5.9. 
 
Figure 5.12 Residues contributing to variant 29 antigenic distinctness in the infection of 
mouse 04.  In a multiple sequence alignment of mature NTD amino acid sequences, 
positions where residues of the mature variant 29 NTD were different from all of variants 21, 
23a, 23c and 27 are shown in magenta.  As with the images of cDNA clones, the position of 
conserved cysteine residues (cysteines were in the same position for all Set_14 mosaic 
NTDs) are shown as bars protruding from the top of the diagram.  The underlined regions 
correspond with regions predicted to be exposed at the top of the molecule. 
 
 
A similar approach was employed to identify the likely epitopes of the mAbs.  
Monoclonal antibody mAb-21A gave a pattern of cross-reaction similar to the 
polyclonal antibodies raised against variants 21, 23a, 23c and 27, and the variant 
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expressed in the mouse 05 infection (05-27).  Because this mAb was able to bind 
to live trypanosomes, it is unlikely that the CTD contains its epitope (Schwede et 
al., 2011).  Positions in the alignment where all the antibody-binding VSGs had 
the same amino acid, but variant 29 (which did not bind the mAb) differed, were 
recorded.  The results, if just the NTD is considered, are shown in Figure 5.13.  
Was the mAb-21A epitope a linear one, these regions would be the strongest 
candidate for its location.  However, the epitope may be conformational, so it is 
impossible to draw any conclusions about its location without further 
experiments. 
 
Figure 5.13 Residues contributing to the mAb-21A epitope structure.  In a multiple sequence 
alignment of mature NTD amino acid sequences, positions where the variants that bound 
mAb-21A (21, 23a, 23c, 27 and the mouse 05 Set_14 variant 05-27) were identical to one 
another but different from the variant that did not bind mAb-21A (29) are shown in magenta.  
Figure is annotated as Figure 5.12.  Note: analysis of additional experiments, performed 
following submission of this thesis, produces a different figure.  Please see Figure 7.39 for 
an updated version, and Appendix 7.4.4 and 7.4.5 for details. 
 
 
 
Figure 5.14 Residues contributing to the mAb-21B epitope structure.  Positions where the 
variants that bound mAb-21B (21 and 23a) were identical to one another and different from 
the most similar variant that did not bind (23c) are shown in magenta.  Figure is annotated 
as Figure 5.12, with the positions of cysteine residues conserved amongst variants 21, 23a 
and 23c shown.  As mAb-21B could not bind to live trypanosomes, the entire mature VSG is 
shown, with a black bar separating the putative boundary between the N- and CTDs.  Note: 
analysis of experiments performed following submission of this thesis produces a different 
figure.  Please see Figure 7.40 for an updated version, and Appendix 7.4.4 and 7.4.5 for 
details. 
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Table 5.9 Amino acid substitutions associated with antibody escape.  Three tables show the 
amino acid substitutions associated with variant 29 antigenic distinctness (left, see Figure 
5.12), abrogation of mAb-21-A binding (middle, see Figure 5.13) and mAb-21-B binding 
(right, see Figure 5.14).  ‘Pos’ = amino acid position in mature NTD; ‘X-rct’ = identities of 
amino acids at those positions in cross-reacting antigens; ‘29’ or ‘23-c’ = identities of amino 
acids at those positions in the antigenically distinct antigens.  Emboldened rows 
correspond with positions predicted to be exposed on the top of the molecule.  Note: 
analysis of experiments performed following submission of this thesis produces a different 
figure.  Please see Table 7.11 for an updated version, and Appendix 7.4.4 and 7.4.5 for 
details. 
 
Monoclonal antibody mAb-21B gave a different pattern, binding just 21 and 23a, 
and then only in an acetone-fixed state.88  Comparing 23c, which didn't bind the 
antibody, with the two VSGs that did, it can be seen that just four differences at 
the amino acid level abrogated binding of this mAb.  These are shown in Figure 
5.14.  All these differences were located in the generally more exposed NTD, but 
                                         
88 Note that the findings presented in Appendix 7.4.4 and 7.4.5 would cause revision of much of 
this paragraph. 
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evidently affected an epitope that was made accessible when the coat was 
disrupted by acetone.  Differences at or near these positions were not 
consistently seen when comparing the antibody-binding 21 and 23a VSGs with 
any of the other non-antibody-binding variants 27 or 29, or 05-27 from mouse 05 
(data not shown).  That there is no specific region in which changes are 
necessary for antibody escape suggests that mAb-21B’s epitope is 
conformational, as changes to different parts of the molecule all have the same 
effect of abrogating antibody binding.  Although mAb-21B did not have any 
functional activity, the fact that just four amino acid changes could abrogate its 
binding is consistent with the finding that VSGs do not require many changes to 
their amino acid sequence to enable escape from individual antibodies (Baltz et 
al., 1991).  The amino acid substitutions associated with antibody escape are 
shown in Table 5.9.  Non-conservative changes to charged residues in the region 
of variant 29 predicted to form the exposed loops may underlie that variant’s 
antigenic distinctness. 
 
Neither of the variant 29-binding mAbs bound any of the other Set_14 variants.  
Compared with the cross-reacting Set_14 VSGs presented here, 29 is generally 
more distinct at the amino acid level (see Table 5.1).  The different results seen 
when performing immunofluorescence with the two different 29-specific mAbs 
on live cells suggests that there were two different epitopes, one of which was 
more exposed on an intact surface coat than the other. 
 
Considering the patterns of segmental contribution by the donor sequences in 
Figure 5.11, the antigenically distinct variant 29 was the only mouse 04 Set_14 
mosaic considered here that showed no contribution of donor 14-C (tryp_XI-
1034g11_assembly).  The region that 14-C contributed to the cross-reacting 
mosaics was replaced in variant 29 by two large segments from 14-A and 14-B.  
This difference may help explain the antigenic distinctness of variant 29.  
 
5.4.2 Changes associated with antigenic distinctness were 
located in the predicted N-terminal loops 
To speculate further on the effects that amino acid differences have on the 
structure of the mosaic VSG, structural prediction algorithms I-TASSER and 
PHYRE2 were used to predict the tertiary structure of the mosaic VSGs (Kelley & 
Sternberg, 2009; Zhang, 2008).  In essence, I-TASSER predicts the secondary 
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structure of the query sequence and uses this pattern to search a database of 
solved crystal structures for similar secondary structure patterns.  Each of the 
best matches from this search is used as a template to which the query sequence 
is fitted.  PHYRE2 uses PSI-BLAST to find putative templates, and thus depends 
more immediately on the amino acid sequence itself.  Predicted structures of 
Set_14 variants were attempted using both I-TASSER and PHYRE2.  When 
predicting structures, I-TASSER frequently identified the two solved VSG 
structures (MITat 1.2 and ILTat 1.24: PDB identifiers 1vsg and 2vsg respectively) 
as the best matches.  PHYRE2 was not able to predict a full structure based on 
automatic alignments alone.  However, if a solved VSG structure was specified 
(in this case, 1vsg), PHYRE2 was able to thread the amino acid sequence to this 
template.  The predicted structures of variant 29 are shown in Figure 5.15. 
 
Figure 5.15 Variant 29 structure predictions.  The three-dimensional protein structure for 
variant 29 dimers, as predicted by I-TASSER (Zhang, 2008) and PHYRE2 (Kelley & 
Sternberg, 2009), are shown.  For each structure, the two constituent monomers are 
coloured a different shade of green, with the cysteines of one chain coloured in yellow.  On 
each figure, each pair of cysteines that likely lie in close proximity to form disulphide 
bridges are indicated and connected by black lines.  Images were generated using Pymol 
(Schrödinger, LLC). 
 
There are considerable differences between the two predictions, particularly in 
the more disordered N-terminal loop region.  Furthermore, it is likely that both 
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of these structures vary from the actual three-dimensional structure of a Set_14 
VSG: while the query sequence was fitted to a type A VSG NTD (1VSG) for both I-
TASSER and PHYRE2, Set_14 mosaic VSGs have B-type NTDs.  No crystal structure 
has yet been solved for B-type NTDs, but the disulphide bridges formed by the 
conserved cysteine residues have been identified (Bussler et al., 1998).  Neither 
the I-TASSER nor the PHYRE2 models placed all of the disulphide-bridge-forming 
cysteines in close proximity, although PHYRE2 managed somewhat better than I-
TASSER.  The predicted structures must therefore be treated with caution.  
Nevertheless, even imprecise predictions are likely to be informative when it 
comes to the gross features of VSG structure: what parts of the sequence are 
likely to constitute the buried alpha helices and what parts of the sequences are 
likely to contribute to the exposed N-terminal loops (Blum et al., 1993).   
 
 
Figure 5.16 Predicted location of residues potentially contributing to variant 29 antigenic 
distinctness in the infection of mouse 04.  The residues identified in Figure 5.12 were 
indicated on the predicted structures of variant 29 in magenta. 
 
In what region of variant 29 are those changes associated with antigenic 
distinctness located?  Figure 5.16 shows the predicted structures of variant 29 
with those amino acids that are possibly associated with variant 29’s antigenic 
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distinctness highlighted (that is, those differences shown in Figure 5.12).  As can 
be seen in the figure, these differences are located primarily in the N-terminal 
loops of the predicted structure.  It is in this part of VSG that forms the most 
immediate interface with the immune system, and where, to date, most 
epitopes have been identified (Hsia et al., 1996).  The differences associated 
with variant 29’s antigenic distinctness therefore likely occur in a part of VSG 
that interacts directly with antibodies, consistent with their role in abrogating 
antibody binding. 
 
 
Figure 5.17 Predicted location of residues contributing to mAb-21A binding.  Predictions of 
variant 21’s three-dimensional structure were made using I-TASSER and PHYRE2 as with 
variant 29 (Figure 5.15).  The residues identified in Figure 5.13 were indicated on the 
predicted structure in magenta.  Note: analysis of experiments performed following 
submission of this thesis produces a different figure.  Please see Figure 7.41 for an updated 
version, and Appendix 7.4.4 and 7.4.5 for details. 
 
Predictions of variant 21’s three-dimensional structure were also made, and the 
putative mAb-21A and mAb-21B epitopes described in section 5.4.1 were 
investigated.  These are shown in Figure 5.17 and Figure 5.18.  Consistent with 
its ability to bind live trypanosomes, differences associated with the abrogation 
of mAb-21A binding were predicted to occur predominantly at the membrane-
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distal N-terminal loops of the VSG.  For mAb-21B, which was unable to bind to 
live trypanosomes and likely binds a conformational epitope, three out of four 
differences associated with variant 23c being unable to bind the antibody 
occurred at positions expected to form exposed surface loops.  The more 
membrane-proximal position,89 which may be less accessible in a live surface 
coat (especially to an IgM antibody), probably makes a greater contribution to 
the epitope structure in this case.   
 
 
Figure 5.18 Predicted location of residues contributing to mAb-21B binding.  The residues 
identified in Figure 5.14 were indicated on the predicted structures of variant 21 in magenta.  
Note: analysis of experiments performed following submission of this thesis produces a 
different figure.  Please see Figure 7.42 for an updated version, and Appendix 7.4.4 and 7.4.5 
for details. 
 
5.5 Discussion 
5.5.1 Key finding of this chapter 
In this chapter, the products of related mosaic VSGs that had appeared in the 
same chronic mouse infection were analysed serologically to test the null 
                                         
89 For variant 23c, the change at this position was non-conservative (threonine to alanine). 
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hypothesis that they were antigenically indistinguishable.  Immunofluorescence, 
complement-mediated lysis, and agglutination assays all showed that a mosaic 
variant that had appeared later in the chronic mouse infections was completely 
serologically distinct from related variants appearing earlier in that infection.   
 
The same set of related donor VSGs was therefore able to combine in various 
ways through mosaicism to produce more than one antigenically distinct variant.  
Mosaicism is capable of contributing directly to antigenic variation during an 
infection. 
 
5.5.2 Further experiments 
This study has identified at least one epitope amongst a set of mosaic VSGs that 
changes over the course of a single infection.  Additional experiments could be 
carried out to further validate these results.  For example, a Western blot using 
the mAbs would verify that they do indeed bind to the variant band seen in the 
SDS-PAGE.  Transmission electron microscopy of the transgenic cell lines would 
show whether these lines are in fact able to produce the dense layer of VSG that 
is characteristic of the surface coat.  Immuno-gold labelling would conclusively 
demonstrate that the mAbs raised do indeed bind to the coat itself. 
 
An expanded palette of mAbs would be invaluable in dissecting the epitope 
structure of mosaic VSGs.  In particular, mAbs directed against other Set_14 
variants (besides variants 21 and 29), and additional mAbs targeting exposed 
epitopes, could be used to indirectly map the number of different VSG epitopes 
and how they change over the course of an infection.  If the screening approach 
used live cells (either through immunofluorescence as described in section 
5.3.1.1, or by complement-mediated lysis), rather than acetone-fixed ones, 
generation of mAbs with functional relevance would be favoured. 
 
In the case of the Set_14 mosaics, structural analyses could reveal the extent to 
which segmental gene conversion affects the form of the expressed antigen, and 
would throw more light on its effects on epitope structure.  Co-crystallisation of 
the mosaic VSG with the mAb antigen-binding fragment could be carried out 
alongside, to specifically show the epitope(s) involved. 
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In the longer term, improving the reliability and throughput of the expression 
system would enable a variety of experiments.  A one-step transfection 
approach (replacing the telomere-proximal VSG 427-2 with a defined exogenous 
VSG) would make the process of generating transgenic lines both quicker and 
easier.  Linking exogenous VSG expression with a fluorescence gene like GFP 
would provide an easily detectable proxy for expression of the expected surface 
coat, providing a quick way of confirming correct VSG expression and increasing 
the confidence with which VSG-binding antibodies are identified.  The scope of 
this analysis could then be easily expanded to include other mosaic sets. 
 
In essence, a refined VSG expression system could ultimately be a way of 
creating a stable ‘snapshot’ of the antigenic profile of what is naturally a 
constantly changing trypanosome population.  This would allow the researcher to 
experimentally define the parameters that affect the composition of a 
trypanosome population, that is, identify and quantify the forces that influence 
antigenic variation in the dynamic in vivo population. 
 
5.5.3 Concluding remarks 
The experimental results reported in this chapter show that in an infection, 
related mosaics—expressed VSGs formed from the same set of donor genes—can 
be antigenically distinct.  These results demonstrate a functional role for 
segmental gene conversion during a chronic infection.   
 
With such a large archive of silent VSG genes, what could mosaicism contribute 
to the broader survival strategy of African trypanosomes?  In the following 
chapter, the findings reported here will be evaluated with regards to the key 
findings of Chapters 3 and 4, and previous work. 
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6 Discussion 
6.1 Introduction 
This research set out to assess whether segmental gene conversion plays a 
prominent role in changing the antigenic profile of the trypanosome population 
over the course of an infection.  The general pattern of antigenic variation 
consists of three steps: generation of diversity, expression of diversity, and 
success of diversity under selection.  For African trypanosomes, beginning each 
infection with a large, diverse antigen archive, we might naively have 
considered Trypanosoma brucei antigenic variation within a host as being solely 
a question of expression: what specific archive VSGs are expressed, and when 
they appear.  The large degree of archive pseudogeny hinted that this may not 
be the case, and the results presented here suggest that VSG expression goes 
hand-in-hand with generation of VSG diversity. 
 
The key findings were:  
(i) There was a diverse range of antigens expressed during infection:  
Relatively short infections, lasting 4–5 weeks, can show the expression 
of a large number of different VSGs.   
(ii) Expressed VSG diversity was generated during infection:  Segmental 
gene conversions can introduce diversity that did not exist in the 
genome at the start of infection, with a limited number of donors 
forming large ‘sets’ of mosaic VSGs.   
(iii) Mosaics were antigenically distinct:  VSG diversity produced over the 
course of infection by segmental gene conversion has functional 
relevance in the evasion of adaptive immune responses.   
These findings will be discussed in the broader context of African trypanosome 
biology and general pathogen survival strategies. 
 
6.2 Population diversity during infection 
6.2.1 ‘Diversity’ comprises species richness and species 
evenness 
The notion of ‘diversity’ is multifaceted.  Diversity is an important aspect of 
ecological investigation, as scientists attempt to quantify the effects of various 
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environmental changes on wildlife populations.  Broadly, species diversity breaks 
down into two independent components: species richness (the total number of 
different species present) and species evenness (the difference in abundance 
between the species present) (Hill, 1973).  These concepts are further 
complicated by relatedness between species—many different but similar species 
might be considered a less diverse population than a population of fewer, more 
distinct species (Leinster & Cobbold, 2012).  Both richness and evenness function 
in African trypanosome antigenic variation, and these will be considered first in 
sections 6.2.2 and 6.2.3, before moving on to discuss relatedness in section 6.3. 
 
6.2.2 Antigen richness in trypanosome infections is probably 
related to weak immune selection and the dominance of 
differentiation-dependent control 
There is much ‘antigen richness’ in the data presented here.  Even in those 
samples where only one distinct variant was detected, it does not seem unlikely 
that many other sets were present in that host’s blood at that time, beneath the 
limit of detection.  How does this pattern come about, and how does it 
contribute to the African trypanosome's survival? 
  
The observation of many different variants at the same timepoint could be due 
to a low rate of clearance of old variants, and/or a high rate of activation of 
new variants.  With this host-parasite combination there is evidence for both 
these processes.  The mouse sustains a large number of parasites with TREU927 
relative to its size: if the parasitaemia is estimated at ~107 ml-1, the total 
population is ~2 x 107 parasites, approximately 1 x 109 parasites per kg of body 
mass90.  This varies between hosts: cattle, for example, may have a much lower 
parasitaemia, usually between 1 and 100 parasites per ml, suggesting a total 
population of up to 2 x 106 parasites, approximately 6 x 103 parasites per kg of 
body mass91 (L. Morrison, PhD Thesis (2004)).  All things being equal, mice have 
fewer immune effectors and less lymphoid tissue per parasite than is the case 
with most other hosts (La Greca & Magez, 2011; Morrison et al., 2005).  In 
addition, defined mechanisms of immune suppression mean that particularly in 
the later stages of infection, mice probably exert only very weak immune 
                                         
90 Assuming a mouse body mass of 20 g and a blood volume of 2 ml. 
91 Assuming a cow body mass of 320 kg and a blood volume of 20 L, and rounding to one 
significant figure. 
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selection, if at all (Radwanska et al., 2008).  That the parasitaemia did not 
generally peak and trough over the course of infection (although see section 
6.2.5, below) is consistent with the premise that density-dependent 
differentiation is the main influence on the size of the parasite population in this 
mouse model (MacGregor et al., 2011).   
 
Maintaining a large parasite population also favours the occurrence of rarer VSG 
activation events in the population, and by keeping their numbers below the 
threshold for inducing immune responses, density-dependent differentiation 
promotes the persistence of these expressors (Gjini et al., 2010).  A back-of-the-
envelope calculation, estimating a generic switch rate of 10-3 per parasite per 
generation (Turner & Barry, 1989), a generation time of 6 hours (Turner, 1990) 
and a population of 107 parasites for 30 days gives a figure of 1.2 x 106 switch 
events.  This is certainly an overestimate (accounting neither for parasite death 
nor for non-proliferative non-switching stumpy form trypanosomes) but it does 
not seem unreasonable to reckon that the total number of switches in the 
parasite population within each of these infections is at least in the thousands.  
Antigen richness in the parasite population might therefore be expected, as 
might the persistence and reappearance of antigens. 
 
How relevant is the observation of antigen richness to other host-parasite 
combinations?  The later stages of infection are generally underrepresented in 
the data.  The observations of Capbern et al., (1977), who identified antibodies 
against as many as 98 different VATs over 45 days of T. equiperdum rabbit 
infections, make the 31 sets observed in mouse 04 over 10 days not excessive.92  
Through its carrying capacity and rate of immune response, the host species 
could affect the antigen richness of the parasite population, as could parasite-
intrinsic factors such as the activation probabilities of its VSG genes (Barry, 
1986; Gjini et al., 2010).  Still, barring exceptional circumstances, the textbook 
figure showing sequential, homogeneous parasitic waves is certainly a misleading 
oversimplification.   
 
A study conducted on Borrelia burgdorferi encountered similar non-saturating 
diversity amongst antigenic variants cloned from an infection (Coutte et al., 
                                         
92 Rabbits also have a substantially lower total carrying capacity than do mice. 
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2009).  Extreme antigenic richness may therefore be a factor common to many 
antigenically variable pathogens in their pre-emption of specific immune 
responses. 
 
6.2.3 Polyclonal VSG activation may play a role in infection 
dynamics 
‘Antigen evenness’ refers to the relative abundance of the different variants in 
the population.  A variant’s activation probability could affect its relative 
abundance both through the normal dynamics of a peak (when a variant is 
activated for the first time, the population expands until it is subsequently 
controlled and cleared), and through convergent switching (higher activation 
probability encourages different parasites to convergently switch to a variant).  
In the mouse model, where density-dependent factors may control the parasite 
population (MacGregor et al., 2011), switching to a novel variant is often not 
advantageous: switchers will not be able to rapidly expand in a clonal manner, 
as the population is already saturated.  Convergent switching may therefore play 
the more important role in determining the dominance of a particular antigen 
type.  When the immune system eventually removes a dominant variant, space is 
left for a subpopulation to expand.  A polyclonal variant subpopulation, made up 
of multiple convergent switchers, has a greater ‘head-start’ over other variant 
subpopulations (that are not so easily switched to), so even if those other 
variants have appeared in the population they are crowded out by the polyclonal 
expansion of the convergently-formed VAT (Lee & Van der Ploeg, 1987; Timmers 
et al., 1987).  The number of related VSGs with different 3’ donations reported 
in Chapter 4 might indicate convergent switching, representing a specific VSG 
that has undergone different conversion events to become activated (Michels et 
al., 1983)  
In this context it is interesting to note that Plasmodium falciparum var genes 
have a convergent switching hierarchy.  For each clone, switching is directional, 
and a particular var variant switches via one of several possible second 
‘intermediate’ variants to a third variant (Recker et al., 2011).  This ‘single-
many-single’ switching pattern is proposed to be an advantageous compromise 
between protecting the archive and maximising the switching options of an 
individual, and thus is better able to cope with encountering a non-naïve host.  
Such a highly structured pattern may be particularly necessary for P. falciparum, 
Chapter 6   276 
 
as its var archive is substantially smaller than that of the African trypanosomes 
VSG archive (~60 vs. ~1600 (Kyes et al., 2007; Marcello & Barry, 2007a)) 
For trypanosomes, convergent switching observed here is a population-level 
effect, and therefore it is unlikely that it represents anything more than an 
aspect of the switching hierarchy.  Its ultimate effect on the outcome of 
infection would be inconsequential in most cases, but its occurrence may have 
implications for our understanding of activation probabilities (activation 
probabilities may be greater than appreciated) and infection dynamics (VATs 
may frequently be polyclonal).   
 
6.2.4 Hierarchy is robust, but further knowledge of later switching 
mechanisms is required 
Despite observed antigen richness, expression of diversity is evidently 
controlled: given that potentially thousands of switches could occur, ‘only’ 83 
different sets were detected over all 22 infections analysed, and their 
appearance varied over time with both early and late variants distinguishable.  
At a gross level, the timing of appearance of a VSG set was associated with its 
putative genomic location, consistent with previous studies (Morrison et al., 
2005; Robinson et al., 1999).  On the other hand, that some sets represent 
damaged genomic copies while some intact genomic copies are not detected at 
all suggests that ‘ease of activation’ is not appreciably affected by intactness, 
discussed in further in sections 6.4.2 and 6.4.4. 
 
The occasional re-expression of some early-appearing genes in the later stage of 
infection is consistent with the tendency of strains to revert to their original 
antigen type following passage (Gray, 1965), as these genes have apparently high 
activation probability.  Turner (1999) made a distinction between ‘real’ and 
‘effective’ switch rates to highlight this occurrence, predicting that ‘effective’ 
switch rates decrease as infections progress.  If early VSGs do indeed have a 
greater activation probability, and the mouse is capable of only weak immune 
selection, why was this not observed more often?  It could be that as array genes 
become involved in ‘stage 2’ antigenic variation (see section 6.2.5), VSG specific 
homologies become a more important determinant of activation probability (that 
is, the switch-off VSG affects the switch-on VSG).  As a mechanism, switch rates 
changing relative to the VSG that is expressed has been proposed in the context 
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of mosaic VSGs by Pays et al. (1985a).  This relativism could also include 3’ 
donation or even VSG-specific UTR flanks (discussed further in section 6.4.4).  
Relativistic switching would minimise unproductive switching to ‘early’ VATs, 
and thus would have particular relevance later in infection.  Detailed 
examination of 3’ donation and flanking regions may increase our understanding 
of the genetic mechanisms underlying hierarchy, shedding more light on the 
events that come to the fore after the early stage of infection.   
 
6.2.5  ‘Stage 2’ antigenic variation may become the ‘new normal’ 
as early VSGs expire 
The later stages of infection were associated with several characteristic features 
when compared with the earlier stages: 
a) Greater levels of within-set variation: a lack of 3’ donation and 
mosaics. 
b) Greater numbers of identifiable array VSGs corresponding with the 
sets. 
c) Disappearance of earlier-occurring sets (Set_08, for example). 
d) Elevated level of parasitaemia. 
e) Follows a deep trough in parasitaemia—a population crash. 
These patterns have been referred to as ‘stage 2’ antigenic variation93 (L. 
Marcello, Ph.D. thesis, 2006, University of Glasgow). 
 
One explanation for these phenomena is that the host has finally raised 
productive immune responses against all the easily-accessible ‘early’ variants.  
As those trypanosomes are destroyed, subpopulations of variants activated less 
easily, previously suppressed by density-dependent differentiation, can 
proliferate and rise to pre-eminence.  This shift in expression marks a distinct 
change in the use of the archive, and the appearance of array genes is 
coincident with an increase in within-set variation of mosaics and 3’ donations.   
 
Is ‘stage 2’ antigenic variation the ‘new normal’ as the infection progresses?  
The shift occurs approximately two weeks before the mouse mean time of 
death, so it is impossible here to separate ‘stage 2’ antigenic variation from the 
                                         
93 Not to be confused with second-stage sleeping sickness, when parasites invade the central 
nervous system. 
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terminal stages of trypanosomiasis.  Conceptually, the parasitaemia up to the 
crash might represent the first ‘peak’, that is, the switching between and 
eventual exhaustion of a block of VSGs ‘between which switching occurs rapidly’ 
(Gjini et al., 2010).  In larger hosts, where the kinetics of antigenic variation are 
accelerated (Barry, 1986), the exhaustion of the initial ‘block’ would occur more 
rapidly, and ‘stage 2’ antigenic variation would assume prominence for the rest 
of infection.  If the infection lasted long enough, there may be further stages, 
perhaps corresponding with groups of even less accessible archive VSGs.  
Investigating VSG expression with relation to the genome in a range of hosts may 
provide data to complement this study, helping to dissect these patterns.   
 
6.2.6 Easily-accessible VSGs may help an invading population 
form a ‘bridgehead’ 
If the later stage is the normal state of infection, why have an early stage of 
infection at all?  The possible risks associated with segmental gene conversion 
(outlined in section 6.4.8) might make it advantageous for the trypanosome 
population to build up numbers in the new host, forming a ‘bridgehead’.  
Analogous patterns have already been characterized in metacyclic trypanosomes 
present in a tsetse fly’s salivary glands, which show heterogeneity in expressed 
MVSGs, pre-empting circulating immunity when they are deposited during tsetse 
fly feeding (Barry et al., 1998).  By coming equipped with a number of easily-
accessible, functional VSGs, the initial bloodstream form population can 
proliferate and begin antigenic variation without having to rely on riskier 
recombination events.  During this period, there are abundant opportunities for 
members of the population to attempt more risky, low probability segmental 
switching events, forming a population to initiate ‘stage 2’ antigenic variation 
(section 6.2.5).   
 
Having easy access to a set of functional VSGs would also be more competitive in 
the early stages of mixed infections, particularly where differentiation controls 
parasitaemia, as described in section 6.4.8.  Strain-specificity in this ‘block’ of 
VSGs could be easily developed, by direct exchange between ES and telomere 
for example, allowing reinfection or superinfection of partially-immune hosts.  
VSG expression and infection progression is summarized in Figure 6.1. 
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Figure 6.1 VSG expression and the progress of infection.  In this simplified model, the three 
subsets of genomic VSGs—metacyclic, ‘bridgehead’ and archive—are shown at the top.  As 
the infection progresses, different parts of this repertoire are used.  The infecting 
metacyclic trypanosomes express a range of metacyclic VSGs, allowing them to overcome 
previous immunity.  Over the next few days they switch to the telomere-proximal, 
‘bridgehead’ VSGs.  This easily-activated ‘intermediate’ subset allows the trypanosome 
population to outcompete strains that progress too rapidly to inefficiently-activated (and 
mostly pseudogenic) subtelomeric archive VSGs.  Progression to array VSG expression has 
occurred by c. 20 days later (Morrison et al., 2005) and is frequently accompanied by 
segmental gene conversion events that can both open up the wealth of archive diversity 
and generate variability in the process.  The ‘bridgehead’ (and indeed the metacyclic) VSG 
population can be replaced, perhaps via gene conversion from the expression site as 
indicated, a process that could develop strain-specificity and facilitate re- or super-infection 
of subsequent hosts. 
 
 
6.3 The patterns of generated diversity 
6.3.1 Expressed VSGs were frequently different from their donors 
and were often unique 
When comparing expressed VSGs between infections and with the genome, 
patterns of within-set variation were clear: point mutations, 3' donation, and 
mosaicism.  Only five clones matched their corresponding genomic copy exactly.  
Each of these patterns will be discussed, before a broader discussion on the 
consequences of infection-generated diversity for African trypanosome antigenic 
variation. 
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6.3.2 Point mutations are probably a minor process in antigenic 
variation within a host 
Point mutations were detected between related VSGs within an infection.  
Although there was not time to measure directly the degree to which they were 
artefactual, calculations and comparisons indicated that most of them were 
genuine.  Despite this, there was no evidence that point mutations were 
contributing to antigenic variation directly: non-synonymous mutations were not 
especially favoured, and they did not tend to accumulate in parts of VSG 
associated with antigenic variation.  Partly, this could be due to convergent 
switching alongside weak immune selection on the part of the host, and the 
crowding out of point mutation variation by more substantial between-set 
variation and mosaicism.  It is possible that point mutation has a more important 
role when access to diversity is limited: when more substantial switch events are 
disallowed, point mutations in VSG are demonstrably able to abrogate the 
binding of specific monoclonal antibodies (Baltz et al., 1991; Lu et al., 1994).  
Would this often occur in real infections?  Few pathogens generate sufficient 
antigenic variability to maintain a chronic infection from point mutations alone: 
those that do are viruses, able to exploit a latent phase and accumulate 
mutations in the absence of constant immune selection (Bowen & Walker, 2005; 
Wolinsky et al., 1996).  In T. brucei, point mutations have not been able to 
confer resistance to physiologically relevant polyclonal antibodies, as antibody 
responses against VSG are too broad (Graham & Barry, 1996).  Furthermore, 
given the apparent ease with which segmental gene conversion occurs (section 
6.4.2) it is implausible that African trypanosome antigen variability routinely 
becomes so restricted that they come to rely on point mutations for persistence 
within a host.   
 
Nevertheless, point mutations could play an important role in the long-term 
diversification and therefore survival of African trypanosomes in a host 
population, similar to the process of antigenic drift by influenzavirus (Boni, 
2008), and may be a useful mechanism to build up strain specificity (Hutchinson 
et al., 2007). 
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6.3.3 Segmental gene conversion is a frequent occurrence in 
antigenic variation 
As a means of generating an expressed VSG, segmental gene conversion is 
sometimes characterized as an ancillary process, only undertaken by ‘desperate’ 
parasites to make the best of a ‘damaged’ archive or to drag out an infection 
when the host has developed immunity to the products of intact archival genes 
(Barbet & Kamper, 1993; Barry, 1997).  The chronic mouse infections described 
in Chapters 3 and 4 produced an abundance and variety of segmental gene 
conversion events.  If these events are indeed genuine (for reasons of time they 
could not all be verified by PCR) this pattern is inconsistent with both of these 
models.  A subsidiary role for segmental gene conversion does not explain the 
rapid appearance of mosaics (within 3 weeks of infection), the range of mosaic 
diversity seen within a single infection (15 distinct variants) or the evidence for 
mosaicism in 28 out of 83 sets analysed, including between ‘functional intact’ 
donor genes.  That the finer-grain ‘within-set’ variation of segmental gene 
conversion is clear amidst complete ‘between-set’ variation suggests segmental 
gene conversion is a principal aspect of T. brucei antigenic variation.  How do 
related-but-different mosaics and 3’ donations observed here affect our 
understanding of the mechanics of T. brucei segmental gene conversion?  What 
are their roles in antigenic variation, and how might they contribute to the 
trypanosome’s survival and continuing evolution? 
 
6.3.4 3’ donation is akin to variable region cassette exchange  
The 3’ donation events for which donors could be found are consistent with a 
model whereby the 3’ end of recombination occurs within the CTD-encoding 
region of the resident VSG, as many of the 3’ donors identified were probably 
telomere-proximal.  Therefore, just the variable region of the telomere-
proximal VSG is replaced, and the region encoding the structural CTD is 
(partially) conserved.  In this way, 3’ donation is akin to the use of variable 
region cassettes by numerous antigenically variant bacteria: N. gonorrhoeae pilE 
and A. marginale msp2, for example (Vink et al., 2011).  Possessing just a single 
copy of a conserved region is an efficient use of genomic space, and prevents 
deleterious mutations, fixed by genetic drift, from precluding expression of a 
variable region.  If 3’ donation is able to efficiently exchange domains in T. 
brucei, why are there so many VSG CTDs in the archive?  The mechanism of gene 
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conversion may demand a region of homology in the 3’ flank that is routinely 
provided by the CTD-encoding region, and it is possible that variability in the 3’ 
flank of recombination, which overlaps part of the VSG CTD-encoding region, 
plays a role in determining activation probabilities of VSGs, as it does in B. 
hermsii Vsp/Vlp (Barbour et al., 2006).  Comparisons between T. brucei, T. 
congolense, and T. vivax suggest that CTD exchange evolved only in the T. 
brucei line, whereas VSG diversity is ancestral (Jackson et al., 2012).  It is 
therefore possible that archive CTDs are degraded relics that have freely 
accumulated mutations in the absence of their expression (Taylor & Rudenko, 
2006). 
 
6.3.5 Are mosaics built up progressively? 
What do the observed patterns of mosaicism tell us about the development of 
mosaics?  The current model holds that sequential segmental gene conversion 
events progressively build up in an expression site VSG to form a ‘string’ of 
related mosaics (Barry et al., 2005).  This is analogous to the mechanism seen in 
Anaplasma, where later msp2 variants showed more complex patterns of 
segmental conversions (Futse et al., 2005; Palmer et al., 2007).  Evidence for 
such a model of ‘progressive mosaicism’ was found in two sets where it appears 
that some mosaics have accumulated more segments than others (section 4.5.8).  
However, other mosaic lineages are less clear, showing either no direct 
relationship between sequentially-expressed mosaics, or an apparent decrease in 
complexity (the apparent number of segmental gene conversion events required 
to produce the mosaic) over time.   
 
Given the antigenic richness of the large parasite population alongside weak 
immune selection (discussed in section 6.2.2), it is likely that the lack of 
evidence for progressive mosaicism reflects difficulties in isolating an individual 
mosaic string.  Perhaps it is only once a mosaic has stably formed that the 
parasites expressing it grow to great enough numbers to be detected, and once 
there, these mosaic expressors dominate and persist in a similar way to non-
mosaic sets described in Chapter 3.  Furthermore, a mosaic string may indeed 
become increasingly complex as an infection progresses, but without a potent 
immune response rapidly removing those variants that have not changed, the 
more complex variants will remain rare and hard to detect, particularly in an 
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infection controlled by differentiation.  Meanwhile, within the parasite 
population, other parasites may reactivate the first donor, which then embarks 
on a new process of segmental conversion and mosaicism, forming a parallel 
lineage.  Deeper, more frequent sequencing may be necessary to better witness 
longitudinal development of mosaic strings in an infection.  It may also be that 
‘complexity’ is a poor metric—for some sets apparently simple mosaics might 
require the interaction of donor sequences that do not so readily combine. 
 
6.3.6 Mosaics appear quickly 
How quickly are mosaics made?  Some expressed mosaics are complex, with as 
many as eight distinct segments, and are detected as early as day 21.  It is 
therefore unlikely that the addition of a segment occurs at the background 
switch rate of maximally 0.01 per cell per division (Turner & Barry, 1989), since 
on average only one segment would be added every ~1.5 days (assuming a 
doubling time of six hours and that all segmental conversion events are 
successful) and require a large number of predecessors in the lineage to provide 
sufficient substrate for segmental conversion to occur.  The number of diverse 
mosaics identified in a given infection, coupled with the lack of predecessors 
detected in previous samples of that infection, suggests that segmental 
conversion occurs much more rapidly.  One possibility is that mosaics can be 
‘nucleated’: once an initiating donor VSG is present in an expression site, other 
donors can contribute easily thanks to extensive sequence homologies (Pays et 
al., 1985a).  It is also possible that the RAD51-independent recombination 
pathway that is the most promising candidate for driving segmental 
recombination occurs at a higher rate in pleomorphic cells than in the 
monomorphic lines in which it was characterized (Conway et al., 2002). 
 
In Borrelia burgdorferi antigenic variation, ‘intermittent recombination’ has 
been reported, where replication apparently ‘skips’ back-and-forth between 
templates to produce a multiple-segmented mosaic, possibly in one step (Coutte 
et al., 2009).  Interestingly, intermittent recombination was found to occur 
more readily in a mutant lacking a component of the replication machinery, 
RuvA helicase, involved in Holliday junction resolution (Lin et al., 2009a).  It is 
possible that a similar process could occur in T. brucei, helping to produce some 
of the multiply-segmented VSG mosaics here. 
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6.3.7 Mosaics are formed from similar donors but junctions do 
not require much identity 
Regardless of the speed at which complex mosaics are formed, there is a clear 
preference for using homologous donors.  The maximum divergence between 
donors observed here was 0.269 differences/nt (that is, 73.1% identity), so it 
remains the case that all mosaics identified to date are formed from donors of 
the same VSG ‘family’.  Homology between donors may reflect structural 
demands—perhaps combinations of more variant donors do not form a stable VSG 
fold.  Alternatively, and more likely, it might reflect the mechanics of 
recombination: segmental gene conversion between more diverse donors is 
disfavoured by the recombination machinery, even though it could produce a 
functional VSG.  It would be interesting to test these options, by artificially 
producing non-homologous mosaics and attempting to express them in 
trypanosomes.   
 
Despite general homology across their whole length, mosaic gene conversion 
does not occur in regions of extensive identity.  For some junctions, there was 
no region of complete identity between sequences, and the size of some 
converted segments was very short.  This is in common with Neisseria 
gonorrhoeae and B. burgdorferi, where regions of identity at a junction can be 
short and segments small (Coutte et al., 2009; Criss et al., 2005).  Nonetheless, 
in these pathogens too, donors show homology with one another.  In A. 
marginale, segmental gene conversion occurs in a variable region between 
conserved flanks (with a boundary of recombination ‘anchored’ in one, the 
other, or both flanks) (Futse et al., 2005; Meeus et al., 2003), and in B. 
burgdorferi, invariant regions in the expressed antigen are shared amongst 
donors (Zhang et al., 1997).  Some homology between donors may be necessary, 
aligning them and preventing disorderly and inexact segmental gene conversion 
from introducing radical changes into the expressed VSG (such as large additions 
or contractions, or changes to the number or spacing of critical cysteine 
residues), or from mis-directing recombination elsewhere.  Shorter conversion 
events in parts of the gene that varies between donors would generate greater 
diversity than longer conversion events that require identical flanks.  That 
segmental conversion events do not seem to concentrate in one part of the VSG 
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gene is also consistent with the premise that segmental gene conversion is 
broadly an undirected process.   
 
The appearance of identical mosaic junctions in different infections is intriguing, 
but further work is required to confirm it is more than an artefact or an 
exception.  It would be interesting to examine whether there are indeed specific 
segmental conversion events that occur more readily between donors, as this 
might show that there is more structure to T. brucei segmental gene conversion 
events than is currently reckoned.    
 
The need for homology has some important consequences.  As only 40% of VSGs 
are in families (Marcello & Barry, 2007a), does this mean that mosaicism is 
restricted for most archive VSGs?  Certainly, if non-family VSGs are able to 
interact it is at a much lower rate than that between family VSGs, and so would 
appear much later on, if at all.  3’ donation hints that lower-homology 
interactions are still possible, although these may not involve the same 
recombination machineries.  If homologous donors are favoured in mosaic 
interactions, does this restrict the diversity that mosaicism can introduce?  This 
question is addressed in sections 6.4.5 and 6.4.6 below.   
 
6.4 The role of generated diversity 
6.4.1 With such a large archive, why does T. brucei need 
segmental gene conversion? 
If segmental gene conversion is indeed an integral mechanism, it means that 
expressed VSGs are frequently different from all of the silent archive VSGs.  This 
is not exceptional amongst antigenically variant pathogens—indeed, only 
Plasmodium and Giardia appear to have mechanisms whereby antigens do not 
routinely segmentally recombine during an infection (Prucca & Lujan, 2009; 
Scherf et al., 1998).  However, most segmentally-recombining pathogens have 
only small archives,94 and therefore depend on combinatorial diversity for 
antigenic novelty.  For African trypanosomes, which possess an archive of silent 
genes unequalled in size, what might be the advantages of a dysjunction 
between archive and expression?  This question is all the more important given 
                                         
94 Babesia bovis, with ~350 silent ves1-! and ~80 ves1-" constitutes another exception (Brayton et 
al., 2007). 
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the potential for error that segmental gene conversion brings to the process: the 
dangers of introducing frameshifts and stop codons must be overcome or 
accommodated for it to be a stable strategy.   
 
There are four possible advantages of a dysjunction between archive and 
expression, which can broadly be described as Reparation, Relaxation, Hierarchy 
and Variation.  These are discussed in the following sections. 
 
6.4.2 Segmental gene conversion can repair damaged VSGs 
Evidently, with an archive where the majority of silent VSGs are otherwise 
unusable, segmental gene conversion provides a means for their reparation.  
Sixteen of the 28 mosaic sets utilized segments from a total of 24 damaged 
genomic copies, and 26 of the 47 sets showing 3’ donation corresponded with 
genomic copies with damaged C-terminal domains.95  Altogether 53 out of the 91 
genomic VSGs used were damaged.96  Utilization of pseudogenic donors was 
previously shown for the mosaics and 3’ donations described by previous studies 
(Aline et al., 1994; Barbet & Kamper, 1993; Roth et al., 1989; Thon et al., 
1989).  It would be interesting to see whether T. congolense and T. vivax, both 
of which have a greater proportion of non-pseudogenic archive VSGs (Jackson et 
al., 2012), show a similar degree of segmental gene conversion.  If reparation is 
the main advantage of a disjunction, they might be expected not to.   
 
Reparation of damaged VSGs can be clearly observed as a consequence of 
segmental gene conversion.  Yet segmental gene conversion also occurs to 
undamaged VSGs, or to parts of a damaged VSG that are not damaged, and it 
generates extensive variability in the process.  Segmental gene conversion may 
also generate damage, through out-of-frame recombination (in this study, one 3’ 
donation event rendered an atypical VSG dysfunctional).  The supposed 
advantages of archive reparation as a factor driving segmental gene conversion 
also begs the question: if the expression of damaged archive genes is so 
important, why not have a wholly intact archive in the first place?  Is it simply 
that selection on each individual VSG for functionality is so low that they drift 
                                         
95 This figures includes 11 ‘atypical’ VSGs, whose functionality is uncertain. 
96 This total relates to those genomic VSGs for which any donor sequence could be found, thus 
includes incomplete reads and read assemblies.  See Appendix 7.2.9 for further details. 
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towards degeneracy, and segmental gene conversion has developed as an 
imprecise compensatory mechanism?  If that is the case, how is it that T. 
congolense and T. vivax have managed to maintain equally large archives with a 
lower proportion of pseudogenes?  Differences in their lifecycles may provide 
some answer: T. brucei goes through tighter population bottlenecks in the tsetse 
fly than congolense and vivax do (Oberle et al., 2010; Peacock et al., 2012), 
which may help to fix pseudogenizing mutations. 
 
6.4.3 Segmental gene conversion may relax demands for 
functionality, unencumbering archive evolution 
Perhaps it’s the other way around, and that the ability to be repaired has 
relaxed the demand for silent VSGs to be completely functional.  By forming a 
further level of separation between an archival VSG and its expression, 
‘reparation’ permits silent VSGs to mutate—but to mutate within limits.  Imagine 
‘expression ability’ was instead a binary functional/non-functional for all 
archival VSGs.  A new VSG gene appears—is ‘born’—perhaps by duplication.  For 
this gene to be a useful addition to the archive, it must encode both a functional 
coat and a divergent antigen.  These are opposing pressures, and the likelihood 
is that as mutations accumulate, it would become dysfunctional and before it 
became usefully divergent.  Once it has become a dysfunctional gene and is 
completely released from the selective pressure of expression it is more than 
likely to degrade and ‘die’ completely: the framework alpha helices and the 
conserved cysteine residues necessary for VSG’s function as a barrier would not 
be maintained.  By permitting ‘shades of grey’ in functionality, segmental gene 
conversion might relax this tension, encouraging more radical divergence in 
archival genes whilst retaining a mild level of selection for function, as 
described in Figure 6.2. 
 
There are some problems with this theory: the homology apparently required 
between segmental gene conversion donors means that the ‘mild selection’ of 
partial expression is limited in extent and couldn't sustain useful divergence 
beyond the threshold of recombination.  In addition, the greatest ‘relaxation’ 
appears to be on the 3’ end of the VSG gene, where divergence is not clearly 
favoured in antigenic variation.  Nevertheless, re-evaluating selective pressures 
on the antigen archive in light of the role of segmental gene conversion in VSG 
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expression will undoubtedly be important in understanding how VSGs evolve.  
This is considered further in section 6.4.7 below. 
 
 
Figure 6.2 Segmental gene conversion could harness the diversity produced by archive 
evolution.  In this simplified scheme, a VSG is ‘born’ by duplication of an intact VSG, either 
from elsewhere in the archive or by retrograde copying from the expression site.  By 
accumulating mutations, the probability of becoming antigenically novel increases, but so 
does the probability of accumulating pseudogenizing mutations (and thus the ‘death’ of the 
gene).  The probability of evolving an useable, antigenically novel VSG is increased if a 
degree of pseudogeneity is permitted, such as through use of segmental gene conversion. 
 
 
6.4.4 Segmental gene conversion staggers expression and 
contributes to hierarchy 
Mosaic VSGs generally appear later in infection.  Indeed, in the data presented 
here, unambiguous mosaics do not appear until day 17 of infection.  The 
requirement for segmental gene conversion to activate certain archival VSGs 
might be a mechanism for retarding their expression.  By ‘insisting’ on 
mosaicism or 3’ donation, the roll-out of the archive can be staggered (Thon et 
al., 1990).  Yet there are other mechanisms by which the expression of a 
particular genomic VSG could be delayed without compromising its integrity, and 
it is notable that some VSG sets corresponding to intact genomic copies (Set_21 
for example) consistently appeared late in infection with little within-set 
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variation.  Such a pattern indicates that hierarchy could be determined by other 
means beyond imprecise segmental gene conversion.  Borrelia hermsii, for 
example, uses the positions and homologies of flanking sequences to exquisitely 
modulate vsp/vlp gene activation rates (Barbour et al., 2006). 
 
Segmental gene conversion could relate to hierarchy more subtly.  Progressive 
mosaicism is implicitly hierarchical, as successive events accumulate in an 
expressed gene (Futse et al., 2005; Pays et al., 1985a).  More broadly, the 
mechanisms behind segmental gene conversion could play a role in hierarchy 
beyond mosaicism or reparation.  Segmental gene conversion is a mechanism 
that is clearly promoted by homology between donors, but these homologies do 
not necessarily need to be inside the NTD-encoding region of the activated 
genes.  The formation of complex mosaics may be one aspect of a looser, more 
promiscuous, less efficient homology-driven recombination mechanism.  The 
increasing prevalence of mosaics and 3’ donations during an infection might 
signal the late-stage pre-eminence of this switching mechanism: a mechanism 
that causes VSG-specific homologies to determine switching hierarchy, rather 
than non-specific homologies between the 70-bp and telomere repeats.  Such a 
mechanism would clearly have relevance to the ‘block’ structures of 
mathematical models (Gjini et al., 2010). 
 
6.4.5 Segmental gene conversion directly contributes to antigenic 
variation 
Segmental gene conversion in trypanosomes may be an important, or even the 
only, way of generating and expressing antigenic variability, as it is in 
Anaplasma MSP2 (Zhuang et al., 2007), B. burgdorferi VlsE (Zhang & Norris, 
1998) and N. gonorrhoeae PilE (Hamrick et al., 2001).  In these pathogens, a 
small number of donor genes can combine in various ways to produce a wide 
range of epitope structures, and therefore dysjunction between archive and 
expression can be a source of diversity over the course of infection.  Could 
segmental conversion in trypanosomes generate a further layer of antigen 
variability beyond that directly encoded in the archive?  This question was 
addressed directly by the present work.  Here, a set of related mosaics, Set_14, 
constructed from the same subset of donor genes, were identified both within a 
timepoint and from different timepoints of the same infection (Chapter 4).  The 
products of these Set_14 mosaics were tested serologically, and it was found 
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that while antibodies raised against the earlier variants cross-reacted with one 
another, the later-appearing variant was antigenically distinct.  This finding is 
consistent with previous studies on African trypanosome mosaicism, which have 
also shown some antigenic variability amongst related mosaics using monoclonal 
antibodies, although not from immediately longitudinal samples (Barbet et al., 
1989).  Segmental gene conversion therefore contributes directly to antigenic 
variation.   
 
Alongside ‘between-set’ variation, how important is this more subtle kind of 
variability to the overall process of antigenic variation?  In other antigenically 
variable pathogens, accumulating segmental conversion events in the expressed 
antigen is the main source of antigen diversity, with B. burgdorferi and A. 
marginale both able to persist for years with only a handful of silent antigen 
genes in their repertoires (Coutte et al., 2009; Zhuang et al., 2007).  In T. 
brucei, despite numerous genetic differences between related mosaics of 
Set_14, the yield in terms of (experimentally verified) antigenic novelty was not 
great.  Out of five mosaics generated from the same palette of four donors, only 
one was antigenically distinct from the others.  This seems not to be a 
particularly good use of the archive: combining four related silent genes to 
produce only two distinct expressed variants.  Moreover, the antigenically 
distinct variant was divergent to 0.125 differences/aa in the NTD: unusually high 
for mosaic sets, with most other sets divergent to only 0.05–0.10 differences/aa 
in the NTD.  It is therefore reasonable to presume that many of the members of 
these other sets are also incompletely antigenically distinct.  It is possible that 
in longer infections and with stronger immune selection, the parasite population 
would reveal a greater number of distinct variants readily made from the same 
set of donor genes, or the segmental involvement of VSGs that do not share 
overall homology.  Still, as far as these easily-made mosaics here are concerned, 
antigenic novelty does not come readily.   
 
6.4.6 Complete antigenic distinctness may not be necessary in 
the context of similar mosaics 
In the context of a complex infection, complete antigenic novelty may not be 
essential for each step in a progressive mosaic string.  A slight change to epitope 
structure may decrease an antibody’s binding affinity sufficiently to enable 
escape, particularly if those antibodies are at low titre and their clearance can 
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be enhanced by hydrodynamic flow-mediated antibody clearance (Engstler et 
al., 2007).  As the immune response develops with the assistance of antigen 
presenting helper T-cells, antibodies increase their affinity for their specific 
epitope and lose valency as they switch from IgM to IgG isotypes.  If the antigens 
being presented and targeted are those of previous mosaics, increasing affinity 
for an out-of-date epitope and decreasing the avidity of the antibodies could 
assist in immune escape for the later mosaic expressor.  Reinfection studies may 
help to resolve this question.  In addition, mathematical models of infection 
indicate that incomplete cross-reaction can benefit a later mosaic by keeping 
that later variant’s population below the threshold for specific antibody 
induction (Gjini et al., 2010; Johnson et al., 2012).  If partial antigenic 
distinctness were sufficient for immune escape, segmental gene conversion may 
be a mechanism for expressing epitopes separately, rather than generating 
completely distinct variants.  
 
Viruses can induce a phenomenon known as ‘original antigenic sin’ whereby the 
immune system mounts a non-neutralizing response against a later variant 
thanks to its immunological memory of a related variant (Kim et al., 2009).  
Similar mechanisms may be relevant to VSG mosaicism: in a field population, 
memory may assist mosaic expressors in reinfection or superinfection. 
 
6.4.7 Would mosaic ‘saving’ be an efficacious way of increasing 
archive diversity? 
If introducing antigenic novelty was a key advantage of segmental gene 
conversion we might expect parasites to have means of circumventing the 
difficulties of creating useful mosaics.  An obvious one would be the ability to 
retain the new information: a retrograde pathway for the expressed mosaic VSG 
to become part of the archive.  Such VSG saving has not yet been clearly 
observed, but the presence of abundant minichromosomal telomere ends makes 
the mechanism of telomere exchange a possible pathway (Taylor & Rudenko, 
2006).  The advantage of saving this information for future infections might 
make intuitive sense from the point of view of an individual parasite: it has 
gained another easily accessible variant to deploy during its next infection.  
However, if ‘damage’ to archival genes can be frequently repaired during an 
infection as VSGs are activated and segmentally converted across the 
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population, as suggested by the results presented here, saving a repaired gene 
may not be exceptionally useful from this perspective. 
 
What about archive diversity?  For retrograde transfer to increase the antigenic 
diversity of the archive, it would have to occur only when the expressed VSG is 
antigenically novel (otherwise it would essentially only duplicate existing 
information, which could be detrimental where there is selection for limiting 
archive size).  Given that four out of five mosaics tested here had some 
antigenic cross-reaction, it is likely that of all possible mosaics, the majority are 
not antigenically distinct from all of their donors or from one another.  While it 
is possible to envisage mechanisms encouraging the saving of a mosaic that is 
antigenically distinct to that infection97 it is unlikely that a mechanism could 
assess archival antigenic diversity, and save only those mosaics that increase it.  
More likely would be a mechanism that operates at a constantly low background 
rate, and thus would more frequently duplicate, rather than expand, antigen 
diversity. 
 
Nevertheless, this form of gene ‘duplication’ is probably an important pathway 
for replacing those archival VSGs that have succumbed to degeneration, 
producing intact members of the VSG subfamily that can accumulate mutations 
and diverge.  In addition, acquiring a new telomeric VSG would shuffle 
hierarchy, providing an accessible ‘bridgehead’ VSG that could be beneficial in 
the early stages of superinfection or reinfection (see section 6.2.6). 
 
6.4.8 Are the disadvantages of segmental gene conversion 
indeed serious? 
This section has been premised on the assertion that segmental gene conversion 
is accompanied by particularly deleterious disadvantages: the risk of frameshifts 
and errors, the loss of a surface coat, and so on.  Are these disadvantages really 
that great?   
 
                                         
97 For example, perhaps retrograde transfer is a stochastic process whose likelihood of occurring 
increases with the amount of time that has passed since the most recent segmental gene 
conversion event, thus favouring VSGs produced by those segmental gene conversions that 
allow the parasite to survive for longer.   
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If segmental gene conversion has evolved as a mutator phenotype, it seems 
likely that mechanisms have evolved to control the immediate problems that 
segmental recombination brings to an individual parasite.  Feedback loops to 
promote reparation of a damaged expression site-occupying VSG (hinted at by 
the response to lack of VSG mRNA (Smith et al., 2009)) backup VSGs in other 
expression sites, and demands for homology to disfavour clearly incompatible 
donors: all of these may act to restrict the damage that segmental gene 
conversion could cause.  Other mutator phenotypes systems have evolved similar 
mechanisms to restrict the potential for damage that enhanced mutation brings, 
for example by targeting mutation to specific loci (Pavri & Nussenzweig, 2011) or 
activating mutator phenotypes only in times of environmental stress (Caporale, 
2003). 
 
It is clear that many African trypanosome strategies evolve through second-order 
selection, so to understand the risks of segmental gene conversion we must also 
look beyond individual parasites.  If individual parasites are frequently killed as 
a result of imprudent segmental gene conversions, what is the consequence for 
the infecting population?  Particularly where density-dependent differentiation 
is dominant, parasite numbers are not restricted by replication rate or the 
availability of nutrients (Seed & Sechelski, 1988), so replacing those parasites 
that have fallen is not a great burden on the population.  In clonal infections the 
benefits of segmental gene conversion could easily outweigh the costs.  Attrition 
is commonplace in B-cell lineages, and is easily accommodated at the population 
level (Melchers et al., 2000). 
 
In mixed infections, which are likely to be commonplace (Balmer & Caccone, 
2008; Macleod et al., 2001), there is inter-clone competition for host resources 
or carrying capacity (Balmer et al., 2009).  There is thus more of a disadvantage 
of risky segmental conversion, as parasite strains that access only functional 
genes will be able to outcompete less efficient segmental converters in the early 
stage of infection.  It is only later on that the potential for mosaic variation 
becomes advantageous.  This might explain why mosaics do not appear in the 
earlier stage of infection: a strategy has evolved, whereby parasites strike a 
balance between efficacy of activation and scope of variability, with each 
strategy becoming deployed at different points in the infection.  This proposition 
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could be tested with mathematical models of mixed infections, and analysis of 
archive use by different field isolates. 
 
6.4.9 The role of segmental gene conversion in T. brucei infection 
Segmental gene conversion is probably a mechanism under complex selection 
pressure, and has multiple functions and outcomes. It is unlikely that 
trypanosomes are able to restrain archive mutation, as selection on the archive 
is so indirect, and diversity is necessary for its function.  Like other eukaryotic 
multi-gene families, such as olfactory receptors (Young et al., 2008a), alpha-
defensins (Das et al., 2010) and immunoglobulin heavy chain variable regions 
(Ota & Nei, 1994), the VSG archive is probably subject to a process of birth-and-
death evolution: genes are born by duplication, and while some ‘die’ by the 
accumulation of pseudogenizing mutations, others diversify and persist (Nei & 
Rooney, 2005).  Segmental gene conversion has clear utility in accessing 
epitopes encoded by damaged VSGs, ‘extending the life’ of silent VSGs and 
harnessing the divergence introduced by mutation.  In accommodating 
pseudogenes, segmental gene conversion introduces an additional layer of 
variability, extending the function of the archive even further.  I propose that 
the key role of segmental gene conversion in African trypanosomes is as a 
mechanism of generating increased diversity from a degenerating and 
diversifying archive.   
 
6.5 Concluding remarks 
6.5.1 An holistic view of antigenic variation demands 
consideration of mechanisms 
African trypanosomes possess archives of antigen genes unparalleled in size.  But 
antigenic variation, even in trypanosomes, is driven not by the repertoire of 
silent genes, but by the genetic and epigenetic mechanisms that facilitate their 
expression, maintenance and evolution.  It is these adaptive mechanisms that 
are likely subject to the greatest selection pressures.  Trypanosomes must be 
prepared for uncertainty: they are at the whim of their vectors and have no 
control over where they end up.  The size, immuno-competence, immunological 
memory and infection status of their next host cannot be anticipated.  Archive 
use reflects this need for flexibility.  In T. brucei at least, the archive should be 
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considered a resource that can be interpreted creatively, rather than a set script 
that is dogmatically adhered to.  In this sense, the term ‘archive’—with 
connotations of fixed records preserved for future reference—is an inadequate 
metaphor.  Silent subtelomeric VSGs are more akin to a toolkit, albeit one that 
is highly dynamic.  How this resource is managed, and utilized to such 
remarkable effect, will be a fascinating subject of research. 
 
To what degree are these patterns shared with other, non-brucei African 
trypanosomes?  There are clearly differences between species with regards to 
archive intactness and VSG relatedness (Jackson et al., 2012), and it is likely 
that some of the genes involved in the maintenance and expression of the 
archive vary amongst African trypanosomes.  Are the different species subject to 
different selective pressures?  Have T. congolense and T. vivax developed 
different mechanisms for their archive’s expression?  It would be interesting to 
examine the relationship between genotype and phenotype in these species, to 
see whether their archives reflect differences in expression, and whether 
differing strategies between the three species have different evolutionary, 
epidemiological and ecological consequences. 
 
6.5.2 What can trypanosomes tell us about the evolution of 
adaptability? 
African trypanosome antigenic variation is a model system and a classic textbook 
example of a chronic host-parasite interaction.  Many might consider deeper 
analysis of the system unwarranted: simply a case of tidying up loose ends, 
particularly as further studies of antigenic variation do not hold much promise 
for immediately useful therapeutic application.  But the importance of our 
understanding of antigenic variation extends beyond disease control to diverse 
aspects of basic and applied biological science.  Many fundamental mysteries 
remain.   
 
The scope of our current understanding now puts us in a position to examine 
antigenic variation beyond the one-dimensional ‘arms race’, and consider it in 
an ecological and evolutionary framework.  By examining how adaptability itself 
evolves and changes under differing selective pressures and host environments, 
competition from peers, and broader host and vector population structures, 
there is much we can learn from African trypanosomes.
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7 Appendices 
7.1 Oligonucleotide sequences 
!"# $%&'()*'+,# -()*'(#+.*'# /'01'+2'#
!"
#$%&'(')*+',-",("!"#."
(/,$")01#"
2%&')34"53*43/" GTTTCTGTACTATATTG 
678$3/" GTGTTAAAATATATCA 
93.+'-:"*-+':3-')"
;*/'*+',-"<=">?@"
23+AB6AC" CGCAAACGCAACTATTAGCC 
23+AB6A@" CAAGTGCAACAGCCTTCTTG 
23+ABDAC" GCTCTCAGCCTAGGAAGCAA 
23+ABDA@" TCAGTGTTGGCGCTATTGTT 
23+A6EAC" AGTAACAGACAGGGCCAACG 
23+A6EA@" CTGCTGTTTCGATCTCTTCT 
23+A6FAC" AAAGGAAGGCACAGAAGG 
23+A6FA@" GCAGTAATGTCTGATTCG 
23+AE6AC" AGCCGCTGTTTTGCGTATAG 
23+AE6A@" CGGAGTTACTCAGGAAAGCC 
23+AEEAC" CCAACGACAAAGCACTCA 
23+AEEA@" TGGCTTTGTTGATCGTGT 
9G<G&'-AC" CCAAGCTCGGCTACACGGTGT 
9G<G&'-A@" GGCTCAAACACAGCGTTCGA 
2)/33-'-:"),&,-'3."(,/"
'-.3/+"
H6!C" TGTAAAACGACGGCCAGT 
H6!@" CAGGAAACAGCTATGACC 
F"
93.+'-:"$,.*')'.$"<="
>?@"
6F8#C" ACGGCCAAACCGGGATGAAA 
6F8#@" ATCGCTTCGCGGACTTCCTC 
6F8IC" CCATTGTCGACGCAACCGTT 
6F8I@" GGCCGTCGACACAAAGACAG 
6B8#C" CATAACCGCAATAGCCAGG 
6B8#@" TTGTTTGGGCTATGCCTG 
6B8IC" CGTAACCGCAATAGCCCAC 
6B8I@" CGGCCTGTGCTATTTGTG 
 >,&JAC"
"
GTGACGGTTCAGGGAACACT 
 >,&JA@" GCACCGAAATTTGACTTGGT 
 >/3%*/'-:"%/,<3"(,/"
2,G+K3/-"<&,+"
9<66LBMLBBBNA1AC" CAAAGAGCAAAAGAGATGACC 
9<66LBMLBBBNA1A@" TGATTCGGTTGTTGCTGTC 
Table 7.1 The sequences of custom oligonucleotide sequences used in this work.  Table 
continues on the following page. 
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!"# $%&'()*'+,# -()*'(#+.*'# /'01'+2'#
!"
#$%&'$(")*$"
+$'+,$,-%*."*)"/01"
2('3415)36!7" ATCAAGCTTGGCCGGCCAGTCCTGCAGGAATTCGAT 
2('3415)3687" ATCGAATTCCTGCAGGACTGGCCGGCCAAGCTTGAT 
#$%&'$(")*$"('9:'.;%.<"
%.('$-"
+=1>6%.('$-62" GAGGAGAAAGAATAGTAACC 
+=1>"%.('$-6?" GAAATTTGAGGGGGGAAAG 
@'(-%.<"'A*<'.*:("
!"#"'A+$'((%*."
@:5:B%.62" CCAAGCTCGGCTACACGGTGT 
@:5:B%.6?" GGCTCAAACACAGCGTTCGA 
CDEFD62" ATGCCTTCCAATCAGGAGGC 
CDEFD6?" TGTATCGGCGACAACTGCAG 
1'-6GC62" AAAGGAAGGCACAGAAGG 
1'-6GC6?" GCAGTAATGTCTGATTCG 
CDEFC62" TAAAAGGAGACGGAGTGG 
CDEFC6?" GCTCTAGTTTGTTGTTGTTG 
CDEFH62" ACCTGACATCGGACGGTAAC 
CDEFH6?" GTCGGTTATGTCGGCAAGTT 
CDEFI62" GTAAACGGTCCGGAGTTCAA 
CDEFI6?" CATTTCCGCGTTGTCTTGTA 
J&+B%)%;,-%*."*)"!"#("
)$*&";KLJ"
1+B%;'M"N',M'$" GTTTCTGTACTATATTG 
GHF&'$" GTGTTAAAATATATCA 
J&+B%)%;,-%*."*)"!"#("
)$*&"+B,(&%M"
NF1615)3" GATCCCTGCAGGTTTCTGTACTATATTG 
@F/615)3" GATCCCTGCAGGTGTTAAAATATATCA 
Table 7.1 (continued) 
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7.2 Supplementary information to Chapters 3 and 4 
7.2.1 Pedigree of trypanosomes used for chronic mouse 
infections 
 
Figure 7.1 Pedigree of TREU 927/4 GUTat 10.1 trypanosomes used for infections.  Purple 
boxes indicate verified cloning events.  Blue boxes indicate stabilates.  Red boxes indicate 
experimental mice.  The identity of the trypanosomes was confirmed with genome markers 
specific for 927 (L. Marcello, Ph.D. Thesis, 2006, University of Glasgow).  *The original 
source of TREU 927 was a tsetse fly in Kiboko, Kenya, in 1969/70 (G. Cross, pers. comm., 
http://tryps.rockefeller.edu/DocumentsGlobal/lineage_TREU927.pdf) .  **The exact timing of 
the event(s) connecting stabilate GUP 3138 with WUMP 6070 is not known.   
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7.2.2 Parasitaemias of chronic mouse infections 
 
Figure 7.2 Parasitaemias of chronic mouse infections.  Termination of the infection is 
indicated by a cross on the x-axis.  A dagger indicates the transient dip in parasitaemia, 
described in Chapter 3.  Figure continues on subsequent page.
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Figure 7.2 (continued) 
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7.2.3 VSG clone details 
 
Table 7.2 Clone sequence details.  See the end of the Table for details. 
! "
!!"##$#% !! # #% &'()#* + %,- . / # 0
!!"##$#1 !! # #1 &'()#* + %,- . / # 0
!!"##$#2 !! # #2 &'()#* + %,- . / # 0
!!"##$#3 !! # #3 &'()#* + %,- . / # 0
!!"##$#4 !! # #4 &'()#* + %,- . / # 0
!!"##$#5 !! # #5 &'()#* + %,- . / # 0
!!"##$#6 !! # #6 &'()#* + %,- . / # 0
!!"##$#7 !! # #7 &'()#* + %,- . / # 0
!!"##$*# !! # *# &'()#* + %,- . / # 0
!!"##$** !! # ** &'()#* + %,- . / # 0
!!"##$*% !! # *% &'()#* + %,- . / # 0
#4"%#$#3"8'9 4 %# #3 :23#8'9; &'()#* + %,- . / # 0
<&="#1"#*"#* >?)#* 1 #* @ &'()#* + %,- . / # 0
<&="#1"#*"#% >?)#* 1 #% @ &'()#* + %,- . / # 0
<&="#1"#%"#* >?)#% 1 #* @ &'()#* + %,- . / # 0
<&="#1"#%"#% >?)#% 1 #% @ &'()#* + %,- . / # 0
<&="#7"#1"#* >?)#1 7 #* @ &'()#% + 4 / / # 0
*#"*#$#% *# *# #% &'()#1 + 4 A / # 0
*#"*#$#1 *# *# #1 &'()#1 + 4 A / # 0
*#"*#$#2 *# *# #2 &'()#1 + 4 A / # 0
*#"*#$#3)B *# *# #3 C-D9'8EF &'()#1 + 4 A / # 0
**"*#$#3 ** *# #3 &'()#1 + 4 A / # 0
**"*#$#5 ** *# #5 &'()#1 + 4 A / # 0
**"*#$*# ** *# *# &'()#1 + 4 A / # 0
**"*5$#2 ** *5 #2 &'()#1 + 4 A / # 0
**"*5$#3 ** *5 #3 &'()#1 + 4 A / # 0
**"*5$#4 ** *5 #4 &'()#1 + 4 A / # 0
**"*5$#7 ** *5 #7 &'()#1 + 4 A / # 0
**"*5$*% ** *5 *% &'()#1 + 4 A / # 0
*%"*#$*#"-88 *% *# *# +*#3-88 &'()#1 + 4 A / # 0
*%"*#$*%"-88 *% *# *% +*#3-88 &'()#1 + 4 A / # 0
*%"*5$#* *% *5 #* &'()#1 + 4 A / # 0
*%"*5$#% *% *5 #% &'()#1 + 4 A / # 0
*%"*5$#1 *% *5 #1 &'()#1 + 4 A / # 0
*%"*5$#3 *% *5 #3 &'()#1 + 4 A / # 0
<&="#7"#1"#1)B >?)#1 7 #1 @ &'()#1 + 4 A / # 0
<&="#7"#2"#* >?)#2 7 #* @ &'()#1 + 4 A / # 0
#*"%5$#7 * %5 #7 &'()#2 G * A . H2I 0
#*"1%$** * 1% ** &'()#2 G 1 A . # 0
#3"%5$#1 3 %5 #1 &'()#2 G 1 A . # 0
#4"%5$*% 4 %5 *% &'()#2 G 1 A . # 0
<&="#7"#1"#2 >?)#1 7 #2 @ &'()#2 G 1 A . # 0
#2"1*$*4 2 1* *4 &'()#3 + 3J / / # 0
**"*#$#*"8'9 ** *# #* +57#8'9; &'()#3 + 3J / / # 0
*%"*#$#3 *% *# #3 &'()#3 + 3J / / # 0
*%"*#$**"8'9 *% *# ** :5328'9 &'()#3 + 3J / / # 0
<&="#7"#1"#5 >?)#1 7 #5 @ &'()#3 + 3J / / # 0
<&="#7"#2"#% >?)#2 7 #% @ &'()#3 + 3J / / # 0
<&="#7"#2"*#)B >?)#2 7 *# @ &'()#4 +KL * / / # 0
**"#5$#% ** 5 #% M(NA &'()#5 + % / / # 0
**"#5$#2 ** 5 #2 &'()#5 + % / / # 0
**"#5$#5 ** 5 #5 &'()#5 + % / / # 0
**"#5$#6 ** 5 #6 -(.A; &'()#5 + % / / # 0
**"*#$#1 ** *# #1 &'()#5 + % / / # 0
**"*#$#7 ** *# #7 &'()#5 + % / / # 0
**"*2$#* ** *2 #* &'()#5 + % / / # 0
*%"*5$#2 *% *5 #2 &'()#5 + % / / # 0
*%"*5$#6 *% *5 #6 &'()#5 + % / / # 0
*%"*5$#7 *% *5 #7 &'()#5 + % / / # 0
*%"%2$#% *% %2 #% &'()#5 + % / / H%I 0
<&="*2"#3"#* >?)#3 *2 #* @ &'()#5 + % / / # 0
#*"%#$#% * %# #% &'()#6 G % . / %O -P
#$%&'($)'
!*+,
-$&./0'()$-'
#$%&,
12'#$%3'
4$5%#3
12'
#$%
6789":$%9'%.-9 ;%(906/$%
*/-9'
8$/%6
":$%9'
<
/%63'
&9=,
>$#& ?96
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! "
!"#$!%!& " $! !& '()*+ ,-(.!/ 0 $ ) 1 $2 '3
!"#$!%!4 " $! !4 ,-(.!/ 0 $ ) 1 $2 '3
!"#$!%!5 " $! !5 ,-(.!/ 0 $ ) 1 $ 6
!"#$7%!" " $7 !" ,-(.!/ 0 $ ) 1 $ 6
!"#$7%!$#8-9 " $7 !$ :"7"/8-9+ ,-(.!/ 0 $ ) 1 $ 6
!"#$7%!7 " $7 !7 ,-(.!/ 0 $ ) 1 $2 '3
!"#$7%!; " $7 !; ,-(.!/ 0 $ ) 1 $ 6
!"#$7%!& " $7 !& '()*+ ,-(.!/ 0 $ ) 1 " 6
!"#$7%!4#8-9 " $7 !4 :"7"/8-9+ ,-(.!/ 0 $ ) 1 $ 6
!"#$7%!/ " $7 !/ ,-(.!/ 0 $ ) 1 " 6
!"#$7%!5 " $7 !5 ,-(.!/ 0 $ ) 1 $ 6
!"#$7%"! " $7 "! ,-(.!/ 0 $ ) 1 $2 '3
!"#$7%"" " $7 "" ,-(.!/ 0 $ ) 1 $ 6
!"#$7%"$ " $7 "$ ,-(.!/ 0 $ ) 1 $2 '3
!"#7$%!"#8-9 " 7$ !" :"7//8-9+ ,-(.!/ 0 $ ) 1 $ 6
!"#7$%!$ " 7$ !$ ,-(.!/ 0 $ ) 1 $ 6
!"#7$%!7 " 7$ !7 ,-(.!/ 0 $ ) 1 " 6
!"#7$%!; " 7$ !; ,-(.!/ 0 $ ) 1 $ 6
!"#7$%!4 " 7$ !4 ,-(.!/ 0 $ ) 1 " 6
!"#7$%!< " 7$ !< ,-(.!/ 0 $ ) 1 $ 6
!"#7$%!5 " 7$ !5 ,-(.!/ 0 $ ) 1 " 6
!7#$!%!" 7 $! !" =(>* ,-(.!/ 0 $ ) 1 $ 6
!7#$!%!$ 7 $! !$ ,-(.!/ 0 $ ) 1 $ 6
!7#$!%!7 7 $! !7 ,-(.!/ 0 $ ) 1 $ 6
!7#$!%!; 7 $! !; ,-(.!/ 0 $ ) 1 $ 6
!7#$!%!& 7 $! !& ,-(.!/ 0 $ ) 1 $2 '3
!7#$!%!< 7 $! !< ,-(.!/ 0 $ ) 1 $ 6
!7#$!%!/ 7 $! !/ ,-(.!/ 0 $ ) 1 $ 6
!7#$!%!5 7 $! !5 =(>* ,-(.!/ 0 $ ) 1 $ 6
!7#$!%"! 7 $! "! ,-(.!/ 0 $ ) 1 $ 6
!7#$!%"" 7 $! "" ,-(.!/ 0 $ ) 1 " 6
!7#$!%"$ 7 $! "$ ,-(.!/ 0 $ ) 1 $ 6
!7#$7%!" 7 $7 !" ,-(.!/ 0 $ ) 1 " 6
!7#$7%!$ 7 $7 !$ ,-(.!/ 0 $ ) 1 $2 '3
!7#$7%!7.? 7 $7 !7 @'A9-8BC ,-(.!/ 0 $ ) 1 $2 '3
!7#$7%!; 7 $7 !; ,-(.!/ 0 $ ) 1 $2 '3
!7#$7%!& 7 $7 !& ,-(.!/ 0 $ ) 1 $2 D
!7#$7%!4 7 $7 !4 ,-(.!/ 0 $ ) 1 $2 '3
!7#$7%!< 7 $7 !< '()*+ ,-(.!/ 0 $ ) 1 " 6
!7#$7%!5 7 $7 !5 '()*+ ,-(.!/ 0 $ ) 1 " 6
!7#$7%"" 7 $7 "" ,-(.!/ 0 $ ) 1 $ 6
!7#$7%"$ 7 $7 "$ ,-(.!/ 0 $ ) 1 " 6
!&#$"%!" & $" !" ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%!$ & $" !$ ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%!7 & $" !7 ,-(.!/ 0 $ ) 1 " 6
!&#$"%!; & $" !; ,-(.!/ 0 $ ) 1 $ 6
!&#$"%!4 & $" !4 ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%!< & $" !< ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%!/ & $" !/ '()*E ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%!5.? & $" !5 @'A9-8BC ,-(.!/ 0 $ ) 1 $2B '3
!&#$"%"! & $" "! ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%"" & $" "" ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%"$ & $" "$ ,-(.!/ 0 $ ) 1 " 6
!&#$"%"7 & $" "7 ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%"; & $" "; ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%"& & $" "& ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%"4 & $" "4 '()*+ ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%"< & $" "< ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%"/ & $" "/ ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%"5 & $" "5 ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%$! & $" $! ,-(.!/ 0 $ ) 1 $2 '3
!&#$"%$" & $" $" ,-(.!/ 0 $ ) 1 $2 "3
#$%&'($)'
!*+,
-$&./0'()$-'
#$%&,
12'#$%3'
4$5%#3
12'
#$%
"6$%7'%.-7 8%(709/$%
*/-7'
:$/%9
"6$%7'
;
/%93'
&7<,
=$#& >79 9?:7
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! "
!"#$%&$$ " $% $$ '()*!+ , $ - . % /
!"#$%&$0 " $% $0 '()*!+ , $ - . $1 23
!"#$%&$4 " $% $4 5)67 '()*!+ , $ - . $1 8
!9#$!&!% 9 $! !% '()*!+ , $ - . $1 23
!9#$!&!$ 9 $! !$ '()*!+ , $ - . % /
!9#$!&!0 9 $! !0 '()*!+ , $ - . $1 23
!9#$!&!4 9 $! !4 '()*!+ , $ - . $1 23
!9#$!&!9#2:: 9 $! !9 ;$"$2:: '()*!+ , $ - . $1 23
!9#$!&!< 9 $! !< '()*!+ , $ - . $1 23
!9#$!&!+ 9 $! !+ '()*!+ , $ - . $1 23
!9#$!&!= 9 $! != '()*!+ , $ - . $1 23
!9#$!&%! 9 $! %! '()*!+ , $ - . $1 23
!9#$!&%% 9 $! %% '()*!+ , $ - . $1 23
!9#$!&%$ 9 $! %$ '()*!+ , $ - . $1 23
!9#$0&!% 9 $0 !% '()*!+ , $ - . % /
!9#$0&!0 9 $0 !0 '()*!+ , $ - . % /
!9#$0&!4 9 $0 !4 '()*!+ , $ - . % /
!9#$0&!" 9 $0 !" '()*!+ , $ - . % /
!9#$0&!9#:(> 9 $0 !9 ?%49!:(>@ '()*!+ , $ - . % /
!9#$0&!< 9 $0 !< '()*!+ , $ - . % /
!9#$0&!+ 9 $0 !+ '()*!+ , $ - . % /
!9#$0&!=#:(> 9 $0 != ?%0%+:(>@ '()*!+ , $ - . $1 23
!9#$0&%! 9 $0 %! '()*!+ , $ - . % /
!9#$0&%% 9 $0 %% 5)67 '()*!+ , $ - . % /
!+#$!&!% + $! !% '()*!+ , $ - . % /
!+#$!&!$ + $! !$ '()*!+ , $ - . $1 23
!+#$!&!4 + $! !4 '()*!+ , $ - . % /
!+#$!&!" + $! !" '()*!+ , $ - . % /
!+#$!&!9 + $! !9 '()*!+ , $ - . $1 23
!+#$!&!< + $! !< '()*!+ , $ - . % /
!+#$!&!+ + $! !+ '()*!+ , $ - . $1 23
!+#$!&!= + $! != '()*!+ , $ - . $1 23
!+#$!&%! + $! %! '()*!+ , $ - . $1 23
!+#$!&%% + $! %% '()*!+ , $ - . $1 23
!+#$!&%$ + $! %$ '()*!+ , $ - . % /
!=#$!&!% = $! !% '()*!+ , $ - . % /
!=#$!&!$ = $! !$ '()*!+ , $ - . % /
!=#$!&!0 = $! !0 '()*!+ , $ - . $1 23
!=#$!&!4 = $! !4 '()*!+ , $ - . % /
!=#$!&!" = $! !" '()*!+ , $ - . $1 23
!=#$!&!9 = $! !9 '()*!+ , $ - . $1 23
!=#$!&!<*A = $! !< B2C>(:DE '()*!+ , $ - . $1 23
!=#$!&!+ = $! !+ '()*!+ , $ - . % /
!=#$!&%! = $! %! '()*!+ , $ - . $1 23
!=#$!&%% = $! %% '()*!+ , $ - . % /
%%#!<&!"*A %% < !" B2C>(:DF '()*!+ , G - . G /
%%#%!&!4 %% %! !4 '()*!+ , $ - . % /
%%#%<&!$ %% %< !$ '()*!+ , $ - . $ /
%%#%<&!0 %% %< !0 '()*!+ , $ - . $ /
%%#%<&!< %% %< !< '()*!+ , $ - . $ /
%%#%<&!+ %% %< !+ '()*!+ , $ - . $ /
%%#%<&%% %% %< %% '()*!+ , $ - . $ /
%%#$%&!4*A %% $% !4 B2C>(:DF '()*!+ , G - . G /
%%#$%&!<*A %% $% !< B2C>(:DE '()*!+ , $ - . $1 23
%$#%<&!9 %$ %< !9 '()*!+ , $ - . $1 23
%$#%<&!< %$ %< !< '()*!+ , $ - . $ /
%$#%<&%! %$ %< %! '()*!+ , $ - . $ /
%$#%<&%% %$ %< %% '()*!+ , $ - . $1 23
%$#$4&!% %$ $4 !% '()*!+ , $ - . $1 23
%$#$4&!0 %$ $4 !0 '()*!+ , $ - . $ /
%$#$4&!4 %$ $4 !4 '()*!+ , $ - . % 8
%$#$4&!+#2:: %$ $4 !+ H%0=2:: '()*!+ , $ - . $ 8
#$%&'()%
*'+(&)
#$%
&'(
,-. ./0-
&'(1%2'3%
!456
7'189:%23'7%
&'(16
";'(-%(87- <(2-:.9'(
497-%
0'9(.
";'(-%
=
9(.)%
1->6
?'&1
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! "
!"#"$%&'#()) !" "$ &' *!+'()) ,-./&0 1 " 2 3 " 4
!"#"$%!! !" "$ !! ,-./&0 1 " 2 3 " 5
!"#"$%!" !" "$ !" ,-./&0 1 " 2 3 "6 (7
!"#"$%!$ !" "$ !$ ,-./&0 1 " 2 3 "6 (7
8,*#!$#&9#&" :;/&9 !$ &" < ,-./&0 1 " 2 3 "6 (7
8,*#!$#&=#&! :;/&= !$ &! < ,-./&0 1 " 2 3 "6 (7
8,*#"!#&0#&" :;/&0 "! &" < ,-./&0 1 " 2 3 "6 (7
8,*#"!#&0#&+ :;/&0 "! &+ < ,-./&0 1 " 2 3 ! 5
&!#+"%!& ! +" !& ,-./&' > = 2 3 $ 4
&$#+!%+?#)-@ $ +! +? A!9!?)-@B ,-./&' > ! 2 3 $ 4
8,*#""#&?#&! :;/&? "" &! < ,-./&' > + 2 3 & 5
&!#"?%&0 ! "? &0 ,-./!& > = 2 2 ! 5
&!#"?%!& ! "? !& ,-./!& > = 2 2 ! 5
&!#"?%!" ! "? !" ,-./!& > = 2 2 ! 5
&!#"'%&" ! "' &" ,-./!& > = 2 2 ! 5
&!#"'%&$ ! "' &$ ,-./!& > = 2 2 & 5
&!#"'%!& ! "' !& ,-./!& > = 2 2 & 5
&!#"'%!! ! "' !! ,-./!& > = 2 2 + 4
&$#"!%+' $ "! +' ,-./!& > = 2 2 & 5
&$#"!%$& $ "! $& ,-./!& > = 2 2 & 5
&$#"+%!9 $ "+ !9 ,-./!& > = 2 2 & 5
&$#"+%!' $ "+ !' ,-./!& > = 2 2 & 5
&$#"+%"! $ "+ "! ,-./!& > = 2 2 & 5
&$#"+%+= $ "+ += ,-./!& > = 2 2 & 5
&$#"+%$+ $ "+ $+ ,-./!& > = 2 2 & 5
&9#"+%"? 9 "+ "? ,-./!& > = 2 2 ! 5
&9#"?%&! 9 "? &! ,-./!& > = 2 2 & 5
&9#"?%&$ 9 "? &$ ,-./!& > = 2 2 & 5
&9#"?%!= 9 "? != ,-./!& > = 2 2 & 5
&9#"?%"+ 9 "? "+ ,-./!& > = 2 2 ! 5
&9#"?%"' 9 "? "' ,-./!& > = 2 2 ! 5
&9#"'%&9 9 "' &9 ,-./!& > = 2 2 & 5
&9#"'%!+#)-@ 9 "' !+ >!!'$)-@B ,-./!& > = 2 2 & 5
&9#"'%!9 9 "' !9 ,-./!& > = 2 2 & 5
&9#"'%!? 9 "' !? ,-./!& > = 2 2 " 4
&9#"'%"! 9 "' "! ,-./!& > = 2 2 & 5
&9#"'%"$ 9 "' "$ ,-./!& > = 2 2 & 5
!!#"?%&$ !! "? &$ ,-./!& > = 2 2 ! 5
!!#"?%!& !! "? !& ,-./!& > = 2 2 ! 5
!!#+&%&" !! +& &" ,-./!& > = 2 2 & 5
8,*#""#&?#&"#)-@ :;/&? "" &" < *!+9)-@ ,-./!& > = 2 2 & 5
&$#"!%&= $ "! &= ,-./!! > " 2 3 & 5
&$#"!%$$ $ "! $$ ,-./!! > " 2 3 & 5
&9#"+%&$ 9 "+ &$ ,-./!! > " 2 3 ! 5
&9#"+%!& 9 "+ !& ,-./!! > " 2 3 ! 5
&9#"+%!9 9 "+ !9 ,-./!! > " 2 3 ! 5
&9#"+%!0 9 "+ !0 ,-./!! > " 2 3 ! 5
&9#"+%"$ 9 "+ "$ ,-./!! > " 2 3 " 4
&9#"+%"= 9 "+ "= ,-./!! > " 2 3 ! 5
!!#+&%&= !! +& &= ,-./!! > " 2 3 " 4
!!#+&%!" !! +& !" ,-./!! > " 2 3 ! 5
!!#+&%!$ !! +& !$ ,-./!! > " 2 3 ! 5
!!#+&%!= !! +& != ,-./!! > " 2 3 ! 5
!!#+&%!? !! +& !? ,-./!! > " 2 3 & 5
!!#+&%"9 !! +& "9 ,-./!! > " 2 3 ! 5
!!#+&%"0 !! +& "0 ,-./!! > " 2 3 & 5
!!#+&%+& !! +& +& ,-./!! > " 2 3 ! 5
!!#+&%+$ !! +& +$ ,-./!! > " 2 3 ! 5
!!#+&%+9 !! +& +9 ,-./!! > " 2 3 ! 5
8,*#""#&?#&+ :;/&? "" &+ < ,-./!! > " 2 3 ! 5
&!#"?%&= ! "? &= ,-./!" > 9( 2 3 = 5
&$#"!%&" $ "! &" ,-./!" > $ 2 3 = 5
#$%&'($)'
!*+,
-$&./0'()$-'
#$%&,
12'#$%3'
4$5%#3
12'
#$%
"6$%7'%.-7 8%(709/$%
*/-7'
:$/%9
"6$%7'
;
/%93'
&7<,
=$#& >79 9?:7
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! "
!"#$%&'" " $% '" ()*+'$ , " - . / 0
!"#$%&$/ " $% $/ ()*+'$ , " - . / 0
!"#$%&$1 " $% $1 ()*+'$ , " - . / 0
!"#$%&%! " $% %! ()*+'$ , " - . / 0
!"#$%&%$ " $% %$ ()*+'$ , " - . / 0
!"#$2&!3 " $2 !3 ()*+'$ , 45 - . / 0
!"#$2&!1 " $2 !1 ()*+'$ , 45 - . / 0
!"#$2&'' " $2 '' ()*+'$ , " - . / 0
!"#$2&'/ " $2 '/ 5*-67 ()*+'$ , " - . $ 0
!"#$2&'1 " $2 '1 ()*+'$ , 45 - . / 0
!"#$2&$2 " $2 $2 ()*+'$ , 45 - . / 0
!"#$2&$3 " $2 $3 ()*+'$ , " - . / 0
!"#$2&%" " $2 %" ()*+'$ , " - . / 0
!"#$2&%/ " $2 %/ ()*+'$ , 45 - . / 0
!"#$2&%2 " $2 %2 ()*+'$ , " - . $ 0
!"#$2&%3 " $2 %3 ()*+'$ , " - . / 0
!"#$2&"/ " $2 "/ ()*+'$ , " - . / 0
!"#$2&"2 " $2 "2 ()*+'$ , " - . / 0
!"#$1&!$ " $1 !$ ()*+'$ , " - . ' 0
!"#$1&'! " $1 '! ()*+'$ , 45 - . / 0
!"#$1&'' " $1 '' ()*+'$ , 45 - . / 0
!"#$1&'/ " $1 '/ ()*+'$ , 45 - . / 0
!"#$1&$3 " $1 $3 ()*+'$ , " - . / 0
!"#$1&%' " $1 %' ()*+'$ , " - . ' 0
!"#$1&%% " $1 %% ()*+'$ , 45 - . / 0
!"#$1&%4 " $1 %4 ()*+'$ , " - . ' 0
!"#%'&!4 " %' !4 ()*+'$ , 45 - . / 0
!"#%'&!2 " %' !2 ()*+'$ , " - . / 0
!"#%'&!3 " %' !3 ()*+'$ , 45 - . / 0
!"#%'&'! " %' '! ()*+'$ , 45 - . / 0
!"#%'&'4 " %' '4 ()*+'$ , 45 - . / 0
!"#%'&%/#8)9 " %' %/ :'$$48)97 ()*+'$ , 45 - . / 0
!"#%'&%3 " %' %3 ()*+'$ , 45 - . / 0
!"#%'&%1 " %' %1 ()*+'$ , 45 - . / 0
!"#%'&"% " %' "% ()*+'$ , " - . ' 0
!"#%'&"" " %' "" ()*+'$ , 45 - . / 0
!"#%'&"/ " %' "/ ()*+'$ , 45 - . / 0
!4#$2&!3 4 $2 !3 ()*+'$ , " - . $ 0
!4#$2&'$ 4 $2 '$ ()*+'$ , 45 - . / 0
!4#$2&'% 4 $2 '% ()*+'$ , 45 - . / 0
!4#$2&'2#8)9 4 $2 '2 ;4228)9 ()*+'$ , 45 - . / 0
!4#$2&'3 4 $2 '3 ()*+'$ , 45 - . / 0
!4#$2&$4 4 $2 $4 ()*+'$ , " - . / 0
!4#$1&!' 4 $1 !' ()*+'$ , 45 - . / 0
!4#$1&!" 4 $1 !" ()*+'$ , 45 - . / 0
!4#$1&!/ 4 $1 !/ ()*+'$ , " - . $ 0
!4#$1&!2 4 $1 !2 ()*+'$ , 45 - . / 0
!4#$1&!3 4 $1 !3 ()*+'$ , 45 - . / 0
!4#$1&'! 4 $1 '! ()*+'$ , 45 - . / 0
!4#$1&'' 4 $1 '' ()*+'$ , 45 - . / 0
!4#$1&'3 4 $1 '3 ()*+'$ , 45 - . / 0
!4#$1&$! 4 $1 $! ()*+'$ , 45 - . / 0
!4#%'&!/ 4 %' !/ ()*+'$ , 45 - . / 0
!1#%"&!$ 1 %" !$ ()*+'$ , 45 - . / 0
!1#%"&!"#8)9 1 %" !" ,'!3/8)97 ()*+'$ , 45 - . / 0
!1#%"&!4 1 %" !4 ()*+'$ , 45 - . / 0
!1#%"&!/ 1 %" !/ ()*+'$ , 45 - . / 0
!1#%"&'/ 1 %" '/ ()*+'$ , 45 - . / 0
!1#%"&'2 1 %" '2 ()*+'$ , 45 - . / 0
!1#%"&'3 1 %" '3 ()*+'$ , 45 - . / 0
''#$2&!% '' $2 !% ()*+'$ , 45 - . / 0
''#$2&!3 '' $2 !3 ()*+'$ , 45 - . / 0
#$%&'()%
*'+(&)
#$%
&'(
,-. ./0-
&'(1%2'3%
!456
7'189:%23'7%
&'(16
";'(-%(87- <(2-:.9'(
497-%
0'9(.
";'(-%
=
9(.)%
1->6
?'&1
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! "
!!"#$%&' !! #$ &' ()*+!# , - . / 0 1
!!"2&%!&"3)4 !! 2& !& 56$03)4 ()*+!# , 67 . / 0 1
8(5"##"&$"&- 9:+&$ ## &- ; ()*+!# , - . / # 1
&6"#!%&6 6 #! &6 ()*+!2 < # . / #= >
&6"#2%&2 6 #2 &2 ()*+!2 < # . / #= 7
&6"#2%&? 6 #2 &? ()*+!2 < # . / #= 7
&6"#2%!0 6 #2 !0 ()*+!2 < # . / #= 7
&6"#2%#& 6 #2 #& ()*+!2 < # . / #= 7
&6"#$%#$ 6 #$ #$ @*AB ()*+!2 < # . / #= 7
&0"#'%&6 0 #' &6 ()*+!2 < # . / #= 7
8(5"#-"&'"&! 9:+&' #- &! ; ()*+!2 < # . / #= 7
&!"#$%&$"3)4 ! #$ &$ ,!&6$3)4 ()*+!- < 2 . . 0 C
&!"#$%!!"3)4 ! #$ !! ,!2'03)4D ()*+!- < ! . . ! 1
&!"#'%&6"3)4 ! #' &6 ,!2003)4D ()*+!- < ! . . ! 1
&!"#'%&' ! #' &' ; ()*+!- < ! . . ! 1
&!"2#%&? ! 2# &? ()*+!- < ! . . ! 1
&2"2#%&$ 2 2# &$ ()*+!- < ! . . ! 1
&-"#!%&- - #! &- ()*+!- < # . . & 1
&-"#2%&$ - #2 &$ ()*+!- < # . . & 1
&-"#2%-& - #2 -& ; ()*+!- < # . . & 1
&-"#2%-$ - #2 -$ ; ()*+!- < # . . & 1
&-"#2%-? - #2 -? ; ()*+!- < # . . & 1
&-"#$%&$"3)4 - #$ &$ ,?6-3)4D ()*+!- < # . . & 1
&-"#$%!$ - #$ !$ ; ()*+!- < ! . . ! 1
&-"#$%#! - #$ #! ; ()*+!- < ! . . ! 1
&-"#$%#6 - #$ #6 ; 7*.BD ()*+!- < ! . . 6 E
&-"#$%-- - #$ -- ; 7*.BD ()*+!- < ! . . 6 E
&-"#'%&0 - #' &0 ()*+!- < 2 . . & 1
&-"2!%&! - 2! &! ()*+!- < 2 . . & 1
&-"2!%&0 - 2! &0 ()*+!- < 2 . . & 1
&-"2!%2! - 2! 2! ; ()*+!- < 2 . . & 1
&-"2!%22 - 2! 22 ; ()*+!- < 2 . . & 1
&-"2!%2- - 2! 2- ()*+!- < 2 . . & 1
&-"2!%26 - 2! 26 ; ()*+!- < 2 . . & 1
&6"#2%!# 6 #2 !# ()*+!- < # . . & 1
&6"#$%&' 6 #$ &' ()*+!- < ! . . ! 1
&6"#$%!' 6 #$ !' ()*+!- < # . . & 1
&6"#$%#& 6 #$ #& ()*+!- < # . . & 1
&6"#$%#! 6 #$ #! ()*+!- < # . . & 1
&6"#$%#? 6 #$ #? ()*+!- < ! . . ! 1
&6"#$%2# 6 #$ 2# ()*+!- < # . . & 1
&6"#$%22 6 #$ 22 ()*+!- < # . . & 1
&6"#'%#2 6 #' #2 ()*+!- < # . . & 1
&6"2!%&6 6 2! &6 ()*+!- < 2 . . & 1
&0"#'%&$ 0 #' &$ ()*+!- < 2 . . & 1
&0"#'%!& 0 #' !& ()*+!- < 2 . . & 1
8(5"#?"!&"&# 9:+!& #? &# ; ()*+!- < 2 . . & 1
8(5"#?"!&"&2 9:+!& #? &2 ; ()*+!- < 2 . . 6 F
8(5"#?"!&"&- 9:+!& #? &- ; ()*+!- < 2 . . 6 F
&2"#$%!# 2 #$ !# ()*+!0 , 2 B . 6 GH
8(5"#?"!&"&$ 9:+!& #? &$ ; ()*+!0 , 2 B . 6 GH
&2"#'%&2 2 #' &2 ()*+!$ < # . . I6J 7
&2"#'%!' 2 #' !' ()*+!$ < # . . I6J 7
&2"#'%## 2 #' ## ()*+!$ < # . . I#=J G
&2"2#%!! 2 2# !! ()*+!$ < # . . I6J 7
&?"2-%&! ? 2- &! ()*+!$ < # . . I#=J 7H
&?"2-%&# ? 2- &# ()*+!$ < # . . I#=J 7H
&?"2-%&2 ? 2- &2 ()*+!$ < # . . I#=J 7H
&?"2-%&- ? 2- &- ()*+!$ < # . . I#=J 7H
&?"2-%&6 ? 2- &6 ()*+!$ < # . . I#=J 7H
&?"2-%&$"733 ? 2- &$ ,'?#733D ()*+!$ < # . . I#=J 7H
&?"2-%&? ? 2- &? ()*+!$ < # . . I#=J 7H
#$%&'($)'
!*+,
-$&./0'()$-'
#$%&,
12'#$%3'
4$5%#3
12'
#$%
"6$%7'%.-7 8%(709/$%
*/-7'
:$/%9
"6$%7'
;
/%93'
&7<,
=$#& >79 9?:7
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! "
!"#$%&!' " $% !' ()*+,- . / 0 0 1/23 45
!"#$%&,! " $% ,! ()*+,- . / 0 0 1/23 45
!"#$%&,, " $% ,, ()*+,- . / 0 0 1/23 45
!"#$%&,/ " $% ,/ ()*+,- . / 0 0 1/23 45
!"#$%&,% " $% ,% ()*+,- . / 0 0 1/23 45
!"#$%&,6 " $% ,6 ()*+,- . / 0 0 1/23 45
!"#$%&/! " $% /! ()*+,- . / 0 0 1/23 45
!"#$%&/, " $% /, ()*+,- . / 0 0 1/23 7
!"#$%&// " $% // ()*+,- . / 0 0 1/23 45
!"#$%&/$ " $% /$ ()*+,- . / 0 0 1/23 45
!'#$%&!, ' $% !, ()*+,- . / 0 0 1/23 45
!'#$%&!$ ' $% !$ ()*+,- . / 0 0 1/23 45
!'#$%&!- ' $% !- ()*+,- . / 0 0 1/23 45
!'#$%&!" ' $% !" ()*+,- . / 0 0 1/23 45
!'#$%&!' ' $% !' ()*+,- . / 0 0 1/23 45
!'#$%&,! ' $% ,! ()*+,- . / 0 0 1/23 45
!'#$%&,, ' $% ,, ()*+,- . / 0 0 1/23 45
!'#$%&,/ ' $% ,/ ()*+,- . / 0 0 1/23 45
!'#$%&,% ' $% ,% ()*+,- . / 0 0 1/23 45
,!#$!&!6 ,! $! !6 ()*+,- . / 0 0 1/23 45
,!#$!&!- ,! $! !- ()*+,- . / 0 0 1/23 45
,/#$!&!' ,/ $! !' ()*+,- . / 0 0 1/23 45
8(9#/"#,!#,! :;+,! /" ,! < ()*+,- . / 0 0 1/23 45
!,#/-&!6 , /- !6 ()*+," . , = = 1$3 >
!$#/-&!/ $ /- !/ ()*+," . , = = ! >
!$#/-&!" $ /- !" ()*+," . , = = ! >
!$#/-&!' $ /- !' ()*+," . , = = ! >
!$#/'&!6 $ /' !6 ()*+," . , = = ! >
!$#/'&," $ /' ," ()*+," . , = = ! >
!$#$/&!, $ $/ !, ()*+," . , = = ! >
!$#$/&!/ $ $/ !/ ()*+," . , = = ! >
!$#$/&!$ $ $/ !$ ()*+," . , = = ! >
!$#$/&!% $ $/ !% ()*+," . , = = ! >
!$#$/&!6 $ $/ !6 ()*+," . , = = ! >
!$#$/&!? $ $/ !? ()*+," . , = = ! >
!$#$/&!' $ $/ !' ()*+," . , = = ! >
!$#$/&,! $ $/ ,! ()*+," . , = = ! >
!%#/-&!, % /- !, ()*+," . , = = ! >
!%#/'&,- % /' ,- ()*+," . , = = ! >
8(9#/"#,,#!, :;+,, /" !, < ()*+," . , = = ! >
8(9#/"#,,#!6 :;+,, /" !6 < ()*+," . , = = ! >
,!#,!&,! ,! ,! ,! ()*+,' @ , 0 = ! >
,!#,!&,, ,! ,! ,, ()*+,' @ , 0 = ! >
8(9#/"#,,#!/ :;+,, /" !/ < ()*+,' @ , 0 = ! >
8(9#/"#,,#!$ :;+,, /" !$ < ()*+,' @ , 0 = ! >
8(9#/"#,,#!% :;+,, /" !% < ()*+,' @ , 0 = ! >
8(9#/"#,,#!- :;+,, /" !- < ()*+,' @ , 0 = ! >
8(9#/"#,,#!" :;+,, /" !" < ()*+,' @ , 0 = ! >
8(9#/"#,,#,, :;+,, /" ,, < ()*+,' @ , 0 = ! >
!6#/-&// 6 /- // ()*+/! . $ = = 6 >
!6#/-&/% 6 /- /% ()*+/! . $ = = 6 >
8(9#/"#,,#!' :;+,, /" !' < ()*+/! . $ = = $ >
!/#$/&!, / $/ !, < ()*+/, @ / 0 = , >
!/#$/&!/ / $/ !/ < ()*+/, @ / 0 = , >
!/#$/&!$ / $/ !$ < ()*+/, @ / 0 = , >
!/#$/&!% / $/ !% < ()*+/, @ / 0 = , >
!/#$/&!6 / $/ !6 < ()*+/, @ / 0 = , >
!/#$/&!- / $/ !- < ()*+/, @ / 0 = , >
!/#$/&!' / $/ !' < ()*+/, @ / 0 = , >
!/#$/&,!#A)B / $/ ,! @,!-$A)BC ()*+/, @ / 0 = , >
!/#$/&,, / $/ ,, < ()*+/, @ / 0 = , >
!/#$/&,/ / $/ ,/ < ()*+/, @ / 0 = , >
#$%&'()%
*'+(&)
#$%
&'(
,-. ./0-
&'(1%2'3%
!456
7'189:%23'7%
&'(16
";'(-%(87- <(2-:.9'(
497-%
0'9(.
";'(-%
=
9(.)%
1->6
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! "
!"#$%&'( " $% '( )*+,'% - ' . / % 0
!"#$%&$!#1*2 " $% $! 3%"4!1*25 )*+,'% - ' . / % 0
!"#$%&"( " $% "( )*+,'% - ' . / % 0
!6#'(&$! 6 '( $! )*+,'% - ' . / % 0
!6#'4&%' 6 '4 %' )*+,'% - ' . / % 0
!6#'4&%4,7 6 '4 %4 )*+,'% - ' . / % 0
!6#'4&$! 6 '4 $! )*+,'% - ' . / % 0
!6#'4&$$ 6 '4 $$ )*+,'% - ' . / % 0
!6#$%&!% 6 $% !% )*+,'% - ' . / ' 0
!6#$%&!' 6 $% !' )*+,'% - ' . / ' 0
!6#$%&!( 6 $% !( )*+,'% - ' . / ' 0
!6#$%&!8,7 6 $% !8 )*+,'% - ' . / ' 0
!6#$%&!4 6 $% !4 )*+,'% - ' . / ' 0
!6#$%&%! 6 $% %! )*+,'% - ' . / ' 0
!6#$%&%% 6 $% %% )*+,'% - ' . / ' 0
!6#$%&%' 6 $% %' )*+,'% - ' . / ' 0
!6#$%&%$ 6 $% %$ )*+,'% - ' . / ' 0
!6#$%&%9 6 $% %9 )*+,'% - ' . / ' 0
!6#$%&%4 6 $% %4 :+.; )*+,'% - ' . / ' 0
!6#$%&'! 6 $% '! )*+,'% - ' . / ' 0
!6#$%&'' 6 $% '' )*+,'% - ' . / ' 0
!6#$%&'$ 6 $% '$ )*+,'% - ' . / ' 0
!6#$%&'" 6 $% '" )*+,'% - ' . / ' 0
!6#$%&'9 6 $% '9 :+.; )*+,'% - ' . / ' 0
!6#$%&$! 6 $% $! )*+,'% - ' . / ' 0
!6#$%&$' 6 $% $' )*+,'% - ' . / ' 0
<)=#'8#%%#%$ >?,%% '8 %$ @ )*+,'% - ' . / ' 0
<)=#'8#%%#%" >?,%% '8 %" @ )*+,'% - ' . / ' 0
!'#'!&!%#:11 ' '! !% ="!":11 )*+,'' - 9 . . 6 A
!'#'!&!9 ' '! !9 @ )*+,'' - $ . . " BC
!'#'!&!( ' '! !( @ )*+,'' - $ . . " BC
!'#'!&!8 ' '! !8 @ )*+,'' - $ . . " D
!'#'!&!4 ' '! !4 @ )*+,'' - $ . . " BC
!'#'!&%% ' '! %% @ )*+,'' - $ . . " D
!'#'$&!% ' '$ !% @ )*+,'' - $ . . " BC
!'#'$&!' ' '$ !' @ )*+,'' - $ . . " BC
!'#'$&!" ' '$ !" @ )*+,'' - $ . . " BC
!'#'$&%! ' '$ %! @ :+.;5 )*+,'' - $ . . " D
!'#'$&%% ' '$ %% @ )*+,'' - $ . . " BC
!'#'$&%' ' '$ %' @ )*+,'' - $ . . " BC
!"#'%&!$ " '% !$ )*+,'' - ' . . ' 2
!"#'%&!6 " '% !6 )*+,'' - ' . . ' 2
!"#'%&!4 " '% !4 )*+,'' - $ . . " BC
!"#'%&%! " '% %! )*+,'' - $ . . " BC
!"#'%&%% " '% %% )*+,'' - ' . . ' 2
!"#'%&%$ " '% %$ )*+,'' - $ . . $ B
!"#'%&%"#1*2 " '% %" E"!$1*2 )*+,'' - $ . . " BC
!"#'%&%(#:11 " '% %( E((!:11 )*+,'' - $ . . " BC
!"#'%&%4 " '% %4 )*+,'' - $ . . " BC
!"#'%&'' " '% '' )*+,'' - $ . . $ B
!"#'%&'$ " '% '$ F+G; )*+,'' - ' . . ' 2
!"#'%&'" " '% '" )*+,'' - ' . . ' 2
!"#'%&'( " '% '( )*+,'' - $ . . " D
!"#'%&'8 " '% '8 )*+,'' - $ . . $ B
!"#'%&$!#1*2 " '% $! -%!!$1*25 )*+,'' - ' . . ' 2
!"#'%&$' " '% $' )*+,'' - $ . . " D
!"#'%&$9 " '% $9 )*+,'' - $ . . " BC
!"#'%&$( " '% $( )*+,'' - $ . . " BC
!"#'%&$8#1*2 " '% $8 -%!!$1*25 )*+,'' - ' . . ' 2
!"#'%&"% " '% "% )*+,'' - $ . . " D
!"#'%&"$ " '% "$ )*+,'' - $ . . " BC
%%#%(&!% %% %( !% )*+,'' - $ . . " BC
#$%&'($)'
!*+,
-$&./0'()$-'
#$%&,
12'#$%3'
4$5%#3
12'
#$%
"6$%7'%.-7 8%(709/$%
*/-7'
:$/%9
"6$%7'
;
/%93'
&7<,
=$#& >79 9?:7
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! "
!!"!#$!% !! !# !% &'()** + , - - . /0
%1"*2$!. 1 *2 !. &'()*, + , 3 3 % 4
%5"*2$!! 5 *2 !! &'()*. + * 6 - *7 4
%."*!$%# . *! %# &'()*1 + * 6 3 *7 8
%."*!$!5 . *! !5 &'()*1 + , 6 3 . 8
%,"*2$%! , *2 %! &'()*5 + * 3 3 % 4
%,"*2$*, , *2 *, &'()*5 + * 3 3 % 4
%*"*,$%2 * *, %2 9 &'()*# : , - 3 5 ;
%."*,$*# . *, *# &'()*# : ! - 3 5 <0
%."*,$.!)= . *, .! >?<@'ABC &'()*# : D - 3 D 4
%."*,$.2)= . *, .2 @EFFBG &'()*# : ! - 3 5 8
%."*#$,, . *# ,, &'()*# : 1/ - 3 5 H
%."*#$.I . *# .I &'()*# : 1/ - 3 5 H
%1"*2$*1 1 *2 *1 &'()*# : 1/ - 3 5 H
%1"*2$*2 1 *2 *2 &'()*# : ! - 3 5 <0
%,",*$!* , ,* !* &'()*I : ! 3 3 % 4
%!"*#$%. ! *# %. &'()*2 : , 6 - % 4
%!"*2$%I ! *2 %I &'()*2 : , 6 - % 4
%*"*,$%5 * *, %5 9 &'()*2 : , 6 - % 4
%*"*#$%# * *# %# 9 &'()*2 : , 6 - % 4
%*"*#$!%)= * *# !% &'()*2 : , 6 - % 4
%."*,$,, . *, ,, &'()*2 : , 6 - % 4
%."*#$%, . *# %, &'()*2 : , 6 - % 4
%."*#$*5 . *# *5 &'()*2 : , 6 - % 4
%."*!$*5"AJ?>( . *! *5 &'(),% + ! 3 3 % 4
%."*,$!5 . *, !5 &'(),! + , - - 1 3
%."*,$1% . *, 1% &'(),! + , - - 1 3
%."*#$%5 . *# %5 &'(),! + , - - 1 3
%1"*#$%5 1 *# %5 &'(),! + , - - . /
%1"*2$,* 1 *2 ,* &'(),! + , - - . /
%1",!$!. 1 ,! !. &'(),! + , - - . /
%1",!$!I 1 ,! !I &'(),! + , - - . /
%1",!$*! 1 ,! *! &'(),! + , - - . /
%1",!$,!)= 1 ,! ,! >?<@'ABK &'(),! + , - - . /
%5"*#$%5 5 *# %5 &'(),! + * - - * 4
%.",!$.* . ,! .* &'(),* : * 6 - *7 ?
%.",!$.1 . ,! .1 &'(),* : * 6 - 1 ?
!!",%$!1 !! ,% !1 &'(),, : * - - % 4
!!",%$*! !! ,% *! &'(),, : * - - % 4
!!",%$*# !! ,% *# &'(),, : * - - % 4
!!",%$,5 !! ,% ,5 &'(),, : * - - % 4
%,"*#$!% , *# !% &'(),. : 1/ - 3 1 H
%1",!$*1 1 ,! *1 &'(),1 : ! - 3 5 8
%1",!$*2 1 ,! *2 &'(),1 : ! - 3 5 8
%2"*%$%2 2 *% %2 &'(),5 L *8 - 3 * 4
%."*,$%! . *, %! &'(),# : ! 3 3 . E
%."*,$%5 . *, %5 &'(),# : 5 3 3 . 6
%."*,$%I . *, %I &'(),# : 5 3 3 . 6
%*"*,$%# * *, %# 9 &'(),I : , 6 3 % 4
%*"*2$%, * *2 %, 9 &'(),2 + ! - 3 % 4
%*"*2$%.)= * *2 %. >?<@'ABK &'(),2 + ! - 3 % 4
%1"*2$%* 1 *2 %* &'(),2 + ! - 3 % 4
%1",!$%. 1 ,! %. &'(),2 + ! - 3 % 4
%1",!$!1 1 ,! !1 &'(),2 + ! - 3 % 4
%5"*,$%* 5 *, %* &'(),2 + ! - 3 % 4
%5"*,$!* 5 *, !* &'(),2 + ! - 3 % 4
%*"*#$%! * *# %! 9 &'().% + * - - * 4
%*"*#$%5 * *# %5 9 &'().% + * - - ! 4
%*"*#$%I * *# %I 9 &'().% + * - - ! 4
%*"*#$!! * *# !! 9 &'().% + * - - ! 4
%*"*#$!* * *# !* 9 &'().% + * - - ! 4
%."*,$!% . *, !% &'().% + * - - * 4
#$%&'()%
*'+(&)
#$%
&'(
,-. ./0-
&'(1%2'3%
!456
7'189:%23'7%
&'(16
";'(-%(87- <(2-:.9'(
497-%
0'9(.
";'(-%
=
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! "
!"#$%&$'#()* " $% $' +,$%()*- .)/0"! + $ 1 1 2 3
!'#$%&24 ' $% 24 .)/0"2 + $ 5 5 ! 3
!$#$%&!, $ $% !, 6 .)/0"$ 7 2 1 1 ! 3
!$#$4&!2 $ $4 !2 6 .)/0"% + $ 1 1 $ 3
2$#%!&!" 2$ %! !" .)/0"% + $ 1 1 $ 3
!'#$%&2% ' $% 2% .)/0"" 8 $ 1 5 ! 3
!"#$9&!$ " $9 !$ .)/0"' 8 $ 5 5 ! 3
!"#$%&$! " $% $! .)/0": + $ 1 1 2 3
!"#$%&!" " $% !" .)/0"9 + $ 5 5 ! 3
!'#$%&!$ ' $% !$ .)/0", + $ 1 1 : ;
!%#$4&!" % $4 !" .)/0"4 + $ < 1 =2> 3
!%#$4&$" % $4 $" .)/0"4 + $ < 1 ! 3
!"#$%&!% " $% !% .)/0"4 + $ < 1 ! 3
!"#$9&2! " $9 2! .)/0"4 + $ < 1 ! 3
!"#$4&!2 " $4 !2 .)/0"4 + $ < 1 ! 3
!"#$4&!% " $4 !% .)/0"4 + $ < 1 ! 3
!"#$4&!' " $4 !' .)/0"4 + $ < 1 ! 3
!"#$4&2$ " $4 2$ .)/0"4 + $ < 1 ! 3
!"#$4&%: " $4 %: .)/0"4 + $ < 1 ! 3
!"#%2&%$#()* " %2 %$ +2!44()*- .)/0"4 + $ < 1 ! 3
!"#%2&"2 " %2 "2 .)/0"4 + $ < 1 ! 3
!"#$2&$2 " $2 $2 .)/0'! + $ 5 5 2 3
!'#%2&!%0? ' %2 !% @AB*)(CD .)/0'! + $ 5 5 : E
!'#%2&29 ' %2 29 .)/0'! + $ 5 5 : E
!'#%2&%% ' %2 %% .)/0'! + $ 5 5 : E
!%#$4&!$ % $4 !$ .)/0'2 + : < 1 ! 3
!%#$4&2$ % $4 2$ .)/0'2 + : < 1 ! 3
!'#$%&!'#A(( ' $% !' +2!,"A(( .)/0'2 + : < 1 ! 3
!'#$%&$$ ' $% $$ .)/0'2 + : < 1 ! 3
!'#$%&$% ' $% $% .)/0'2 + : < 1 ! 3
!'#$%&$' ' $% $' .)/0'2 + : < 1 ! 3
!$#$4&!4 $ $4 !4 6 .)/0'$ + $ 5 5 ! 3
!'#$%&2" ' $% 2" .)/0'% + 'A 5 5 ! 3
!%#$4&$! % $4 $! .)/0'" + 'A 5 5 : ;
!"#%2&!$ " %2 !$ .)/0'" + 'A 5 5 : ;
!"#%2&!% " %2 !% .)/0'" + 'A 5 5 : ;
!"#%2&!" " %2 !" .)/0'" + 'A 5 5 ' ;
!"#%2&!4 " %2 !4 .)/0'" + 'A 5 5 $F ;
!"#%2&22 " %2 22 .)/0'" + 'A 5 5 : ;
!"#%2&2$ " %2 2$ .)/0'" + 'A 5 5 : ;
!"#%2&2%0? " %2 2% @AB*)(CG .)/0'" + H 5 5 H 3
!"#%2&2" " %2 2" .)/0'" + 'A 5 5 : ;
!"#%2&$4 " %2 $4 .)/0'" + 'A 5 5 ' ;
!%#$9&!" % $9 !" .)/0'' + % 1 5 " @
!%#$9&!: % $9 !: .)/0'' + % 1 5 " @
!%#$9&!9 % $9 !9 .)/0'' + % 1 5 " @
!"#$%&%'#()* " $% %' +22'"()*- .)/0': 8 $ 1 5 ' A
!'#$9&2" ' $9 2" .)/0': 8 % 1 5 " I
!'#$4&!% ' $4 !% .)/0': 8 % 1 5 " I
!$#$9&!$ $ $9 !$ .)/0'9 8 : 1 5 " <
!$#$4&!$ $ $4 !$ .)/0'9 8 : 1 5 " <
!$#$4&!: $ $4 !: .)/0'9 8 : 1 5 " <
!$#$4&22 $ $4 22 .)/0'9 8 : 1 5 " <
!"#$2&$' " $2 $' J/K< .)/0', + 2( 1 5 : J
!2#$4&!: 2 $4 !: .)/0'4 + $ 1 1 2 3
!$#$4&!9 $ $4 !9 6 .)/0'4 + $ 1 1 2 3
!%#$9&!% % $9 !% .)/0'4 + $ 1 1 2 3
!%#$4&$2 % $4 $2 .)/0'4 + $ 1 1 2 3
!'#$%&29#()* ' $% 29 +'::()*- .)/0'4 + $ 1 1 $F AL
!'#$%&$2#()* ' $% $2 +'::()*- .)/0'4 + $ 1 1 $F AL
!'#$9&2! ' $9 2! .)/0'4 + $ 1 1 $ 3
2!#%!&!:#()* 2! %! !: +2!,9A((- .)/0'4 + $ 1 1 $F AL
#$%&'($)'
!*+,
-$&./0'()$-'
#$%&,
12'#$%3'
4$5%#3
12'
#$%
"6$%7'%.-7 8%(709/$%
*/-7'
:$/%9
"6$%7'
;
/%93'
&7<,
=$#& >79 9?:7
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! "
!"#$%&!' " $% !' ()*+'! , - . / 0 1
!"#$%&-' " $% -' ()*+'! , - . / 0 1
!0#23&2" 0 23 2" ()*+'- , 2 4 / ! 5
!%#2-&$0 % 2- $0 ()*+'2 , 06 . . 0 5
!%#2$&!3 % 2$ !3 ()*+'2 , 06 . . - 5
--#27&!0 -- 27 !0 ()*+'2 , 06 . . 0 5
!%#2$&!2 % 2$ !2 ()*+'$ 8 2 4 . - 5
!%#2$&!0 % 2$ !0 ()*+'$ 8 2 4 . - 5
--#$!&!% -- $! !% ()*+'$ 8 2 4 . 2 5
--#$!&-3 -- $! -3 ()*+'$ 8 2 4 . 2 5
!2#27&!$ 2 27 !$ 9 ()*+'% , $ . . 0 &:
!2#27&!% 2 27 !% 9 ()*+'% , $ . . 0 &:
!2#27&!0 2 27 !0 9 ()*+'% , $ . . 0 &:
!$#$2&!" $ $2 !" ()*+'% , $ . . 0 &:
!%#27&22 % 27 22 ()*+'% , 2 . . 0 ;
!%#23&!7 % 23 !7 ()*+'% , 2 . . 0 ;
!0#27&!2 0 27 !2 ()*+'% , 2 . . 0 ;
!0#27&!0 0 27 !0 ()*+'% , 2 . . 2< )
!0#27&2'= 0 27 2' ()*+'% , 2 . . 0 ;
!0#23&2' 0 23 2' ()*+'% , 2 . . 2< )
!-#$2&!0 - $2 !0 >*?4 ()*+'0 , 06 / / ! 5
!2#23&!" 2 23 !" 9 ()*+'' 8 $ / / ! 5
!2#$2&!" 2 $2 !" 9 ()*+'7 , 2 4 / 0 @
!%#2-&!- % 2- !- ()*+'" 8 $ / / ! 5
!%#2-&$- % 2- $- ()*+'" 8 $ / / ! 5
!0#2$&-- 0 2$ -- ()*+'" 8 0A / / B%C @
--#$!&-$ -- $! -$ ()*+'" 8 $ / / ! 5
--#$!&$- -- $! $- ()*+'" 8 $ / / ! 5
--#$!&$2 -- $! $2 ()*+'" 8 $ / / ! 5
--#$!&$7 -- $! $7 ()*+'" 8 $ / / ! 5
!%#27&-2 % 27 -2 ()*+'3 , $ / / ! 5
!%#27&-$#6;; % 27 -$ D72!6;; ()*+'3 , $ / / ! 5
!%#27&-0 % 27 -0 ()*+'3 , $ / / ! 5
!%#23&!" % 23 !" ()*+'3 , $ / / ! 5
!%#23&!3 % 23 !3 ()*+'3 , $ / / ! 5
!%#23&-% % 23 -% ()*+'3 , $ / / ! 5
!%#23&-0 % 23 -0 ()*+'3 , $ / / ! 5
!0#27&-- 0 27 -- ()*+'3 , $ / / B%C @
!0#23&!3 0 23 !3 ()*+'3 , $ / / B%C @
!0#2$&!' 0 2$ !' >*?4 ()*+7! 8 2 4 / ! 5
!0#2$&!3 0 2$ !3 ()*+7- , 2 4 / ! 5
!%#2$&-$#6;; % 2$ -$ ,7-%6;; ()*+72 , $ 4 / ! 5
--#-%&!2 -- -% !2 ()*+7$ 8 2 / / ! 5
--#-%&!% -- -% !% ()*+7$ 8 2 / / ! 5
--#-%&!0 -- -% !0 ()*+7$ 8 2 / / ! 5
--#-%&!' -- -% !' ()*+7$ 8 2 / / ! 5
--#-%&!7 -- -% !7 ()*+7$ 8 2 / / ! 5
--#-%&!" -- -% !" ()*+7$ 8 2 / / ! 5
-2#-!&!2 -2 -! !2 ()*+7$ 8 2 / / ! 5
-2#-!&!- -2 -! !- ()*+7% , 2 . / 0 @
-!#-!&!3+E -! -! !3 F6GH);=I ()*+70 2 / / ! 5
--#-%&!$ -- -% !$ ()*+70 , 2 / / ! 5
--#2-&!$ -- 2- !$ ()*+70 , 2 / / ! 5
--#2-&!' -- 2- !' ()*+70 , 2 / / ! 5
--#2-&!" -- 2- !" ()*+70 , 2 / / ! 5
-2#-!&!$ -2 -! !$ ()*+70 , 2 / / ! 5
-2#-!&!' -2 -! !' ()*+70 , 2 / / ! 5
--#2-&!-+E -- 2- !- F6GH);=I ()*+7' ' . / ! 5
-2#-!&!7 -2 -! !7 ()*+7' , ' . / ! 5
-2#-!&!" -2 -! !" ()*+7' , ' . / ! 5
-2#-!&!3 -2 -! !3 ()*+77 , 2 . / ! 5
#$%&'()%
*'+(&)
#$%
&'(
,-. ./0-
&'(1%2'3%
!456
7'189:%23'7%
&'(16
";'(-%(87- <(2-:.9'(
497-%
0'9(.
";'(-%
=
9(.)%
1->6
?'&1
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Table 7.2.  Clone sequence details.  Column ‘int seq?’ indicates the clones that were 
sequenced with an internal primer.  ‘Mods’ indicates manual modifications made to the 
sequences (e.g. ‘A132del’ indicates that an ‘A’ at 132 was deleted, removing a frameshift 
and providing a sequence amenable to analysis) and/or abnormalities associated with the 
sequences.  Abnormalities included in-frame stop codons (‘stop’), failed forward or reverse 
reads, or in two cases, the loss of a part of the sequence.  ‘Atyp’ indicates an atypical GPI 
anchor as a result of a frameshift towards the very 3’-most end of the sequence.  A tilde (‘~’) 
indicates that the associated abnormality was associated with a tract of A or T nucleotides, 
and thus may have come about by polymerase slippage, and a ‘|’ indicates it was due to 
possible sequence loss.  ‘Dons for NTD?’ indicates whether a suitable (set of) donor(s) has 
been found for the NTD-encoding part of the gene (described in Table 7.2.8).  ‘Mosaic from 
dons?’ indicates whether the expressed clone is an apparent mosaic from comparisons 
with the donor sequences.  ‘3’ don bound.’ indicates whether the expressed VSG has 
undergone 3’ donation, and where, the expressed sequence diverges from the NTD donors.  
The code is as follows: ‘1’ = within GPI anchor sequence, ‘2’ = between GPI anchor 
sequence and C-terminal-most cysteine, ‘3’ within cysteines of C-terminal-most subdomain, 
‘4’ = between subdomains, ‘5’ = within cysteines of N-terminal-most subdomain, ‘6’ = 
upstream of N-terminal most subdomain.  For one-subdomain CTDs, categories ‘3’ and ‘4’ 
were removed, whereas for type 2 CTDs, which have a more extensive region between the 
C-terminal-most cysteine and the GPI anchor, ‘2+’ indicates that the boundary was closer to 
the cysteine than to the GPI anchor.  Where the code is in curly brackets, identification was 
by comparing clones.  ‘3’ don’ indicates the source of the 3’ donor sequence, if known (see 
Chapter 4 section 4.4.4).  ‘—‘ = donors not sought, ‘?’ = donor could not be found, ‘*’ = 
identical patterns in multiple infections.  
  
! "
!"#$%&'" " $% '" ()*+%, - ' . . ! /
!"#$0&'1+2 " $0 '1 3456)789 ()*+%, - ' . . ! /
!"#$0&$$ " $0 $$ ()*+%, - ' . . ! /
!:#$0&'% : $0 '% ()*+%0 ; : < . 1 =
!"#$%&:' " $% :' ()*+,! ; ' > . " /
'!#'!&!1 '! '! !1 ()*+,' - ' > . ! /
'!#'!&!, '! '! !, ()*+,' - ' > . ! /
'!#'!&'$ '! '! '$ ()*+,' - ' > . ! /
!:#$%&!' : $% !' ()*+,$ ; : > . ! /
!:#$%&'' : $% '' ()*+,$ ; : > . ! /
'!#'!&!' '! '! !' ()*+,$ ; : > . ! /
'!#'!&!% '! '! !% ()*+,: - $ > . ! /
!'#$0&!: ' $0 !: ()*+,? ; $ . . ' /
!1#$%&!' 1 $% !' ()*+,? ; $ . . ' /
!1#$%&!$#)75* 1 $% !$ @*A<8 ()*+,? ; $ . . ' /
!1#$%&!: 1 $% !: ()*+,? ; $ . . ' /
!1#$%&!? 1 $% !? ()*+,? ; $ . . ' /
!1#$%&!" 1 $% !" ()*+,? ; $ . . ' /
!1#$%&!%#)75* 1 $% !% -0:04778 ()*+,? ; $ . . ' /
!1#$%&!, 1 $% !, ()*+,? ; $ . . ' /
!1#$%&!0 1 $% !0 ()*+,? ; $ . . ' /
!1#$%&'! 1 $% '! ()*+,? ; $ . . ' /
!1#$%&''#)75* 1 $% '' @*A<8-':$7)68 ()*+,? ; $ . . ' /
!1#$0&!' 1 $0 !' ()*+,? ; $ . . ' /
!1#$0&!$ 1 $0 !$ ()*+,? ; $ . . ' /
!1#$0&!: 1 $0 !: ()*+,? ; $ . . ' /
!1#$0&!? 1 $0 !? ()*+,? ; $ . . ' /
!1#$0&!1 1 $0 !1 ()*+,? ; $ . . ' /
!1#$0&!0 1 $0 !0 ()*+,? ; $ . . ' /
!1#$0&'$ 1 $0 '$ ()*+,? ; $ . . ' /
'!#:!&!' '! :! !' 6A@@8B ()*+,? ; # . . / /
'!#:!&!? '! :! !? ()*+,? ; $ . . $ /
'!#:!&!, '! :! !, ()*+,? ; $ . . $ /
'!#:!&!0 '! :! !0 ()*+,? ; $ . . $ /
'!#:!&'$ '! :! '$ ()*+,? ; $ . . $ /
'$#:!&!$ '$ :! !$ ()*+,? ; $ . . $ /
'$#:!&!: '$ :! !: ()*+,? ; $ . . $ /
'$#:!&'! '$ :! '! ()*+,? ; $ . . $ /
'$#:!&'' '$ :! '' ()*+,? ; $ . . $ /
#$%&'($)'
!*+,
-$&./0'()$-'
#$%&,
12'#$%3'
4$5%#3
12'
#$%
"6$%7'%.-7 8%(709/$%
*/-7'
:$/%9
"6$%7'
;
/%93'
&7<,
=$#& >79 9?:7
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7.2.4 ‘Genomic VSG database’ 
The ‘genomic VSG database’ was obtained in May 2010 by collecting all available 
VSG sequences from both TriTrypDB (Aslett et al., 2010) (using the text search 
query ‘vsg’ and applying a filter to TREU 927/4 genes) and from VSGdb (all 
entries) (Marcello et al., 2007).  The list was made non-redundant by removing 
duplicate sequences.  Where sequences in the two databases differed, the 
TriTrypDB sequence was favoured, unless the VSGdb sequence better matched 
the expressed clone sequence(s). 
 
7.2.5 ‘Reads database’ 
The ‘reads database’ was obtained in December 2011 by collecting the following 
files from ftp://ftp.sanger.ac.uk/pub/databases/T.brucei_sequences/ : 
T_brucei_chrIXa_reads.20Oct2001, T_brucei_chrIXa_reads.29May03, T_brucei_chrIXb_reads.20Oct2001, 
T_brucei_chrIXb_reads.29May03, T_brucei_chrI_reads.03Feb2000, T_brucei_chrXI_reads.V1_17Oct2002, 
T_brucei_chrXI_reads.V2_14Mar2003.fas, T_brucei_chrXI_reads.V3_11Jul03.fas, 
T_brucei_chrX_reads.03Mar2003, T_brucei_chrX_reads.20Oct2001, T_brucei_chrX_reads.30Apr2001, 
T_brucei_reads.21Dec1999, TbchrIXa_reads_26May04.fas, TbchrIXb_reads_26May04.fas, 
Tb927_IC_II_reads.fas, Tb927_IC_I_reads.fas, 177bp_repeat.dnaTb927_MC_cons.dna.crunch, 
177bp_repeat.dnaTb927_MC_test_reads.dna.crunch, 927MC_readsII.fas, 927MC_readsIII.fas, 
927MC_readsIV.fas, 927MC_readsV.fas, 927MC_readsVI.fas, 927MC_readsVII.fas, 927mcIII_v1.cons, 
927mcII_v1.cons, 927mcIV_v1.cons, 927mcIX_v1.cons, 927mcVIII_v1.cons, 927mcVII_v1.cons, 
927mcVI_v1.cons, 927mcV_v1.cons, Tb927MC_telo1_contigs.fas, Tb927MC_telo2_contigs.fas, 
Tb927MC_telo2_v2contigs.fas, Tb927MC_telo9_contigs.fas, Tb927MC_telo9_v2contigs.fas, 
Tb927MCtelo_1_test.fas, Tb927MCtelo_2_test.fas, Tb927MCtelo_9_test.fas, Tb927_MC.cons, 
Tb927_MCIX_contigs_6Mar08.fas, Tb927_MC_III_reads.fas, Tb927_MC_II_reads.fas, Tb927_MC_IV_reads.fas, 
Tb927_MC_IX_reads.fas, Tb927_MC_VIII_reads.fas, Tb927_MC_VII_reads.fas, Tb927_MC_VI_reads.fas, 
Tb927_MC_V_reads.fas, Tb927_MC_test_reads.fas, Tb927_MC_testreads_newlib.fas, uniprot-1-
xTb927_MC_cons.dna.crunch, uniprot-1-xTb927_MC_test_reads.dna.crunch, TPunknown_May06.cons, 
Tbrucei_extrachr_testreads_Dec05.fas, chr_unknown_test_reads_Jan06.fas 
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7.2.6 Read assemblies 
!""#$%&'()*$#( +#,( -#*."( +/012#(
!"#$%&'''(
)*+#&,--.$*/01 2.3&+41
!"#$%&'''()*+#56)71 8*!"#&9:&3.-3;.,<-&=.>/?*5@,-1
!"#$%&'''()*+#5A)7(;.B1 8*!"#&9:&3.-3;.,<-&=.>/?*5@,-1
!"#$%&'''(+)*+)5A)7(;.B1 8*!"#&9:'''&;.,<-5@,-1
3;06&C(DE*)"5A)%(
;.B&,--.$*/01 2.3&+E1
3;06&C(DE*)"5A)%(;.B1 8&*;F%.?&%G;C&;.,<-54+H6;"++)1
3;06&C'(!)+*)+5A)71 8&*;F%.?&%G;C'&;.,<-5I4&))JF/+45@,-1
!"#$%&I'(
K*+"&,--.$*/01 2.3&+D1
!"#$%&I'(K*+"56)71 8*!"#&9:&I'&;.,<-5@,-1
!"#$%&I'(K*+"5A)7(;.B1 8*!"#&9:&I'&;.,<-5@,-1
!"#9:&I(+),+!56)71 !"#9:&;.,<-I5@,-1
!"#9:&I'(+)%)+5A)7(
;.B1
!"#9:&;.,<-I'5@,-1
!"#9:&I(+),+!5A)7(;.B1 !"#9:&;.,<-I5@,-1
3;06&C'(
)+4EL))&,--.$*/01 2.3&)E1
3;06&'C,("EG+!5A)%(;.B1 8&*;F%.?&%G;'C,&;.,<-5"+M%3"++)1
3;06&C'()+4EL))56)71 8&*;F%.?&%G;C'&;.,<-5I4&))JF/+45@,-1
3;06&C'()+4EL))5A)7(;.B1 8&*;F%.?&%G;C'&;.,<-5I4&))JF/+45@,-1
3;06&C'(
!4E<)"&,--.$*/01 2.3&)K1
3;06&C'(!4E<)"5A)7(;.B1 8&*;F%.?&%G;C'&;.,<-5I4&))JF/+45@,-1
3;06&C(44E<+K56)%1 8&*;F%.?&%G;C&;.,<-5+49,;"++41
3;06&'C*(
"4E%+4&,--.$*/01 2.3&)#1
3;06&'C*("4E%+45A)%(;.B1 8&*;F%.?&%G;'C*&;.,<-5"!9,0+41
3;06&'C*()D)<+D(6)%(;.B1 8*%G;'C*&;.,<-&"K9,0+E5@,-1
3;06&C'(
)+DN<+)&,--.$*/01 2.3&)#1
3;06&C'()+DN<+)5A)71 8&*;F%.?&%G;C'&;.,<-5I4&))JF/+45@,-1
3;06&C'())").))56)71 8&*;F%.?&%G;C'&;.,<-5I4&))JF/+45@,-1
!"#$%&I'(N,+#56)7(;.B1 8*!"#&9:&I'&;.,<-5@,-1
3;06&'C,(
"!*+"5A)%&,--.$*/01 2.3&"D1
3;06&'C,("!*+"5A)%1 8&*;F%.?&%G;'C,&;.,<-5"+M%3"++)1
3;06&'C*(4+)L+N56)%1 8&*;F%.?&%G;'C*&;.,<-5"!9,0+41
!"#$%&'I(
D.))&,--.$*/01 2.3&"!1
!"#$%&'I(D.))56)71 8*!"#&9:&'I&;.,<-5@,-1
!"#$%&'I(D.))5A)71 8*!"#&9:&'I&;.,<-5@,-1
3;06&'C,(
)+@+"&,--.$*/01 2.3&4"1
!"#$%&'C()+<+"5A)71 8*!"#&9:&'C&;.,<-5@,-1
3;06&'C,()+@+"56)%1 8&*;F%.?&%G;'C,&;.,<-5"+M%3"++)1
3;06&'C,(
"+,+D&,--.$*/01 2.3&D)1
3;06&'C,("+,+D56)%1 8&*;F%.?&%G;'C,&;.,<-5"+M%3"++)1
3;06&'C,(K<))5A)%1 8&*;F%.?&%G;'C,&;.,<-5"+M%3"++)1
3;06&'C*()D4%+456)%(;.B1 8&*;F%.?&%G;'C*&;.,<-5"!9,0+41
3;06&'C,(
"!.)"&,--.$*/01 2.3&DE1
3;06&'C,("!.)"56)%1 8&*;F%.?&%G;'C,&;.,<-5"+M%3"++)1
3;06&'C,(E,)"56)%1 8&*;F%.?&%G;'C,&;.,<-5"+M%3"++)1
3;06&'C*(4K)*+#56)%1 8&*;F%.?&%G;'C*&;.,<-5"!9,0+41
Table 7.3 Read assemblies.  ‘Source’ refers to the file in which the read sequence was found 
(see section 7.2.5), ‘Set’ refers to the set for which the read assembly is putative donor.  
Table continues on following pages.  
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!""#$%&'()*$#! +#,! -#*."! +/012#!
"#$%&'())*+,&-../012$! 3/"&45!
)6708&9:(;<++=%+>(#/?! @1)67&AB&9:&#/-<.=*-.!
)6708&:9(+,<,7=%+>! @1)67&AB&:9&#/-<.=*-.!
"#$%&'(+),8+,=C+8(#/?! @&1#D8/E&8F#'&#/-<.=;,G%#6,,+!
"#$%&'(6+5-,4=C+8(#/?! @&1#D8/E&8F#'&#/-<.=;,G%#6,,+!
"#$%&'(6HI/,I=C+8! @&1#D8/E&8F#'&#/-<.=;,G%#6,,+!
"#$%&'(6771+,=C+8! @&1#D8/E&8F#'&#/-<.=;,G%#6,,+!
"#$%&'(;;I*,+=C+8(#/?! @&1#D8/E&8F#'&#/-<.=6,J8"6,,+!
"#$%&'(;H8,;=C+8! @&1#D8/E&8F#'&#/-<.=;,G%#6,,+!
"#$%&'())*+,=%+8! @&1#D8/E&8F#'&#/-<.=;,G%#6,,+!
"#$%&'9(+5;<,;=C+8-(#/?! @&1#D8/E&8F#'9&#/-<.=:6&+5A-#6,,
;=*-.!"#$%&'9(
++47-,5&-../012$! 3/"&4)!
"#$%&'9(++47-,5=%+>! @&1#D8/E&8F#'9&#/-<.=:;&++KD2,;=*-.!
"#$%&'9(++47-,5=C+>(#/?! @&1#D8/E&8F#'9&#/-<.=:;&++KD2,;=*-.!
"#$%&9'-(
+,<,+&-../012$! 3/"&7+!
"#$%&9'-(64L,5=C+8(#/?! @&1#D8/E&8F#9'-&#/-<.=6,J8"6,,+!
"#$%&9'-(+,<,+=C+8(#/?! @&1#D8/E&8F#9'-&#/-<.=6,J8"6,,+!
"#$%&'9(
+,,)-,4&-../012$! 3/"&76!
"#$%&9'-(7-++=%+8(#/?! @&1#D8/E&8F#9'-&#/-<.=6,J8"6,,+!
"#$%&'9(+,,)-,4=%+>(#/?! @&1#D8/E&8F#'9&#/-<.=:;&++KD2,;=*-.!
"#$%&'9(+,44*,+=%+>(#/?! @&1#D8/E&8F#'9&#/-<.=:;&++KD2,;=*-.!
"#$%&'9(
;);*,I&-../012$! 3/"&75!
"#$%&'9(;);*,I=C+>! @&1#D8/E&8F#'9&#/-<.=:6&+5A-#6,,
;=*-.!"#$%&'9()5)1,6=C+>(#/?! @&1#D8/E&8F#'9&#/-<.=:;&++KD2,;=*-.!
"#$%&'9(+,)IL,+=C+>(#/?! @&1#D8/E&8F#'9&#/-<.=:;&++KD2,;=*-.!
"#$%G;+L)=C+"(#/?! @&1#D8/E&8F#9&#/-<.=,;M/16,,,!
"#$%G6)-+,=%+%(#/?! @&1#D8/E&8F#9&#/-<.=,;M/16,,,!
"#$%&'9(6,5*,5=%+8(#/?! @&1#D8/E&8F#'9&#/-<.=:6&+5A-#6,,
;=*-.!"#$%&'(5I*,5=%+8(#/?! @&1#D8/E&8F#'&#/-<.=;,G%#6,,+!
"#$%&'9(;);*,I=%+>(#/?! @&1#D8/E&8F#'9&#/-<.=:6&+5A-#6,,
;=*-.!
"#$%&9'1(
;748+,&-../012$! 3/"&7H!
"#$%&9'1(;748+,=%+8! @&1#D8/E&8F#9'1&#/-<.=6)A-$,;!
"#$%&9'1(H6/,)=C+8(#/?! @&1#D8/E&8F#9'1&#/-<.=6)A-$,;!
"#$%&9'1(;;5L+6=%+8(#/?! @&1#D8/E&8F#9'1&#/-<.=6)A-$,;!
"#$%&'9(+++7F,5=C+>! @&1#D8/E&8F#'9&#/-<.=:;&++KD2,;=*-.!
"#$%&9'1(6751+,=C+8(#/?! @&1#D8/E&8F#9'1&#/-<.=6)A-$,;!
"#$%&9'1(+/+6=C+8(#/?! @&1#D8/E&8F#9'1&#/-<.=6)A-$,;!
"#$%&9'1(6I6<++=C+8! @&1#D8/E&8F#9'1&#/-<.=6)A-$,;!
"#$%&9'1(;56L,4=%+8(#/?! @&1#D8/E&8F#9'1&#/-<.=6)A-$,;!
"#$%&9'1(;748+,=C+8(#/?! @&1#D8/E&8F#9'1&#/-<.=6)A-$,;!
"#$%&'9(+++7F,5=%+>(#/?! @&1#D8/E&8F#'9&#/-<.=:;&++KD2,;=*-.!
"#$%&9'1(+64F,H=C+8(#/?! @&1#D8/E&8F#9'1&#/-<.=6)A-$,;!
"#$%&9'1(6I6<++=%+8(#/?! @&1#D8/E&8F#9'1&#/-<.=6)A-$,;!
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!""#$%&'()*$#! +#,! -#*."! +/012#!
"#$%&'()
*+,-.+&/001234$! 51"&66!
"#$%&'()7.+837.9%7:)#1;! <&3#=>1?&>-#'(&#1/@09A*&77B=4.*9C/0!
"#$%&'()77+D1.E9%7:F)
#1;!
<&3#=>1?&>-#'(&#1/@09A*&77B=4.*9C/0!
"#$%&'()77*G1.E9H7:! <&3#=>1?&>-#'(&#1/@09A*&77B=4.*9C/0!
"#$%&'()+*DC.79%7>)#1;! <&3#=>1?&>-#'(&#1/@09A+&78I/#+..
*9C/0!"#$%&'()*+,-.+9H7:)#1;! <&3#=>1?&>-#'(&#1/@09A+&78I/#+..
*9C/0!"#$%&'()*+,-.+9H7:/)#1;! <&3#=>1?&>-#'(&#1/@09A+&78I/#+..
*9C/0!"#$%&'()**.C.+9H7:! <&3#=>1?&>-#'(&#1/@09A+&78I/#+..
*9C/0!"#$%&'()**.C.+9H7:/! <&3#=>1?&>-#'(&#1/@09A+&78I/#+..
*9C/0!"#$%&'()G7+/.79%7:)#1;! <&3#=>1?&>-#'(&#1/@09A*&77B=4.*9C/0!
G+62>&((()
61.,&/001234$! 51"&6G!
G+62>&((()61.,9%7:! <3G+6&IJ&(((&#1/@09C/0!
G+62>&((()61.,9H7:! <3G+6&IJ&(((&#1/@09C/0!
G+62>&A()
8/7+&/001234$! 51"&D.!
G+62>&A()8/7+9%7:! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A(),@.*9%7:! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A)D@779%7:! <3G+6&IJ&A&#1/@09C/0!
G+62>&A)7@.*9H7:)#1;! G+62>A&;79>KL0!
G+62>&A()7+>.79H7:)#1;! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A()G>7.9H7:! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A()77M.89%7:)#1;! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A()
8M.*&/001234$! 51"&D7!
G+62>&A()8M.*9H7:! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A)E@.*9H7:! <3G+6&IJ&A&#1/@09C/0!
G+62>&A()+M7+9H7:! <3G+6&IJ&"10"#1/@0&L1F4?39C/0!
G+62>&A)E@.,9%7:! <3G+6&IJ&A&#1/@09C/0!
G+62>&A()7.1.69H7:! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A()
E>.,&/001234$! 51"&D+!
G+62>&A()E>.,9%7:)#1;! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A()E>.,9H7:)#1;! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A()8/.,9%7:)#1;! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A(),1779%7:! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A(),1779H7:)#1;! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A(),-.+9%7:! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A()61.E9H7:)#1;! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A()7*>.*9H7:! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A(()
7*-.6&/001234$! 51"&D*!
G+62>&A(()7*-.69%7:)
#1;!
<3G+6&IJ&A((&#1/@09C/0!
G+62>&A(()7*-.69H7:)
#1;!
<3G+6&IJ&A((&#1/@09C/0!
G+62>&A((),-.79%7:)#1;! <3G+6&IJ&A((&#1/@09C/0!
G+62>&A(()6M.*9H7:)#1;! <3G+6&IJ&A((&#1/@09C/0!
G+62>&A((()7C.D9H7:)#1;! <3G+6&IJ&"10"#1/@0&L1F4?39C/0!
G+62>&A(()77>.,9%7:! <3G+6&IJ&A((&#1/@09C/0!
G+62>&A()77C779%7:)#1;! <3G+6&IJ&A(&#1/@09C/0!
G+62>&A((()
78@.G&/001234$! 51"&D8!
G+62>&A((()78@.G9%7:! <3G+6&IJ&A(((&#1/@09C/0!
G+62>&A((()78@.G9H7:! <3G+6&IJ&A(((&#1/@09C/0!
G+62>&(A),-779%7:! <3G+6&IJ&(A&#1/@09C/0!
G+62>&A((),/.,9H7:)#1;! <3G+6&IJ&A((&#1/@09C/0!
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!""#$%&'()*$#! +#,! -#*."! +/012#!
!"#$%&'()***+
,"-.(/001&234! 516(78!
#$%&'()***+,"-.9:-;+<1=! >2#$%(?@()***(<1/"09A/0!
#$%&'()***+,"-.9B-;+<1=! #$%&')***(=-9'CD0!
#$%&'()***+-,2.89B-;! >2#$%(?@()***(<1/"09A/0!
#$%&'()***+-E"-.9B-;+
<1=!
>2#$%(?@()***(<1/"09A/0!
 
Table 7.3 (continued) 
 
7.2.7 Number of sets detected across infection 
 
Table 7.4 Number of sets detected at different timepoints.  The table shows, for the 22 
infections under consideration, the number of sets detected at each timepoint.  The row and 
column totals do not equal the sums of the row or column as some sets were detected in 
multiple infections and timepoints. 
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7.2.8 Genomic copies 
!"#$ %&'(($ )*+*,-(.$ )*+*,$
/&'(($
01#23"$ %1#23"$
!"#$%&' ()*+,"' -.&%/01/%%%&' 2' 3' 42'
!"#$%4' 5*6*78*' 9*6*78*' :' '' ''
!"#$%;' <=' >4?<=$@@@A&.%?$2(("<.,B' )C<' 3' D'
!"#$%1' <7(2)=' #EBF$GAH1.&4/I&=AE"0$2(("<.,B' )CE' J' A'
'' '' -.&%/01/%%D&' *=CF' J' ;'
!"#$%H' <=' >4?<=$K@AD.%4$2(("<.,B' )C<' 3' H'
!"#$%D' 5*6*78*' 9*6*78*' :' '' ''
!"#$%?' 5*6*78*' 9*6*78*' :' '' ''
!"#$%L' ()*+,"' -.%>/01/%%??' M' J' 4'
!"#$%>' ()*+,"' -.%>/411/&HL%' M' 3' ;'
!"#$&%' <7(2)=' -.&&/;&/%%%&' M' 3' D'
'' '' -.&%/01/%&D&' *CF' 3' D'
'' '' -.&&/&1/%%%&' *CF' 3' D'
!"#$&&' <7(2)=' -.>4?/;/&>%' M' 3' 4'
'' '' 9*6*78*' :' '' ''
!"#$&4' ()*+,"' -.&&/;%/%%%H' =CF' 3' 1'
!"#$&;' ()*+,"' -.%>/01/%&%4' 2' J' ;5'
!"#$&1' <7(2)=' -.&&/%>/%%%H' 2' J' &5'
'' '' -.&&/&;/%%%;' *CF' J' ;'
'' '' #EBF$G@A&%;1+&&$2(("<.,B' *=CE' J' N'
'' '' -.&%/01/%%%>' *CF' J' 4'
!"#$&D' <7(2)=' -.&&/1L/%%%;' =CF' 3' ;'
'' '' #EBF$G@A>;1N&4/I&6$2(("<.,B' *=)CE' 3' N'
!"#$&?' <7(2)=' -.&&/H?/%%;4' *=CF' J' N'
'' '' -.%>/411/%%>%' *CF' J' &'
'' '' #EBF$G@A&%HLN%&$2(("<.,B' *)CE' J' A'
!"#$&L' 5*6*78*' 9*6*78*' :' '' ''
!"#$&>' ()*+,"' -.>4?/H/H%L%' M' 3' 4'
!"#$4%' <7(2)=' -.>4?/?/DH;%' =CF' J' ;'
'' '' 9*6*78*' :' '' ''
!"#$4&' ()*+,"' -.&%/01/%%LL' M' 3' 4'
!"#$44' <7(2)=' -.%H/HOH/;;%' =CF' 3' 4'
'' '' -.&&/4&/%%%1' 2' 3' 45'
'' '' -.>4?/H/1L1%' 2' 3' 45'
!"#$4;' 5*6*78*' 9*6*78*' :' '' ''
!"#$41' <7(2)=' -.%L/4?P4/1D%' M' 3' 4'
'' '' #EBF3412H/F&F' )CE' '' ''
!"#$4H' E"2N' #EBF$@G2A4>.%4/I&=$2(("<.,B' =)CE' 3' &'
!"#$4D' 5*6*78*' 9*6*78*' :' '' ''
!"#$4?' ()*+,"' -.%>/&14/%1?%' =CF' J' ;'
!"#$4L' 5*6*78*' 9*6*78*' :' '' ''
!"#$4>' <7(2)=' -.%>/411/%&H%' =CF' J' ;'
'' '' >4?<=$@KAH"&&$2(("<.,B' =)C<' J' A'
Table 7.5 Genomic copies.  See the end of the Table for details. 
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!"#! $%&''! ()*)+,'-! ()*)+.
/%&''!
01#23"! $1#23"!
"#$%&'! ()*)+,)! -)*)+,)! .! /! /!
"#$%&0! 1+2345! 67'89&:;9''<'! 3! =! >(!
!! !! 678>?9<9:&?'! @! =! >!
"#$%&>! 1+2345! 67'89A>9''8'! 5BC! D! E!
!! !! $FGC%HI3/0'@'>%322#17JGK! )4BF! D! /!
"#$%&&! 1+2345! 67'89A;9''?0! 5BC! D! E!
!! !! 670'9A;9''&0! @! D! >!
"#$%&;! 24)LJ#! 67'89A;9''?&! 5BC! D! 0!
"#$%&:! 24)LJ#! 67'89A;9''?:! )BC! D! 0!
"#$%&<! 24)LJ#! 67'89A;9''MM! 3! N! >(!
"#$%&?! 1+2345! 67'89A;9'0>&! 5BC! D! 0!
!! !! -)*)+,)! .! !! !!
"#$%&M! ()*)+,)! -)*)+,)! .! !! !!
"#$%&8! 24)LJ#! 67'89A;9'0??! @! =! 0!
"#$%;'! 1+2345! 670090;M'! 3! =! >(!
!! !! 670'9A;9''<&! )BC! =! >(!
"#$%;0! ()*)+,)! -)*)+,)! .! !! !!
"#$%;>! 1+2345! 670'9A;9''?'! @! N! 0!
!! !! 678>?9M90?'! 3! N! 0(!
"#$%;&! 1+2345! 670'9A;9'0'>! 3! =! >(!
!! !! 670'9A;9''M0! )BC! =! >(!
"#$%;;! 24)LJ#! 670'9A;9'0;:! @! D(! >!
"#$%;:! ()*)+,)! -)*)+,)! .! !! !!
"#$%;<! 1+2345! 670090<9'''&! 3! =! >(!
!! !! 670'9A;9''8:! @! =! >!
"#$%;?! ()*)+,)! -)*)+,)! .! !! !!
"#$%;M! 1+2345! 67009&:9'''0! 3! =! 0(!
!! !! 67'89>;;90&8'! 5BC! =! 0!
"#$%;8! 1+2345! 67009;&9'''>! )5BC! =! >!
!! !! $FGC%IH/8'8L'&9O0*/F#A! 4BF! /! /!
"#$%:'! 24)LJ#! 67009;89''':! 5BC! =! >!
"#$%:0! 1+2345! 67009:?9''>&! )5BC! =! 0!
!! !! $FGC%HI3/>'3':%322#17JG! 4BF! =! /!
"#$%:>! ()*)+,)! -)*)+,)! .! !! !!
"#$%:&! ()*)+,)! -)*)+,)! .! !! !!
"#$%:;! 1+2345! 67009A;9''>8! @! =! :!
!! !! $FGC%HI3/>8#0>%322#17JG! 4BF! /! /!
!! !! $FGC%I/88@0'%322#17JG! )5BF! =! :E!
!! !! -)*)+,)! .! !! !!
"#$%::! 24)LJ#! 67009A;9''&0! 5BC! =! E!
"#$%:<! 24)LJ#! 67009A;9''&:! 5BC! D! 0!
"#$%:?! 24)LJ#! 67009A;9''&M! @! D! <!
"#$%:M! 24)LJ#! 678>?9&90M'! 3! =! 0(!
"#$%:8! 1+2345! 678>?9&9>?'! )BC! =! >!
!! !! $FGC%IH/00:?3';%322#17JG! )54BF! E! E!
Table 7.5 (continued) 
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!"#! $%&''! ()*)+,'-!
()*)+.
/%&''!
01#23"! $1#23"!
"#$%&'! ()*+,#! -./012324/'! 5! 6! 07!
"#$%&8! 9:! /019:%;<<<=3>8'%5((#9.,?! )@9! 6! =!
"#$%&0! 9A(5):! -./012B24&1'! 5! 6! B7!
!! !! -.'B2BCB230'! D! 6! B7!
!! !! -.'/2E42''&8! *@F! 6! B7!
"#$%&3! 9A(5):! -./012B24/3'! *@F! G! 0!
!! !! $H?F%I<=8''1>8'2J8K! *)@H! =! =!
"#$%&4! 9A(5):! -./012L240'! :@F! 6! 8!
!! !! -.'/20442'3&'! *:@F! 6! 8!
"#$%&B! 7*K*AM*! N*K*AM*! O! !! !!
"#$%&&! 7*K*AM*! N*K*AM*! O! !! !!
"#$%&1! H#5>! $H?F%I<=8'L4D'/2F8K! *:)@H! 6! =!
"#$%&L! 7*K*AM*! N*K*AM*! O! !! !!
"#$%&/! 9A(5):! N*K*AM*! O! !! !!
"#$%1'! 7*K*AM*! N*K*AM*! O! !! !!
"#$%18! H#5>! $H?F%<I5=8'>'8%5((#9.,?! )@H! 6! =!
"#$%10! H#5>! $H?F%I<=8''/5'B%5((#9.,?! )@H! 6! =!
"#$%13! 7*K*AM*! N*K*AM*! O! !! !!
"#$%14! H#5>! $H?F%I<=3/3D'L%5((#9.,?! )@H! 6! 0!
"#$%1B! 7*K*AM*! N*K*AM*! O! !! !!
"#$%1&! H#5>! $H?F%<I.=31B:8'%5((#9.,?! H! 6! &!
"#$%11! H#5>! $H?F%I<=30BP'0%5((#9.,?! )@H! 6! 0!
"#$%1L! 7*K*AM*! N*K*AM*! O! !! !!
"#$%1/! 9:! /019:%<<<=1#'B%5((#9.,?! :)@9! G! =!
"#$%L'! 9:! /019:%;<=4580%5((#9.,?! :@9! G! >!
"#$%L8! 9:! /019:%;<=4+'3%5((#9.,?! 9! 6! 8!
"#$%L0! 9:! /019:%;<=&:'B%5((#9.,?! 9! G! 3!
"#$%L3! 9:! /019:%;<<=83P'1%5((#9.,?! )@9! 6! =!
"#$%L4! 9A(5):! /019:%;<<<=84>'/%5((#9.,?! 9! 6! 0!
!! !! N*K*AM*! O! !! !!
Table 7.5 Genomic copies.  Table shows, for each set, the putative donor sequence(s) 
(‘Donor(s)’).  Details provided by L. Marcello (Ph.D. Thesis, 2006, University of Glasgow) 
were confirmed and supplemented by additional analyses to type and class sequences.  
‘Donor class’: ‘f’ = full-length intact from arrays, ‘a’ = atypical, ‘p’ = pseudogene, ‘n’ = NTD 
frameshifts or stop codons, ‘c’ = CTD frameshifts or premature stop codons, ‘i’ = incomplete 
sequence, ‘m’ = minichromosomal read or read assembly, ‘r’ = read or read assembly, ‘?’ = 
unknown, ‘u’ = uncertain functionality, ‘d’ = degenerate. 
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7.2.9 Summary of genomic copies 
!"#$$% !&'()%
*'""%"+(,)-%.()#/)% 01%
#)23./#"% 04%
#55#2%3$+'6&,+(+% 70%
!"#$%&'%# !"# ((#
!$# ()#
!"%$# )#
8.(./-5&8&$&8#"%5+#6% 09%
!"#$%&'%# !"# *#
!$# +#
!"%$# *#
&'()*+# ,#
5+#6% 0:%
!"#$%&'%# !"# +#
!$# (#
!"%$# )#
&'()*+# (,#
.(*+55+6%'(;(&<(% =>%
?&)#"%,+(+$% :0%
!"#$%&!"'(%")"*+",( --.(
Table 7.6 Summary of classes of donor genes.  ‘incom.’ = incomplete sequence. 
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7.3 Supplementary information to Chapter 4 
7.3.1 Examples of point mutation 
Two examples are provided (Figure 7.3, Figure 7.4) to illustrate the presence of 
point mutations in expressed VSGs.   
 
 
Figure 7.3 Point mutations in Set_13.  Primary donor: Tb09.v4.0102.  Images have been 
drawn similarly to those in Chapter 4 (Figure 4.13), except in monochrome: the position of 
cysteine codons are indicated by a thick bar projecting from the top of each diagram and 
the boundaries of the mature NTD are indicated by dashed and solid lines at the N- and C-
terminal ends respectively.  Black lines spanning each image, denoting point mutations, 
have been drawn in triple thickness for clarity.  05-23c03 and 05-23c16 were from 
independent reverse transcription-amplification reactions from the same mouse.  They 
show a consistent pattern of point mutation, which is not shared with the clone from a 
different infection, 06-29c05.  Each of these clones has also undergone 3’ donation.  Further 
clones from mouse 05 show differing point mutation patterns (data not shown). 
 
 
 
Figure 7.4 Point mutations in Set_21.  Primary donor: Tb10.v4.0088.  Images have been 
drawn as in Figure 7.3.  05-29c12 and 05-29c30 were from independent reverse 
transcription-amplification reactions from the same mouse.  They show a consistent pattern 
of point mutation, which is not shared with the clone from mouse 04 (04-31c47).  Each of 
these clones has also undergone mild 3’ donation.  Different patterns of point mutation in 
the expressed copy of Tb10.v4.0088 were also found in mouse 02 and mouse LM_11 (data 
not shown). 
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7.3.2 Sets undergoing 3’ donation 
!"#$
%&"'#()("&$)*+,$
!
!"#$
%&"'#()("&$)*+,$
&+'$ -.'$
!
&+'$ -.'$
"#$%&'! (! (!
!
"#$%)*! +! (!
"#$%&,! (! (!
!
"#$%-.! +! (!
"#$%/&! (! (!
!
"#$%/-! (! !!
"#$%//! (! (!
!
"#$%)0! (! !!
"#$%/)! (! (!
!
"#$%.0! (! !!
"#$%/.! (! (!
!
"#$%.*! (! !!
"#$%/0! (! (!
!
"#$%.-! (! !!
"#$%)&! (! (!
!
"#$%0-! (! !!
"#$%)/! (! (!
!
"#$%0'! (! !!
"#$%))! (! (!
!
"#$%**! (! !!
"#$%)1! (! (!
!
"#$%*1! (! !!
"#$%./! (! (!
!
"#$%*'! (! !!
"#$%.)! (! (!
!
"#$%-&! (! !!
"#$%.1! (! (!
!
"#$%-1! (! !!
"#$%0&! (! (!
!
"#$%10! (! !!
"#$%0.! (! (!
!
"#$%1,! +! !!
"#$%*&! (! (!
!
"#$%'&! +! !!
"#$%*0! (! (!
!
"#$%&0! !! (!
"#$%*-! (! (!
!
"#$%/1! !! (!
"#$%*,! (! (!
!
"#$%&1! !! (!
"#$%-)! (! (!
!
"#$%/'! !! (!
"#$%-0! (! (!
!
"#$%0,! !! (!
"#$%'0! (! (!
!
"#$%-'! !! (!
! ! ! !
"#$%-,! !! (!
Table 7.7 Sets undergoing 3' donation.  A /＊ 0 in indicates whether 3’ donation was identified 
from the donor (‘don’) and/or by comparing clones (‘cln’).  The left hand table shows only 
those 23 sets that fulfil the conservative definition of 3’ donation (both from donor and 
between clones) whereas the right hand table shows the additional 24 sets that are included 
in the more inclusive definition of 3’ donation (from donor or between clones).  A tilde (‘~’) 
indicates that comparison with the donor was being performed with an incomplete donor 
sequence. 
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7.3.3 Analysed boundaries of 3’ donation 
 
!"#$%&$'(%& )%*& +,&-#$#.&
/0&
-#$#.&
1#$#.&23&
4'.5'65"5*7&
8%$9*:&#;&6#<$-'.7&
=%.;%>*&5-& ?@AB&5-&
!"#$!%&!' !(' )*!"+,-+!!..' /' !+--.' $-' -('
!0#$1%!1' &1' )*!"+,-+!&!$' /' !+-1&' $.' &!.'
!-#1&%-$' 1$' )*!"+,$+!!"!' /' !+-.1' &&' 1.'
!-#$1%10#234' 05' )*&&+,-+!!10' /' !+-0' 5' "'
!0#$1%&.#234' 0"' )*"$.+1+$.!' /' !+-0"' &1' 1.'
&!#1!%!5#234' 0"' )*"$.+1+$.!' /' !+-0"' &&' 1.'
!$#$!%!5' $$' )*!0+060+11!' *' !+155' "' &5'
!0#$.%!5' 1&' )*!0+060+11!' *' !+--&' &0' 1"'
!0#$.%&-' 05' )*!0+060+11!' *' !+11&' $.' 0$'
!0#$.%!0' 5-' )*"$.+(+-$!' 3' !+101' &&' &"'
!-#$1%$.' $.' )*!"+&-$+!-.!' 7' !+-0-' &-' $$'
!$#$!%!(' $$' )*!0+060+11!' 8' !+-&1' &5' 1('
!-#$&%!1' $$' )*!0+060+11!' 4' !+-(.' &(' 1-'
!-#$1%&5' 1&' )*"$.+5+01.!' 9' !+-.' (' &&'
!-#$1%!&' 1.' )*!"+,-+!&$1' :' !+-$.' (' &&'
!0#$&%!0' &1' )*!"+,-+!&!$' ;' !+1!.' .' &!'
Table 7.8 Analysed boundaries of 3' donation.  ‘1º donor’ = donor that was repaired by 3’ 
donation; ‘3’ donor’ = 3’ donor variant (see Chapter 4, section 4.4.4); ‘Donor NA variability’ = 
full length nucleic acid variability, in differences/nt; ‘Length of boundary’ = length of region 
of perfect identity, or greater than 90% identity (i.e. fewer than 0.1 differences/nt).  Lengths 
are given in nt. 
  
Appendices  326 
 
7.3.4 Diagrams of all mosaics 
In this section, images representing all expressed mosaics are provided.  Two 
diagrams are provided for each unique98 clone.  The upper is drawn as described 
in Chapter 4: the position of cysteine codons are indicated by a thick bar 
projecting from the top of each diagram and the boundaries of the mature NTD 
are indicated by dashed and solid lines at the N- and C-terminal ends 
respectively.  Segments best matching a donor are coloured white (donor A), 
dark grey (donor B), light grey (donor C) or stippled (donor D) accordingly.  A 
dark line spanning the upper diagram indicates points in the alignment where 
the expressed clone matched none of the putative donors; for clarity this line 
extends slightly below the diagram for clones for which more than one donor 
could be identified.  The lower image provides a track for each donor.  A black 
line indicates the location of a mismatch between the donor and the clone.  
Extensive regions coloured black indicate missing donor sequence.  As imperfect 
automated scripts produced these images (see Chapter 2 sections 2.7.2.4 and 
2.7.2.5), care must be taken in interpretation, as point mutations are 
occasionally misdrawn as segmental gene conversion events, particularly if many 
donors are being considered.  
Data for each mouse-timepoint was produced from different reverse 
transcription-amplification reactions.  Additionally, clones from mouse 05 with 
identifiers c13–c50 were produced from different reverse-transcription reactions 
from those with identifiers c01–c12. 
Note that clones sequenced by this work have the format ‘XX-YYcZZ’ where ‘XX’ 
is the infection number (01–12), ‘YY’ is the day of infections and ‘ZZ’ is a two 
digit number unique to that mouse-timepoint.  Sequences from Marcello & Barry, 
(2007a) have the format ‘VSG-AA-BB-CC’, where ‘AA is the day of infection, ‘BB’ 
is the infection number (01–11, refers to LM_01–LM_11) and ‘CC’ is a two digit 
number unique to that mouse-timepoint. 
                                         
98 Clones with duplicate patterns of segmental gene conversion, or differing by only a couple of 
nucleotides, have not been included, and are referred to in the captions. 
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Figure 7.5 Set_04 mosaics.  Identified mosaicism from donors and amongst clones.  Donor 
A = tryp_X-54b12.q1c-rev_assembly, donor B = Tb10.v4.0061.  Donor A is an incomplete 
partial sequence.  
 
 
 
Figure 7.6 Set_32 mosaics.  Identified mosaicism from donors and amongst clones.  Donor 
A = Tb09.v2.0090, donor B = tryp_IXa-10f02_assembly.  Donor B was is an incomplete 
sequence. 
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Figure 7.7 Set_10 mosaics.  Identified mosaicism from donors and amongst clones.  Donor 
A = Tb11.31.0001, donor B = Tb10.v4.0161, donor C = Tb11.14.0001.  Clones not drawn: 05-
29c15 matches 05-27c01; 05-29c13, 05-29c21, 05-29c24 match 05-29c05; 01-27c10, 01-27c12, 
01-29c02 match 01-27c08; 01-29c10 matches 01-29c04; 04-23c19, 04-23c21, 04-23c36, 04-
23c43 match 04-21c40. 
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Figure 7.8 Set_16 mosaics.  Identified mosaicism from donors and amongst clones.  Donor 
A = Tb11.48.0003, donor B = tryp_XI-934d12_assembly.  Donor B is an incomplete sequence. 
Figure 7.7 (continued) 
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Figure 7.9 Set_11 mosaics.  Identified mosaicism amongst clones only.  Identified donor: 
Tb927.3.190.  Clones not drawn: 05-23c10, 05-23c15, 05-23c18 and 05-23c26 match 05-23c04; 
11-30c25, 11-30c30, 11-30c34 match 11-30c12; 11-30c35 matches 11-30c16; 11-30c28 
matches 11-30c17.  
 
 
Figure 7.10 Set_24 mosaics.  Identified mosaicism from donors only.  Donor A = 
Tb08.27P2.460, donor B = trypA24a5.p1p.  Donor B is an incomplete sequence. 
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Figure 7.11 Set_14 mosaics.  Identified mosaicism from donors and amongst clones.  Donor 
A = Tb11.09.0005, donor B = Tb11.13.0003, donor C = tryp_XI-1034g11_assembly, donor D = 
Tb10.v4.0009.  Clones not drawn: 01-29c05 matches 01-27c11-del; 04-27c07-del matches 04-
23c07; 04-23c47 matches 04-23c40; 04-27c44 matches 04-27c25; 04-31c01, 04-31c06, 04-
31c31, 04-31c33, 04-31c34 and 04-31c35 match from 04-29c06; 05-27c19, 05-27c20, 05-27c21, 
05-27c32, 05-27c33, 05-29c23 match 05-23c12. 
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Figure 7.11 (continued) 
Appendices  333 
 
 
Figure 7.12 Set_17 mosaics.  Identified mosaicism from donors and amongst clones.  Donor 
A = tryp_XI-1058d01_assembly, donor B = Tb11.57.0030, donor C = Tb09.244.0090.  Clones 
not drawn: 03-29c19 and 03-29c11 match 03-29c03; 08-34c05 matches 03-34c01; 08-34c09, 
04-34c11, 08-34c15 and 08-34c20 match 08-34c02; 08-34c07, 08-34c08, 08-34c14 and 08-
34c22 match 08-34c04; 09-34c03, 09-34c08, 09-34c10 and 09-34c14 match 09-34c01; 09-
34c09 and 09-34c12 match 09-34c07; 10-30c07 and 12-30c09 match 10-30c05 (thus it is 
possible that this particular mosaic variant was present in feeder mouse F3).  Donor A is an 
incomplete sequence. 
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Figure 7.13 Set_20 mosaics.  Mosaicism identified from donor only.  Identified donor: 
Tb927.7.6530.  It was not possible to find the additional donor read referred to by L. Marcello 
(Ph.D. Thesis, 2006, University of Glasgow).  Most patterns of mismatch with the identified 
donor are conserved across infections, thus it is likely that mosaicism was not formed over 
the course of these infections and was pre-existing in feeder mouse F. 
 
Figure 7.12 (continued) 
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Figure 7.14 Set_22 mosaics.  Identified mosaicism from donors and amongst clones.  Donor 
A = Tb05.5K5.330, donor B = Tb11.21.0004, donor C = Tb9275.4840.  Clones not drawn: 02-
23c01, 02-23c02, 02-23c04 and 02-23c12 match 02-20c06; 02-20c11 and 02-23c10 match 02-
20c08; 04-21c05, 04-21c11, 04-21c24, 04-21c30 and 04-21c38 match 04-21c03; 04-21c10, 04-
21c14, 04-21c17, 04-21c19 and 04-21c36 match 04-21c09; 04-21c23 and 04-21c28 match 04-
21c22; 04-21c32 and 04-21c41 match 04-21c27. 
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Figure 7.15 Set_64 mosaics.  Mosaicism identified from donors and amongst clones.  Donor 
A = Tb927.8.420, donor B = Tb09.244.0360.  Clones not drawn: 02-27c05 matches 02-27c03; 
04-29c07 matches 04-27c22; 05-27c26 matches 05-27c05; 05-29c26 matches 05-27c02. 
Figure 7.14 (continued) 
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Figure 7.16 Set_29 mosaics.  Mosaicism identified from donors and amongst clones.  Donor 
A = Tb09.244.0150, donor B = 927mc_IV-5e11_assembly.  Clones not drawn: 02-27c07 
matches 02-23c06.  Donor B is an incomplete sequence. 
 
 
Figure 7.17 Set_31 mosaics.  Mosaicism identified from donors and amongst clones.  Donor 
A = Tb09.354.0060, donor B = Tb927.6.5370.  Clones not drawn: 04-23c50 and 04-27c06 
match 04-23c16; 05-29c32, 05-31c14, 05-31c18 and 05-31c21 match 05-27c06.   
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Figure 7.18 Set_33 mosaics.  Mosaicism identified from donors only.  Donor A = 
Tb10.v4.0031, donor B = Tb09.v4.0071. 
 
 
 
Figure 7.19 Set_37 mosaics.  Mosaicism identified amongst clones only.  Identified donor: 
Tb09.v4.0123. 
 
 
Figure 7.20 Set 43 mosaics.  Mosaicism identified from donors and amongst clones.  Donor 
A = Tb10.v4.0102, donor B = Tb10.v4.0081. 
 
 
Figure 7.21 Set_46 mosaic.  Mosaicism identified from donors only.  Donor A = 
Tb11.16.0003, donor B = Tb10.v4.0095. 
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Figure 7.22 Set_40 mosaics.  Mosaicism identified from donors and amongst clones.  Donor 
A = Tb11.1480, donor B = Tb10.v4.0063.   
 
 
Figure 7.23 Set_42 mosaics.  Mosaicism identified from donors only.  Donor A = 
Tb927.8.170, donor B = Tb10.v4.0070. 
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Figure 7.24 Set_48 mosaic.  Mosaicism identified from donors only.  Donor A = 
Tb11.35.0001, donor B = Tb09.244.1360. 
 
 
Figure 7.25 Set_51 mosaics.  Mosaicism identified from donors and amongst clones.  Donor 
A = tryp_IXa-20a05_assembly, donor B = Tb11.57.0023.  Clones not drawn: 05-23c22, 05-
23c23 and 05-23c25 match 05-23c05-add; 03-29c12 matches 03-23c02.  Donor A is an 
incomplete sequence. 
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Figure 7.26 Set_49 mosaics.  Mosaicism identified from donors and amongst clones.  Donor 
A = Tb11.43.0002, donor B = tryp_XI-909g03.q1k-rev.  Clones not drawn: 04-29c01, 04-29c03 
and 04-29c05 match 04-27c10; 04-31c41 matches 04-23c03.  Donor B is an incomplete 
sequence. 
 
 
Figure 7.27 Set_62 mosaics.  Mosaicism identified from donors and amongst clones.  Donor 
A = Tb927.5.4670, donor B = Tb09.v4.0061, donor C = Tb05.5K5.320. 
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Figure 7.28 Set_84 mosaics.  Mosaicism identified amongst clones only.  Identified donor = 
927mc_VIII-14d09_assembly.  Clones not drawn: 06-27c02, 06-27c03, 06-27c04, 06-27c05, 06-
27c07, 06-27c08, 06-27c09, 06-27c10, 06-27c11, 06-29c02, 06-29c03, 06-29c04, 06-29c06, 06-
29c09 and 06-29c12 match 06-27c01; 10-30c08, 10-30c09, 10-30c12, 12-30c02 and 12-30c10 
match 10-30c04.  Clone 10-30c01 has lost a fragment of the CTD-encoding region, possibly 
through the process of plasmid cloning and amplification. 
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Figure 7.29 Set_54 mosaics.  Mosaicism identified amongst clones only (too many patches 
of mismatch for confidence in the additional donors).  Donor A = Tb11.v4.0029, donor B = 
tryp_IXa-29e12_assembly, donor C = tryp_X-99f10_assembly.  Donor B is an incomplete 
sequence.   
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Figure 7.30 Set_59 mosaics.  Mosaicism identified from donors and amongst clones.  Donor 
A = Tb927.3.270, donor B = tryp_XI-1157a04_assembly.  Clones not drawn: 05-23c21 
matches 05-23c17.  Donor B was made by from two non-contiguous sequences and thus is 
incomplete. 
 
 
Figure 7.31 Set_63 mosaics.  Mosaicism identified amongst clones only (insufficient donor 
B sequence).  Donor A = Tb927.5.4930, donor B = tryp_XI-1007d10.  Clones not drawn: 04-
23c05 matches 04-23c02. 
 
Appendices  345 
 
7.4 Note added in proof 
7.4.1 Introduction 
Experiments were conducted following submission of this thesis that, whilst not 
changing the overall argument and conclusions, do resolve some outstanding 
issues and affect some of the details and figures presented within.  The key 
findings are summarized below. 
 
7.4.2 Additional PCR reactions were consistent with segmental 
gene conversion occurring during infection 
Further to Chapter 4, section 4.5.2, PCR reactions were set up to test whether 
segmental gene conversion events were genuine and occurred over the course of 
infection.  The design of the primers is described in Figure 7.32 and Table 7.9, 
and the results of the reactions are shown in Figure 7.33Figure 7.37.  Balancing 
sensitivity and specificity meant that in some cases it was difficult to obtain a 
single specific product for a primer pair (see for example Set_04 A-B reaction, 
Figure 7.37).  In addition, attempts to identify segmental gene conversion 
junctions failed in cases where the mosaic VSG had been expressed earlier on in 
infection, since the segmentally-converted VSG was absent, or present only at 
very low abundance, in the terminal samples (see for example Set_10 A-B 
reactions on gDNA templates from mouse 01, mouse 04 and mouse 05, Figure 
7.36).  However, the overall pattern is that the segmental gene conversion 
junctions tested appeared over the course of infection, and represent neither 
experimental artefact nor pre-existing genomic variation. 
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Figure 7.32 Further tests for segmental gene conversion.  These diagrams were drawn as 
those in Appendix 7.3.4, with the different segments coloured according to the mosaic 
diagrams presented in Chapter 4.  Primers were designed for five sets, Set_17, Set_12, 
Set_32, Set_10 and Set_04.  Forward (F) and reverse (R) primers were designed to bind the 
donor sequences at the positions indicated.  In the case of Set_12, the test was for 3’ 
donation and the forward primer was the same in both reactions. 
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!"#$#%$&"$#"'#"($ )*+,"*$-.,"$ )*+,"*$!"/0"12"$
!"#345$
4567389:;$ CCTACTAAGCGCCAACGAC 
456<389:;$ CCTACTAAGTACCGACGCC 
45673:=>?$ CGGTGACGCCCGAGTC 
456<3:=>?$ CTGCCACGCCCGAGGT 
!"#3=4$$ !""$Table 7.1$
 
!"#3=>$
=>673>:@;$ AGTAACAGACAGGGCCAACG 
=>673==::;$ CTGCTGTTTCGATCTCTTCT 
83"1(3=89>?$ TTACCTTCTTCAGCGCCTG 
!"#3=:$
=:6735=4;$ TCGAACGGACAATTGCCC 
=:6<35=4;$ TCGACCGAAAACTTGCAA 
=:6<3:@>?$ TGTATTTATGCTGGGTTGGC 
!"#38>$
8>6<3A9:;$ CGACAACGGGAAGCAATG 
8>673A9:;$ CCACATCGGCGACCAACA 
8>6<3B95?$ TTGGTGTGCTTTAGGTGGG 
8>673B95?$ TTGGTGTGCTTTAGGTGCA 
Table 7.9 Oligonucleotides used for testing of segmental gene conversion. 
 
 
Figure 7.33 PCR tests for Set_17 mosaicism.  PCR was applied to genomic DNA obtained 
from both the first peak of parasitaemia (day 8), and the terminal sample (day 34), of primary 
clonal infections.  gDNA from mouse 08 at day 8 was at low concentration, contributing to 
the low abundance of product from the B-B and PolI reactions.  In both mouse 08 and 
mouse 09, segmentally-converted product was present only in the later sample, although it 
is also possible that the low gDNA concentration from mouse 08 at day 8 prevented 
detection of a product in the A-B reaction. 
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Figure 7.34 PCR tests for Set_12 3' donation.  PCR was performed on samples as described 
in Figure 7.33.  No product of the correct size is observed in pre-infection gDNA, or gDNA 
from the first peak of parasitaemia (day 8). 
 
 
Figure 7.35 PCR tests for Set_32 mosaicism.  PCR was performed as described in Figure 
7.33.  For this reaction, cDNA was also tested, to ascertain whether the mosaic junction was 
expressed by parasites in the population.  Reactions were performed on the products of a 
reaction to which no reverse transcriptase had been added, as a control for gDNA 
contamination. 
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Figure 7.36 PCR tests for Set_10 mosaicism.  Reactions were performed as in Figure 4.11 
and Figure 7.35.  For mouse 01, mouse 04 and mouse 05, gDNA was only available from the 
terminal sample, from which no Set_10 mosaics were detected.  It is therefore likely that if 
the mosaic junction remained present at day 31/32, it was at such low abundance that it was 
undetectable.  Set_10 mosaics were detectible in mouse 11 at day 30, as evidenced by the 
clone shown in Figure 7.32 and the product seen here, however, there was insufficient 
cDNA remaining to test its presence by PCR.  
 
 
Figure 7.37 PCR tests for Set_04 mosaicism.  Reactions were performed as in Figure 7.35.  
There was insufficient time to optimize reaction conditions to be both sensitive and 
completely specific, and thus a larger product was amplified from gDNA in the A-B reaction.  
The low abundance of product from the A-B reaction, when applied to the 05-31 gDNA 
template, may reflect the fact that Set_04 mosaics were not obtained from the terminal 
mouse 05 sample. 
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7.4.3 There were only four Set_14-related VSGs in the genome 
It was discovered that the cross-reacting bands present in the Southern 
hybridization (presented in Figure 4.22) were most likely due to the means by 
which the probe had been made.  In section 4.5.10, probe DNA was obtained by 
amplifying 14-A (Tb11.09.0005) directly from gDNA, and although the product 
was gel purified it is likely that it was an additional contaminating product that 
was labelled and hybridized to the blot.  Here, a probe was made from DNA 
amplified from plasmid-isolated copy of 14-A, and was hybridized to another 
gDNA blot.  The results are shown in Figure 7.38.  As can be seen in the figure, 
the unexplained band in the earlier attempt is no longer present.  As described 
before, the single band that does not have an annotated genomic copy is likely 
to be 14-C, as this band gave the strongest signal when hybridized to a probe 
made from 14-C DNA (data not shown).  This evidence lends support to the 
premise that the varied Set_14 VSGs are constructed by segmental gene 
conversion, and not by the direct expression of pre-existing genomic copies. 
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Figure 7.38 Southern hybridization of gDNA for detection of Set_14 donors.  The blot was 
prepared using pre-infection 927 genomic DNA digested with one of nine restriction 
enzymes as described in Chapter 2, hybridized with a probe complementary to 14-A and 
washed to medium stringency (55ºC, buffer prepared according to kit instructions).  
Predicted positions of 14-A (Tb11.09.0005), 14-B (Tb11.13.0003) and 14-D (Tb10.v4.0009) 
fragments indicated by ‘A’, ‘B’ and ‘D’ respectively.  Italics correspond to bands that do not 
encompass the entire gene.  The remaining band indicated with an arrowhead, and 
corresponds with the band indicated by a ball-and-stick in Figure 4.22.  This band is 
predicted to correspond with 14-C (tryp_XI-1034g11_seq) as it hybridized strongly to a 14-C 
probe (not shown).  Note that the ordering of some of the larger bands could not always be 
resolved. 
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7.4.4 Cells referred to as ‘variant 21’ in Chapter 5 were in fact 
duplicate variant 23a-expressors 
To ensure that the transgenic VSG expressors described in Chapter 5 were 
expressing the exact Set_14 mosaic VSGs under consideration, VSG cDNAs were 
cloned and sequenced from these lines.  The sequenced clones were as expected 
for all variants except for variant 21 and variant 29 (VSG 427-4-expressors were 
not tested).  In the case of variant 29, two out of five clones obtained did not 
match variant 29.  As neither of these sequences contained the EcoRV site that 
caused the cutting of all detectible amplicons (Figure 5.4) it is likely that they 
were at very low abundance in the population, a premise supported by the fact 
that further variant 29 clones made from post-complement-mediated lysis cDNA 
samples all matched variant 29 (3 clones sequenced).  ‘Variant 29’ expressors 
were therefore expressing variant 29.  In the case of variant 21, however, all 
cloned sequences exactly matched variant 23a.  To test whether ‘variant 21’ 
expressors were in fact expressing variant 23a, VSGs amplified from ‘variant 21’ 
cDNA were tested by SacI digestion: variant 21 possesses a SacI site, whereas 23a 
does not.  Samples obtained immediately after transfection were completely 
digested, whereas later samples made from blood-borne parasites, or from 
recloned cells, were not digested by SacI (data not shown).  It is therefore likely 
that variant 21 was contaminated by 23a-expressing cells at some point after 
transfection, most probably during attempts to infect animals.  Variant 21 was 
exceptionally difficult to obtain in vivo growth: many different infection 
protocols were attempted (data not shown), and during this period variant 21-
expressing and variant 23a-expressing cells were cultured in neighbouring wells 
in the incubator.  The apparently successful infection attempt reported in 
Chapter 5 required 1 x 106 cells, and it was from this infection that cells were 
recloned for use in experiments.  The strong selection for growth and survival 
that in vivo growth placed on the trypanosome population meant that a small 
contaminating population of 23a expressors could have survived or out-competed 
the 21 expressors, resulting in the contaminated population on which subsequent 
experiments were performed. 
 
Stabilates made of variant 21 expressors immediately after transfection were 
tested by RT-PCR and amplification digestion as described in section 5.2.3, and 
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the results were consistent with their expressing solely variant 21 (data not 
shown).  Expressed VSGs were also cloned and sequenced, and were found to 
match only variant 21.  In addition, SDS-PAGE of crude cell lysate as in section 
5.2.4 showed a variant band of the size predicted for variant 21.  Therefore, as 
the post-transfection cells were expressing variant 21, the question of whether 
variant 21 was antigenically distinct could be addressed using these cells.  
 
7.4.5 Variant 21 was in fact antigenically different from variant 23a 
To test the serological properties of genuine variant 21 expressors, attempts 
were made to raise polyclonal antibodies against this VSG.  However, as before, 
infections with genuine variant 21 expressors failed in the two times they were 
attempted, despite using the infection protocol that worked for other variants.  
Variant 21 was therefore tested only with heterologous antiplasma.  The results 
are given in Table 7.10.  As can be seen in the table, variant 21 crossreacted 
with polyclonal antiplasma raised against variants 23a, 23c, 27 and 05-27.  In 
that sense, it acted similarly to variant 23a.  This means that the conclusions of 
the polyclonal antiplasma experiments remain as they did in Chapter 5.  
However, none of the four monoclonal antibodies bound to variant 21 
expressors.  This finding resolves the identification of the putative monoclonal 
antibody epitopes.  Figure 5.13 and Figure 5.17 were corrected to give Figure 
7.39 and Figure 7.41, and Figure 5.14 and Figure 5.18 were corrected to give 
Figure 7.40 and Figure 7.42.  An updated version of Table 5.9 is given as Table 
7.11. 
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Table 7.10 Updated summary of serological cross-reactivity.  Table 5.8 Summary of serological analyses of Set_14 mosaic VSGs.  A summary of the results 
shown in Table 5.3, Table 5.4, Table 5.5, Table 5.6 and Table 5.7. ‘I’ indicates the results of IFA on live cells, ‘C’ indicates the results of CML, ‘A’ indicates 
the results of agglutination, ‘I(f)’ indicates the results of IFA on acetone fixed cells.  For the immunofluorescence assays, ‘3’ indicates strong, eggshell-like 
fluorescence.  ‘2’ indicates strong fluorescence, but perhaps with a speckled appearance or posterior accumulation.  ‘1’ indicates patchy or weak 
fluorescence.  ‘-‘ indicates no signal.  For CML and agglutination assays, the score is given as the number of threefold dilutions still able to give a signal 
(that is, 1 = 1/6, 2 = 1/18, 3 = 1/54 and so on).  ‘X’ indicates that that particular test was not carried out with that antibody-VSG combination.  23b was 
omitted due to inconsistencies in VSG expression (section 5.3.7). The non-reciprocal cross-reaction seen in the agglutination test with variant 29 is 
discussed in section 5.3.3. 
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Figure 7.39 Residues contributing to the mAb-21A epitope structure.  In a multiple sequence 
alignment of mature NTD amino acid sequences, positions where the variants that bound 
mAb-21A (23a, 23c, 27 and the mouse 05 Set_14 variant 05-27) were identical to one another 
but different from the variant that did not bind mAb-21A (21) are shown in magenta.  This is 
an updated version of Figure 5.13. 
 
Figure 7.40 Residues contributing to the mAb-21B epitope structure.  Positions where the 
variant that bound mAb-21B (23a) were identical to one another and different from the most 
similar variant that did not bind (21) are shown in magenta.  Figure is annotated as Figure 
5.12, with the positions of cysteine residues conserved amongst variants 21, 23a and 23c 
shown.  Although mAb-21B could only bind fixed trypanosomes, it is unlikely that the 
epitope was contained in the CTD, as the only differences between variants 21 and 23a 
outside of the predicted NTD were in the GPI-anchor signal sequence. 
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Table 7.11 Amino acid residues associated with mAb escape.  Three tables show the amino 
acid substitutions associated with abrogation of mAb-21-A binding (left and middle, see 
Figure 7.39) and mAb-21-B binding (right, see Figure 7.40).  ‘Pos’ = amino acid position in 
mature NTD; ‘X-rct’ = identities of amino acids at those positions in cross-reacting antigens; 
‘29’ or ‘23-c’ = identities of amino acids at those positions in the antigenically distinct 
antigens.  Emboldened rows correspond with positions predicted to be exposed on the top 
of the molecule.  This is an updated version of Table 5.9. 
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Figure 7.41 Predicted residues contributing to abrogation of mAb-21A binding.  Residues 
identified in Figure 7.39 are indicated on the predicted structure of variant 21 in magenta. 
 
Figure 7.42 Predicted residues contributing to abrogation of mAb-21B binding.  Residues 
identified in Figure 7.40 are indicated on the predicted structure of variant 21 in magenta. 
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